var title_f21_42_22176="Scaphoid shift test 4";
var content_f21_42_22176=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Scaphoid shift test: Step 4",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    While maintaining pressure with your thumb on the scaphoid tubercle, use your other hand to move the wrist into radial deviation. With an intact scapholunate ligament, the scaphoid will flex, despite the pressure, and become more prominent; there will be no clunks or significant pain in the scapholunate space. Pain as the wrist is moved into radial deviation, possibly accompanied by a clunking sensation, constitutes a positive test, and is consistent with a scapholunate ligament tear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin deWeber, MD, FAAFP, FACSM.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_42_22176=[""].join("\n");
var outline_f21_42_22176=null;
var title_f21_42_22177="Pyogenic granuloma periungual";
var content_f21_42_22177=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Periungual pyogenic granuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGVAhwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDn1kAFWILgDAFZ69aktFO855qziZvpJmP3pFkAIFRIMR+9RAEvTEW3ckfWqzP8x9Kn2Er1qEp830osBA7E1E4wOvNXPLG05qCdAB7mkMgj71JuwuBUYU5x7U1zzgUDB34xmmhsnAqJ+SaSMknjpRYZaxk0mwk01XwanDgigZJpkRlv4kHTOa9o0CER2qjHavLPCFt52obsZAOK9isIwkKD2rmqvWx1UVpctqKlUU0DinrUJGjEIxTT0p3ekYcUxEJ60DjrSnrTWOelSMYx5NRE9c1Ix5qEnJoKRGxpjnAzTmPNRPQWkM65puaceBTTjbQURseaY55p5HNMccmgaGDmnUg4pDmgbQE5plL0NIp600KwmMnmo2XnAqTJ7daaBnmmIicgDFQNkVO65JNREY60ykQE4BGKZz1qR+pqPPUUiiNjnOetVpDkmp5CAearOfmNS0UkRtndioJDzUrMNxqu5+aoZSQkhGOaqy9amkOTUTEZqWFiFqhzyalfqTUDHBqR2I3HNULkYar5IIzVG5OXOKARh6zH5ls49q8m1NDFeOPevY7pN6MK8v8AF1t5V0WA6mt6D1sY4mPu3MVXqRXqmGqRXroscaZbDVYhes9WqeN6TRSkbVs9dp4EjM2sR+grz62k5Ar1L4T2zS3zSMOB0rKexome36dHiFB7Vpx9MCqNsNqgCr6EKPeqMmSLxTs4NMBzzQc9aQrCOeeagYgZZjTpmPU1XfdnJ5PpSGkMmJf2Xp/jTVHpxQSSwA60pOMAD60DGvkJx3pU+VQMCmTMQMntSA5GTTA8Rt5Qe/Jq9asAaxImK45q/bS/MM10pnA0bqP8tMDANnPGahibK49aRxzTQrF5ZcjGaQtgnHPrUEXIxUnAGB1qhA8hA59KiZtx5qVwCOaYqjIosA0qe1U5iQ2O9azrgACqM0f7zH8qQykBnNSxLngUjYViBUkbDHFAxduOlCqT+VDOegqW3BeVEH8RxUlI7vwHYbEDkck5r0qFcKAK5rwnaiK1TjtXUpwK5JO7O2Csh+OKcOlNBzThTQMMUxhT80xjmgRExFMONtPcDNRN1qSrEbd6iPFTMB3qB+vWgtDCOaY/WnNTcEigojI4pn0qamsAKB3IWXH1prjP1qZh82e1RuRnjpQVch2+oo74p5OOtRA85phuNc03OBzSkgtSH+dAWEB4pueTg0pOBTQQOTTAa5OaiPIzTyeOaiZuMUDSIn5qu/DVKzcmq8h5oLQkhzVVjkmpS3U1XLYqSkiKU4JqB3GRRM+4+1VnfmobNFEezEn2qNuppDIAaJGBxjvUsTGMcmoZO9SucVAWqRETA461WnHBqy/Q1VkGQTRcCnKPlNcP4zsw8LMByK7iQ1h65AJoHBHaqpysyakbxaPH3BUkUBsVoanbeVcOuO9UGTFd55g5XqVXqqcg05WpAaMEmDXu/wAGlWW0MgHevn6J+a+iPglAU0NXI6nNY1N0aRZ6xEOlWFyagjIxVhOVwKYEiHpSs3HFA46016QEUhH5VEDnJPfpT2Uke1RyZ6fhSAI1ySx79PpTTgNinBsDgcCqrsfmPrRsC1FuPmUY9aTcRTWzxzTN3qDQB4RHnaPpU0LHcOelR9MemKS3bLH0rdHE0bto+VzmrHU5Pes6B8JxVpJhgZPNWmS0X41Gfahx121DFNzjNTbhsOOtUSNJyeTxUsIBwajIAWnxcuBTAsOMLkVRkxn8a0JF+XpVF1O7mkO5SnjI6VGmV4q/KoxVGYEdKBig9q09AhM2oxjHAOaxkb58d67DwRamS83nmonojSCuz1XRIdlsvHatYDjFVrFNkKirgrlSOxiAYpRQ1J+NMQNUZp5IqJmx1pMENk6ZqAmpHeoHOOam5aQSGoDk9KczcUgbjHegpaDMc4ppO3in9Oe9RsOeaBiM2OaaTmg8n6UMCqH1oGICTwKikGCCacGKKTjJprEEAmmhoY/z9KhbIOKezkcjrTD0yaChMZP1pGI7Ggtl/btUch2tTAU+h4pj9cUhYufQCiQEYNADW9agYE5NKzk5qKR8KQDRcpIic81E7AKfU05j71BM4yPSlcuxBITzUErYU1I7bicVXmIwR3qC0irI/OM4qtK+G4qWbgdaqSEg1DZqkSK4708NlhVYN3qWNuc0kTJD3OeKix1pzNlqbnGaGtSCNxxUD4EZFWZOVqq44xTEUJV5JrNvRlGrZlUDNZd2ucikgPM/EUey5JxWIVBrq/Fdvg765cCu6DujzaitJkDpUflnNWyM/SgLirIEghAwTX018Jownhy3IGMivmdclgPU19R/DSLyvDtoP9kVjU+JFwO5iXOKtJ04qtDyBVtBgc0DYoBphySalxTD1xUiIzUP3iT0HQVO4zkComG047elAEb8LgVXcZxgVYlwAB3PJqF2wPegEQMeSfSmkrnvS4LdM00x0DPCm6DNQwyASYpLiQrmqEbtvBrZI5NzpIXyvFTqfQ81kQT4Tg9qnS5wetUiWjVjJzxVyN84ArLimzirkcgwBVpktFwtgcc06N/mNRK2RinRgZ5qiS8ZRsJqmzkt0qyMbOaqMfnNIB8gyoqpMgAwBzVrcCnXmo8CgpGUQUlHrXqPw9tP3Kuw5NeeNb7pF9Sa9h8E2vl2keR2rGq9DeitTrolwoFSihRxS1lY6LjTTCakPNMbmkMjPSo3OacxxTD1qWUiI1G+akY88VG5pWKRHTQeaHPvTA2BQBKSMGonIIpjPxULSj1oBIlJ29aV3G2qTyHdTHn96LlcpZdx5fPWq7NjvVZ5s9DTTMAv1o5i1EmLcc9aaGIIJ6UyBleUbzhe+aS5lBlfGB6Ci4+tiWRgq9eagznqai8zPWm+ZxwaY0rE4YDPSoppuij6k1XkkOWGaj3gL7mhspRJjIFUmoGfvSNzk1A7UFJDmY9c1XlbNK7nGO1QSNxUlJDXbb9aqTMd1STNg8VVLZc1LNEhk2aqvU0r/NjsKhkOagtDAf0p4J7VEBz7U8dQBQhSJT0GKRqeAAPWo3OOlUYjHbiq7cVZ2NIPl61XYZ5NS0CIJKpzx5Bq844NV3GeDTBnGeKbYvAxArgWGGI9K9Z16ENaMPavK71Nlw49666W1jgrrW5DTlHFRjrinitTnJ7ZAZVPbIr6j8Aj/iRW3+6K+XrTJnQdtwr6k8DkLotsB/dFY1PiRpDqdjAuAMVaQEiq1ucira8CkJikVGwPNP6VFIeSaBoa/AxURyW+anMcilBx160A9CN1BBJ79KhdPTrUzkf/AFqifK0CRXbI45FRuSpxmpJeT6VCxGfmJzSLSueE3UIYgY71SaLbyO1blzDgDPU1mOnO33rc40yuCQox6UbyGz7VMygcDoKrcZNCGX7e4wRzWlHKSARWEvysPrWvZsDjd0zxVIho0onOATUyT/NxVVMEZ6AU6MZbI6CrIsX2lOAKqO53mpkGQSe1RlOrHrQA+Nvl96WR9v40kcZC7jTioxk9aBk2lIZtQiVv72a9v8OwhLZOO1eQeE7VptXUkHAr3PSrfy7VSfSsamrsdFLRFgjAprGpH5OKjaszdCDOKY/FSA01hxRYZA9QytgZqWTAFVZW+WoZSGlqikemk1GT1pWKEZiTR2pDTC1O1gHEE1C8RNSFzTC5xzRZBcheJu1VpYmzVwuTUbE9aOVFKZQMZHWopFbNXHBBqGTJPTmocS1MqNuFMYkdeancZOKjZBj3pWLUkRB6BJg5NMcYPFMx1potWZLuDNyaYzgNioWOPrURPqaZSiTvJ6VE5GPemZpsmAOaCrA2cVBL8vXrT5JcgCq8rE8k0ikiGY1Vk6Zqw54qsxJ4qXqaJEL5PNRscsB6VO3y5BFQEc57VLQw4zUyL8uajC/MM9KsKQCAOlNIykwCHjNAi3PtqRTwT3FRK7K5amZO5etY0t0kaTkbT+dYrf1q7PcMy7eg71SfrQ2ugoJrVkbDFUp2IY1ceqs44qS0ZWpNviIrzLXY/Lu24616beDg1wHimLEm7Het6L1sc2Jj7tznxTxTFp6iuk4CzZ/6+P8A3hX1D4JOdHtgP7or5eteJoz/ALQr6f8AAnOjWx/2RWNT4kaU9mdtbH5c1cTkZrPh7VfjPy0CY7qOaikxmpsZqJwM8dKQIg6dqY3Pc+gqVx6UzaVXcaBsZtOM56VG4Jp5JyfTrUbknJ557UCIJOQADVdomJ46VaYDGTUeT6UFp2PHL888DJzWQ4JJ+tbkyDzMDnmqE8IUuRWxwxMmTPP1qsSRV+4GMjHvVNlBc47Ui0OTqKvRSbDkniqUeBwKmZtqk00waLyXGSAeBmr9tOCR6VgQsS/PAzWjE2BxWiM2jYEy8+lNaYc9sVniXpStubmmI1Ipty1Yiww+asyzznJrQSTAz6UAdr4Ftt9yZSOM4r1qB8Qge1ee+AYc26NjrzXoKDCVzyep1QWiEY80wnmkZuaaTUG6Q8NStyOtRDk8UO20U0DRDL3qhO3bNWp2IBrNnbEgBpMuI4vT4l3jrzUDHccLQZ1hU5bmjYlj5F+bAPFRswXgdaSNnnHyA4q1FZ7QC/U0bkt2KynnpSGNjWmsKgcCnbAB0p2J5jHaNwcAHFIyNitZ1GOBULKCORRYfMZDAio2APXFassanoMVUlgGeM0WGmZzYB5qCbpx9auy255Iqo6lVYEHmoZaZQkbB5qEtnpTLrzDIcDiqrSshway59Tqiy52prD8qgSfccVODnmqTvsXcic4NQsxP0qeQZqndFgMJ0obsbQ1HNj1qCXJp8Cu1OdMHGelTe5exVKkpzVZwQRjmrsiELn1qIDbkkc0mx3Kjqe9IybQKmkO4knoKgeRi3vSuLUei5PNSkD0qGNsHBqVyMiqRjLcXcBnFNxuGR6c016SPd5g5470XJsRNnJFQScYFTyOC7Y6Z4qvMeRUsaGN0qrKSatMcg4qvKoxmgDNuhlTXE+KUBjJrubkZQ8Vx3iZcwtWlN6mdZXgziQalSoT941Kn8q7DyyzB/ro/wDeFfT3gYY0a2H+wK+YbMbrqFf9oV9R+Dl2aXbj0UVjU+JGlPqdbb5wKuRHNU4BxVxeKBsm4xUbUoOaU49OlInYYcYxjiojjmpSPlyaaE6dqBEP8OPWoyOmRUr5znnFNGWJPYUAQuvQ4B9KhYLuqxJ19BVcnBpjPJJo2JJX1rPnyoYe9bhXCYHpmsm8I3sMc5rZnGmZUyhnJNV3jABwOtX2h3McdaqTBlHzcVLNEysU2Gms2c1K7gj3qDHJz0zSTGJG21+a1IXBT5qxz9/ArQtyQPmq0yWi6oy6+lXFACjNQQLnk9KdJJhsHpVJkWLUCjr2qwPmYDtmqlu25cngVcsh5t7Cg6FgKYWPZfBUOyyj+grrm4WsPw1CI7NPpW0xyMVzN6nbFEJpjNinyEVA5qTZEiSYqKWWmFsVWnfFVcLahJJ1rNlffIT2FSTzYU81i318II2bPSolKxpGDexcuL5bdCSee1M02CW/fzZMrFXP6a76ldBpD8gNd5bFEt1jjXAFKD59XsTVXs9FuXLbyoYAiLz60vJOTTI1AFSVdzmsBFBHFBNNJpXCwx+ajIOKkNNNAyFxxUDjrVlzwfaqzHrTuBARVWRQSelW26cVWYdaGNGRc2/JK1Re2DE5GcVuyrVCdKycLmsZnPzxtExZPyqKO+I+V+K154cg1lXFqCckVjJST0OmEk9yQXAfoacp3deaom3ZSSlPgmKvtfg04Tf2jdNdDUiHy8DFMEa7/n4FT2pDDPalniyQR3rewlLUz5ss3A4prw7j0q20YA4600frUuPcvmM24h2jAqgy4kx3rdmXvjpWXOoV84zSasVGVyqvDZNSj5jmmupXrSBvlxUkyQsn3sCmSOcEDikY4INMkbnI6UjMiZsGmOcjNJLTC2CBSKELYpjHIOaeehNRt93AoEyjdNhSK5LxFzA1dVcg81y3iD/UNVw3M6nws4FzhzUiN+dRyf6xqVa7jyjQ03m/tx/tivqbwrxp1uP9kV8saSC2o2+Ou8V9UeF1I0+DPZRWNT4ka09mdVD0q0nvVSDoKtJzSEO6cinqy7/n4WgjA6VGRuPFMQ48jPHJpjkn0oyc9OBTf4uvSkIQnJPOO1NJ28DpTsqAKjcjccUARy/5FVymTngVO55qBnwaBo8+SAFW/vVi6tCoJx1xW6xZd2OtYuoIzOB69a6DhKNquMk9cVR1NATjvWjsK8D0qjcgnnBJqWjRMxW+XFHUZNTzRnqRVYdamxoIDh+KuQONo9arGPcc09QYyCOaaE0bFucqST+FRTvufNV4JDzn6VLH+8fJqyWi5Ax2+grb8LQm51uAD7qnJrE4C8V1Xw6j8zVmIH3cUN6BFXaR7dpqeXaqB6VazwaitxiFB7VIWAWuY7EQSmq5bmpJW61XZwAaRshJGwKoXUvFSzy4HWsu8lwDzQ2VGJDczgA5PFcdrN009ysEZzk1r6pc7ImJNZPhy1a6vmncZGeK5pvnkoo7KcVCLmzpfD1j5US8V1MCYqGygCRjAq2vH0rq2Vjzpy53ceDtGaDJjmmMT+FRO2RUtkpEzTUnnCqrEmmk4pIfKXDKDSFxnrVPfSGQ1QuUst05PFQtUTyHHWojKcUC5SR+lQMvGaV5cVE0ox1oCwyQcVTkHNWXkBqrKwNIpIrSCqc6cVbdhiqszcVL1NEZk5Zfu1l3DnfnGDWvcYJNZlyuc4rCUTqpsv6RdFvkY810K4ZcDkgVw0MzQyow9a7PSpBKFauilLownpqJJFsQE8saqshBBIOK6mbTvOtgyDt1rDvLZg43LtA4xXRKJMKqloZtzxGcVnSx/Jk1p3EZHXpVG5BMZFc8kbxZlXTfMD2pinjmn3OAozz2FQA461i9GW1oSNk1C/XFSFuTUbkY+tMzZC5yars2WPtUzthfpVfqCaQ0PyStNX3pgfHSnDmkhMp3XRjXJ+Im/ctXW3pG3ArjfETYiatIbmU/hZw0v3z9aVDzTJD8x+tEZ5ruPLN3w3H5msWqj++K+ptATZZxD0UV8z+AYfP8QQcZAOa+nNK4hQegrCT980gvdN63+7VhOKqwHjNWhk4pkskJ+XHamk9O1KelM6mgQMxAAHWmHk4NKD146/pSHH40ARv19qYWpznDeoFRseOaQyN2xmq5bnmpJTVZzg0i0jktpaTpWbqabDkDmtrHzZxVK+TcfmFdJ5pjCItGoA5NM+yBYwSM1fZRGM96rSTgJjvmhlJnNX6bWcehwKzH4cgDvW7foMse5NY0qfvCcVLNUMztNTbsqOKYR6DNHOMUiiaLHJNSo2GFVUODxTi2CCTimhM0g+4DHpXofwptw00knqa8yik6AV7J8JbbFiJMdTmiew4L3j0rooFMY9aVzUTEYNctztitCGQ5PFVZuOtXUdUJLdayr2QliR0p7GkdWVbiTjrWbcvnrViWTOayr6farZPNZzeh0RiYWuymSQRIeWOK6nwzZiK3TiuW0+E32o7jyAa9G0uBY41FRQW8wxUuWKgX4VCqBQx+YAU48VEeXzWzZ54rCoyM052PQU1RipuURstMZamJ5pjGmMhIqIjmrDYNRsuaYED5xURPFTupxUDDmncYxjx71C9SN0qF6LgiJ+lVpDU7nHWq7nIpXKIJDmq8tWHFQSVNykUph7VSlUGtCUVUfltvepduprEz2hLyKq9ziuq0pFhlMKNuCADI7msCRNvI61r+GVdmlZug9aum7Owpu6ud1Y3DvatGANvSsPUiXlwvQcAVpWE2yIj1qGaNQxkkx7V19Dni+V3MO+t/KhjL43NmsK5bsK6HUmMwDcYGQMVz10hHasKh20ndamXMcsCfwqk7YJGelaN0uAG6Y4rHuWPmHFcstDqjqWVbdxTJjgYqO3kAGe5HFLIeMmhO5lJWZDK2FpnRKY7ZNKelADMc08nApvehjQSyleNhSa4zxI/7tq62/bg1xPiST92a1pLVGNbSDOTbk0q009acK7TzD0L4SwCTVi57V9E2C/u1x6V4P8Hbc+bJNjjNe9aafkX3rm3mzVaRRrWy4QetXI/U9Kqw57VYU9q0IY89OajkpzNxUTSck46UMSDoPfvSMwGfameZkn0pm4YyetSVYUnvULv1okeoGzQxpA5ycVAzDNLITioc0rlWMaJlxzVW/UmMlRzSLJyasKQ64rpaPMRzy73dlPrTJ7baGPtWpNGI2J4xVWVvMB9AKYznL1CCWPpmsib5jgV0V2vmScjAxWd9iBIx3FS0WmUYlUrgD8apznbJ1xWu0Gz7v0rEv0YPUs0TBZueKe75Iyarwg5xjFTcKcmgqxZRicYFfQ3w3tfI0KA9yoJr59sl8+eKMcbmC/rX0x4Vh+z6VCnooqaj0LprU12Iwaru3FTMeaqzNjrXMdcUQSP1rOun61amfis26Y07m0UULmTaSQa53V7ghW55rZu34Nc7MpuLxYxzzzXLVbeiO2kktWbfhG1OwOw613lrGAoNYuh2whhRQO1bwO1MDrXTFcsUjzK8+ebYjEZNM6mkPWkpNmSQH3pMcD0oJpGbtQUIcdqjJzSsaaKYDWqM8ZqV6gY0xjXf1qEsDmnsaiJoAR8VCwp7HJqJjTAhlHNVXHFWJGqu5pFIgfiq8nX2qy4yc1XmYLkmpZa1K8h61nkg3DHIwP1ouboljjgVkz3gDdawnUR2UqLZsttPU1t6RNHDauoxlq4Nr8jadxyeBWxpMkknzEnaPelCu09CauGajdncQ3GwIo+915qw8277/euZSeVGEmSTWtBcpNEC+Ax4xXfComckoWFvQmQF6Y9axbwAA1qXKhehyO9ZV4eDTlqaUzKv+YB69aw5FHOeta9w2QQayJ8b81yzO2nsQqdrcVI7EpTF6mnOeMDvUIJlRz89Bbmmv948dKjaUKygnljgUEsnzzTHbGaQtzUMrcUyWUNRk4bNcL4jmydtddqcuFNcBrMu+c10UVqcmJdo2M8Ud6KkgTzJkUdSQK6jgPb/AIT2nl6UjY+9zXr+nrhBXn3gC1+z6TbqR2FeiWnCgVzQ11NpaKxpxGpN2OtQRkAc08EHrWpkSM3WoZG49utPzyM8CopGGTgdallxQ0cg56dKQ8CmAnnnignHWkU0Rtjdk9KY7jBxSSNub0FQO3ekOwkj9arFvenSNzxURK560hpHPhufrUsJIziqELs2M9quxNnkcV2WPJHTqHT1NUQmGC9u9aaIWK56UTQKoJHU0ho569gz83vWc5K4HviukvICU47VizRAMeOM5pFJmRKznscA1mXJBY5HJNdRLCnlNxyKwL2ICdiaTNIszWBU8DioJWx1NX7kArwMZFZlwp5wKk0Rt+D1a78QWUQ5G/Jr6h01PLtEHtXzv8IbE3HiMykcRL/Ovo1BtjUe1Y1Wb00JK4UAdzVSYg1LOeM1VlOEyawbOiKKlxLzWdcyZBqzcvjrWXcuc1LkdMEZ9/IFBzVLQYTcXxkI4zTdUkzwOpro/DtkIraNscsM1jD35+hvVl7On6nQ2SbEHHSrLHqSajiHApWHPJyK6WeQ3qCnLH0pvOaXAFBqRi9xTWpw9TTTVARtSdKVutNNMoaxqFjUj1C5pgMY96jIpzdKjJxQMa3eoJKlJ9aikNA0VpKrOeanlNV3PNSUhkjYBNZd/KT8oP1q9cMAhJ6CsmUiSQsxxGoyeaxqytojeitblJ42lO0Zx3qnc2gUn2rUYDqOBUEihlP+cVxNvZHdGWpzskYFwuegrotJYBeCelZV0iKhY9qt6ezAqAM+9bU1Y2rvmgdTbjcEB6nmrl0ixQhl6is20nKgZ5xxzVu4l8yP612rY8iSfMMW7EkLFz8y8D3qjcy8Gq8n7u4wPu46VFcvhevWqjNtamqik9Cjdv19qzJ2+arc7ZLZNZ8rYrOTudUQ3YpwbHJ9KrM/FBYlBzWYSQjnr71Ukh3XMch6LVoiomPXHancgczdaqXMnBxUzNhaz7uTANNCZi6zPhG5rh7p98zGuk12fCGuVPJJrtoq0TzcTK8rB3rU8N2/2nV4Exn5qy67D4bWnn6v5hHC1VR2izCKu0j3nw5GIraNfQCuttvu1zelLtVa6OD7lZU9jWe5dToKcW9KYOlL2xxVkIeW3E4pj89OmKToMUhbtSKQ1sDHaoHbP0qaXGQO1V2Gc46VJSInbvUMzn8qkl6/Sqsrc0mWkNJ6jv3qLPvmk3c+5ppOD0zUobRiqoDADinowVsmqvmHcCDxTmau48UvC4AWm/aC5wTVJVJxnpU8a96GMleTcpGPrVGdFCMSKt4BBFMmjUoc+mKkZjswIcdiKoXFqGDOe4q7cx44T3poiZ7YZ6AGhlJnNXMZyMelZkpAIyK6Foi4+nFYd6iq5HcGoaNos9L+B1sXnvJ8cFgBXtbnivM/gpaiHQTJjl3LV6JM3y7fWuWq9TrprQinkBAC9B1NUpJe57dKsT4ERHrVSfHlj1rFs3iijOxYnNZV9LhSB2q/dS7FJrnb6csDjqa56k7I7aULkVnGby9APKg13thGFhVR2rmdAtvKjDMPmbmumt38vB7VtQXLHU5cXU5pWWyLjyCMDJwTQj7+e1UzmWUse1WkGOlaXucZIAd2c0p60A8U4UIY0jikIp5OaYTwc1QiJhTCeKkY1E9UURsc1ERUhHNRmgCJ+lRMaldhUT0DImNQSnipXqtK2KRSIpDzVdj1qSRuuaru3FSWinfyYTaO/JrIuczMgDBUQ7m98dBV+8kzk1llh5QUH7x+b3rlqu7OylH3SRrgswROAP1qtfyFYyFPUU9E3HeAcDv/ACqpqDYjbJ+asbnVTS5jK1GZtwjB+XHNaWkySAJxnjrWHd5Nyrk9utdRpgAtFY8EgcV0043NsS1GCRqRvgDNWFkJHJyBWfhtqnsDmpFdiuK6LHltEl4MjI7VnzyfpVtmyrZ9KzLr5GweMjNLZlQ7FS4f5sCqMxqeRs5PaqczcE9ql6nREjZ/l+tPXJGewqLbvA/u9/pTi42GptYcn2HFuM5qLPWmNJwBmm7+MUXMwkbAPPWsjUJQFNaFw+F61zmr3GFbmrgrsibsrnN6xcb3K1lGpbqXzJWNRV3pWVjyJPmdwr1H4XWmyAzEcsa8wiXfIqjucV7j4LtBbaZAuOcZNY1npY0oq8rnoWmcY+lb1qelYOndBW5bt0xRDYqZoClPJNQo9PyOMc1TM0hQecntUbt8xpWJ55qNyARj0qWaJAxB+lQs2KUnJz2pjt6UmUkRyNke9V2HrUz428darufXtUjREVG+m8elLupPxP5VI2c2ifu80q9cdalUZSq27Dn68V6B4pLJKFBp0co24J6VVcZcA011ZUYjvQMtLNljjoaV2LriqUGUwG69auZ9KTQkRm3CkA9O9QuQihB0zVlmLA57cVnSlwxUjkmpKKF4hG/Z3asS9sW89m6nriur+zEI5I96zrpHiZnK5JHHtSZrFnrfwzt/s3hq3Vvv4yfrXVyDgH0rD8FRmPQLXPUoCa6BgFGTXDP4md8dkUZfm61QumwOK0rojJxxWVc8nmueRvB9zK1DJiyayILdprldw+UcmtW+YuAoFOtY9sQB+8etY8nPLU6nV9nDzZat1KbcDjOBV8HcQBwBVNMKM9asIc49K6bnnN3ZbgGCfSrK1XTtUqnFNCJgaduwKgLUhfirFYm301mqPdTGamOw5jUTGkL80wuCDnrTAUtxUbEUMe9Rk0XCwjdahc09mqB2zmgZG7VWlbJ+lTSGqcp60mykQu3WqdzLtRsdTxU0zYptjCk7yNIUwo4V327ieOD7dazd3ojVWWrMWZZXcnB2qMnA7VSiQswUc966K6hDCeGJQqbwnm7y24gYx9Ceayhb+RMwcouX8nDHkHufp7+9YSptbnXCpdEa/L1H4A9azdSUlW9TXQC1GXlZQqjhR6+4P51k6ko6dPWplC2jNKVRc2hy1w+xTnr3BH5V0mlzebZK/Vgozx0rm9XkRI22DB6Cr3hW5aeylUjGG6+wropfFY6sSuanzHVht9qSMetJbj9wc1Wtpc2xUduOakimBXArdHmDZZMAg1nanKGmJXoABVi5fk1l3jfKvvWT3NILUrSP2qvK3GPWlkeoS3z80I32ElkK8KcZ4/Cm7sLzUUzfNTS3y1NrA9hztz1prNgCoi2TxTZXx3oIIryYBTmuO126ySAeTW5qlxtU81xd9N5s554rqow6nDiqllyor9TS0mKD1rpOA0dBgNxqkCY43CvetHjEcca+gFeNeA4PN1dWxkLXtumLyM1zVXeR00VaNzpbEfLWvB1HHasiy45rUgPNOISL0ZAX3p6tgVCvJp2fWrZNhQTz78U3A5zTzwKacfj9allJkbthahLcYPWnSntURYA8/SpZSGk5FQEj3qVx39ajx1zUspEJIBz2phc+hqVwMYFQ4ouBhJu2lcHJqCVdrgHsK002YAqjerkEiu08Urb/AJz71YJBjGe1U0Uhxmrm3EfuaYEDY3ZFTWzAjDVCsRZvao3LRsffpTEW3dQ+B0qw0CFd5XnFYjTNvBPrWvDdLJGFpNDRPtjMOSO1YOq/NGSBxit1EEjADoKp6tCkVtjFSUmen+C2LaBak/3BW5OCeg4FYPgnA0O3X0UV0junknjmuCa1Z6KeiMuXnJNZswLPgd60ZAzE4qk67GBJ6iuY6EZfkFpsnoOamICjJxVqWMogJ4JOTWeSbifIyI14GO5oStoY1KrmxzTKuE69yavWhLLuYc/yoitoWAzjrzkVaYDbheAO9VYhDlYD0NODZ6A1DtGADk4qQYySByapFDs80xmOadn2ph5qrjQu/imM9I3FQuadyhxemFqjZuKaWp3Cw8uaYX4pme5prHmgQ53GKgZutJI3FQM9Fx2FkbiqsrU+R+KrTuMLj05qRohlbJqlcMANwUHbyBU7vVSc/LUM1joRWerS28qDG7ahRQBkNnJ5HfqaiheS7SKSV1NvbnHTkqTzj1Pf6VqeCLSK88WRQyBt7RSPEQfuuozn8gR+NUYJktI9Yt5X221vMzQqMfeJK/iMcVUIScVzPQ1c0m1Fa6fiaN1NuufIQhoYELKccM3AwKwrpA7Pu6CremzNcWz31yqJGAAcjJZwOBk9OM9KzZZMl8dGqKzvqVTVnbsc1r6qLXcmDyfwqTwpcCPTpYtmD95m9fQVF4gxHb+WpyWOaz7K8CHyo1wpAyfXFFKVnc9Bpzpcp2VtMAhXIBC5JqezbO5vyFc/BeZQgnrV+zuSyegFdEdjjlBpMt3LAE4I4rHunyetXZZeGPrWRcyfN1qGOmiORskVEzfNxTJXqNn2nPYCkjZiswLsc8dBUMj9qRmxGD3PSockmghkoPAqtdy7Qeakd9ozWLql1tU804xu9DKcuVXZl63ecEA81gZyc1JdzGaUnNRiu6KsrHkVJ88ri0EUtLVEHd/DS3+aSUj2r1iwGMV578P4PL09W7sc16FZngVxTd5NnZBWijes26CtSE81j2n3hWrCen1rSOxMjQXgACpBUMZyBUq8liegqyAJAB9aidjj2pWfmopHzmpZaQjkEEjmoSc9e1K0gGM55qFnGDzUlocz8YqNmzk5ppbuKjLYFTcdh7njrzUJIz1pHkznFQeYB161NwSM5Ce9Ru2TjtUDSsJcDpUoBIr0DxBPL+bJ6USORn0pjy4GD9aemHwCOnWmMSKTA570kyeYRjtTZBtOQKiV2UYPegQrW4JPpSRJ5akU9ZCWCj8aSSQA/SqQi3Y3G19p61Z1S2EsJz061j+YF/eLWnDdG5iKA8haloaO3+H8pGjiMtkqSK6lTuyPWuC8ETeVM0BPHWu7U9celefWVpHpUneCGMNyMB+NVltzcTxomdo+Y/SroQ7cAZzUkTJaPg43N3rHluU5NLQo31vuXFZQgKthRgV1hhDjOMiq8loo5C0SiYwdjETKDFLu5q5LbY7VUeJt3AqLM2TTBT3xS7qhZivGKb5tNFWJ8/nRuFQGXuaQycdadwsSs4IqJ6jZ/SmmTJxTuArelRuDSlstQSCadwuRMcUwtzUjVGQCDTuK5DK1QsakfrUTdKLjuQSNzVaU81NL3qtIev6VDY0yJhVWccVZY1VnOe9K5aYaDf8A9k+I7PUWJCWwdjgZzlCAPxNYNnDLqmobASHnYySEDIUdXbHoBk1av5NtvcAA7yuFYH7vr+nFZ0Uk+mR3K4IuJ0a3BRuUHBYjHqMCmpX0ex1U46cy3Jr+eRtFhmyotYbg2lqYz/rcHe7tnrxj8WxUyyLJCpByawr4yg20cwjCRIVjVGz3ySfcn+VTxXWyHr24rKo22dSh7uhna44eVscgcViwjZMxq/fTD5snn+VZaSfvG9egpwR1RVo2Nq2kCqScc8CtyIgQAKO1c9ZANCqnBbOfxrZ3eXDtz+Ndcdjkq66CzyZBrLnf5iakllPJqlI+WxUPUIqwkjZNRyNkY7UxmzzULtukx2pWGySd+ABzSE4NMZvnzTGfHWgybI72bYhrkNWutzFQa1tavNikA81y8rl2JNdVGOlzz8VVu+VDRTxTRS1ucY4U6Pl1HvTRUtou65jHvQB654Tj8rToR7V2Fm3Irl9CXbaRD2ro7NuRmvP6nopaHRWn3Qa0oW4XHSsm1fgCtKNgAP1reJk0X1c4B/Cn7qrRtmnsSKoixI7ZFRPjPPSkJ4qORhtqGUhkrc8fhVfdnqac74yT+FVmfBOKls0RKz9elQSSnsaieTHSopJM/WouUkTmTv8AlVd9zMSOajaTAHPHWozIe2aVyrBNGu4EYzUkKgrjHWmEHJJqa1IBO7rXpHz5QuYwJwDVqGPbFk9TRfRjfuFIsm5MZ6U0AkiqTjrxUMyqAT6USFhyM81F5ckh284oArebtY4pXQuo29+tLNFsbntU1sw2EmmBWeM7No7UadM0U5/unip5JFAYdzVVlx060xHW6DOIbxZMjBOK9Gik3Rgg8YrxS1vXSUJnpXp3hfUBeaemT8w4NceJh1O3DS+ydKku1c4yB2zVKfLud55P6U8Nikb5uT9a5NzrtYv6fdAfu5cbh+taDSRMvXJrnn7Y606KZ0f5TkehrVGUqV9UbMkSyDjv61Vns9ig+tNhvFc4J5HHNWRL5p+8DgYANJxRk047mRPAC2MVBLbKi5PQcmttoFY8Yz1rP1CNsbR3rJxKU2YjkHJqu7MtW5oiDgdKjWAkFm6CocTZTsUzKR1NIZsjrU09vuI7VnzRuhOBxUttGiaZbWWjzqz/ADiBzQJuOtCkJxNHzc0x5AB1qj53PWmtP6mqUiOUsu3FQyOPWoDPUMk3vQ5D5SR3zVeQ80wy5qJpKjmKSBz1qtI3WnPJVaRsjA70XGijcXb2+oWpjjVwHEjbvukA9D9aqfKL8tAQ7ht28HODnrU92QyH1xVK2lSAuz53HgH0puXQ6aewasj3N2ZZSBgAMQAP896wryfYeOBWnq18uSFcHAxwK5i8m3N1pPc78Om0rjLu43MTmq8TY+b1qvMSWIJ4qeyBlkA5wK0UTeUktDc01WZBu6dq0pW2oATUNnFtj3twM7V9/WoryXAPNdOyOJvmkV5ny3WqzvzTJZdoJ9ag355rO+poTMfWq6HL5FLM2EPqeKZD8qk+nFCRMmOJ5J7Cql1MEQkmpZTtHX3rndbvMAop5NaQhdnJWqciuZuo3JnmOOgqoKPenCuw8tu7uwAp1AFOAoENBq9okfmajEO2aokc1ueEod+oqewqZu0WVBXkkepaYNqKB6VuWvBFY9iPlA6Vt2o6VwnomxaN8y1ppyMVlWvX6Vpwn5c9zWyMpFxPlAyeTzTyxNVy2OM0hkxmqZmSM9RGT5MVE8nFQySfLUNlJDpn447VVlftTZJ8fL+NVZJecZrNs1SJJZMDAqu71G8mTUTNk5zUstEpkz1qIuTULv1AphOe9Io2JHBHyioFZi+BWjDbrs5qrcBYpMrXqnzg5lLjJ7VCkZBI709JSflHU0btsoz170AI5wRkcU+OQHOBT5Ajx5pEKg47UAZ12jO2B3qS3g4wO1WLllJNVI5yOB3oQFedCJuegpBgHPWrl4u6MEelZPmMWwAeKoCUptJfvmup8GagILtoy3ysM1yuWl46U23eW1uN4bHaplFSVioScXdHt6SBkDA9aeD71zfhTVVvbNVY/vFGCDXRg8V5souLsz1YyUldD9o2k459KYRzyf0pQTnHtSA/eJ69qaGDR7gQv4moorh42Y5DKOgJ5qckmAgenJrOkc7towcdsVQkubRmrb6kpzvJU9t1TtNHLgk4+tc47AjIGAOw71ElxJCWwxxjoOaTRLoX2N2aNWJxjFQSx8ADpWVHqEvzMwyFGeO9INcj3YYkH3FQ0Q6M10L0sWSTiqs8YK4IFTRanDIAcj8DQ00UmTkVLRGsdzIuLVe31rGmYxyEGulkXJJ9ayb22DMSKxlDsawn3M3zj1zTGn561O9mxHy96ozwOprJpo2TTJGmBqJ5eetVmV1qHzuuTzUOZSiWzJzTGlqqZfemmTPempD5Sd34qCRyMkGkL1BI3FWmJIguDgH3rIu2IyRWnOwwazLgZOKZtTdmYl27bsdazZSQSc4Fat3HhyfUYrKnBzg9PSqiejCV1oUJyzHj1q/ozMZDsAJHAJ7VXePC7u9X9BUxxuxA5Oee57V0RasZyTvc6KYmGJUPBA6Y6VkXcoPSi4uCQcE+59az5pMnArWTuiIxtuSO4YgH65pmRvJHToKi3fM3txSg4Gai1iriyfM6r2pzsFXA6Cmxckt37VDO4UHmhK5jOVitqFwI42YnGBXJTymWUse9X9YuvMfy1PA61mCuyEeVHlVqnPIXtTlFJinDgVZiLS5ppNFACk11ngePMrue1cia7fwOpEJY9zWVX4TSirzR3toOmK27TgjPTvWPZ881s2Q3MBXItzuNe2HTPSr8fA4qnbjgH8qtrwnuelbxWhjJjt3zcVG0mTjtTXbHFVmkwSaljRJJMAxqtLPweeO9QTzjmsu6u/LbYx+b0FZuRpGNy5JPkkg8VA0uelV3EssarCCCe+Ks22nylG8zAA6mkotlOSW5XebHGab5vX1NaMumhuVOQO/rTJNLZVypIHrT9myfaRM8tgHnmozLjvWgdMdgS7bU7k1lSxMJGC9M8UcjWqHGSZ2Ucny89ahaISMc1HvGR7UyS5CDrivSPAHFVifnrVa6lG4etNeYmTnpVa6kDqSDQgLccxZT6VGzNjjPNVYpCFVR+NXYxnk9AKYFC7kkLYGeKgguCsnz9BV6R1GcjrWdMQWAH50IDWMyvBntVSOWFN4IAPUVHG3yqvYcGqV3w+TQBdjnHmnbUN8xxx0NQW7hTmrE37xRjk0wLPh7VJbC7DqSY+jA169p92l1bqynkgE14YA0RIJ6HOa7/S9S+yJbNGf3LgfgawrQ5ldHTQqcujO/YjaOhpgJY+wqpb3YnUMjA56irAPBIHT3rksdtx/mlTjriqUgG5jk5NSu+FIIHP51VkbI+U0XLihjnPBwQPwqrKQFABI+tSSn1qtKc0XNUhpkKoeAQeh9/WqEy5OOgqzI3B/KoWOe35VLNFoUsYbPTAp/2mZWVY5MgDLZ5FLKNoJxVckBT79amw2lIuSawUIyrbMYBFPGpxtIELYOMnNYcpyc+lVZWLElupqXqS8PFnXQzJKpZMEdKgkCsAex4Brn7C98hWjYkAjAIqw9426NycR4wqd8DvScLrQwlQcWaMsSlSMdayprEdVNOn1NYgDIV3EZ4Oce1V4dYimlEYPPUg1hOmEYTSuivJaulVH3JWmdQhkYqGUn06VWuJYWTJxg1zuDWxak1uUvNprycVFKVwWRgR7VXebacE81pF66mijcdM1UZiQfc0+WUc81QuLpc5JrRdi4xIrvBJFY9z1YDtV24n3E4PNVTG3DEYJ9apbnTT0IZD+6CDPX5qtWTeWGx90jFU5ODnsP1qa1kDKewHH1rSLKk9B854zniqwODnv2qy/zgZ4Wq7sFZj1NbJ3IuBUIpB+8etNb7tJnjk0McqPSnsS3YUv5cYA9KxtVvPLjIB+Y1bvJxGhJ7CuYupjNKWPTtW1KHVnBiKv2UREliSepoxxQOtPHIroOERRS4pRQTQAgFFFJnmgBMZNd94SAS0XFcF3rvfC5xaoKxr/Cb4f4jtbNjgVu2PAzXP2JyRXR2Ywg7nNcsVqdkjXgycewqbzMdPpVeLO0EdKC/wA3HStzGw6U5PFUbqXap5qxI+BmsbUptqc9azmy4RuRs81xcokAweuT2FakGkImJH5kY5JPao9GhZozO3V+BW/bQcfMcmilG/vSIq1LaIpRWwUAqvAokU4x0HWtUx4+lVZ1GeK6LWMVK5RLHA9AOlNe5OzaVyO9PmHBqm/XmpZaimOubgygKOEHQVRMaE81JKQBxVMsc96hmkYdi3E5I45zSyxsce3WkjjZDnHSr0exlwepFdh4hm/eJH4UjW52gjk1eeFVbI60gUHnNO4GagKygVo7CIenJqpMvlyZI6GrsVyrLz6UwM26I3barrESN2PpV6UIzepNOdlWMKBQBRgIwQ3fmkuYlK81IFxLnsDzU0sQeMnPTpQwM0RgqAgpshZVxyK0rS3VEO7681XlCu7KPrTQGWzSSsMkmt3Trny0iLv8n3SOwNZpi2E+h6VPCq7cNnY3P0PrSeo07G9pGsT2F4YnDNEzcd9v/wBavQra9WWMFCCSO1eZWtzEqbX2l3+UH1qfT9cfTbpldi8RI4z0rCdO+x006ttGeizMCwzxUQYDnqT07U2ORbiFJAR8w60kmQQOorlaaO2Ek0Mm5zz8x9RzVSUYOMVbY7lAz+BFVZVx04+tSaxZUkI3H0FQkkn1qSUH8OtQk/nQajJearyDHNTt97moicknrSC5Qm4zVSQZIq7MME1UbgfhipNkyozbWJX73TPWoZpnZgxbkDAqw8eBwc1VkXByaRSaIZW3bQeg55qnCwhnSQjIBPA71bPXJ/Cq7LkYPak0PyIoXbewY5D8EnqPeoZXZgdpCMTgAHpT29ahlPIPHTHNS4J7jcVe4yF5I4pnZyAvCLmqUskxQZY5PNTyyFl24AweKbK+7y0GBgZYkd6hU7AlZ3KU7OBjdnHB5qlKck/NnBxVy6beuE4AyelU0iCJyScnmnylxbE5IJH41M8mY8jk8KKZ2KkDB5puCmQOTVAyvcZ3BR171PbRlEAP5UqJtOXGWPanM3zH1qkribGyg/57VCR8pPfoKm3HBqGWQIv8hWiRm5WGSKSox0FRTTBUCjr60S3J8vZ0GeTWFqd6VykZ5PBNawg5bnNVqqKItWuN77EPHc1m7aUMT1NL1rqSsrHmtuTuxApJpy8mnnpgU0ccd6YhcUoFLjaPelHA5oAawAFMI7088nmkIoAZXbeF3H2Za4quq8KyfJt96yrK8TbD/Geh6celdLZfc5rmNMbIFdLZnhQfWuaB2yNVSQijioycHJppfNNZu3etGQkNnbArDv8ALzIi9S2K0rh8ZrNs0aa+LnkDpXPVd9DWKtqdTpaEQIp6L0FbES/Lk1S09AIx6Von5VAFdVPRI4Ju7InPH8qrS9TVlvX0qvJ3qriRRnOBVKTBq9OeTVSRQcmobN4mfOvWqbA54q/OODVQg9qhs2iasjDGMYNV2Y5yppszkjFNV+QG6V3HgExkZ0PqKgHmIeR3qYMFSpoCJTjFMCrP+8UjHNRW6HGOnNX7iPygSKqRyqJMY600A63t8z/N0FW5IVxwOahkuAoyBUSXm59pHNAFS6RhJgDg1NvCoq+oxUtw4zuxTIoRLlj9RSQyhJORKq9M8Go2XZODngnmp9StCPmU89RVJw3lZJ5pgF2xeVFQ85xVhADDuDcA4qpbIXyxPzEYFPwY2VD0NDAiuSX3FOCOntUEc7wokjneV7HrUkxYSDb06GmuF5V+KVtATN7TfFNw1uijajRjGP71dpo+rx30I3YDdMdxXkrgRSbU6Gp4NTnsZ18skYqJQUjaFRxPX3kAOAc0hfKEAnk9q5fR9XM2wSE7W5yfStVdQilmKK3fp3rllBxO2FVSLNwPYEn2xVN8gZPSrDSAg85zVaViVwTgAYArFnRGRDI3SombORTpyAgIIzVV265pXNVqPuAFYbvT1qi/3iamcknJ4JqCT7xpFJ2IXPGPxqu2SealfrULkgHBx9KRaIHUCTBPC9aqSc5PTNWZMY5qq5Gc/wCTTKTIpenrVeXGMZ6e9TSMOc1XcE9PqaCkyq+AeKgfGf8APWp5OMj+lRgBSWPVRn1xQVcrSIxI4OO9QMMnpVmWffkED0z3qsXwflpWC46RemcZoSRFPKk/jULMW5PWmsec9qdiWyxLIuwAE7m55qqzL2IJP6U2VuetRgguNxwKpLsQ3YkLgDcfuj9TVGeXOSade3KA5LAKBxXO3+pGQlIThfWtqdNs5qtZRLN/f7TsjOWrIZi5JNRgnOTyaUGulJLRHBKTk7sdjBqQD5aZUgPGKZJJGABk9aNuAWNNXrUr8qBQA1Vyu49KaAWPtTt3RR0p5cbcKKBELZJxTT6U88DnrTSMCgY0AZwa6HwzIBLt6Vz2Mc1q6FdJFcqXHtiomrxLpy5ZJnqOlMDt9K6e0PA9q47RZvMINdfZHiuaKO6TNFBxk9hTJPfgCnjpUcw3A44A5NN6BFlC9OAcUmiRlssRyzZougAh3Vp6RDtTkfSubeZVSVom9Z/cVRV6ROp9BgVUtl2ACrTvwBnrXZDY4HuQvwCKqOasSuMVRlbrQy4orznJ61VkOTU0jc9aruc5rJs2iirLxxVVjzVmbBzVVsZqGzZE/OcEVI0R2k9qtyxAYYCqNxKykqoP0r0kfPlm12EYbBNDTJE+1ao2xfJJ4zVl4xnJ60wJpZg6ms84Eox0qWaPgFTUEkny+9CGaHyFOnvUcaRbyxxkVUhlOMH6VKYjng4pgOuXXacDpVe0uSXCA9OKkjjJbD89qouv2e6yOM/pSQF+6DshA6CslI3aRkY9ORWx5wdR7jFUJYXW7UjjccGgCrFGyTEfiKku0bHHXrVi7j+zEOT161QuLzgYGcHFAAEbOcdarXcRyGbjPFWra8V8AjlTUeoypIdvHHIosBSWPygrk5APQ1ZuokuFSSIHI645/CqNzMAAqHINWLIhgCGIPqKLAXIp5LaMFmYKjZyOwxSR6qBcRy79pJ55qjdXEjwvC+OT96qDoVUk87elK3cu/Y7i31sg75WVx2A61ppqsUsAkJ2j0avNYZ2ClxyMdKt2Woma3dLiQ4Pas5UYyNIV5RPQBdRyrlGFMd17VxbXT2tvH9ncvk9M1pG5uYvJabo/v0rmeHfQ7IYpdTaduc96id8jB/WsKXXoo7sQtkAnqR1qwdVhkY4IHtms3Tkuh0RrRfUvMQTkVBI3pUQu4yu4MMUSSoYxtP1NQ1Y1U0RSnNVXPf0qSST3qrI5PFBomIx5ySeKh8z926jksaY7H8qDIsSHODI3YjoKCnIicbcliOO1VppQVVE+6OWP940sjlySzZ5zVdiPWgObuMYmmHjih5EUnLCqst7CnVx+dUotidRLclY4NRu1ZdzrMCZ2tk1l3GtuwxEPzrWNJswniYo35plXkkCsq91SONSEOWrDluppT8zVDkHrmto0ktzlniJS2LE11JPlnPHQCq1LnOKK1OcWnKKYDUgOKAHAU9R61HmnZ4oESL1zTmbsKiJxUqgbcnrQAIOppY+MmkBwtInLe1AClcnJpNpbntUx+bpSMAq470AQH5uB0pIn2yqR2NObCpgdah5Ue9Az07wxch40Oa7iwfcBXkHhK+8uURu3XpXqelTBkGDWDjZnXGfNE6JDkdaR/u4qKFvlHvTpGwAPWs5lxZWZDJdIuMgfMa39Pi5H61RtrYopkYctzWxaIUjBxjNYU463IqTuWjjnFMeTatKx+Udgagmfg9zXRcxQ15M9+KqStyaWRiKrs/XNS2bJEbnrVdzgVK5z0qCTnNZtmqIJG61WZue9Ty9Kqv8Ae71JojbLFlxVV1CyfOOanSTY3zDjNEiGcZHFeofPETldoKgVDJJmL3NTGBk4akEQLYNMEU4/MckZ4FSxwgDkc0+aRLc8U37Uj/SgCEpmX+lOml8vHrSCQBsinSRB0znPemMVZwYie9UJZFklJP61esoVlDDsKo3apFIy96QFjacgoflHNJqDM6bk6gZzVWCU7AoPPSnXDPDBg8mmBXnle4g+Y9s1lrJiUhuhrQtmLkp/EaiurFhLx25pDGoqk7l6ng0x4soC59qBuhfafrU8aednsp5oYijJCqRk9SKhgkKbgvfpWo1qJgQp68VRa2MMgMhxg4oGULlpHk2nOGpZWZVCdc8GpnmUy8LkKetJE672Zhx1FAGfKkoTagxUcimJQgPzdau3N8oJKr14qOyhFwDNKelACJcSL5QPIU5B9K1brVYrlIkYklTyPSsqVgjMByO1UXQq/mg9aHqM3NQQte28ibeOoNN1VIIs+X80koC8dqyjcySKGcfd6ZpFuC86SFgFDDIPapsVcsX0V3BEsXmMu1c9etT3l9cRaRbrGCJMfNnvUuqSx3eqWrKQ6qB8yng/Wi5MmpXpSNQsK/KRQ0upSnJbMoS3t3b2yySYZ2HQVHFrE62xkmjOT0A61NcqrXZs4gzbMBTRdwSXUhVVVfKXDcdKh04mirzXUqSatMLNZpE2lzwM1nya3OELsrfnU15ZPHJ5RYnK/KKr3Vk62vlTALs5Jz1o9nHoilXn3Kia1cyZwnHrmqsmr3TsQoA96utAsdqpRcM52gHt70n2KGCBicGVxwetPkXYftpPqY817cytt3/lVaZJSfnZj9a3be0gETzONwTjHqaTT7P7Ussrj5F9RTtYnmvuc6UI5xTSDmtma1ae58uJPy7Cq8tqVkEYwWJxQFzP20mOa0LqyMMmznI61FJaPGAW780DKtKKkaFgucHFM2kdaAExThRjNOWgAHr2oByacSMYoHpQIByaeGJOM8Uz7vHelI2D3NAD/vHHanbcNtFMTgbqcCep60ATEheF60xxzkmliUkbjQAXkGelAEbKM5NIy7j7VPIo6CkIwuBQBFC7RTKynBWvT/CmqLPAgLcivM3Gxfc1paPfNYSq2TtJ6VLVyoyse3wThhViI+bOinoTXJ6Tqi3ESsGGcV0FncDepzXPNdzpi9NDr1QMVXjAq6cAKDgVz9tqAyMnHvWlHcB+WPvTSsYNNblt8HkfSqsmM+wp3mYGT0qGR8qB3NJjTIpAD9TVKYFQauO3J/KqrvzgjANZM0jIq5wOaYz1PKoY4HBqnKpUnFSzVO4yRhVRutSSMR1qq8nzUrmqN+GRHHPerDOkXI6VlKrA8Zz6VMCSh3dfSvUPAJ5rsOCCOapTTlQdppp4lweh61IY4wuSetAFWWNplBJqJISoPYVpRgbSB2qrJjfgHimMZEFz8x5qXeSpVfujioGiDNndio5JvJO3qT2piLdpKsO73qCeLz5t/rxUC5lG9eDT43bpnkc0DI3tmSQFDzSSSSE7WWp7i42JlRz1qrb3DOxJXvxQBDFDILpXPC5qbUJTG6v1HSpL5mK4QYI5qGe7he22PjeR+VIZR+0q4BccDrTorsBNqjGKm+zxG3z6ikt7WNnBzgd6GBH5phDbGyTyBVG+uHkTD8E1qrbIbnOeF61m6qq+YcfdHTFAWKtsAqrnBzxU0sKsqhD9aprMiZ54PSpoJCRvU4BGMUMZT1Ly1YIBzUlo3mgInAPWmzRbwZJKWyiMMbODweRSQWCeICQIDn1qK9ULhVPSmBpPOLA8mpEMb5MrfPTAoTSszBAMKacERZAuevWnOywliwyO1RRrvBlB69KLjsSCQrchYTj1rat5khuItnLNy/0rmEV0lMu7rV22mCxvJKTu6Cla4zcR40vpPKG5pDz/ALNAnihnlk6zE/cH8Q9awba4kTe6HrUi3JEjSPwT04pWAuWYlvtSlKp8rfdJ/hNU7uNZFfLF51kxIMdhVzSGZJnBDAScsKrlS98wU7Aufm9aLjM+aVr2eSaKHEI/dqvp71AkOL+SMEssaZH1q/Yx7bh/nzDnLKOTUSZcXaxxYUvhC3U+1A7kLovkJG8e1yeQOuPWriIljpMsikOJPuqPWrej2TXhupZZW/cJtKvjJPoKmFtbK+w/MnlbgM5A9aBXOe0mKVbSaYxlHb7r+1Z9rB9ollkc5KdR0/GupF0s8ItiNgQYC9MiqjxxQW8jxgiQsQcdCKB8xjx2jyyxRlsPI33j3p+t262zJCuS2RkelWYI5pW84gYc7Ix2A9akgjF5dXJZiXiHB9fpSKuZl4quixxqp2jAx3pLrTVtrEGX/XN/D3Fa5tY4xGD82eXYc49KZ5Iu9SCmXKKMBj0HtQCZza2D+Q0jcL2qv5LLnj3rptWgWORY0zgfwDt71DPFGFEI2l35PuKRVzndvGaRAMk1uvpym3PQE8c9qoNY4iZlI2g9aLjKPU5pMgnmp/JbbhQfrUZjxnPWmAhfOAKc7KcAUwLgHNCKOTQBMjZYDOBUpZVz61VBxljT4cs+5ulAE6nBJPerEYQ4PXFV2KnoaWAlnPOBQISQLvJPanqvn8LxilnRSwWPr3NMVSjbVPJ60Aa2mag9pKiIxIrttL1lJVA3jNebq6x9OW9akgllhfzFcj2qZRTLhNxPYYbzcow1W4dRkTHzZX0NebaXrb+WDMcCt+31NZQNrA1k42OiMoyPQbPV45sKxwR1Bq6sqyHKtxXnAu8kAHmr9tq0sHIfcOgBqLA6XY7mTJ4HJqKRMZLViad4giLqsrbG/wBrpVvVtds7cRxhw0jDcdvOBS5WzPlknaxM4I+bNVnJzzzk1HDqkFwBtZT34NSB0Ykg5GPWs2i7tbkVzsCL6mqZVQef51PKd7HP+RVZhk5OeanlKUjcmOw4AHsartKSPQ1O7rg5/Ks5nMkpQA7fX0r0zyB2/L570TnIAzihQyNtbpUj+W0RB60wJbVQ8OB19azLrdDN97qa07NwjFf1rP1SJpJgUyBmh7jBlYKJAapysGmG6rhb92FNVri1LpuX60wHpIR9wcVGC28+/Iqa3HkQEyjmozKp5OMUDE3Kh2yHNSQvHH0GcUyaD5FkHI71k3VxIsi7Qdp4oEas0rOjEDgVmxRLIXkfOO1atsYzahW+8eOaz72J7Ypg/ITzQMI5VIZF7dKgujJHna2M84q9LDDDbiUHn0qjJuuG+UYA5pDQyKWRiFUnLVV1QyQ4XbknirMQMFxl26dKvhI7l98g4xxSA5aKPOQ2QfSlnDLtVcgdau6iRBPuVcKeKrq/mglxx2oGF4+YEAxg9aitDvdQX+UdqSe2lYZUkr2pfJ2R+YnDd6LgF/JGJtkfBqvcKuFOeTSNH/y0YZamqjMuWBOelAxtzKrCNEGT3okxtEcWd1WraBVYsQBn1pUt8bpcgEUagZsUcksnlMMEmr1za7VSJuM1T86VLkSEfKD1qzLK0zh15FMHcr3Y+zKozxTWcSBQOtR3W+dueMUqR+XH975u1AFt7h7dkxU8EsPmeZITuPUA1UePMO8ncabGF2bh1pPUDZ0+4t43mZYgWPIJ6H2IrNt47qaYwu22335GeCpNU2lKEKT17itNVkEAfr35pWGRWf8Aot/dBGZ2+6YzyGH1qAySteS28KKqzMFDt/B6/hVuyASfdIyoGOSTyRTIngi1KV5Mtv42gcbfX60AUnRbSe4Z5C08eEiQclie/wBK0LNGu5yzL5cUQCOf7xHJpYLVri/+1sp2x5dCw646Cs61mmGqhAxdZXLSKP4aVx2uaEyQiVUVyVc5VB/CTwKrXaNDIILeMEh/9YByfWpkaOHUJI4lEzZ+TJ+8aS4S4geGDKfbB6n165HtTArSwhopJGI37tm0dU9/xqHS2H77dGDApCLnufr61fllSCAw2gWS4kQmaXsn4VF9lxFaWqP5duD5m4dZD6YpBfuMiiN3qfkLJteMb2JOC3p+VV7qBYJ9zjc8nQddorRuLRLCKeZSxu2cKAv8RPaoYI2Ecl0u1j92U53Dceg/AUhmdJLLcbY0x5hO0HFPe0KWh7Qpk89zVyGKOO9+zyOu/blSpzg1DMks11t42Jj92P8AlqfcUDTEj09vs0aldsjjezA5BX1qj/Z6+Wzgcvwv+yPetS/kENm4Hys5whJ4UdyfYUt3KqxRIAjNGuZJB0b3pDTOefTcyMgONvUGqTWkhlKAHC8mt/zNsQZAfn555qWOzP2aV3zG5xgdiP6UDucs8TbgoFBbam3GK2YIVZyxX930zVOeyLXQjz8x5weKdxlFmwvHWnRyFFPHNOktXWQgA47Ux4nDhWFMCxG4EZc9RzTIWySzdTzUM4KHYPxokPlrtB5xzQBKrFpST0o3tu578AVCHCpgHk09XCjHc0ATSTt5Pl55qa3vpbNAFbOeTVFcA7mPWkJ3sfQUAdLDroEYLGtG11ZZRndxiuI+8cHhRUomYbQhwBUuKNFVkjuBfKc4alF4uODXENdyoQqtUp1B4yBnJqXT7Gqr9zslvSrAq5U+oNXYPEM8JwxDr+tcJ/aTAAmnHUiFye9T7MbrJ7npUfiaEqQ+QfennxFbE8N+leZDUBjJNKNQ9DS9kTzxPoK6iBbPfuKYqRBM8Z9ailaR1JzzVF2dTjOD1NdKPMLQI8zDHjsahuCpmAB4qBGZsnPerCxqQTmmAm4xklehNSk+YpHoOlQJu8wjqBzViPlGOcHpigClGCGbeMjtT3uwF2gZxSCRvNII4qRbbJ3AcelAzPur0mLaw69TVaPMybQeOlXb60G4Dt3pRFFAgC96aAYrlU8onI6VFcIjR5wOKklYbvl781FIOMA8nmgBrzRyINhwy0G48+IrIM4qjFiKdkbqelab24gtyTj5uaAIEt3lgJJ+UdAahUqkZw3zDg4pPtcyt5MaE7qiitpWuhuGFPWkxlO4W4adHUZFW53liRVU/lVi9YQuqk9eDSNtMO7qwoAoar+9tQNpLUyJT9lC7OcVpWcf2gMsmFVeRUUoSKQojbs+lIZmR3TNKqNwucGrF2ImYLEc55p/2SIMSRgt604RxIuQRuHFAGeUPmbccHgmkl/cMCMYzVi4hlRSwGVPSqNyzSR/KpyOtAEt1IkrKIzhjUE6yghAeGqOxiaYMztgrVmFtsrF8uAODQMqzAiBowBkVn25lJ8pM5zV+3gllu3lAJT0qMM0d9vCgYNAxtxGylY2GGNQygRsMnI6Vbvmad97jA7GqS2zzElSStAIW4mMUOIznNQgu0HGasC2XaSDkrRbHzGaNgBQBVj3k4C7sVpQ3Upj8r0qGDbFdEfeWgyxpc7geD2ppgxzhpphubB7VphI2KAKSV6kVniSKSUkcEdKuWV35e8EDnvRYRJaOEuJEXfhxwA3AqtC/wBm1K5aUKSq4BBwSTTomIleVWHFRQ7DPJPNkk+tJoaY/RxMksrEqWkbjeOYx61Lp0Bu9QuGuCxmiztJHDHt+FSWkz73niVSBnAPTNJYXU0In3FI4hzgdSfT6VNmMLuAAs8f+pJHmKo2tu/wqTyIIL9EmmJMEe9GXkepOapRSGfUfNmYhVPQZO+o7l3eS4VYh5DEBGwcr7fnQMs3ty04R4FTzQGMjkEmMHv9cUJbJZ2kC3EhW2mbzNuOT6H8apy/aJb0Qx8y8K0Z4yo/pVjUJBLLDFAzS7lJLZGAx9PYUAVpokP2qRgWcEBW7F/7oPtxRptrNdXwnZgWiUyEk46ela99bvZaba2vleVKuXRwOSPU+9ZOpLPaxxTTMUlkA3xJ/BH2/OluBFcLHPdxKzF4ZWDSEcHGen4n9BS3No1y8nlgqA/lx88k+p9hWzBaQ2GnPfN8zSqditgqMjGaybGRxJH56pG6D5cj5fUD6mjcCa4iPlpIIsMOBHnrjgE/jzSJHboxiScSxMMyN0Jb1+lQ3UqTODavmSRtrKBxjvUF/LHC6mzAaJzhMjlsDq3sKLDRbkVAH8uLDZ2j0kX1/CqMNus4muEdXAOPvYYe5HoaUbvLht2uAYiSzOrZCjuv49qbZiKS1keHPmNKVx0BUDr9KVgQkBU3UfmttXdk56H2FNcwTXbhF+UtlmxkD0/CoXiZlV0z5LZCs3fHUmrOn26wSPg/vNucdQwosVczdRhSOcjgySNx7CqV9aSRyAlfyrdjiRr43DZKx85X+D0pl+WlcyOoZi235Rgk+1A0znPKKkNJwD0prZd8ngCt6+sx8rsMySYVABj65+lVb2wWJgqZJAyR6U0wMpyS2BQW2jaD161ZNjKDkjr0qAwlDzzTGNZiO/NKCAoJ6mm8b+aQncfagB4JLFj0pAcyZPSm5IJFP6Jn1oAGO5wMcelI3zPim5PXPNOQgBievagBG9ulOBGBmmZ60oGRmgD6SclZGQHiqtzEN27PNFFWcaIoU3MOcVZRQMnrRRQNIYeJAR3qwYgq7h+VFFDArXYCoWA5pLKZuh6UUULYS3EnbLsDWdGDLKwY8DkUUUFLcZIu0nBpPK4VtxzRRUtsQ5bOOSUMxORT5HJkMR5VaKKaKKlu5W6bpxUl1uLFgxBHpRRTewBdxI9oHYfNjrVOJiIsZ60UUW1BjEdlQkGq0i+XMjqeaKKTAkvVaV4xuK59Kgvv9GQBecjvRRVW1GiSS8eSzRcAYqrdL8hAOOM8UUUNA9CvbYjiwB1rQtkX7OeBn1oopJAyK7U2qbYjjf1qF4YyoLLlsZzRRSQyoZDLGysBgVFuaGyYoaKKYFa0YmJ2JJLVNCix2zSYyx70UUhsfCojhdsAkis103KXzg5oop20EiW2jDsSScgVJasXkZGPyg0UU4gaEaBDwOCOlUNRnYREAAUUUNCW5JotzIbWRSeFqzpY81ZTISwxnBoopbobJ7VjA5MfHoPSrTxKddNuCwRFB4P3jjkmiihpAmZ01v8A8Th08x+nBBwcelWYpFh1F0SNBGyg7cdDRRUWGQaxcTXOoiJ5W2oVxnnk9/8A61M1k4mtWlzLJPhnYnGR0x9KKKuS95oYXV48fnW4AMb4IHpnjH0AqrtElnKH+byTgE8kk9z78UUVLG9CTTYI7Ww89QWkmZhyfugcf/XrKfdxGXYhpPJX/ZU8n86KKVgRLcWiRQyKD8zSFSwGDgAYH61oxsi6dbBI1QrGYiV4yO5+poopIA1G1jiuwhG5REHPbJxxVW8At12/fKqJNx4PsKKKaWwIi81o4IJRjdI+XxxkelSWCfarwwMSoB4I6g9Qf0oopPYbI9UndPOuTtZ2O3BHA9SPrUYTECxxnaWZV3deOtFFDBFqWJBp+9QQVYjGeCR0NZ8Fmk6yeZ95ecgYzRRUvRFIpTWMaWxcEkk4+lZ8kQjJAOcUUVSGQgZNK3XFFFMBD1ApSeKKKAHYwAPWkIwaKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_42_22177=[""].join("\n");
var outline_f21_42_22177=null;
var title_f21_42_22178="Patient information: Lupus (The Basics)";
var content_f21_42_22178=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15480\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/40/30339\">",
"         Butterfly rash caused by lupus",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?30/8/30850\">",
"         Patient information: Antinuclear antibodies (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/5/16466\">",
"         Patient information: Discoid lupus (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/21/26962\">",
"         Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/49/36626\">",
"         Patient information: Lupus and kidney disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/30/7651\">",
"         Patient information: Lupus and pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?28/35/29238\">",
"         Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/42/36518\">",
"         Patient information: Systemic lupus erythematosus and pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Lupus (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/lupus-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H482505446\">",
"      <span class=\"h1\">",
"       What is lupus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When it is working normally, the body&rsquo;s immune system kills germs and &ldquo;bad&rdquo; cells that could turn into cancer. Sometimes, instead of killing only bad cells, something goes wrong and the immune system starts to attack healthy cells. That is called an autoimmune response. It is what happens in lupus. In other words, if you have lupus, your body is attacking itself.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482505453\">",
"      <span class=\"h1\">",
"       What are the symptoms of lupus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with lupus may:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feel tired or weak",
"       </li>",
"       <li>",
"        Lose or gain weight",
"       </li>",
"       <li>",
"        Get fevers",
"       </li>",
"       <li>",
"        Get headaches",
"       </li>",
"       <li>",
"        Get a rash on their nose and cheeks shaped like a butterfly, especially if they spend time in the sun (",
"        <a class=\"graphic graphic_picture graphicRef79355 \" href=\"UTD.htm?29/40/30339\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Lose some hair",
"       </li>",
"       <li>",
"        Get chest pain",
"       </li>",
"       <li>",
"        Have trouble breathing",
"       </li>",
"       <li>",
"        Bruise easily",
"       </li>",
"       <li>",
"        Have joint pain and stiffness",
"       </li>",
"       <li>",
"        Get sores in the mouth",
"       </li>",
"       <li>",
"        Get cold fingers or toes that turn pale or blue",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Lupus can also make it hard to think clearly, and it can make people feel anxious and sad. That is partly because the disease attacks the brain, and partly because the disease is hard to deal with.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482505460\">",
"      <span class=\"h1\">",
"       Can I do anything on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It can help to eat a healthy diet, full of fruits and vegetables. It&rsquo;s also important to stay active, even if you do not feel well. If you rest too much, your muscles will get weak and you may feel even worse later. Also, any time a doctor or nurse gives you medicine, make sure he or she knows you have lupus. Some medicines make lupus worse. It is important that you not take them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482505467\">",
"      <span class=\"h1\">",
"       What are the treatments for lupus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are medicines that can ease lupus symptoms, decrease the autoimmune response, or both. These medicines include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        NSAIDs, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;) or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand name: Aleve&reg;), which can ease joint pain",
"       </li>",
"       <li>",
"        Malaria-fighting medicines, which help with lupus even though they were originally made to treat malaria",
"       </li>",
"       <li>",
"        Steroids and related medicines, which partly &ldquo;turn off&rdquo; the immune system, and can help with many of the problems caused by lupus (These are not the same steroids that athletes take to build up muscle.)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Steroids can do a lot of good, because they control the disease. But they can also cause problems of their own. For instance, steroids can cause weight gain, make bones weak, or make diabetes worse (or even cause diabetes).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482505474\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women with lupus are more likely than other women to have problems with pregnancy. But they can have healthy babies.",
"     </p>",
"     <p>",
"      If you would like to get pregnant, speak with your doctor or nurse before you start trying to get pregnant. There are ways for you to reduce the chances of having problems. For instance, it is important that you wait until you have not had lupus symptoms for at least 6 months.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482505481\">",
"      <span class=\"h1\">",
"       How will lupus affect my life?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You will have lupus for the rest of your life. It may be severe, or it may be mild. Either way, doctors and nurses today know a lot about how to handle the disease. You are likely to live a long time. And you may even find that your symptoms go away for long periods.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482505511\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/30/7651?source=see_link\">",
"       Patient information: Lupus and pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/49/36626?source=see_link\">",
"       Patient information: Lupus and kidney disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/8/30850?source=see_link\">",
"       Patient information: Antinuclear antibodies (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/21/26962?source=see_link\">",
"       Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/5/16466?source=see_link\">",
"       Patient information: Discoid lupus (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=see_link\">",
"       Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/42/36518?source=see_link\">",
"       Patient information: Systemic lupus erythematosus and pregnancy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?21/42/22178?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15480 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_42_22178=[""].join("\n");
var outline_f21_42_22178=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482505446\">",
"      What is lupus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482505453\">",
"      What are the symptoms of lupus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482505460\">",
"      Can I do anything on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482505467\">",
"      What are the treatments for lupus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482505474\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482505481\">",
"      How will lupus affect my life?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482505511\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15480\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/40/30339\">",
"      Butterfly rash caused by lupus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/8/30850?source=related_link\">",
"      Patient information: Antinuclear antibodies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/5/16466?source=related_link\">",
"      Patient information: Discoid lupus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/21/26962?source=related_link\">",
"      Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/49/36626?source=related_link\">",
"      Patient information: Lupus and kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/30/7651?source=related_link\">",
"      Patient information: Lupus and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=related_link\">",
"      Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/42/36518?source=related_link\">",
"      Patient information: Systemic lupus erythematosus and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_42_22179="Levocabastine (ophthalmic): Drug information";
var content_f21_42_22179=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Levocabastine (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/62/41955?source=see_link\">",
"    see \"Levocabastine (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F187841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Livostin&reg; Eye Drops",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F187872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, Second Generation",
"     </li>",
"     <li>",
"      Piperidine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F187843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Allergic conjunctivitis:",
"     </b>",
"     Adults &le;65 years: Ophthalmic: Usual dose: Instill 1 drop in affected eye(s) 2 times/day; may increase to 1 drop 3-4 times/day. If no improvement within 3 days, consider discontinuation of therapy. Continuous therapy &gt;16 weeks has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F187857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Allergic conjunctivitis:",
"     </b>",
"     Ophthalmic: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16265515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16265516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F11231174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Livostin&reg;: 0.05% (5 mL, 10 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11231148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11231171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical ophthalmic use only. Shake bottle well. Wash hands prior to use. Avoid touching the dropper tip to surfaces to avoid contamination.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F187833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of seasonal allergic conjunctivitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F187876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Levocabastine may be confused with levobunolol, levOCARNitine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Livostin&reg; may be confused with lovastatin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Livostin [Canada and multiple international markets] may be confused with Limoxin brand name for ambroxol [Indonesia] and amoxicillin [Mexico]; Lovastin brand name for lovastatin [Malaysia, Poland, Singapore]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F187870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Ocular: Irritation (16%; similar to placebo)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Epistaxis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Dry eye, fever, insomnia, keratitis, nasal congestion, nausea, pruritus, rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F187836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to levocabastine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F187823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Soft contact lens wearers: Solution contains benzalkonium chloride which may be absorbed by soft contact lenses. Avoid use while wearing soft contact lenses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical ophthalmic use only.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F187827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11231145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies when using doses much larger than the equivalent maximum human ophthalmic dose.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11231146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following ophthalmic application, minute amounts of levocabastine have been detected in human breast milk (Simons 1999).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F187837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bilina (ES);",
"     </li>",
"     <li>",
"      Histimet (AR, PL);",
"     </li>",
"     <li>",
"      Levophta (FR);",
"     </li>",
"     <li>",
"      Livocab (DE, ES, NL);",
"     </li>",
"     <li>",
"      Livostin (AE, AT, AU, BE, BG, BH, BR, CH, CL, CN, CO, CY, CZ, DK, EE, EG, FI, GB, GR, HN, HR, HU, IL, IQ, IR, IT, JO, KP, KW, LB, LU, LY, MX, NO, NZ, OM, PT, PY, QA, SA, SE, SY, UY, VE, YE, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F187822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potent, selective histamine H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor antagonist for topical ophthalmic use",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F187835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 10-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Incomplete, within 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic (minimal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~30% in patients with allergic conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, elimination: 33 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (65% to 70% as unchanged drug); feces (10% to 20% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bielory L, Lien KW, and Bigelsen S, &ldquo;Efficacy and Tolerability of Newer Antihistamines in the Treatment of Allergic Conjunctivitis,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2005, 65(2):215-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22179/abstract-text/15631542/pubmed\" id=\"15631542\" target=\"_blank\">",
"        15631542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Owen CG, Shah A, Henshaw K, et al, &ldquo;Topical Treatments for Seasonal Allergic Conjunctivitis: Systematic Review and Meta-Analysis of Efficacy and Effectiveness,&rdquo;",
"      <i>",
"       Br J Gen Pract",
"      </i>",
"      , 2004, 54(503):451-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22179/abstract-text/15186569/pubmed\" id=\"15186569\" target=\"_blank\">",
"        15186569",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simons FER and Simons KJ, &ldquo;Clinical Pharmacology of New Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Receptor Antagonists,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1999, 36(5):329-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22179/abstract-text/10384858/pubmed\" id=\"10384858\" target=\"_blank\">",
"        10384858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stokes TC and Feinberg G, &ldquo;Rapid Onset of Action of Levocabastine Eye-Drops in Histamine-Induced Conjunctivitis,&rdquo;",
"      <i>",
"       Clin Exp Allergy",
"      </i>",
"      , 1993, 23(9):791-4",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22179/abstract-text/10779311/pubmed\" id=\"10779311\" target=\"_blank\">",
"        10779311",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16008 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_42_22179=[""].join("\n");
var outline_f21_42_22179=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187841\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187872\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187843\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187857\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265515\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265516\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231174\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231148\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231171\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187833\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187876\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187870\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187836\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187823\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299589\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187827\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231145\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11231146\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187837\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187822\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187835\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16008\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16008|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/49/6932?source=related_link\">",
"      Levocabastine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/55/43891?source=related_link\">",
"      Levocabastine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/62/41955?source=related_link\">",
"      Levocabastine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_42_22180="Evaluation of the infertile couple";
var content_f21_42_22180=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Evaluation of the infertile couple (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/42/22180/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/42/22180/contributors\" id=\"au6547\">",
"       Wendy Kuohung, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/42/22180/contributors\" id=\"au5916\">",
"       Mark D Hornstein, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/42/22180/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/42/22180/contributors\" id=\"se5918\">",
"       Peter J Snyder, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/42/22180/contributors\" id=\"se3550\">",
"       William F Crowley, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/42/22180/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/42/22180/contributors\" id=\"de4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?21/42/22180?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVERVIEW OF INFERTILITY",
"     </span>",
"    </p>",
"    <p>",
"     Infertility is defined as the inability of a couple to become pregnant after one year of unprotected intercourse. Infertility is a common condition: in any given year, about 15 percent of the couples in the United States who are trying to conceive are not able to do so.",
"    </p>",
"    <p>",
"     The ability of a couple to become pregnant depends on several factors in both the male and female partners. Among all cases of infertility in developed countries, about 8 percent can be traced to male factors, 37 percent can be traced to female factors, and 35 percent can be traced to factors in both the male and female partners [",
"     <a class=\"abstract\" href=\"UTD.htm?21/42/22180/abstract/1\">",
"      1",
"     </a>",
"     ]. In about 5 percent of couples, the cause of the infertility cannot be traced to specific factors in either partner.",
"    </p>",
"    <p>",
"     Because fertility involves a complex interaction of male and female factors, healthcare providers routinely involve both partners in the evaluation.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      EVALUATION OF INFERTILITY IN MEN",
"     </span>",
"    </p>",
"    <p>",
"     Fertility in men requires normal functioning of the hypothalamus, pituitary gland, and testes. Therefore, a variety of different conditions can lead to infertility. The evaluation of male infertility may point to an underlying cause, which can guide treatment. A healthcare provider usually begins with a medical history, physical examination, and a semen test. Other tests may be needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      History",
"     </span>",
"     &nbsp;&mdash;&nbsp;A man's past health and medical history are important in the process of evaluation. A healthcare provider will ask about childhood growth and development; sexual development during puberty; sexual history; illnesses and infections; surgeries; medications; exposure to certain environmental agents (alcohol, radiation, steroids, chemotherapy, and toxic chemicals); and any previous fertility testing.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Physical examination",
"     </span>",
"     &nbsp;&mdash;&nbsp;A physical examination usually includes measurement of height and weight, assessment of body fat and muscle distribution, inspection of the skin and hair pattern, and visual examination of the genitals and breasts (",
"     <a class=\"graphic graphic_figure graphicRef68075 \" href=\"UTD.htm?21/43/22194\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Special attention is given to features of testosterone deficiency, which may include loss of facial and body hair and decrease in the size of the testis.",
"    </p>",
"    <p>",
"     Other conditions that might affect fertility include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Varicocele, a varicose vein of the testicle",
"      </li>",
"      <li>",
"       Absent vas deferens or thickening of the epididymis (",
"       <a class=\"graphic graphic_figure graphicRef68075 \" href=\"UTD.htm?21/43/22194\">",
"        figure 1",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Semen analysis",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Lab testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;A semen analysis (sperm count) is a central part of the evaluation of male infertility. This analysis provides information about the amount of semen and the number, motility, and shape of sperm.",
"    </p>",
"    <p>",
"     A man should avoid ejaculation (sex and masturbation) for two to seven days before providing the semen sample. Ideally, a sample should be collected in a clinician's office after masturbation; if this is not possible, the man may collect a sample at home in a sterile laboratory container or chemical-free condom. The sample should be delivered to the lab within one hour of collection.",
"    </p>",
"    <p>",
"     If the initial semen analysis is abnormal, the clinician will often request an additional sample; this is best done one to two weeks later.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Blood tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood tests provide information about hormones that play a role in male fertility. If sperm concentration is low or the clinician suspects a hormonal problem, the clinician may order blood tests to measure total testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and prolactin (a pituitary hormone).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Genetic tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;If genetic or chromosomal abnormalities are suspected, specialized blood tests may be needed to check for absent or abnormal regions of the male chromosomes (Y chromosome). Some men inherit genes associated with cystic fibrosis that can result in male infertility due to a low sperm count. However, these men do not have the other usual signs of cystic fibrosis, such as lung or gastrointestinal disease.",
"    </p>",
"    <p>",
"     Although infertility treatments may be able to overcome genetic or chromosomal abnormalities, there is a possibility of transferring the abnormality to a child. In this case, genetic counseling is often recommended to inform a couple about the possibility of parent-to-child transmission and the possible impact of the abnormality.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Other tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a blockage in the reproductive tract (epididymis or vas deferens) is suspected, a transrectal ultrasound test may be ordered.",
"    </p>",
"    <p>",
"     If retrograde ejaculation (movement of semen into the bladder) is suspected, a post-ejaculation urine sample is needed.",
"    </p>",
"    <p>",
"     A testicular biopsy (collection of a small tissue sample) may be recommended in men with no sperm on the semen analysis. The biopsy can be done by surgically opening the testis or by fine-needle aspiration (inserting a small needle into the testis and withdrawing a sample of tissue). An open biopsy is usually done in an operating room with general anesthesia, while a fine-needle aspiration may be done with local anesthesia in an office setting. The biopsy allows the physician to examine the microscopic structure of the testes and determine if sperm are present. The presence of sperm production in the testes when there are none in the ejaculate suggests blockage in the reproductive tract.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      EVALUATION OF INFERTILITY IN WOMEN",
"     </span>",
"    </p>",
"    <p>",
"     Although a variety of tests are available for evaluating female infertility, it may not be necessary to have all of these tests. Healthcare providers usually begin with a medical history, a thorough physical examination, and some preliminary tests.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Medical history",
"     </span>",
"     &nbsp;&mdash;&nbsp;A woman's past health and medical history may provide some clues about the cause of infertility. The healthcare provider will ask about childhood development; sexual development during puberty; sexual history; illnesses and infections; surgeries; medications used; exposure to certain environmental agents (alcohol, radiation, steroids, chemotherapy, and toxic chemicals); and any previous fertility evaluations.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H30288200\">",
"     <span class=\"h3\">",
"      Menstrual history",
"     </span>",
"     &nbsp;&mdash;&nbsp;Amenorrhea (absent menstrual periods) usually signals an absence of ovulation, which can cause infertility. Oligomenorrhea (irregular menstrual cycles) can be a sign of irregular ovulation; although oligomenorrhea does not make pregnancy impossible, it can interfere with the ability to become pregnant. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"      \"Patient information: Absent or irregular periods (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Physical examination",
"     </span>",
"     &nbsp;&mdash;&nbsp;A physical examination usually includes a general examination, with special attention to any signs of hormone deficiency or signs of other conditions that might impair fertility. The provider will also perform a pelvic examination, which can identify abnormalities of the reproductive tract and signs of low hormone levels (",
"     <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"      figure 2",
"     </a>",
"     ). The physical examination may be performed by the patient's primary physician, gynecologist, or infertility specialist.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Blood tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood tests can provide information about the levels of several hormones that play a role in female fertility; in women, key hormones are produced by the hypothalamus, the pituitary gland, and the ovaries. These hormones include follicle-stimulating hormone (FSH) to assess how well the ovaries are functioning, TSH to test thyroid function, and prolactin to assess the presence of a benign pituitary tumor.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Tests to evaluate ovulation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ovulation (the release of an egg from an ovary) is essential for fertility. Abnormalities of ovulation can often be determined from a woman's menstrual history or hormone levels such as the pre-ovulatory LH surge or luteal phase progesterone&nbsp;(",
"     <a class=\"graphic graphic_figure graphicRef79496 \" href=\"UTD.htm?13/13/13530\">",
"      figure 3",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Basal body temperature",
"     </span>",
"     &nbsp;&mdash;&nbsp;Monitoring of basal body temperature (measured before getting out of bed in the morning) was previously recommended to determine if ovulation occurred. A woman's temperature usually rises by 0.5&ordm;F to 1.0&ordm;F after ovulation. However, basal body temperature patterns can be difficult to interpret and are not generally recommended in the evaluation of infertility.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Hormone levels",
"     </span>",
"     &nbsp;&mdash;&nbsp;Levels of luteinizing hormone (LH) rise abruptly approximately 38 hours before ovulation. This hormone surge can be detected using an over-the-counter home urine test. However, this kit fails to detect the hormone surge about 15 percent of the time. Therefore, a clinician may recommend a blood test to confirm ovulation.",
"    </p>",
"    <p>",
"     Blood levels of the hormone progesterone are a more accurate indicator of ovulation. Normally, levels of progesterone rise after ovulation. A test to measure the progesterone level is usually performed 18 to 24 days after the first day of a menstrual period.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Tests to evaluate the uterus and fallopian tubes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Uterine abnormalities that can contribute to infertility include congenital structural abnormalities, such as a uterine septum (a band of tissue that makes the uterine cavity small) (",
"     <a class=\"graphic graphic_figure graphicRef53932 \" href=\"UTD.htm?23/47/24304\">",
"      figure 4",
"     </a>",
"     ); fibroids; polyps; and structural abnormalities that can result from gynecologic procedures.",
"    </p>",
"    <p>",
"     Scarring and obstruction of the fallopian tubes can occur as a result of pelvic inflammatory disease, endometriosis, or pelvic adhesions (scar tissue) from abdominal infection or surgery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Hysterosalpingogram",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hysterosalpingogram (HSG) is used to help identify structural abnormalities of the uterus and fallopian tubes. It involves inserting a small catheter through the cervix and into the uterus. A liquid that can be seen on x-ray is injected through the catheter, which fills the uterus and fallopian tubes. An x-ray is taken after the liquid is injected, which shows the outline of the uterus and tubes. An abnormally shaped uterus or blocked fallopian tube would be visible on the x-ray.",
"    </p>",
"    <p>",
"     The test is done while the woman is awake and lying on an x-ray table. Most women experience moderate to severe pelvic cramps when the liquid is injected, but this usually improves after 5 to 10 minutes. The test is usually performed five to seven days after the menstrual period (before ovulation has occurred).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h3\">",
"      Hysteroscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;In a hysteroscopy, a small tube containing a light source is inserted through the cervix and into the uterus to directly visualize the lining of the uterus and the sites where the fallopian tubes enter the uterus. Air or fluid is injected to expand the uterus and to allow the physician to see inside the uterus.",
"    </p>",
"    <p>",
"     A hysteroscopy is usually performed in women who are thought to have an abnormal uterus, based upon history, hysterosalpingogram, or ultrasound. Diagnostic hysteroscopy can be performed in the physician's office without anesthesia or sedation. If hysteroscopic surgery is necessary, this is usually performed in a day surgery operating room with a regional anesthesia (local, epidural, or spinal) or general anesthesia.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      Pelvic ultrasound",
"     </span>",
"     &nbsp;&mdash;&nbsp;In a transvaginal ultrasound, a small ultrasound probe is inserted into the vagina; this provides a clearer image of the uterus and ovaries than ultrasound that is performed through the abdomen. It does not require that the patient is sedated or anesthetized, and has few to no risks. It is used to measure the size and shape of the uterus and ovaries and to determine if there are structural abnormalities (such as fibroids or ovarian cysts). If abnormalities are seen, further testing may be needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H30288232\">",
"     <span class=\"h3\">",
"      Sonohysterogram",
"     </span>",
"     &nbsp;&mdash;&nbsp;Infusion of sterile saline into the uterine cavity via a small catheter placed through the cervical opening enhances visualization of the inside of the uterus during transvaginal ultrasound.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h3\">",
"      Laparoscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;During laparoscopy, a thin, lighted tube is inserted through a small incision in the abdomen, allowing the physician to view the uterus, ovaries, and fallopian tubes. Laparoscopy is performed as a day surgery procedure and requires that the patient receive general anesthesia.",
"    </p>",
"    <p>",
"     Laparoscopy can detect damage and obstruction of the fallopian tubes, endometriosis, and other abnormalities of the pelvic structures. It is the best test for diagnosis of endometriosis or pelvic adhesions (scarring). Furthermore, endometriosis can be treated during laparoscopy, which can help to improve pregnancy rates in women with infertility who have endometriosis. However, laparoscopy is not routinely done during an evaluation of infertility.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Genetic tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Genetic testing may be recommended if there is a suspicion that genetic or chromosomal abnormalities are contributing to infertility. These tests usually require a small blood sample, which is sent to a laboratory for evaluation.",
"    </p>",
"    <p>",
"     Although assisted reproductive techniques may be able to overcome genetic or chromosomal abnormalities, there is a possibility of transferring the abnormality to a child. Genetic counseling is often recommended to educate a couple about the possibility of parent-to-child transmission, possible impact of the abnormality, and treatments available to prevent parent-to-child transmission.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      EMOTIONAL SUPPORT DURING INFERTILITY EVALUATION",
"     </span>",
"    </p>",
"    <p>",
"     The inability to become pregnant can lead to a variety of emotions, including anxiety, depression, anger, shame, and guilt. In one study, 40 percent of infertility patients suffered with some type of psychiatric disorder; the most common diagnosis was an anxiety disorder (23 percent), followed by major depressive disorder (17 percent) [",
"     <a class=\"abstract\" href=\"UTD.htm?21/42/22180/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Both men and women can suffer from these problems, which can further hinder a couple's ability to become pregnant. Psychological distress is associated with infertility treatment failure, and interventions to relieve stress are associated with increased pregnancy rates.",
"    </p>",
"    <p>",
"     The best approach for treatment of psychological distress related to infertility treatment has not been determined. However, some experts suggest relaxation techniques, stress management, coping skills training, and group support. Evaluation by a psychiatrist may be needed for some persons with significant symptoms of anxiety or depression.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H27\">",
"     <span class=\"h1\">",
"      INFERTILITY TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of options for treatment of both male and female infertility. Separate topic reviews are available. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/5/32851?source=see_link\">",
"      \"Patient information: Treatment of male infertility (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=see_link\">",
"      \"Patient information: Ovulation induction with clomiphene (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=see_link\">",
"      \"Patient information: Infertility treatment with gonadotropins (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/62/40932?source=see_link\">",
"      \"Patient information: In vitro fertilization (IVF) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H28\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H281\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18220460\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/16/11523?source=see_link\">",
"      Patient information: Infertility in women (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/42/40610?source=see_link\">",
"      Patient information: Infertility in men (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/51/31538?source=see_link\">",
"      Patient information: Testicular cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18220497\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/5/32851?source=see_link\">",
"      Patient information: Treatment of male infertility (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"      Patient information: Absent or irregular periods (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=see_link\">",
"      Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=see_link\">",
"      Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/62/40932?source=see_link\">",
"      Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H30\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36919?source=see_link\">",
"      Amenorrhea and infertility associated with exercise",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3367?source=see_link\">",
"      Causes of female infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/54/11114?source=see_link\">",
"      Causes of male infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=see_link\">",
"      Effect of advanced age on fertility and pregnancy in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13706?source=see_link\">",
"      Effects of cytotoxic agents on gonadal function in adult men",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link\">",
"      Evaluation of female infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=see_link\">",
"      Evaluation of male infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/18/9513?source=see_link\">",
"      Reproductive surgery for female infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11482?source=see_link\">",
"      Optimizing natural fertility in couples planning pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link\">",
"      Overview of ovulation induction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14425?source=see_link\">",
"      Overview of treatment of female infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9626?source=see_link\">",
"      Ovulation induction with clomiphene citrate",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=see_link\">",
"      Pathogenesis and treatment of infertility in women with endometriosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16487?source=see_link\">",
"      Strategies for improving the efficacy of clomiphene induction of ovulation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link\">",
"      Treatment of male infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25496?source=see_link\">",
"      Unexplained infertility",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39865?source=see_link\">",
"      Use of assisted reproduction in HIV and hepatitis infected couples",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society for Reproductive Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.asrm.org/\">",
"      www.asrm.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/public/other.cfm\">",
"      www.hormone.org/public/other.cfm",
"     </a>",
"     , also available in Spanish)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H31\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Infertility Conditions Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://infertility.about.com/forum\">",
"      file://infertility.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?21/42/22180/abstract/3-7\">",
"      3-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 23, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?21/42/22180?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     WHO Technical Reports Series. Recent Advances in Medically Assisted Conception 1992; 820.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22180/abstract/2\">",
"      Chen TH, Chang SP, Tsai CF, Juang KD. Prevalence of depressive and anxiety disorders in an assisted reproductive technique clinic. Hum Reprod 2004; 19:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22180/abstract/3\">",
"      de Kretser DM. Male infertility. Lancet 1997; 349:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22180/abstract/4\">",
"      De Kretser DM, Baker HW. Infertility in men: recent advances and continuing controversies. J Clin Endocrinol Metab 1999; 84:3443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22180/abstract/5\">",
"      Gray RH. Epidemiology of infertility. Curr Opin Obstet Gynecol 1990; 2:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22180/abstract/6\">",
"      Guzick DS, Grefenstette I, Baffone K, et al. Infertility evaluation in fertile women: a model for assessing the efficacy of infertility testing. Hum Reprod 1994; 9:2306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22180/abstract/7\">",
"      Templeton A, Fraser C, Thompson B. Infertility--epidemiology and referral practice. Hum Reprod 1991; 6:1391.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f21_42_22180=[""].join("\n");
var outline_f21_42_22180=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVERVIEW OF INFERTILITY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           EVALUATION OF INFERTILITY IN MEN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           EVALUATION OF INFERTILITY IN WOMEN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           EMOTIONAL SUPPORT DURING INFERTILITY EVALUATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H27\">",
"           INFERTILITY TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H28\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/43/22194\" title=\"figure 1\">",
"           Male anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\" title=\"figure 2\">",
"           Female anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/13/13530\" title=\"figure 3\">",
"           Menstrual cycle PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/47/24304\" title=\"figure 4\">",
"           Partial septate uterus PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f21_42_22181="Laparoscopic visualization of the left ureter";
var content_f21_42_22181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Laparoscopic visualization of the left ureter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left ureter is visualized laparoscopically.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_42_22181=[""].join("\n");
var outline_f21_42_22181=null;
var title_f21_42_22182="Granulomatous ISN";
var content_f21_42_22182=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph of kidney biopsy of a patient with granulomatous acute interstitial nephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 255px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD/AXoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDrbn4g6yfH0EFtEWtLsKIj5TIyA4ySMdsHNejw6o1s0VnrF4qm/jKwoeGkIHzMD+IzXGa7rRfSbW90X7PO0koh88kNsU55GD6jHYDkVsWIXV20e/uIi15pyOsRLcDeNpO3vntzkV6dZXtK1tLW81t+J9JVopw0St8vwOP8F6B4Z8I+Or+fRruOa/liZWtnn3GKI7ScqDnt34wRXbQ6nYXdxPFZ3tv9sdTvEbjfjIJ+XPX8K8c+F9zY3HinVtRv9JGmSndm8nmZRgsAUy5wCRnn68817p4ebwgnlXVlZ2kU6qo86GEsOcjAcDkfpyK0xd6dWe7d9/NBOShBSjFt26L81/wDK0nw3oXho3d01uozGHBjQlic/cAHf6etS6Z47N3Dc2el6M9jqe0GD7WAY5AOpYg5GAeh9frXZXtraR7kieBLhzuETEDf7Y/Toa5H+zbO0v5LiK3aO5JYkscHLcY9fTOetYRlGpeUlds56coYq7qXfl0L2rX/AIpbQvLVLK31Qt8zQFmUp32kg4JBGOvPTNchb6DdeNIbePxLfi8+xXB8mSHYykHG+MkLnPyj8jXZLHNO4/etL5WMvu5wD2I9/wD9VeeTaUPBl89/feKrfTdJupt6K0ILM2ckAZ69OR27VtTVoNQ+LyWut77a/wDAKpxhT00XnbZ6WO9urRbFxJuKW8K4QD5QD25NUYopbuaN5La+ulb7rxwgr7nJP61f8R67Z2Xh211kqZ9ERPPnmhiEvmLwcge/PPvWNonxIi8U2TXugq8OnQnYysAJFPONw52jjjrURU3BNLR6f8A0o1Ks9Iq79dtbfe2ebfEyx8VaP4vnl8O6daz2M6oTLLCk2BgcPvBxgjjt6Vu32p2fhnX4ZINPjit9RtVjuFtUH8S/MvJyvJ6DH9a2pPENxNqn9n6fp2oam0hLTGEFQmTkkk/hxnn61o694ftppLK6TTWh2A/JcQq7E578foTW86ilNKotbW067Wb89NDopQjTtTqO9779rdit4N8N6R4XuJ9TttS1No7uEt9lePamOobPt6k+vNV77VNG1SaFItXtJbxztW3SffJ7AknOex/QVY+I3hO5vtNtp9S1e10vTo41jmVB5efRR6n2A7d65PwtoGm6Xq7LYW8t7dpjynbkj0bpwOfSpVnB1U25P7v69B4Ne0k6kJbf12SOsm8Fz24Eq3scKyhpJY0uAPmPpkZycDoRzXIfES2jsbbTo7bW7KwNsWae2+2bpnJxj5Bk5wO/t71U+K+peM9EuLO0gikSGRN6PIVl3nPQDPAHHFcha3dvcW1vJ4g07GtLxIvlBcrxsyPWumlBx5Zyle6e3o9fLtfvZFUr1GnzLR720evk9fQ9f8C30eraO80SkwW2R5z2ofJGDgnGePr3FWpoo9Rhjt3s476OSTe0Atw3IJ56H35/wqHwwllbaFBIIZrOwZwJYo0C7n6nIz7dcelWtP8AFi2WvSxCFhYRqFN2oATd/dI65JHX26VxR5rSlFbf1836GtXmcpOMbv8AC/8Aw/6HKfGBvA32PStP8SWl/FqdupFnDZIIyqsRkOp425A7Z9K3dUe60rw9PEkttPbXlqbdvs8ZOI9uOAehAxz+NcP4z8caHr3jaxi85ZZ0laEzrabpF54AB4x1HWvSfD15purPd2cX2i4gwUjWZCpJxzkHp3rWpH2Eqamvhj16Xd9Oyvrb5nNhqapUpTfvXbbXTp179WeS6Frdpp9rdPFbkybwqqTgnr1OK6nw7d2urlp7eJ45w2GSRsYz36/rUFp/ZfgvxE1zqz2xEjssMU6hB1I4znpkc4rW0zShZ3t7d4jVZ2Em2JAoVeoAAOMe4roqtXdlvt5/8MerGrLmt0tvpo+36jryB3KvC/luj5PAwfarkbkOq+UDjoPxqMlWYlcKOu0Ak0y3lXz4wuCGODuNQzVptFzxDcane+Hri30lII7pVJt/NIA3deS3H0z7VwXhvVfHl9okttrNxGJfMOPNU71QAdh8uOuMitLWdVvJ9cNlblbWCOba/wAm4v6HGD+lbNx/oiGMt5b/AMW5SD07jt9KH7qVOyutf+B+pzUMNHm9r32XTvf1MG+sdReygjtb65N6mfmjx85JAwV7gc07QfDd5HqEb6jqkLNJxJgM79uCTjHPYfrWppN7bajaXUOm7jdcq0jAg9M8enT+fWm6ejafMYJ3Amc5UZHGT7UScnFwvtv/AMH5nTZOTlHR9Buqa6bHUGsFsizIQHmb5Sc849+tOsvE8+ku6Xz32qCaNvLtY+QgJGFHPAHt7Vbns7S9u0utTYDtkKWY8emfp1qhqd/cabrNrANCmkspCRDflSAw6emB9PeiSi7pLRK/3ee/3GMlC0ac/ik/612/yKd/Y6hrtvbz6m1xZlCTt2E5Ax1Gcg1cuNTv5ri00kWci2GQxuJIG3Egfe3H3zwD+lReKL1xe2BaZYrdAQVYgEk9c47dqlni1qeZDaXbf2bgbdow2cd/896J3aTk9bO3ld9PMcaavF2tr+WzI73SIReu7WyPKGyzrkKffHSr0N39njVDbkheAq/pWpp9qgsLgX18RdcEAnJfge/PXp6VKuvyWMMMdnbI00XCttHy/wBcn+tY8zm9tv8AI0dVtcsIXt8ivFY3Ui+ZftDptux4e6Own2APOaz/ABFpd0bGF/DE9jMW+WV4ZSXk755HHfgfrQVXVrkSazr0y7j86iB3IBI4DHjj2qxcWGj6dIkmjTXDTEfM8iFWVieRjqT1yfyp87jJW1fpZf195zWq1Jcs7rySdvm+v9aEWkaZd2NlGdWifzdpP745ORnpnk//AFqkYtNKUt0klXgYRj19eKhudVe1juS8huLmMZeOVstgjOD6A5/Wsu48WaisRgng2Qn7oiHlqPbGSD1pRpytzPU29o1K2/5f1odC2uajoOnyyWKJMzwsiRMm8q+CQSMep5HfmuU8Kza1qLTSaki2pZ8qzx+Vyc54AwB+AFTQak2pWqxRvNaTxSLKJEbk49QDyK2NWiad457K+luEYAPEkhhcE888jJB9aqVlH2aVm3dv02XbUnk9lVdVLdWv0fn116amN4y8MadqMSHyJrfU92WDOXVx2ZSD/SmeFtF1CxaOQ37yoRsTjzQn+zyCR/npXTq4g0oT6xBJA6BiZTKCMAHr+HWuV1jVv7P0iBNJu4p5bomVA0hRRGvLSs3RUAOSx4AwOSQDlVrRdG9SVkur7dde3b7hRlTpRcnp/X9fkSa9ql1o6RCBkuL6Yny4i3ljCjczMeioo5ZjwoH0FYaaBrt/LDr0N3JFFcKUWaSVoxMwb76R4zEmMqu7luWbGQBzOrHU9eu47bS/tE0kzJ5s0i7JLnB3KNhOY4QSCqdSfmfLYA9YttRm8PiyXX7iO5kdGVoZ5A3zknJDc8nPOa44Sr1asarTS1ajs2rby7X6J6Jb67cqlUxMvay0itltfz/ruWfBsuoajZJa+IIXaeLdIkkWwllBAw2Mc8dfar7zRMWtpH4BAKuD856Hr0xn/wDXVXTNc0y3vY5beSSBpSEkhfcFJ7spHbgcVa1Yz2YudRlsRdQmI+U1uFTe45wwBPGR1GM1so2m0uuqXz6f16eW0pezfvppW/FbmRa6JpcmuBZrV0WVMo6ADa2ep6DH9DWv9s0ZPlkuJGdeGOw8muXsfHWh2ekT6t4j0y5BEghigiJbc5BPRjx0+n41AvxQ8FsoIsdVUEZC5bj261rOg5ScqkW0tPmt7d915CeIjKfJroltbqM8T/2D8O9SQXd1NdJdxsEtbcZRI2P3ucA5GcD1GfSvQ9IQX0NpfWlybiCcp5MYbbgFc8cZGR2PpXDeKbTS/E/hLSZNbRtP1HG2OZ4vmAX74OM5HU478e9ZkOoeN/CL6UNPsoNQs4Z2zJCN6tHwADjlcAnGR39BW817WKlF6u979fT7v8zivOMHfXtoe9eNPB1l4u8M/wBjapNN5YdZFmjwrqwzz0x0JH414zot5D8OLvUdP8K341KXeiu10h8sDJ3AYOd3Tnp+VbXxQ8b+K7DxbokOl7YPD8rRl5rceY8xz84I+8MA4wPz9OwvLTQVuLe+s7BJZJPnmZBswccnp1ya54NxpqFT3lJcyXRevn5fqcGCpyh/GjdO+ll/S8jzXVdV8QH4zaTDHo011pYZZIpRG+9UfBaQN93Kk4xjHGOtdL8QbHUJPEiStZzahpbW4O2BS00MpOMsuQc9CCB9K5C80HxTZfE59e05bq40tHDBPtR2qh52Hnp+Yrtbn4gWsWsCOXTWvXiJ3RtOoIbvtB+/07VvPmVVOGqUUv8AP5nTTp1I2mle1+3yNLwI2pSWSS6izQxxXBSGa5G1nXHR1PvkdB1HSvPv2gYdG8R61DYf6d9qsRh5rZAYxuK5GD9BzkY6c11ng7xjca3a68txoF3p9tat5sIQeajE5BI+XPYGsvWPD954iuo5dEs/MiviBdSsdhAUjtkY6d/8adGXsqspSdrXXl5+ujF7FVKntKmiXT/M7X4dGXT/AATZWGjxJNbQ26iBpDhjx/F0BP0/WsmwvtEtvEkulPax2upSupnS0iCI5xuwWHfPbP60/WNft9At30vTblILu3t2EQSEk8ADAwMZO31/nXI+AL3V9f8AEm+UyQWisfMMmNztgn7xwQeuKwhR9nSlN6f5/wBf8Oa06N3Opsnd9b/1+p13ij4gw+F9ZhsZbe5ZHQBGgCuSueuT+PT06VzXi34iTaDrcN1ao0yAEIzkvvbaASemOtdN8SZYNM0fy7Kwj1DVw22JHAJjyCMk446Z/KvJY/GCXVrBDqOkwXTAgSyK2FJ6HCsDzzXXSpQcVNR0as/8/wCt9R4WnSlBu1m9NVo1+v8AwSp4wi1f4siC/tdREfknyntZmKoh65XAOCc+nbrXbeBLifwlb26TXUc12EWEyZLhwPTkdM1uW+kaRpGg298ptdO+04cKs4yx9PY+2OKx/EdnFb3uj6vYk6hYK254ygRgVYEqwP4jp26VMp+3ik/hV7fnbt/Xc7KEaEVKnGPxaPtdfejifiXqXiDxDqN3qGsf6PZWceIh5JX5SxAwO5+brnsa6TwbHYfEfwxZreW11Yz6GSxu5kVknHXAfGeMH1xXd+OfF+k6j8Opro2KlmljSOGULwxYAsOOwz2rg9H1G8+yy+E9J1MtYls3V2dzNKrAfuk64HJU+valKpKdOM7cjTfyikk0l1u3bvd36NnnUo1JL2dOHK01Zea1vfyV9PLudD47vZr3QYE065jQBQu0OASuOB6etYXhW3l0i2kmkuDJI3LJtBT9c0/xBp95pXhhp9ItVvNRRggtyrExx922jBJ7HHSqFgupeIvCV1HJb/2BdTgCOadjtYZ6Lu5XOOv5VUFFUoQbtG9v+Htr/XY9aFSjSU4U05OPyT9Lm5o/g7wDPqp8S6nc3MWqLIZWtfOUIzE9lALdTng966aXWLC7uzLFbvNOFI39F/3uMEGvPfC3g/WfDETf29e2l2ZMNHiQyYXsOvqa7bTNIZgWtr2FGZCQGQgsO/bHXjrmsHZzlUk7vZN9l+hFPD0KdPnTaT2XRX3Wn9fccN4+stH8Q65pzatf3MdzbxlI4+CrZPH3jXZvqWh6dBbR3TXcyDCBzhFI5xgD8P1riNU8PC31Ke6ubmR4WLylQocgd8EnPHYe1aFp4z0ed4bSKaXc5CBZIjjOccnHT3//AF101YKUlJXaStc1hShCCjtd3sn3Lixam9+Wku0WwcllRGy23nAIxkH8aqeIINfvdQsYdFkgis2KmedyC0fJ3M2f4QO9a+l+P9F03U57efRjdhZhGs6FGTHQjDenHTNafjaPSvENld2cHlaebmIxlhGAkQxncegJJPp0HX0SnJVLSVrrfe3nburmNStUkrQi9NU7727+QXWs6fo09otpfxXksce9p4NrL5mOzDJIwTkA1xV34k1HxNf6hxbyybWGIwcsDxxzycdOKxPD/hjTvDt2be78R/a5pBvjtUyqZ5AIO4g46/hiur8FaJY+F72/1e8m+0JJEVCMgXaM5yCc88YxikoqjF8ivLS193r/AF69CoRaiqtr6NN6Xv2+8X4faXNoVh/aV7BLCpckvMMBhjAGemfb86ta4kmsX0l7ZeW3mYYlDgJt749KsQanb66lxHC0h09m2m33EhfwOMmodJ0wabO8FmzyRkkgSY49fahXjKU38V9TohBJ80ui09C8iXcXlLIJIrgJnJOOPx/GtG71W7lhEPmFYjjIQ9eg7dc8VzGqlpoXCTSTM/3Jkk+57cn+XWpILe48MaJHcaw8rxuwRXEgfqMjoTjoe1Lk1SWsuxMnCXvVElba/X0udCdKtfEFz/abzQKbd1aSMMCSPy5PT61f89bJT/Z91bkMhRkiXO0g7cnPc8Vz2ju1ppTXFlFvhmGRKxXeqkkcDOR35rPvdVivW+x2+o21tfD7hmAkAYdiAPQHoD1GayVPnd73itvT8epnOi1e7vFdFb7rf0zbhSyKGbUbpFjByVRgGcc/l/Kq8l/YztJHapEGB+REm3jBPB9ehH5Vz3ht/Eyz3qeK4NLnspImRCskcjMSOCNhOD06gUuh6K9lfS3DyRv5pJVQT8voOnt2q3o5dWrej9DWl+8993t/XQ6wtEjJjLbcbdyDvjOD9c0ltsmctcywWdrubdcPgDOATz64P61PeakLoi4jtom4ChHB2q3XOO//AOuua1uzvtTfP2ry0zvCoNqg/TPtShDmXvOxMYzkrWsy/qT2U2oz7JILnzFCsyvkdB26/pVW30aytPMJjZxIApVjuHXIHSiws2t1aS6umlm28E5xnrj+me2auhwUA24JbGB0B+lJNv3emn4GyhZJLoVrfTba2YtA0mCNoG/gDrj6ZqxCkqTLLAY1lXnpSqEKDadx69Dk9vypxwEJ5JY9CMc0N3uO72My7gl1jWbDQpUKRXLebdDbgfZo8M+fZiUT6SVh+IYfDv8AwmAi0y/TVIbmXfNBbvv2SBiV3ufkMUfVYgQQ2TtY4Iu6lbaZeayZ79FuJWg8nyJZGMeMk58v7p5OeQegrE1XTfs+oRXFsiiGSRXTbnK9M49P8K8erk9XE5gsZUq2jFK0LaPrd389dui1ucNXB1KtdVJfCmtv6/zOgurTSri5ie6kiF1Cdqs0gBxngfn/AJ6VqW6WltYSQXGmW+pwABv9IxlQT1UgHjP0rKezsNXv0tba5EWplfO8oKw8w5OB0xnr3rotEuIbGdoNXt5/NdNoCsAeOcfyP+NenUndKVrtJO3Vf8Dc65yjKEktdb2Xrq/wOfs7SKW5ljECpl8IgXOB14+nT1rfsbswaZPYXDyiP70TJjO4EEk5/CorCCK61JktpW80k+VG4549x+tZmLifWjpzBo3WTLK3HOPmx+nNOaTcm38Nn6eZpNwm+RvbX/gmjrVq0tg0U0RnhmHm4mhADHsBnv8A/Xrzg6tqUZKJpFuFXgDyuw/CvbtVU2FhbPI8sixspUs+T0I6nP5Vwd1carJcyvHPZhGclQUbgE+3FaYOUJw/exTXS9/0+RwqtVlHmpRv6W/U6XXtd0vxfp9rZW1iWsYx9ojePjDcqVKkAjncOK19GtjaaHcSIqraeUilQ4DDB+XA69cflWDYHS/D0ELwloIbdhsmkbZESTkrljk/XtWV8YLrxNq2kWNh4Ukh+y3xY3flNGepUrz1HcnHXvmlTp88owvZLv5av5/qclSPsoKnSjfXXvv/AFqdFceLdPea1069mihnkkwkQG1pgARwDyfTI4zVLQPAloPF8uv/ANs3M14qlvs9yQQAemQABgdsdK838SfDnxC0nhW5tplmvbFFiluPMXcpSRnVipJ4AKj8Pwr3CVJmso2SFbWOJFVin/LQ9yTn8velUlGyjTeklr9+39fMyaurW5ddOv8AXyMSTxpYQapDos08UM4+YbujsTwAT39veu2is7W/0wyRRaal7IC250+YN/eyMEc4r588M+DdS8X+OLmPXFa1s9pdZJF3EgEDYCCCcg9jXsfh3wkLDTbu3TUy9tbMUW2ngJMO3pglicMMEdcZwKMXCnCfJGW1rmddQ78jvfZ9X1F0fxzHYWd7D4ggjtBZ71eVWLB8AcgAAkHPb2rznUvEF/ceMB4mi1AReFoI/MaaKUj5fu7ZEHO7dwBjnivUfIs7yCaC6tIZGnUlvM2napHTn8uB+VYWs6FDF8N9ctdN0uC4ujGUWBXwCCRxtJ5I5I9ccVVLkUuW1udpPyT7dmRLko81SEde3S+v4GJ4U8T+GvFMM95pMEn223+Vmnh2vwOu4Egr83setc34p0r/AITDXbaC1vIra2sflmjkyuScdDgg8/Sj4JWl/Zabdi60eCFTJuBOQ7kDlSOwBAGT696u+GfEFvf6zfwR6OljdOW3eWxcMckYII4/CttYOco9NL+T/r/M9ClFT5VPV7kuv6ncaRY2tppdxG1yi7GlkRSwUADKhuCTg/l61B8P/CMOp38Z1a3hiTJkM6kKcAZ6Zx+Yrn/GrQjX9hu51AC5AtuEPqDnn8h9KmXxPJo9xNb3169yqooXagJAPPJ47H/GtJ0pezVOn2v/AF95tFqfNO9pPS76fIp+IRY6n44ksxLJJCJDbCRgWHBIBGCOD/Wtq18QS6V4i1bQoMyQyxbY2k4AkWPGe+DkfnWtpelaVeyWerx2YQ/89GYhS3OD6Zrh7XxZZp4nnbR/Dsl7eGcK8rsRjJwSBggZ5ofvqU4rRJJX6O//AAAcVBqnJ6u/q/6ep1WieJ7DUNQ0zTHtZH8uEC7jIK7ZAOc9e4z+Irdl1i18FwXuo24ivLidG8h87tj8gFsYx9M5wPywNasvF17epNAlvFbb8LcL5Q2jOOeMjsK7zw9pPhmDT7iLxHLEbgEu5ncqGAz0UHHHtzXPUcItXXNF20Wv3v8ArzMsRJKg+Zt9HbXr6/e/8jkfhzr+vvfz6pcwpNFKcFypO7PuOMdB61SsvCGo6j42u7/Vp4LWzd/MkZZwE2k4wq9QAMDmkt/G8CeLZLXTrEvo7OY0jtmEfy9N3I9Oa6bXtOlNuL213z2bj+Ndu0c9yf096qSlGU6ctHK3/DI1pxhOpGrH3Xayf9dSETaP4c1staajDdW8RDbJ2VlmPoCCeee+K6Ky0zUL2WfVpJLG00p3EltBIzEADpuxwvrj3rzDUNJtbuVWkyHQH+HP4Uy+vtb1HbawQy21pjZkuOR65PP5CiVG70dl1/4HqdNfC1G1Z3lte26/JHo93q8M1zHBe3FpKLcthogH25/H6DH0rhPFWkQXWpQvbR3jRXLLEXQrEgGcfN1yfbI+tRWk2heFjZ2+rR397f3cgU+VKqbE4wxBBJzngV3Pi/RorGeCK31VPssmD5Uy5fce24cA+/HpSjJQlyrS60/z+8xpzoqSpx7tbaXW/wCevTcwtD8GWljFbajPpi/Y1IAf77Lx3yCO2PxFcN8TNG8SXuss2i3KXFmY14WRd0eCRt4HbivTbe8uIHfTZbkiKAAurkuFDDO7ryeR0zXm19HP4Y8enUYby5u9Fd8Ak5LJ6EZ6f0Na0XOHPNaytt5b6eZlXj7SpGM9tdY6Jevr/Xnvw/D7T9Q8LaLc+Ip7sa5art/0VlUFSSRvyvJ+hrfa4ttR06XQVSWG3XCrK+C7MvAPT26Zoh8YaBqCyW1pdoLwuHNuwKsBjOBkDNc+7aqmtkeQwhkchsAAYzx34P1rOnBpc8n70dr7730X5eRtQowkpJrRtv5mEsWq+Fr67CSK4wAFdNu7jr+tXY9W1iWwaK0sZpomYySXEaFyvA6Y966qS60554bU24mnUYG9N2G4z/n6V6B4G0XTpLKeO9hia5805hJ4GPbOD1/CnWrqmudx1/roTiaqw1JzlexxPgCOK10a4j1RLhjcSZi3ZwrAnGM9Otb2pRS6pfyxzeVOscfzB4lCAL1IBOCenNW9eOnw39ytq5aC4bYDGR5akKBw3XIbJ+oxXDC2v49TfYu+It1Vs7wT37g+v0rGCvzVL6vX7yaEY1rVFpdaX9F923zNa71q10/W7e3MUMMAjVoiFwuMck/j6+lcxrd7p/ie/ng8SWNtpDLKYobm0OGxn92JiVI/eYLI6/KTlDhl56vxPqmi2vhWdNT0cXUsHKMXYSIxPA4wVGfQ1wmn6DceIbRZbGyuLW4KMtvDOwuI5I2wGjdcAmNuAVPoCCCARlXjVp0418P7rWlntLuu673to/I5pwnVvy6Sh32a8/N/8E7618N3Vtp1pLEpkgnyI5JjgoO2447+1QeRJskddp2t5ZG4Hn2rn/D2p3NpPDoviK7uobaOVbdY7mUyNbOc7IXJ+8CMmOTHzjg4cEHtdS00wxNNBrVm8KR7RGlsqHg9SSP84qcJiY1oJw+7qn2fn+HXZnTSxvtbOT1fk9PJ+f8Aw5n+fHbGSS3MkcnDYbG31zjHWqY1+SW/tzPp9pNEzHzSHZN/AwPbnPTrmi2upneVZYjPvUxphR1J9fzrP13w3rgIuW09IkwDHiQdM9++ec9K6kou8ZbnVKNOD5am721/plrzvFWu3h+0WWmaPoSyFhHIrBgmP4X5BJwT071W1qa/068NtbvahOCryEhXHrkEfyJqRLLUk0w2zvJIyckhyU9MZzj/APVWZdXWpLaC2vrEz2yglCSMgf7J6/hn/CnTV5OTSttbt5ru/Uzo4d04KEJXS/rfU0bfUkYf6VtgYjghgUI9Qc++e1M1bU7eC13wkTyk/KsZzn8qwbyxF7bNHYO7FcfuJPlP0/Xg1BomjXFqRJdZhkXJCxs2R26jj1qkowSlv5HUoTk7Is6bYS3N6ryrIsjOPl28kkDHI/yK76y0ULZF7qWGPcvKtwR3w3ufasO0jeNkWBgBuG0gklj6jPOfT+laNzaXPnMt3OTFgkgSAt+X41zTlKpO7ZFRNJQUkv1OZ0bw7ZN4kGsfaXUJJmNeNu7I655xjNdFr90lnaTgPC7MgMZJKkc8/oRxznisrWm1KysUfT4YZ7KIlmSUA5HXPqD79f5Va0LVdM8Ww/YFto4L1C7RRs2VYnkjcMdB7VVR2n9Yqara/ZLa/wCpzScafw7L+rnLxabqyMmppGhXIwyEEhW6ZHTHHr9a39StzbyQ30VvK8rQkNGpDnODz3xyO/tzWiun6vBFKJ7iIWMLEzQiIAtz0DZ56+npWL4h1ZzJeSadbC3ymFGd23ORnJHv096acqtRt67ry6WXfz2H704SSXfb0/U4HwJq2vPqE2nv5jWbEu4njdthHBCnsepA5r1yLUvB3lJmC/c4GWML8+9Yeg2FkmnWH2+eRbvyj5ispII7c9+/9a6TyNDT5TcnK8H9w5/rWOKlHEVpT95JvaOnlf8AApUlCnGm3LTsmc1478T2fjfw8iQWD2d7ZSbpkLAZjxt3Z68H6muQg17VNG8PXU1h5gtNyRo7IxEZ549Mkdq9T1rRRNb3A01Lax1KRfL5X5e+MnPHb/69cl4c8N+K/DunXkWrXMUsGrXATDEXHlqpJyFORk5H0C13QnTUElsnovLd/dr67HnQgqSUIPc2vDPiOSPwjban4jlCykmIS5wJOcgkAc8YHrxXodr4h0y4tLW6u7u1nQbTF9mB2N05OepHPXpiuR8Y+CbZPC7NZvFfNDHvRMbSWxzyDycDOOM4rG8EW+oR6ZBYvZwhZWXyowMbTkjnuCc5/wD1ccjhCcFNPqx+ypYlXT0Xy/MTxVpPii9+Jdpq+mX9zForOrqbe42LHjqpXp6Z4IOe9dd448TWfhjRZdUvpbiYPiNmXpJzxjnORn04+lTaxpV3o9nfQny5Jbi3byJgSqLLg7cgfT/PSsHTNJudb8MrpXiyGLUogdxikYjYB0G5cHjHUVonGco1JbaLTsjDkXJelZpde/8Aw3y7mTZ/ErQrnw0ut2MFzCwne18uVsyynAZjkHGMEc+9djpusHXdFtL3SBNaLdBsRSTYLHPVQCQOc/hXmOp/8K90PVYYr9pr5Y0WGGysGzDEpJOd+fmOSe561d+G3im/8QPrFuunta6bYsoto0iOIlOeGJGSfrz+VVVpcsVO1rPr57JLy7l07Tly3u132/4J6lc+MtI0yRNIms5FvpFKhCFcdxucgnAP4145r/i2DQr6XRvC+nWsZRwtxeAlWZs/3hyQCSP886erS2HhbUZtb1B5Jon5jtEBHmvu3EZ5x7k0zxlJ4f17TNN8TXVm+nx3i7zDbzgGXacfN27f57a0aMabsk2nt6ry+/yuSqKpTtH56+Wi6smj0hPEljaXl20cV0PkdxyJAOM571jeMNN8NaLBLqOpmeefaEjgWbAkbhfToBjp7Vnpqkii71a2tp7qzsolW1s4W3hR0+YjPQ9TjvWT4wvLnUdE0HWtY0uNLxmdTxtUIGByyDGMg8dK3pQlzJSd1qvuXNb0Wl38kddaomrLR6Nu213ZfN9jufh9c3+23urmd7jSGAmjsIlDj5cDJBxgAe+ao6p40uNV8Ved4a0WxtCzqED2+55jnksRjJye4NRWPxWs7XUdITTlnkn+zLASsC7I+T8oHJPfn/I9C0Pw2j20Ot6cYor2d/3UGArccEgEkflxXK2qabqR957dvu/UcvZuftXL3VdbvV67+Xn+hDeP4tvZRb6jp+n2uhB97jP7yX0AHIAzg89PyrC+Iut6c2jw2dnYE33JldTyiYyM4PU/5616Fro1Cysobi+njEjAbAAM8fxHHHf9RXnGr+HrXxJqnk6e01tOzEedKVKNz1bAB6D1ow0o3VSXT7v6/wAvIypQc6fPHZO+j0KegQay3h22i0PS7SeacblmeDdMo7gMeB/OoYJNf8IaNdm/1DULvUr4+X9mM7skK475/ixj2rZ8Oi48H3Qsb54ROzbVlt5Tzx12kMTkVX1NdfHiWV7RWu7TgyKQCUGAD+WKqPVSSstf8Wun49Dq9nGpUTWz6/cO0rRtcmsoLy5sPIhkAbc5wcH24rpoYooVQMI1fG0MgO4n3/8ArUy/1++1Gewg+0iRNoynllenYnox69PxrmYfEE0l1Kl4wPz7RtQDHtx/KopwnKN57/5nVzVq9lUsvT7vmHjKWdfEujX9/FBcQxsVjlWMMyEYADE9Vz0/GrHiK3bVohK06tcLlgJfuHPqPrz+NbllqxjsrhpQJbVFy0Z46+hH+eK47X9Zdb6M6crRQ5wxVVd8H2B6Y+lawvKV7bK33f8ADmVOEaV4Sj16ef8AX/Dm3YaRGtkv2mVnuCgQvE3AHcY9s8U/xQtp4T1mw063jvb+S8CkidwEIPGBgDoRWh4VFlqEDy3lxPayRKrKi87z+X4/j9azPiV4k1iGwtdRtrazvX01/kLxt5hHB3Eqcdh2qKcZTnyLXffTW2hhias41E4v3Vv6Pt/XUj/4QDSdS1k6rqUc1pJJzHsAVCyfLjpx0GfrXY6dbJ/wjt9cXFxFE6EtHAAHYsoxnnoTxjHrXN6B4jv/ABT4aguruEW8RYuyiQld2D0zyM4NXbyd7iXyVtQ6LCYw6hsj0PPp/WsbyqtSm72/TSw/ZTceVO2t9LWXX8epk6HrVvJriG2sFF4p+WRslcnpx07+9bniz4cXNxp9xql14gntp8bnijTEe0nJGBg5rKtrdbGQI9oEYEFpGLA/XHY+9X9Uv5pIY0ub+Qo5yquQVA4xgnk44rSXMqnNTdl97Lr0ZzlDklZdet12W9h7Wyx6PZ2tl5cmU+Q8qIguMgDPfHJPcVc08XqiKeKRUuW+87LhQoABJx3/AMaz7rT7rTnjaY7PNXCSK+QRx6fhURaZfkWRym0AjoD3+uKiNNcqSd0Xyc8bRaaZa1AW7PPPeSPc3Kt8wdQgJ9lHNYGtarq1pb3Evhzzba7SHPmpGGG3Pf0+orfs1hluPMvIt1vjacHnr65+ta3hu30y/vbq0e3OZF+WWRvuL1HQjnj8ar2ipe81e1vQyryjClJSTaS8vyPn2y8Tax4gmWw1yKCW7ijcC5lzteInLRz5PzISF5yGUgMCCM131nDrz+F/7TuZJ4dN0x1mKzD97NFnbIJDjEgjTc6yLxJ8hOCGrrLrw7DqD3tleRQyRrgNHL9wDAOWBJAzXFT6/daHdSWGjX7T2OGja1vs3EDdiq5O9BjgANj/AGe1eFm+Dx1So8TlNlK6ck3uk727a7dNLnHVo8vK6EveW/S/VeX+ZtSa7HpL/az5arECR5gwuMdxSw+PofE77N8TpHwI40KnIHXDH6VzGkaHdX3haGC/8uKaMGIfMXDRA4VScAnjackA5qlpPhy70a6Jt4htc/6wOoAOO4wT+VfQWhOnzxVpHqKPPVjKUNLfNM7+A3H2jyzJLJC6FkjQHG7sCPTIH6Vg+JReQysZZJfnx5aklVU9we2cV0Gn3Cx3cdywgKKqgRq4BODk9+px+vtUOsynULiT/RV8mQkmHG4KO2KmjJqTbWli5U5TmraWMF9PN2CiJLHeKvy7Pl3ccg46jr0/KsrW/Eninw9ti042qwhCrC4jWVifc8HA5/ya1bnUo9LeSG1jcXTrtJOSEHI/i6niovDUsr3sjRFlK9SzfK3pkHIODjnH58VX8OPNUSdtr/19xlXp+3vDb07r9P1E8IeKn1HyhrcVvDctMpUW+VJXjPUnH59cV0TpHJqXnESMzEgBmGBx7exrZsPCenXqHUri7sTdBskIygrj+R5znFVZ7u2g3CMJ5ecl51AxjOMc9+v41yqXNKXJdp/1b0/MdOrCTstXHT+vMyNQultfLYNKQxG5c5HOajtdAkS4fUrYKYhIJ28pAHjOMHnsO5Pp+Na1xM1rsvLX7HcRY3OTGMRYxnkN05on8dmbwnJb2tpE7xsE8+3cjHPXp8vp1q/flZQWj0ZNaUnyunG7Xnsr9vuMjxLrQt5JoLq/kgJxOUgXzFVsnH04rMa4sU057yeWW8tWUFhGpBZgwwMYO3JxzWR4hnsNS1KyF3DPayPGMSIpcN25PfHfArsdFvIvDulyWkVjFqVpKdzvKwjx6DnOc/XrVVLQUIQT81tps7f1+JS54wlyrXbT9SLVng1XwiY7O6/sy527Uuz8oCEdCRzn6dK8yPg/xuxLR+JkZDypF9Jgj16V6edDGuW8kWmW4tBvEqxowk2DGDhuOCa5NvA85YnzouT6tW+FqckHCLW76bX+a/NrscuIwsa076p9k1/wT1/xJr99beH7+6jsoJbiK2dzsA3MAD/h/OvGPBHxY13UfEQs9Vtbd0IPk4jYOHAO1QzE43dM+9et2en3E12blCpMQzIM/KF9SD/nmuL+L2bnw7O4htzNC6LDdFiHWPcAVB6NyeCe1TQhGf7m2r6/oc06XI709luiloXxSv7LWrq78SIDpyRkfYbeDy1V2IGNuM46nk9SK6rW/GthE1lf6LbO8d8vnJHJ8nl44IGOOoP/AOquDt4438HaRazt/aN237+RXmJKR4OF3Dp345IwK6+8fwkdDsrm6tRHB5OyNEctjHDAt9cj1/Om4wlJSUd76dPL/MuND2dpa7HQ6N4puPGW+KxWQtb5Vo5mXD55Bz6j6/41lfEHQ/EWoaFNa2dtJGLg7GRJQMp6bgccccHqKw9V02y1rwt5Hw/1EW0kEwMlu0hR+c878k47ZzzXT+B7bU9P0G2tNT1BL29MmB5reYF3ZGMnrj1/+tUJ+xanDvt29SEtHCMUo+n9fkec2XhGw8L2emWnjhYDqVw5NqhYMwUYAUsOgz2zmn/8LH1jRvEsySWVusK5jNv5fzdMKc9D0GCc13fxP8Atqet6Nq1/cO00e2Jo5AJFdQScDBG3BPvSa7pqJp7SWM9jbS2gA+2ywqzhe+MnHH8quM4TtdXut+zvsvIdN89JSureXbTv/X3FV/D1l4z8O2U2uS3FopkyfJ5aLIPByMAH5f061oeKPDnhnULK10y5We6WOMeVJbARzKAMkZIIIPU5H4Vh6DLq134Smv7a5nvJpG4k2Akcjtzgc/QV0ltcCDTnubhlWW3iG9owck4/hHf/AD2NT76kmntdL79TepRjK8pPTqvy6dCTwZpGleD7BUsIZzJcqXK3EkZc9uwz0xnKjmuc8e+Gm8VXdoJ714LCMkyRKoO4kjoanTxD4dFhPqVxc5u4ZMrl2V3UnlNoPQ4Bzj+VbeteIrDxPo+lXOl2s0VmqyOwkOBhe3BJI+WlDmpS5kmua6v521/AytBVLNXXV9Elquv9dTn/AIhfDvS9N8Ef2hClrpjWkasZ4NzSOnTDEdck9h+lVPAnxD8IPpUVxqF7LpzwHyITOSzdMb8AHrwT71a0rx3e+L9STSItGe60yJAJJWPkqB0OcA5OD6ge1XvGvwz8IrZ20VvEksUDfcjkPyZPqp746HP86PdtGjWvzK+3Zrb7979Pxwg6srxctZ7aPv8A5eVn5j5rqPUZvOiupLpHjHkvuOCvYjPQV2F7p2k6JosSXcEc103SSNiXf15wMDHY/rXF3XkaBpsby6dP5SgJDCAY8DHB3EdOP5VS8OeKrPxFezRRrLBFEC8skjB1TA/vcen4VMoScVUlol27noVrTlGEZNRWunW3oc7PrWuXni2S28O6TYpaWsu17q7QPIF3EYLN0454Ga7Wz1GQ6n5obLPwSg6/n+FZp126vrWe0069eCNSVaIAHzQT94H0+lN0TTNQFtNHY3Btbhh/x9H+Anjgep9ua3qpNtuy6W/z63LpU3TpScve829/8h3iKS6F3IsEEjTjmNHIQ4Pc4xT7Xw+LyGMzQiGYDLAEEE5/WqMNvLaXcT3eoSXV825fLliJMnBwQeT7jip9J8PNaOE1Ayu4G4C5Qqf++T+NEpaWTt+v9fqdLckklpp+XY2rdLZLVY518vcCsgU5PtlT19PSs+ay02SAvFApjUfMAgU/iQK1tG8P291O1vBNFErfM8efmJ7jGelc9B4rl1/xHNoHhzRUtdJtWKT37ksHK9eSAAT2Gc1EXZOXRb+Xb5s5Z4qnCsqV25PXyS6mhocKRzI2n7kjKlHQHaDj1/XjHFdZew6K8cVu8cwR4TLNjnPGNmDkYJzn6Csu0mey0y5c2m/95tLgAFCCQDkAY78YrntS16K2u4bSWWXzpVAQhcIBkgAnp61HK6jv2CpT9rPeyvbfc6ewt7DeGtrI2dlEP3kRwN2RgHjPOataK7WfiNjZLHMqQspy3y84zyQOlcBNr81mZzELe8tAQsipJuKn/axnaevBrrPC3iW2WESrZhmbA3BiSBjleOmT3pVaclFq2/8AX3kVaTcJcnvK1rX/AOCX/GsNrYyJM+pWpkufmKBlj2ey8/d9ic1hagEutLgnaDzVRipeNQoVu49DVfxVoVx4w1Zb65EUNnDAzNtbay7f4Dk5yT6jvXWaD4FVvDvmabcCz+1J5iw5Z1yRxuYn+QqXUjS5bvXr/loZUq6w1OPt5JNP+tl/Vvv5VoY5IowWfjs3b0rOvJb2a4K2wfyFAcOrADPf/PFdb4i8PNpljEk1xuvDgFYwQrL6gnqemawLGxMEn7xWYpnIJzn8K2hNOPMtT0aNaFWPPF3Rejj4Bdkz3A7Hp2qv4d1aCz0e7WSNpLv7UwKPyCBkA/1/L6VaVZZnEUS8scAdceuTVrS2h07V7adY2mWLcWVRweOTnv8Al+dZVF7nLu1Z/dcxqJO7eum3fr+hl622o2WhXs0iyRvdFWO/CNgE5wOvQnp6VwHhDS45r+VrraJQ25cEYA9K9y8beNbC0t7ZozHc2L7kul8pmIyBtAPbOT0z0ryu0s/Ml+2aSZJLV5WkLhsDnnBHtnOauE5SoNSVm3f18vuW3mY4Gcq0vaVIcr/LovyOjUbTgdCevauS8cK8aQ3CsdnKsAemcc46+1dbGQEBJ7nHbHtVLW5IH02cSkYKjHPuMVtQnyyWmmx11E5Joq+DJIrjSpTPId0URkDhM5K89e1cHf8AxC1Gz1OUWkMcUPQblDEfU9efwrsfAUZs7ptyq0eJI33AMpB44qxqfgDQDFLfiZooyQ6WY+8fo319qijOnTdSE1dtq36/o/8AI5cQq0qkLSsml9/mYw8SDWrK3uL3S4ftDN87tCOcenY5z71tWmj3k9/Hf2t5dRwoMrbhvkUeyD09f/r0298qztok8k+UjYAOQFOeuMf5xVm21cmLbl4yqA5VVB5HsM8isGp8q87rvodvs0tI2uv62GDSmimZlmFxE5KlnkBz23AA8eufWrojha2ZZ3WUk7dv5Dn/AD2rOjvbS8G2OWMEHO2RMH2xVqSGS5tvL3soI2hw2CMn+VNp82pq0+WxYtY7S70K4sjK0EkmYyY0A4HqMHvTdE05tH0W90eNFuvtJHmzMMCMZzkjvx0x0xmlsNFigtHxL0Zi7F95z9B2/wAasWlqoZ3GWTaGYBgCMcdef88e9Zzs1bopXXr0OWVKm+aV9Xa/yaZDr2n2lto5utDRri+t2D+W+3DgDnGVO08D+tc1G2k+PdA/0RLqznjI3RmQMsbZOcnjjHf6+1dKt7cW1y0OnQK5kJyGDMADxk498Guq+Hfw2h8LaTeG1vYzeXeN8zRZAAzgYJ96mdZ4eCcH+8TVvOL+Lm9NGuvbQ8/FVHhpP2zvBrRPvddlt/SPOpfBWvaXpmnyaHrUoniLB40PzTJxgkng4x0rqtvlfu5ZrpZE+Vl8lDgjqM4rS01tU0nWksA9tdK+3cxTlARz09MfrXeW2jlreJmuNzFQSTEuScVx4lKUlCbatd3Wl7vr+hFbGrDO89VLVf1Z2OQ8M3kVtetNOJPmjMWIx95s4H8q5H4pRaLFE8Wq3NxEqu0rwxxHcrHofQ9zgdKi8T+MofA6W93f2stxIzASRRNjgclue317mur8Yw6L8Qvh7Dq6O8IMIljYrmRc7SQwU89AMdOtenB+zrQlPRT2M61T2Ve6WjVn+h5pp1rZXWiaY3h5pbuOImGVZYgssbA9GHGQev410On6FYWmmPpt0ssk9y5mEfDJGSOVGc9sflXQeDvB50LwsksE63wuj5khYiME5wOpxkDI989eKxidet9Ymuna0jsoWw0EUgL46ccZNONTnTs9tvPsdtKt7Vcid7fn2JPDnhQeErG91mX97a7VViMZAHqBnPXjH9at+E7SbWPET3wv1l0aUyFFW6BUA/MoMZGYivfvxzWp/Zl74g0q7hthttmQ5A+UkdduMcn2qex0+Lw/okFtZRsZLqMiQuOegz074/yKmU+a+vvN6nHNu7jzLm29PX03OQ8U3HiPxJfQwaZHN/Z9vPtjO/76g4JYdSOM4x/SsH4jw6nPpsen6RYyXKzS4Z4l5JXGB/P8q9bt9QlsbHfFEGupiVLMOVXsuPXr2rm9Z1Sz0rS5HubhbeAjLs4PznIwOM/l3rWjVamnFLTRGkHeDp2tH+rnK6C1z4T8JLa38w+0M+9kjIfywR90kcdevbNVrS2v/Eer27q0sWkW7ZZVcp5oxkk4OPxrJ0TStX8S+MJriaC6m0eVm+zGSMorpu+XZ6jHOfzr2waQ2kWZsIZEUSqPM+Re3TB7dadSpGk3CLu3u/Xexq8RCEV3ey9OrPPPFPgKxTW47prYW1osau8bTAZ7bienJ/8A1VY0W01a3vzcXYt/7MC7bYW4AU44+U8kdf8APWpPiL4a1nX1itbBoodPRd8uX/do4J5bjp83H0rB8O6L4k0vVWj1KVJtKiUKsiMWST08vcAcg9elVJ3ppuSbt/VvN9f6YsPVvaL/AOH0667nW2dlc2l1Ml1AifaR5sMEC8tGT98kdO/X0p7W8jaTcSxXElq7hgoBDmM9FcjjncM1Q8Vat4tk1GJ9FvI10uO3RHQgFpDjnO7JH1BrIhgaGMX90sv9o3OF+b5FCjqcfkM1Ki73bV9H/wAD7jSgp142mrX0/r+r/kcz4ZsfE1r4rni1rVrrUNJYsGS5uDIkxJwCFJO0/keMZrX8eWOvaDqNrp/hLS410eSIC48wqzfMPn4J4ABJB69fStzW9Nup9NtrKGLBeY3EmWK5OOPqfvV00OpPDJElm0RaBMF+WMo4/vcjvTlV9/nSvzJ+ieyfr5mcsPyxUaV7K/Xf18r9P0OQ8G+GtEuWE82vlpIgMrbLwmeNpyMnnv09Pbp49Os47fUQ13L9tt1cxiPafOA+71HIPHGevpiuL8Q+JtRvmnshaW0YedgQkXzdTySvrjv61Zh1RdG0c281wVQMXIZN5UE5BOBx+HvSlRqcyu7tv8Pu/Q2jCrOHxWX4L8PzOR8K3Oq3HihrlS+InKuJSTyc/KB616prXiG6tlijv47VJVXhVXcccepNciNWNwqNbyFZcApcqc5/A/Sr2neC7i/1FGN8NjENI7AN8v1z6elVUcJVHVnp5en/AA50VKMaUYurbTq/62NW0nF80ctpKy3DsSTJgYH48HNYMVt4ii8U3d5cShbHIx9mwEzxglR9O+f5V3moWNhoC26wTvPKyMhYldv1A9KqLq8zQvZrLDGJcF0+7uUdOT2+tZRnzR20f+ZhGp7SSq043S7/AI9PuOZvNYgjupLaaSYxu26SVSRyeTn8al1vR4tU0WWFX8gOMiXjKD1ya0LmztbwozwwmRGJDBeSPTjnHHWo7q0XULM2aBQJflCgfNnPHQVrBqMlJaG0vehynO+CNG0DS7O50xdSillvCPOupCTgKSQEXPJ967rwGNFgudQs7tNsWCI5ZyFLKO4IxjgZ+neuZk8Kyaa8YmdzGucYYBP0FHijXo7Xw+dMuVeaAKdsSgHOQVJJ4OOSKzlR9s+WL3d7/wBfI561GMqTVOW/Z9tnt/XqdPFcaf8Aabm9S0lvLLcQjIdwbnHHOT+NbI8Ui3060ms7U28R+RVkjbaAM8ZHT8P6V5V8LdBuLK0N5A74umIEYXbs9ORg5r0bUNIjbSEezvJLW/jIVg6rg+ow3v3BNZVYQ9o47q7V+62OetTpPkVbV6d9NOv+Zlaxrc2pXYu9RubeGKEbfLAYDHfAyef/AK1Y+n6usqMbhNuX+Qs43EHnJ/wqGTT9Qu5iL8SSOQF3eTtAXPXjqOtaUei6bbDzUllnKrwcbUL5HA7njmtfdj7qPSjClSio/gugahqjWOmXMsS+Wuw7pHGTz0C+np/nNc/4cu3u1mubmWby0YnL/dxj2PTOPzrnokudW8QGO5EimJwHLMVVRnnntx71aHinRp7+fQobS6t33bNz7yWIP3sk9e/TFbTp8qcV0s5Pt/X9WIhNJpRteW3md7ZC11a2mCTWsyDBMMjYLAdl6j8/0rk/Dt4Rd6nZGGe3QXPmKgG0AEY6joM9v/r1YXw5fQ200Gn3ctpdrliZVBKjHfI46jnmun0+DTv7EDXt9u1JVALLEeT74HIrnnJcnKtbtW8ra/iJ2hU5tWtPPf07FBQsUMruoZFywYnP1/lXNDWXvLloBDFjONuzkD866m/0+LULVYYZvLZz+8BckFeOTjt3+nXoaqW2iW+mQObe4jLFihALAtj6/iapSSjpu/wN4VLyuzL1W7u9I0+KWzgDvJJtCleBnP8AgP8ACtPQJdSl0lDf2xkmIyTtyFH4UTNI9s0aFjGRgoQOc9a5Pwz4Xu9K8RLqLagYolZiYgGBkBzwR0x60qkV7HmXxR1t1l5X6EzU+e9r3/D5Hoa6O9/b3AQ7yqfNC3G7j17f5+tc83h9VcNHNcRBMja4DY9sdcc1reaZZzKrbShypzgj/OayLu6uI51WWWRmPABwB+Pr1NKKlZ6lU4T5tWYuqW0dvfhhDJHCU+9FGOWycZGfpmus0aIJYCa4FwkmwtGwcKDwchupyfb/AAqKwRr+P7Mo83jcAvJ/AjmsdLDUdMuriW2d1hyPNtLhSp69VJGD3P4d+lTO1Vabr8fn/n6XQSXK3C+7NTUZJLOO4lt4DvAJ8oNwW64OD04rJ0TxHJPdPDcxwBSVH7kHaw54Oc88DB960pJreKBbiTiQMMfPjHt7f/WrE1fU9O00QzW1vBLdyZZ0UhPkwOeOATyAQOxqmvaQ5UtX19O5NSShLmm9NjpbcTnVV2/dYMrZIxkcg/5FTeKPEuuaBpMcOlWDgMrCR2feUXPBAH49c1S0J4tSjtbm2MgDx72jDh2HqBjvj1p9vrOmzeJp9LiiI8oESyK+4Zx03Dvzz09KwUo3dWauoK7+WhjiowqNQfy+XzJPhhczvqIlv/NBkj/do2MhieevOMZr1RvESIxVpowwOCDC2f51wXjQ+Tf2j6QU8tG8qRdwZlOMgjv7dMdqkWXCgOse7HOZGHNclRR5vbT150cWJw8Mbas1bpY5fSoda8feEIU8WaLbLuY/vmk8qZgOhweR6e+M96d4t8Q61Bo6eGdA07yILdViZIo1f5RgDk4B6GvQbbxzBaL5TafIsW4/NwMr24yefWnweIvNvHvLNLR55AQzyAjao6D8s/n713RnOMuaUL2vbsrv+vwMPZ1oq0qWi2d/6Ry/g/TtY1Lw8Ib/AHRX8PBtjKTuHVXwDgcn1HNcXrmm+NtBh1zUJdSurxlRAvmSGXZlh0BJVQB0HtXRH4yaEPELQW4ktr2QiFpo0Eienf0rjm8R3Wk+NLq51N5CryyiRWyfMjJO047DoR9BiuqjGrBvnjtZ2trve36fmWnOo7u1tvNN76rQ9N+FWv6tB8NWvNXaOaZWd/Nxt3D1Yjvx6VmSzeIJbeO4iVxLqUmV8plDQR4G0Ads5zkDPfrWtrer2g8Ngare2VrpiMrAqwjEncA85bjnHen2HjPwvHoV9rGlaiuoP5YjMMn3lkJ6Y6gHHXpgVywTj70Y35n/AMMv1+RCtScmo3k369t/zZb8JQz6PptxJ4imaS5SYkGVzNtXaMAHJGeD79axdTsbXV4LqPWIDPHKQI974O7OeOPQd+xrF1X+19Q8JrfQlYLmWUDyEB3Ip/iPpUvhfSWsIo5ZZZ57tFwVDEiIHPT061so2XtE9W/yOunQXvNu/R9Pkv1OjsYYvC+kpJ5sNrb26iMSuWLgcYUBepJ7DnIP1rz608P+KvF3iW91nSLy9t9GkfaJnuCikKMfd3ZPI/Xmut8SRajc3suivYM9q0AladoGZVGMFu2MZ6+oHNYOs+JfEGj2o8J+FLFv7Mji8uTUDC5HzqGYg/i2TVxuotQtd7vsvLzuc1RT0qQs29u3z/TZGpbJqtzbGdr95beCQW/lLKQr7O7AnB9eRUkXh3UtX16M3N5cQ2hHmHkhAgHJyDyPpXGxW+vaD4Ykk8ON/aM32kCaTy/NZCVzlVPGMjGea9A0m/1fxJ4AWXWIGs72NSm3aYwqhvlyueMhcYOeD71M7wtZ6SbXml0udHt5x9yKV11t1aWvnqcd408LTX+qNeaJ4qmMaMY4LYrJH5WOv4YxzjmpvDa6vJLBp+u2crSsyhLtAGV8nHJ9fx/Cu88KeFrqHbPdwLKdocZydwPoSK5iGXUPGviN10sNbaPDIqGNer46kj168+gpupzReukev5LQdCpToy5Kcr21bv8A11/yNTxVLa6VdR2OpatBDNlY4vNkVS3GTweRyf8A69XmFlpmmEJJ51zIp3yNysfoQe/rXNeM/BfhLVNdS8vYb+WaI+QbdbgKny8FsEZHPoce1L8Qri90TR7R/DFvFcW+0rIpjaV4QuAMAEY78nNKEPaShCPbrpr/AF+Jl7aapr2ie+mm/r+ZnaV4l8Jalr0Wn2d1cXFzyXLxtGrEA5Az6cmszUdc8LXXiea0uZL5rNn8tZo0DKzc4yOCRzjP6VZ8AQ2qiDU20S1tL+5c/vjExI9wGJ29T04rbuJdU0S9efSNN0h43YEyNar5g4GWzkEHPfmtbpynyX7K7131+f8AwfI6LYj3eZ69fO/5f1oNeXTNPu5/sNujWcQwXuYucDOSAvTmsy41d76RjbuYIOEjCRfLjA3bs89ff/Cpr2e51RRE0CqzSu5kTI3FuTn2qDT9Kkhvf9Kt3aIKylge56Y9+tKCUY+f9f1+B3Spy0b39df6+RZ0e9H2ryZ44xj7sifdPb/P+TXQzXlgmfOx5/8ACNg5H1/OuOnOlaPrtvZXt3KZpWyqJtJUHuTx/Kusura3e7kjhdpogOJSBj/PXmlNJSt5XI5oVbO/3eXQvafLCWE2FRcbUBQ4Y9wcDtxWfqOqJozG6aSNHxjceMY5HJ+lZMOt6a9z9mtr4z3ERw0BhkUoM84yADz6VsNaaNrbraXM9s83mruhe5yT+Rzn2zU6Rb5/mY1HGK5073/QwYPGVx4v1OLTNPv0N5tJVTERkAEkjIwTgdzWjpWhW/8AaKyao1xcSxnMhkULnB5UL+ftWCsX/CM+OLiPRLW2h+fyneK3G8eyk5P1wea6+/WOOEzXVwRcyjeWlAAYHPf19qc7qXItItaW/UVKTlBaJJ7W/rsVPFfiH7GkNnosU1qu7cXZt34ADj/9VV9CuLwYn1LUZFMh2r5kuCTjOMfnWnpFnc3aOrGNIgu8STMUUDnpnrWbqfhN9VvtNmXUdKFq21WDTAsrZP8Ah2pXppcuyQ/3VG8G9e+5unR9TvYxcLbSSI/CSO+OB3x1xjnpSyW1zF+4lRTNH8pQFS3IHYdR+IrsryG9bSls9JkVVtyEeZiOcYICnHP/ANfrXi15qmpv49a3tny8jDEhVmYtnGc55yawoylUhKo7LlVzlw2JliJcraW9u/lftoatv5t411He2jqBgHzUOGP1A4NZb+Ehb+f/AGbqCvKw3RXEXzN1yB/eU4zn/wDXXRarol4ZZZrySQgZ3MRlQSTkn3PvWPcaxb+HBFC0k/2hyAkcYO8jIGenGPf3rpTlL4NVvbodsuScVLm12+/9TnLXxDrEc7+GNbtNS+13yeQ128pLkNnY3Q5HI71N8L/Pg+1QXYuJvLmypduw4I74+n4V341XUns4PKhuZrWMttPJA567ef54qU6zp1paLZ3R23hUHMSEqf8AfPG09OvtWNSSqQ5YK0W09OjV7vvZ7W6HPCE6LvPV/Dp26fdb8SpK6X9/5X2b7Dh8lU5DDHfH0xTJyASvmGRUzjjpx7/hV2CxlvLhpbZLgvzwvABH8j0p4sZLmdlSaJJVbaUl+RgePz7UnKN99DoVSEdL7IzPNYIvyoTHyTvGSD3wTz+FUdQ1ea0niVrOSUMAVDKRnj+HNaWq+HovOgtdWeI2suNzo27ywTgk+nc9+Oank0u103SVsbPURe2e0DLHIQg8Yx0xnt703KKaSV7/AJd79fTQJVYtpR1v6/MginiuLQSR9224IIPTv/Kq12qny0lyWYkjjOB65p3kPbRJHbOhVeyjp3/rT2hYBPPPyj72D8x9xUwTS1ZvFKLumb/gbRLK/u5FnZikfIiAwGA756jr7Vu+L/CVnLp7PYSNa3X8KmVtshHODknsDzXkmu67Lp86HTDs/iEm8Lz6DB6/4VJYaxe63dI2ozT3dzGAV3vuA9cDt0H5VlKjUpyVRvT+tzgnhq1XEqrCrZLp/WjIrvQrqW9jaaQLEgAcHB4z145/CofFFr4b+ypb3GZLuZSsSwRFimc/MTkDGe3HfirviSy1HTdbtLuCe3ZHjjDRyTBSpzyf/wBfpW3qDW1pbpcXL20shw7ShgxQnnBPA/Ct+dqpFrW60tt8/wCtdjpqSVeKvom9fP8Ay9enY8w0LSNW0PVpJorpobdoTEudy4Rj97IPB9qbqvieTRdStdK8O6dEyK/+kXUkReWdiO5PQDJ4r0FvFfhq5ldbme+c9HeOIHJzjBJBwPwq7a2tncMJLdY7iMgbJN6h8fTt9OKHUScpVY+81tsr97dbXdu177mSpwnGPLdcr37rtfscn4R8Xzz6vPZXVuJXnLKokyWXkY57DrXeGxumJP8AZw55/wBcv+Fc5b6BBb6u10bWeJirKVlTCgknJB4NXSJQSBeTgdgD0/WuacHzvkatZb33OjlvqrX+f6M4jVrXX9VilsNLH2i5jkyGiYAMMcjPQnJrd+HsfiTRzNaeJdPmiiYAxPKRkEZzj1q34T0jWd97LY24tZ4bdlh8wjDScgdyB0PJ4rNs473SvEYn8Wm4WWUExs0wdUOPmzycE5HOf/rd1R+0jKHbtv8A1/wTgU3KrZv1X5EPjfwPBLqmn6nbpHawtKDMoBBdsg5AAyfTFWPiG0aeH7GdbSNJYpDCZ5Y95hTHA2nsfcHH1r0O0C6ZJDe3AWWBXAFsWKyjP8WDjjt+Na03hC08UWT6jqUkqGX95AsJ27F569iSKzWKSlGdTVLS/e5lWq06UW5aJ9fPtb03/A8C1LxNZar4U0fStZ0zz7uW5wJIz5QMAbaCoA27jkjOOMV22lQ6F4euItOsLaONpwfI8xTPtYDh2z14yPQZzjjFZOk+DotZ8RXVzr+5F06NGtWjKoHZTkKcgg474x9cV01n4dsZvEP9oJcXTzFNpSRwUTJ/hH4/rW1TlXuLZfdd6/cr/ob0YqLk5/f5f8EfrVyNN0grao0l3J8kWOMnHXb+ZxTvC3iFLI2dlPParPgyXkcscjStxxt2jaOeTk9hxUvijUtN8PTQS3t2VizlRuIcnqBjPX8K4268R+G4r6e5sXuLnU7qHIZYtybh91MkggnA7du3NLk54Wt8/wAPw/Mc5U6kbSe/39eh3eq397BFImlSuTckMwdiQEJJC5POP0rC1bxdqOg6hJapbWomIAlATcSCo+bHTuemPeuYvxe2zQS3moSfbb0Ftlu5/ctxiMDkg8gY9K3fFLNBeW0N1HHFcOinzEYDkjJ5PI54+lOMIp2te6f6ahN0+Xlt692bem6ndWnhnfbQMZZE3eURwSTnJHfr0qol/qM2izy26lbl1G1CVwGB5PIx0BxnvWj4RurlbS3nlSR0TeQ8yktIAnK8k5HyjGPWuf8ACmvatrqareeI4F0ywt5UKRwwMilcHPBzk8Dv3qItpOTWzXzu9rfIJVIRqSg1vrc6XQ5vEw8JXUV5cSpO+YbZt/zcjgfLwMc96LOxj+HnhRvPmdtTuGGGic7u+QMcD61LpPiPT49MmuFtJLmASH/WKBIp46YzXIX/AImn1DWGW5sESEuI0iIJZAehA6Y/xqYwct17qd/V/wDAMo4eU5uNuVP8ey/z0NiyZNQso7xA/mv85Ruuf8ev5VuadpEmp2MkiXCBd/CHALHuM568Vyus67YaLNplo3nXM92MBbUL+5GSOQMY6foa2YRGANtw0ZY8kgjPpmqkpadL6/I7ZSdSL9nLZ22vtuiLWNTk02zCTpGxgkxjhdhPGdwzWLF4wt28z7TECuCmY5Qee3BAOOe2f8Oy0oQJf7ta3y2JU7hk7T2G4Z5A/oK310Hw9dJJ5kHh9IHPCxRKr4J5ywYVEq0Kejj8zjrYpUJWcdO6PMY5obtjPCQI3JbjjI75zjFbX7+S0Sd1ZonwFYHIPoRiuA8d3yQeI7vRdGZxp24gSRjcGwTgAjjHTmus8HaHDpNknmMWZ1BIiPOfQn04/WtqqcLX3fTyZ3rERrRU4r3fPf0Hf2DZ3N8L+5szcXMAydzPx+AOAOtbFmp8g3HmxxBSQiqoI6d/TnHrU1zdWmn6YZyt15052jb90HvnocEe/FYenXrzNmeIrbjhI92GY56/0zUtufvP0IgudNRVlf8A4cz9bMcWpyNbb5Jb1SLiVRtKswPI9euav+Hfh54c0VP7U1C5uL+6hcSxoispY9QOGx1FZHiHXr611KEm3jS3UkRopBIHqD1J5HNdNpt/HdacJ2ibI52vjOSPSnVU7KLej/EznQVRcy0a06bdLaaeqM62ujd+KL7V7i2W2WbBC7wfLwuDz9AKwb26vfEviFfKCi1iyu1VIwqnGTnOePausmsWaOE7QWuMgxrjIHuO2f6U/TbJrKZoYrFTI3qnf05GKOZKL5fT0S0NVTpwtyPSKslcwUfUn1w2sfnC2ZRGQQShGODgH37GtfTNKtruZp7eJFMMnknYdjPzg9R09z6itdFSZkuFTAXO5GO7BHByMcZz+Xeq8zmRpJcmHJ3EL8ueegHfHTvWbk2rLTYlNvbf9TZ/tS9tg6u8sdsy8RIyuO3c9O3A9ao2d2jSQS3D26NGcIDGpkAz0BC56n/PWseGDW4ria71BPMsHI2B0bA+pHf8akuAs1oRJLIh4yUPI9qSpx1j0/4BnHDwa0S17fd56nS6pfXd+ro8ka2gA3JEeX/Ejr7Vm3el2DrHJbsTJnG24QExg98+n41RsruO006eOcTyO5DQsMdenze30rKN3e27FVdthxyP/wBVKEH0LpYVx92Dsk/vOtic28cBexEkKkbwFYNtHp0A/AVi+L/D2hmddaiEwjAVpbdHOFOcDk9+enPrxWBceI5ILz7HaztIxyJJCCwA9MA+vNT2+q3lzBNBOvm27YQ7RgEZ6EH6evUVSg6b12e67pkxw0nNTg9V62/rsa5mh8TaO0Wh6pKq2TCVrFIi8pPQn7wyfofSo7uzjfSo5Ipz9qUgOZTtYkjJ/HPas/w6INCunnsLdrO6df8AWKeH5zyD2/wFT3gmvtR+0TOjkndtK4BJHJwKmKcZNL4Y7d/R9N+ppRoVacnd6b/Pr01XqZllqzfakjuo2ZDyGJzn/IJroFjLOUjDCM9GJIA+vpXIa+txBesY41UyLn92/GM5Pb+XvW/oRu7kRqB+8cKNgPJ4/wABVVouFmtmb3c05PSxrm1uYY2WP5tq/ejBPHqeKhR/tLCGW7bzANqjaMYFbd9pV/oWg3eqSyvttYmmaHBYlFBOABj0P5Vy/hPxToPi5ncW93FKG2lpkXrjtg9OO+awlK1P2v2b2v5s4qeKhOTjF8zWum5BLo6WyuCIyv3iHGR9altYHs2aW1sjbsRu3qoUdMZB7nrUmv2ZuhJDp11JHI64SbbkKfYdT/OuA07xjr+h+KhofjOdbqKTbsugcrz0YHjIJGMkdc+lbThKVOVRa21a627262+/yN54tRnCnJfFtdaenr6naatI1wr3EoNxNGvCsDkAen/6+9ZEWuLPbvax2KykjiFmxkj0POD7c1Yu3vZ7tLuxnZ4I3YTYYnIU9F7H/wCvV99HtZUTUUVgzgMu1sA84P16fpU88dLa9n+n6+hrGpGceV6L+tTiJbhY5zGPC7yAnK+Zdnbnkc7FUn+XFWo/EOq2lykusM0VsefKt41Bx06f/XzV3UtWn+0TW6QBUikKpKmA2RjGfUdTVy2vrG50ua/1LY9xEwCuiKzJk9v/AK1a1N0prf8AN9n08zKNOC1i9V+XoejwWmp6lpcUMEKTxyqJkHmYfAAGTk8dQOvHpVRvBmvlifs8HJ/56j/GuJ0fx+LW8b+y7W4urkkqrSsSqqcHJIPHPYV3A+I2v450vT1PoXfivNarUVyO2hyS+uwb+rRTi++n6lDXIdQsJZIVzDcD7hBBAPX+veuP1KWK/vk/tSGdpI8hzDKq7l78HqSR2IPvXdNePcaTaLL++uUUtIzL8xPb/wDXXmmvR3aahcXGo28sScujJkhl7cA4z0yO2R+PqYdc8fM0bfKuda7HpGjXmj2mlrp1nbxSq6mSNzI29E3ZJw2SOT0z/KsbU/HOr21/Pp2nTl9Kggfc6oo24BHBIz1x1+tYnwgjuda12+urjc9vCh3Q525bggAY6DA46c11F6kFrDcrFawRySuzEhcO3+z/APXNZqEI1HBq/wDWpjClTqPlSu99dfw/yOW8K6j9u1QLJLhWiL/MpBbnqc89Twf8K7fVte0nwvoS3V3OkZk4zsbOc4B75H0Fcp4W0OW21szao1vLdyniGPl8E+/0xXXePvCGi+JY9N0vUZZLCMhybiN1G3/Z6Y6j/Paqjg63vv3fIMVUslFK71f3HOeOfBg8WWWmahFeBIY12ynZkEZLFw3Q56Z9u9QHwho1ja+bo1sVvraFyZ3l3KDjCjBOAevNYMkHiXwbrNl4TtrqLUNHdxKJjGXJi/iDc4XAzwPXrWh4hN4LxfKcpaxMoTaT82R1Pt2q4KbtGTvZX8mv6+4VGKnHm2u9Pn/lfQt/CrQLvWtZL6hJItvCN8rngscjK9eM+tdL8Xb2CzjRbBIVazGxWC5CElTjPfgn6Ve8J6Xd3dtF9lu59Os5WHmCBNrSZwOGA47cVxvxa1a307Wf7MtIERbcYkM/zsxODkknnP8AhisqV6uJ5nrboROUfrKXNsnZLp5v/gEngjxjFGbK48UagI4jPst1EZJbjkAAH5Qa6T4r+LvD+m2FhpwtZ5ZpyHj2wNGCmRnGQAc15iNAu9fk0vV5I7aPS4F8ogZ3FwSdqp7g5/D6V3Hxq1DR4/BunwWkB/tGAxtbyBdzIWIyueuTjPPpT9nB4iNru6e2yev5dTPERtVhUV9HbTay6vzdzrvCb6fbaOjwWn2GwuW3pHOfNQyYHJzzzzxnHH589qV3apfXUqpayNnI8uPgDqWJJyMY+mBXJeGdV1PxibTRY/MtpbeIiQIgG1cYZjz97Pr6V6Nrek+H9D0RtKuLeRjdRNBNPI2H2uhBIbsepHHWsoJU5cr1b38v6/rc2co0ZtwvKUr2S7dLt6+R59ZK+sRXd34X1i3u7iOTZLAkO1gvX5WYAHg9Ksac11dlortpY3jGS5iKlW+netn4ceGtP8JRXo0zUbi/nunLRyPEqrGMYHOTk4zyKveII1SF9OeV458/u5FZQQe49cc9j3roVTmm49L6Py8zajial7SV21t18ynLNcrppMbJNKseNrHH5dDVHwkFv9Ad/EmmrZ3KybUuMljOnP8ABkAEYxnpVAz65oEQkvbWLUrPIZpMhiBjGNw5U59QRXTyNeX1va2nh6whkklXd51wpZIhgE5IHHWlOOijtre9+i3X/A+7UKlZK8k2ku2hnaxpOlW0tu9hILkMM5K4247YPPIzW6dDv/JiumW2+zPk4hYnb9f/AK1YV3pHifTdGnbToNLbXSP3bBDtAJ5I3jGfrWd4ah8Q+AdFbWvFniZrv7SgaKxM3mYl3ZHUkYxnOMVEuZxTg7tu1ur8/Jf8Ezq42V1CDvbq+t+n/BsbOp4SURSKEC4IAU4PvyKW1glnhWSKNWiRsBiABn6n+Vc/q/joa/dxJY2EtzqEpxlRhB9O/rWtb6Y1tGG1OXzLo9YIm+VeehP4VbuklLc7qc06aT0f3/5feVn8O/2rqgJ2zBW3SKmMKB759q2lT7HiJIkO4YXDZ59c9+1XbVZp4mntbIJEi7ZFhOCAPYnk+3/16sQhnjKJBJJ5LmTzZAEBUfw8+/8An0iU3LfoYTrO9nt/W5wnjg+LbW5sv7AktdKgKFpL+7MbLuzwgDBsYx2Gea6SwnuF0O0m1fULe81GRQJ5bRcI5wcHoBu9ePSq3xJ0628UCAPK+nxQn5pIWwGyowCMjJB4zj86boVvYWOhfZrG5efyB5ZL924B4x1zj8qdS04wlbXr/wAHv/W1jnw9OWsql7t+unbyS0/C5al89bgy2snzOoDN3PY5B69KzdUvPssbefJkD7qM2Mn6dasa7qMliba4jj3OcZAbpgDp2qguoWeuNLHcIUuzGwikkwAZMHbubnAzgfjVxVkpSWh3KTUeZLZfP/glux8TXepxLZPL5lmg3LkAYPJGeOaklcMzFioBbJwoHP06Vn/Cq/ste0670fVbIWviCAmNZVTy92CSNwHHbB4/xrSmikt5XgbbvjcqcdMjjj8qzi0qk6drOLtb9fmTQq0p/Ardemt+un3eqOa8QeO/+ERkto49Osb2ZyftKzyuHQDooC9ODnOD/StnU9UL/ZZotNjt/tEYlWPcfmz6HHsap6tpNm+qQ372cd3cPgM5/hx0Puf5YreIEpaO4Vp1KjCSfMV9AAewH5ZqqnKpxcFpbXzf/A29CadOcJSqSd2356Lt/SMLS7eCfULm5sp1V4cNNaso3qCevU57dOlNvtYMV4saqqorYOeS31FXba1tdIN1dx4KshZ3YZIXuP8AOT2rMtLOfxSZr61sPKgVym4KNrd+T68iq0TlOb00Sfn/AF/we5rGfK0pdPyKeuxXQK3VuFKM2QSW4AHT9K6KykhNhHPI6qm0M5wCRnvgkfWqb2/m2AtrsHKHIAJHP86wLqzugu22i2lfmLnofXJ79qfL7RRb0aNnGUbpbdDrby2ikELyqkjZ8yFxyp64PX9Dz7Vw+pap4hm1UaTDC9nFITCbiIFyFP8AdPuB29a7LRoxLpyj7Q5C5C46Zz29qpahLeWsLS2khEkZ3fLxk5HT06UqM3JNNLm2TfT+uxjVoxnFxk9Oq7r/AIbexBp2u6npkUnhD+zL66tJEKTahNLgiNgA2FK9MDPXuah0+1svDz7NLiuLkyksAAqkjt+h7f0rR0DW4NVMq3qSmcLwFAbJ4wTn8ahu4iGMUJPmAjB2hivuO2KxjCLvTa00bT6y/mfXV/Imjh/Z3ktZPrpquxLf6reWscE0lvFCWcKed5Hvxj+fak1rQLPxRZ2S6yTbH70EuMMh7jPoT6/X3qvpegpbJLc3U8siA7283PPvjuf/AK9dHZj+2LV7i2zBbRKAFCMd2PXH+elS5ODUoO1tL+vT+ugqlOMo8tW3T5f8G5kHw+bSPyLO9ManIcuwfco4LY7H/CunsNJstP0yCPUdQi+zplVkLhVyefmOcj6VnXXhe71HRrqS3u/JcIXLRnDoO4AI6n1HpWFY+H7SwSAs13qF5Iu7zbtzMDn+7ngYBHas3BOK5Xs9l6b3/wCHJk3Wk4wla278/wBPwNVYtKuGlnhjivZkl3LKMsrqOOR06Vz1gfD/AIfjuh4gmWKEzFYldiAV6jgZJ4wP8Koz3/ilNXidEeC1LkAQr+7wT3xgfhTdYttL8V3trHrWny291GWQsj7EycdRj2//AF10OCTcKr93R3XS2y/TTuKSnJc1P4ttXbtf+vM0NMuNNuNZudL0gQ2krx+bDcOS6yo2CMY+pz9DUR0XxuDhbiNgOhEceD79K7eL4X6Tp1tZ65pM8sV1bwiJI5SJIivXkYBB5POe9Thd43C4iAbnG0cVzUsW7+0UU4yS6X16+euj+856dZ1lpJ6Nr8TOmmaBPM2E+mTxnsK55PP1CQ2TtMXmfayEgAKCT3Hp/Ie9dTaxx63PBaWNzD5soJyZAMJg849a1NaSws4rdbKKN5ogVuJlyQzcYHPXoa6FUUXypa/l2OiVWLkodX/WpT0TTYPD+mLJagLK3EaZBY5OSxI55IrMS4ttSvZPLuEkmjb97tIO0nt+hrEXxsbvWn0bTIjIzqwe5KhivGM8jjB47Y7ZrR0Dw+2kpI5ZmefkyOBjjOPr1quVwvz/ABMKd4tyuv66G/8ADpETxrdHUAn2sIUVi2QTnIKj0Ixj/wDXVz4hXWm6lNcWui3UP9pQ7kuDEc7WI4DY79fyNeevbavY6vai+1SQxzSKrSqxVGJPA2+v6Vh3l3qdz8S0XSbe5so4ZAtwJAVWZQT87DHftmm6H72VVPZfLt/wxyextiIVru+1v19P+HO20OOSw0OZNXmGEKr50rbQhJ4H+1j+vtWpftp8tlYb4olmEfyZP3yDzx+tSjTrXVS1jdqzrcYwkXGJByCfXpise/0DGoiKa4eCALsIBJ2ZXHTPX8OtTFxbbv3Z1X5pNdVqvuNPRPHq2SNp1hNBLIVIhDjarOeBtJwGPHAB57ZrjL9zrmuyNr1rJJdbxmUNsY9OMDGO1YlrcC18RRWcqNNNZzDyCozvdWwgbLcJnmvS/EVnZwDTZrhIU1R0LTqpON2e5PX/AOtzWjjGjNxirN9f66GdBU/a35VeXl8/68zyubxdq+h+NvsOm3QttJtCCkEkYIk46nPJJz1zXoljd6lf+DtS1u6sRdXgYPH5afvHP3flwOOo456U3xRo/wDa1tYRQpZuuVd5tg80Y4KhuuOf84ragv7uG9On2tvFaachCrz83B4z27HtRUcXKM4Rttf5dPn1JUJ2dt23r5Xv/wAMjzez122ufDV9pdtFHpHia7ulSZHIjPlAfMhLYxz26113hW3uIdEbTNX1CO5t0AMCbS+zrkZH/wBemapomiWPi19RkslmvYVJxu/dMxziQrjk+3TjNP1TVIdGs0fVma1e7k3LDEuQFUcnH+FVP33ywWm/nfr8kkvkTRhFJ1Kmjdtfw0/rr5nZaPpVlbaWZbS4CTIxOCen4H/9dcjrtvJeXf2lkeORSCHJwpAPGB+Hap7DULTVLdb2ymnnsRJ5fnBNhU46FTz+NQeI57yawt7TQYpbq4fO5lTcyjnAHp35rOkmpavfubU4uEvaN81/wL+mXc8l6kq7UbfhWHRR056+tQ+LdX1LQJLuLRbpmumx5gjQbXG3jAxx17VgaZ4e8XWLLf67d29lppZdzyS72VSOAQmecgcV1eppYxSR3Cf6Q6p8rSDOCBxjPGKFyKe3MvwB+zryXLqnpprtqrvVHn+geLPEV/q0dtr6PFaO5DZhVABz1J49v/11cvPCWj3hMttMbe46tEyjaf5kHp14+lT3PiRYLx0S0lcMx3sFRh9Rub+VVLeV5dXtJdODMGYplI9nccYwMn862alFya08uh0KnFKMV/X4G7ougQ6PFH9jTMki7S+CDnuM/wCRXS2+nuBKtyY4BCuZCzBiikdwKuQDWjHBbTWtuHhXeolVd4/DOecelYV9EJZtR85mWW6jMMgjIXGePlPbtXPFuXU53UnUvGLWnZ39DjtQ+JVi/iUaLp+mSXqFvLNyrYyehKqM5HHrXpySLprQ2W4rcyjzAGYDCe4IyPukfnWN4S8EQaPHFcWFrcB5MtNOrjcVPbg5I/IVzlrDqVn4w1F9SnNxc27GEGc+aNvbr1HNVU5Zt8miXTv0uY00qsvYuV3q/wDgfJ/mdBqUb3N1HcxXCyPHIT+8Jw2cDt0qrdWBmsJ4718+cNpEfRV/x9z/AIVs/ZWtvD4ucSKshUgtzl+c49sVQtGhnuXjuZsXDbZGiIO7YT97PT8KIz0uun9fqdEJRs7bJ2MvTtC0+ws55fOXyhJlYGYjA7k+vT04qxpSw31wI7R42JbYXB6VW8RazbwNd6XfW10qqNiOkS7Wzj/a689hWDpfhrV9Mgkn0phIznfBZybs47kngD065q3F8t29X3/r+upca7ab6dH/AMA07jVZtK1eaLZGkgIR2Mihz9PUfT2rTtt87AxuHyN2Ryce9YmsWkUNvBd6q+NTkzvSPB2j68+la+i+IV0PVrCztIJXluId8k4xlQxIAA78AHPv0qartHniun5Gk6vLDRJybsvz/Q2ZPKtdOg2hGncEMec9e4z9az7m5gEYZy2/uwGf61LrUaxXExswCkY2qrPncQP88isO1uFuVeO5jbOcYIPB/GiEVy83T/MdGCa5ur1Gaj4fPiV/tEWpWxtrcDNs8uxmzycLmjWJ/E2j6hZJot4sOiwxoFjRQip8vKuTyTnP6VXs7aCSb93gop+UtmptXaeCYQRYkQIGYdM+gyfT/wDV61VnOfLPVJNa9PTz8/NoirhYpqTfW9v8+5sadqkF/O8l9biR5CfNkR8YB6kDsar3JjSdo4h50KjIO/P09/8A9dQaXDMR5syKjtghAeParwKs4ZlAAOOeh/GskuW9tjpSUXdfcRtczRE3UsQto8bTK2FUcfgM1Vv5UvraaK3ubRmkQgGOYNj2wpPTrVLxVcGcxSTSTj5tqxI3yKMdsggf1rP0FtweeCYyKDxuUB4wPfHIP4Vo1yRU1uZxTk3GSRd8P6Tepfo6QsZMgKIxuLH2x3xWj9quLTUWhv8Aw7cIpLKs824ByO+Me3Iz3rc0DULq2n+1WyRFU+Yq54zkZI966G98USalFcW8YWB9oI+bbkj1Oe+cVyzm3JtrfrfY561WtCooxjePXW33nJ3cE62RhitQZGUkM4JyD046YrDgj1e1mzMVjQHCpHEqgtj2ArdurjX0vYriCdU0+JRltucgE4GT26fkKwPiV4ovtJslmgWKW4mPlKoQ7CcZ6KQc9O571rSpSqSVHR36l+39inUmlb1uzatb+/UAy3jsHYB0Ygbhn09OTSajqMd1cS2mSeMquOOeSAR/niuU8KX2tahpjz69ZpbTGTEZRvvpgckZJBzj0qvrkepWF99rtQ8sWMqxYZB75HHc9hU04qblyPVbdntsbtRVqnLb5bHZ2cs6abi2kZVL8gDAHHf3/wAK43xHZy3t151hHK6ll3FMkq4H05rsPB2pw3emyR36CLc+/aoABbGO/v8AzrQWC8092urXYsb5DbAACT1II96zpVnFy5VrfYyqWc2mtenS5FHql7a+GrePUoZ2hgjyMscMQOnHXt16V5Q3xXgZiW0iNWJyRnofSvWIr/7QxS+kaYuxaNM/KeMZweMVXf4XaZK7SC0hw53fdHetMJVweFi4YlehxYn2lNp05KF7+n5HMeDPBdr4f1OMXOqxahOxCmSLIjUHGSvcnnHtyOa7XxBfWsV1NaWkySW69MSYIB9B+lctqOo6X4B0m8GladJd3kkJjElzkiMkcPu24z04HpXD+HhLc5vkvXkunUvIjFlUk9yehHp64rb2bl+8l12/roaUOX2kYW0S7/idR4QttI0bWfsVpLNNLNJjzXj6nHCk5PavXZbBxYKotrgTKoXMg+X8uTzj615P4e0yPRzPqV1dCbUIOI43QovPO/OTnt6deccV27fFM6F4bmutYsVuzEQFMJK7yeBwQfzzWdbnnUvTV2/xZnioVlTU6UdI+dtP63MKyvtD8Q+ILePUUkZrGXesTjaScjOPXp3/AMa0Nc8V6Xbayumypd3F9cFniWNVCxgk/fOeuB0APrXn/hDVLbxR4yutRdbm1k/1gjDZXA+9jH1qF7HVl+KDSIudPE7mO6ZACyYIGPfnp155raVOPNLX4Vp/kCXM4S7vptb/AIP5Hf8AivW9W0Wy0uy0fR2mvbufdJM6EJGMDax46fe9B1rprlprvEl9Knm+Wu4qBsB5yPcdegrx+fWPFN/feIbC21lEFuJLlfMBLRqn/PNuq8D9K1PDGta94g0GJdGBvNYG6FmkcY3ZyH5wDxUzouLV7dm/Pe7v5GcLPmk91d/pp5XX9WOvcQNqNveWMEL4fZLcb1CxdSzE9CfTPNY/ijwZcatNLqd3q5CKu23iIUtu6HHqOK5TV9G1bwFYacNftRcG8VpCI5s/NkZVsZyRn9eM816Z8O4rjV7G3iaJlhLbwHB+VM+/UmnObpL2kXdP8ky3OnOl7TmVlv8A8OZ/h+zuYtOEc5YWsMeJZh8o2D3P+RWhY+JNFvdTlTRLm5fUUIaFJF3A4GCTu6jgnj2rdvdNTUItW0pW+YTMroMr+7PIAGRxyDn6V4zqsOp+BfEUCWKI2obvleRQVKnGAB0HGe/tUU4RrRlbft5f1+hMsSq0/XZd79+99Plc0vHevaTL4qjgvbuSO+hcxzSwkOgbPKsFPGD6flXoEv2fV40g1meC4cxLs+TcCnXcCMe3asK08L22r3dv4k8W2FnHqsqBlWBMJO3ZnAJ3N/8AWrj9En1jSvF1/d+K7+3W1lymFHmvGOdoTaSV+nStGlUjz0/spLz+Xkv8iaUpWVOolfXVbL5v7rHpls2jafp0un2OnspYg+Yxx057nPpwas3MlgttBewPLvijJeNCQ5PJO4Y56Dp+dcfJbJqLW9za3rAfeVgeo9TnpW28B0i3ivbu5QQAjczgt9MjGT+HpWfIr2jrc6qlCEI35mn+ehi+IfFsGuaU9leRKturggR/6xMHIOMYOfcVP4UjS7s4rWye4aPPym63Egn6Zx1+lS6vaWOqWEstlHYifG5J4sKG79hk59x2qLTra50rQrsW8Rm1SfCCNrkxoBkc7sg8Y9a0lyyilDv9woJUoScY2f66GZqF29vqZtUlWSFJWjWSSJWUEcEZI4weK6nSpNN0+YS3V/JFdJj5liL5Y9MN07j161zFobiGAW9/Dazyb+to+/YR1yT/AJ4rrrqw07xLbSNbTQWV1j5MIN/Hp6Htwfp0qZtN2lov+D+priZNU1fbq1by9TSXToZ72e/tI4ftd4p82QMVklx1PlliAeOwHfpXOeLLibT5LVY1Tyyd7LjLHtj8evWtjwpoeq6FqC3V7N9piKYWHzSRwDySTn34zmjVbS31WaS6uzvK4CIny4Pt3P5VEJWm76r+vy/4Y4sPKNOajF3iv89ivpV/5aPhhFHMgDkY3cdMZ6V598Qbu+tddguLJpgjIrSbyfnbJB5rQ+IOo3nhfXdDk06WCWwmykkUg3GT5gD/ADHTHSprLS9RbxVeTa3deZpDD91CzK4bI4G0cgjPcVvHlpXlLW6+/W33r+vLWNaNSpekmt9fTv69PQ2tG8Vifw5HazxO1u5QNgjKnP5dqz7zV9I0e5PiHUnvZrcRLapDAF3F/wCEnnoAPXjFEtibdjBaIgRuApGAB15FQvp1tc2T6dcpHcQ4BZccK3qP8RUU6dOOktnv6f1Y6a+FUot0dG9fv0f4G7pHiDR9dt4NSbTI57dyfJZ8+ZC2TkM3X8qJdYtY7nybu7iEwGcO+GGcYHuP8awbDXfDPgm2+yTWUl9Orgi3JZVQMM7iCMHr75z2qLXfDT6trsHiLQYrU2MipKV3BXBK4wEYcc8e351MYWv7TR2dr9ddF933nIqkI1FCK02bvpfy1/4f7zmNRuZ729J37i8gAycY+taS6Trkfim0ubVJ5bT7MoZ48lUOScH3ANQXGm3wlaS2jJmjACxoAzDsTxn/AOtXoXgOXUrXTDbm0lkyv70SHGDgjJOP84rXFS0dtmmvy/4HqdVVShFTW8XfXbZq34s5fTPFGt3E32S2iFtZJn94ckkNyRz6H2rauLgm1fzgAR1fGTjr/nFc/wCIElt9RK3CSL5b5QLjaq8fh7VtWkfm2B83LLjBAJ6HntRUjGM01on/AF8zSlGPJdb9/M5xI76+uJrmSOOKzThFmOWxjnjpnn/9ddBb2yTwRMSVaMAZJ5xx0qd1MdokqgFV+UhjnGe+T1qNZyXIQkODgqf5dKibcve/rsaQ25U9S4hELfu3OT8pA7L/AJFSRqQ6TBgQ5JHYn36c1laveyw26mztgJH4Mjktz9M1c03Ubm3tEkuLYS3C4YIMe3PP48VDi0lZbkSvZtLUTVdEFxbmKSCWByGZS6lAD2NSeGfCwFlI800cKk5LPJtx6/54qzq/iW41bSBLLDJA0KlUQ9c9M5AHbNcg+rXF3pGoWkkj4BV1Kq2MBssPy/UCnyzqU1zOyTV/I53OsqbaVpffpf8Ay1+VjqbybT9Aiw0s8k0mCBGqkFcHnOemf88Yrl9Gvw+ouZFaLk4LLnefXj2q/ZWJ17SY5N0oNvuRZSuQVGDjHXvz9adpmioLkytPM5QqNjKMHIOO544qOZeycevX1udNO8W3J37kus6pLbWzedGsibeQBgDuCapaVqv22J44CYHQgsoYHnpx/kYrobuEbnSUIwZdu1SCCMf/AF6zNO06xsr1pIERB94jHX/AUm06ei1X3FQl1S0LF1azx6JLNGAZtjMgI+8cDuTisrwBBcahqtzH4ieTyLYDAWMZYkE4yPpV7xOt/rdvFDbMLe3RsHa20AgcLjr3zSWlhe2+m3Nhp9wpupyhkllYKuBzjn/9fFRUTdH2d7NvV9lfv6HO5VHGUm7Pa35v5f8ADGtd6U5lZrAuYFGY2YbQAckDJ74/wrm7/UfF3nOtpEn2RSCwMaMGzjv1/KqE/i86lJc6TDcg30DFT5WQrEYU4JPscZq7orXkl7JaXlztu41G5GmyfXJGSelN3pJ+0Suuj3S7/PuVC1aK5pJro+9vzMi1v1GuJL4hiktljxDEkaZYPjj0788etbJ8R+LIyUhcGJflQiEnIHSjxULSe8gkd1LQKylt/wAo68gHJz7VCmpZRSq37rjhgjYPv1oqNq04xTuvtK9vT9RulGcV7V2/r0ZleAtE1MC5k1ozXSXL+cRcs0jbweCQeBx/KvSo9Bg1CwNnCsJaRRuwCpTByBnp/wDrp+naio01LjTp42imwVIJDY/CuJv9A8RSawXg1qNBNKSIrkNwvXB4x+VaJuo3UvZ7nNqo8kdEvn960JNL0phql5IY5UhkDJLb3TjeFz1GCSBkcE+lc7q8+qeFdSl0+9hsLzTbmNZRDcIWSRTjG08MCPrxWh4y0fxTp+qSXGmaxugcBZUUKoUYJ6E89M4HNS+FDbazazRSvLqs0EmUWZMsgPXBJORxxXRdL33qn+H/AAegR5qkfZ30/P8AE0dEtNKt9Oub3S4jBbynIDFiFGOeWJ9vyrLm8JarrviKx1ewv7JrO3I2xySbWX1K+oxzyR1pvjS7t9Is49N+2fvLh8ojKEO05GML2z61yNlqHiBfFNjZWlzerFHIkcVvESsbgHkkZ5B6n2oVOXJKV9Wnv2Lq1FGMYx7r5M7XxXYR+GtNnu9LtYrQ3Tm1ndZHk88sCT97hR1496j+Dlwlh4n+wWlp5LROkhld928MCcfrUvxM1+XQbbT4riyt72OaZnmilXcGUBRgEfdPv2rb+GelWWr6ql5YxslteKsu6V+QVBGzZ6DnvWWIdqHv9db99fzt3/4bC8U5ttWSafo1f89T0fxNKuoTLaXixw2pIw067kJzndzxxjj8vWuai1qwsvEltpdzO8M0pVY51bZHj/ezxwRx0qj8VPEtxoXiKz023gR4FhW5fLAYG8jgAZ7Z/GmX99pHiiVdTS2kjuGVSw9xjAB9ODWEKfLBJrRrQ5cJSU6cVH4X2/r/ADNn+09O8Napqdxqrv5TuUeQ4YEbgQck89Oneual8S+GPiRfSpaWGpxvZuJTKIgc8fjtHyj8ulVLrWtMnv5tO1SxmumnYA4wyjPsenPf3rY0PWfDvgy9g0OCO2try9XcQY2w+D0Z+nr1I9KuUOSPNFPn/C3X+ma1KXJNVFq9EtbXZLeeVaKkmJGjT5Eck4xnPX1PWsvXvBNvc3Ftc6tDPA87ZQIwVWxg4/L3q18Q47ufQri7G20DP5qeSdpMfHOF57j/ADmofDOt6l4s061iknS6lRShDfLtI4J+taXnCKnF2TumdCftEttNXf8ATpvuatlpcFhpKrpiFZVwFWReGHA9SfT8qi8S31kuni08QR7kmQkeW3KkHG7OQOPSo7GEXetXhu0vbf8As4+VJM6FY3OcZXk5HQ5Aqvq2mWuvSYuUMhU7QXYrkevX2ohZT1e3buS4+21vdd/y1M3SNJ03QrWa9tJbkW0uGKplt2TwVHr0rN8SXv2qyiFvb3NvCHDEzKAW5IGeTitzxDpOp3Fnb2lpN5dpC4j2oemDx9eP8ms+eW1kuRaXs5PlkB9kZwxz69PwrWm+Vqb1e7/JG8W5Oy2WxheG1itrrN496jhs77dwDiu7jsLZtk8ylUlOQzHqO5xnn/69cT4wkSxuUe3QiOQ5VOCOOB834VYl1i7t7QPLqCLIrAeWoVkI68YGR6de1EoSlJST3Oic0klFtHok8yWdur2crDblRzkDPbB9v5VQ062uLa/aMC4QSsCEYEDJ6cgZ5/pUegX4vtIaWPDPsUtHtyCPXPbHJp15rV3Ff292okaKOIRuJHLh8Enqfu9unQiuezaaicsaUruMVd9396M7x+kaRWcclmk95AWbfKcmEnGRjjnOOtHhvTbua4jutaujCg5WMqDuX8Omav8Aiq6l1pLK6dY5GWPk7OSCQRn6U60W8jiM4SUwbfLaZfm2nI6Y5Harcm6aQ6cJRo66N3+8r67KUvMKnLHaiL1z15H+etPfSILTQ2up5ne5kkAaNR8qqRn88/8A6qzPF6zz6YBpVyILocearDOOe549KwdG8P6hpVrctJq8l9ql/GPNErMEjUkHqT83HHpz+FXyLljZ9dv1f9ale0qK0Ip2X4+X/BJdW0rW7vVr6O0FvbymJfsl8sYzGpHIJOe2QMfhV7wtaeJdJ0w2esXP2m4LYjdwWYKemWI579619LsXs7WOSeZ3k24JPP8An6dqmtrtbnWo42eT5R9zy+XGO3fA5qZzc4Xa21/C33eWwo0o05OS10189bkd3qT+EN1/JCZSrBWRWBZs89yO1RafqE/9qLqax3cVtc4fymfBA9P0z/8ArrqbuOEvLcCG1EoceXDJiTaAMfdJyD15rnhdxpcMZlwNxOJAMD6Ajp9KzSUlt6/15GdF+0lKc1d2t+H+ZralZaZcoHi+1zSOCfLYDO4devI5NUEthp6xTTwPGjcgFlOcdiO3BqRo2Yx3Fs/IBJU9xn9epqtes1yIk2su0dD9acbtWvdGtKMkuW911MzUJ3O+FLpLe3IwAVB8wEcgFv6YqHSrdGuGlidmi2jAkPA46f8A6qvNagMokCkjO7Kg9zRNJbQHG48jA+Q5PGegBq5O6sjfljHVDfsq3FwGIIYfxE8E1ZKEs0by7WzyevTvUWmyDUrowsCqbOJN6jJz0559fwFP1G5sdBna2mi86SRVk3s4LKOmMDIzgZ9eam7cnFbr8hTq2fK9+iFZYoy0ZZ5efnI+6y/zpNN0S3t3Z3w0bElRjgA9qydFvRcGZlmEqsC3HOzBxj24rZiN4IM2udmOWJ6DgcDv6UpdYX0uEk7Jp2uc1Bp81r4w1CK0eRrXIcCRyw3NngE++PzrqFiMFyUlCmI/6wg5yecHj+nWnaXoqDTdS1W4uWhht0Mjyldxdhj1+n6Vm+HtQl1KwuL2SGcwmXEbOONoz09flx+dRWmpSlU6e7H52/PqYUpxS9gpXcd9+r0/MttexTSOnlElQQeP5/571DYzG5il8lJEZFIKuu08An8eBUQj+0LKIkWUjJJGe3+f0q3pcVw0MnmK2EVl3Z+UkgjP6/5xSnZLQ6WlGI2yZ1iUjLbvnwDhulee/EbQk1a5RbDXLOO+iXbJZyyhAWYhvlY8ZxjOcdO9d3o08k3yja0ifKdwPzLx6fTua4zxzDoEnieGe8a5gmhKmZraIbWwMjk47deDW+HbhUm+qT6XT8n6+XWxx46HO4xe1/QyRcaP4Y0O0fTb23vfFCy7J54pfljQezcMcjG4D+la0uuN4hmTbpkNtqNyqvcXI+dnA4BPGBwOwpI9BgfxZJeWmg2Z0a6zKJHYNhTgnA7flxz1qrrMjRsxji+zteHKrGMFFBwAMZ9O3vWUFF29nva99/i6Po+V7LZW7ioUrfvKq17dull196/6mk0Vtc2awQRy28sTZE4XdHgDADD+Huc07+zdV7GxI+kf/wATWbou+2Vo7m+8ubeRsySduMYPvXVL4nsY1CCO0IUbck8nH/Aazqc3wxjzf18jr5Of3pfmjV0dLwaWst3psOlOw4tYWOEHqM8g8ZxXceLBAnh2G4VJLuRFBPyAswx26c5xj615xd+MIrq5VL95GlzjzlhIVv14+ldDP4ojj0K2aK1kupbRg6IrfM4xjg444PvVzpTU4u2v9dTiq0ak+ScdXHe3oecRaSdRiuda1XTbzTL+3YtJEYW8uUYyCM88/ifpxTvhxst/ElxJZzssSwkJFJ945YHqODjH6it/wnrY1jxLcXtxbsY9hV4JWBwcAAEDtxUfg680681jVRNoa2d/CxCyWikBBuI2spO3+f8AWumrJuE1JdV8r9O+gmmnG6uc74v8Oi48e6Zd3t7Atm7odkm8OWHQDgjB+vXPsa7ltUtvDV9pVlqSbhfsVV4uFQcE5JOV+96fpVDxTPpWoeLNOs5baWNBslW5ZgY2YE4jI75x2/xrb8d+G9G1TQIroatJBcRIAkqx+ZjfgFQvXtj6DNKclOcVO+q/4bYmU/Zpqz95/j+hyXjUXeo6rPpz2lrLYNtaymk+8G6EbuOfb6cV0Hw50jXtNs7uDT57aKeFSyyT7njXJxggfjxUlxYaJZ/D9Wtppr42uxWZ3CsrE43AHlcVSuNa1rRLWG98OEXNsFBnWSMMSBwOPQEnOPapcnVgoxXyfdW/Pt3KfLKjPk321Mp7TxHrGpMfGUGn3McakRXduSpUZz09OvGMV0GgwWMWiBdPv7MwsxzJLIflwfutkDHtxzxWhbeLBr+i2+oTW9raRRPIbgKrfwjc5z9OeAa5C7utPGmX/wBm0x00yCP7TFcxyllkz0+XGRycc5+mKqKdWyatrt07fnbyCM/Z09rWX5a/oen+HLe0hf7VF5W12UTSx7S0hxnPTtU3jTwvoGrapp91d2JmuYiSrwkCQKfr15x19683+Fl9cX2jTEvGJFkDQqrYwf8Aa969GS7tpdQibWLllhC9I1IVmx03DkcEfn2rjmpQm5JvS60+45K9BqqqsW9Ffz7oyNQtbd3ubXLESs0IjXBdVOeceuB09cVzHh5k8GatJFYw3U0kzp5geIhWA5zjt1rrvFj2OmSRXAguIpZBvDBi7MvPzEc9u/8AOorTVNL1WC3F38ztuWG5i6FuykD19TWql+7s1dM6ISjKPO43TVn3L3iPVJNWji8lmWNcFlbCnP4E55rJhtzNOI7Yp5znAJ7e/FaEVjNPp0wEyxAtsKFSSTz0P+elZ1tZjSZrzAkW+kgdEYclGxwRzjrjnPaiCUY8sR0nGnTcKfTZFXVdY0/S777DFNJczRHbK8QDbXGfxH6/hUOv6UJYBepIv70crJ1bA5/z/wDXrCsfDd7JqRM5Flb8+c+0Mzn68nPFP8S6k+pa3Dp9jG4tLdQq9ggx8zkkc9T/AJ69MY8s/deiWr/r9DaEZJxW76v+v6/ApTC3uWtYboK1tG+W4GSvHSug8a3Os2d9pdt4Kjt7aym2lp7dA5jPRg55wvOc9/wrBuLY3UUk1rG7pEN29RwM8Akj1GaS0j82/dYshXXA2HJ4HQgHp16+lCSvzdk1Z/1vqdWNw6qOLva26/zO+8b31nHambzdswtPIuLi3AyWK4zzx/8Ar715J4H0rXbSzv4pLz7Tpc0bCOVJQ6rIegHPytjscevpXaW1tHfRz2Gp29wltuCv5ny7sHOe386n0rR9J0KG903Qld45j5rNJJli2O47fh/+uY2pUlRWrTT+7rc4IYb2dRW2tv5f09Dh9C8R32hXM9hrFnLPDLnyZGByrD7vPdT3rRk17XNIvI7e7u4rgXS5WBGJGCcE9OOmK2L3RJL6OYLHH9tt13RMxzg/1rB0LwzqMmui61d5rm96RxgbsDtzjj6VrJ0+WUrfLz/RHX7Nqole66t9rfmdNPdtbacZpUi2KMuSN3fpzVDSZJUiu7iONvsbO0oDAKc46Y7VsgfZZmtZcJOeHiPzFcjgEdKW7mtLS8htL8EQzsFZgo+UE8nH4Vmnpy28zWcldyXy/r8jK0jWrm9u3tR5I2jJRR86+ldMYo8CZgvnKm3nlsdf51xOlWVppvj66htZhc22wP5kfynJG7A9fSvQ7KKzuNLa8tGln2EqyEFcH9RU1WozaW2n4q5zOsnTjO1r/wCbX6C2uppA4kls7UzDngHJ7cc4rMuoZL+eSWGS3hbLZMowCfb061Vk1SS3U5gEpY9MhcAc9cHHesG51a41G+RVbyI0OEiiXccfXAJJ/wA4ojSa95AqSU7JWfc62wgksrHZFtZGyHYLuyST19OtU76GYRyGzK+cAAFzgkdOM981FNeWemafFNdyyRytII87S2Cc8HH4VPJfeUNx+QFd24emOv5A1MU007b/AIlreSj03M2wRreUStaXKlB87TAFnJ981po1rdWzrJCwUn5hIBwap2moPeu0U9u6Yw0eW3DnjPAH+fwqxd2EgiLLl5Qm4KBgEntzTa97zNG4uPvFC+gkWRdsgMKke7MPQ/So5bS2u1QTxL5gXaH/AP1c03RLmWW/WGXzW3A7968BuBwP89a6K48gBVjh3uvIG3GffNJtxlbqilNRSjYx7exW0iRbKGNYlz8oHP19+9S+LdfTSbG0jgi8z5WD7icjgencnNEcklxqEURcrECEZVPXnp9a9KuD4WudL8i8Fg0Ua7WWRQHHY8dc1jOqqVSLlFv0OPHV3R5Pdb9DzKCO28T6Jb29y0kMCTfaZkLEKVxjBHTqP1qr4i12a9gt9G0S2ULHiJV2/Kq9hnPJ4HOO/rWmsMNo8kdl88BXHQrn/OTWraJFFCAEhVupBhGSe3J/OmvckpS1avy+V/IurSpqXOlu7nL6R4X1bTIkke8iEhO5htwuPQe/tXR6/PfpaW6m4OJ1zJtQfORjH+H4c0y11hLqSUCG6hgjP+tlXCnHOQSc/pmsTWdbS9vfJiljitbdWdmblyOpIB78UlBufNPdb/MqMpVJRlUSstTP1S7fSXspyZolk3HzQOOOp/WufjsfEmr+JIYtXtYtY0W5Jdb+0QM0aAnALKBjtlSPpTte1+bxTew2NlYNDYW67Fy4Zj/tNjpnj6eprX8O6Emlb5POeGORRhFY5PHpnn8a1q3hBxWk2te610s11XzTM40qmKaqy0Sb+a7Nf1Y1rjdb28dnbp5UMa7RkEcAHH86q6bo5nuWm8qPcq53u2AMd+n+c1OyxzZVzkAjC8kfzzXLeI5fFEmlkad5nlowEoXA4z2HUjpxn3qadFySpxdump3V6roU7pXK2vWtzbalcQmJQJHLKQDzk5zn2rS/4RSKT52vFy3J5H+FVbFb3VdItZWXyrhVZXyocHGBxn8eam8iBeJJjvHB/cZ5+ueamo6lRLkumtGrdtCFFQ31T2Nafw3+8VIpgLYncUZQ7AegP+cVPqGsXnh7w/O3h6zguri2dPNW4jMpMQz2Bz169Oor3S70q3kslSWNZXiG5Wfqfqfxrx7xZY3GnGe4W2kjlYeZCwBAQH0zz6iqoYhYiVmrnmUMXTx8JU17r/r0M3wZ4kj8T2j3sWlrp97CQs4hwY5AR1XIyD9a1766j0TQtX1L+zxPlF8yOFF8yTLcE/n9cZxXJ2uuPFa2T3Vy58yZI98mApYnAIOO3eum0JLlNfnZpsQzkNxncCevH4/pVW5G29t7eV9rnT7J+ytfVHnngXxLJcai0+uaBp9no9ixkjlMUu6KXgcMTjPfA9M11t7rC32r2mnQ2qz2MjEpIThh1IPHtnvmtzxx4bGt6PcQIJYpCfleRiVYjv8Aj+PXNZFs2oaH4dsjptoIL1QFkaREYgY6hT1BB4PFaPlm+eO7v12/rUnDpqPd6f1/wQfwokTmO3L3GkXbCKVvNxJF3Jxjn1rVsLfS/CVpMLq9uG05iSjuoeWHHoQOhzzx7YrU0C5guntZLtpLaU8yODyfXOfeoviDpUer2TxWE8cpRCWbHDDjt+GP8is+b2k1CpsTNuM/Z+T/AOB+JqeHNM0jxNoVxJYx26s4JV7dQqtx97bj6encYrmNTXWU8OXenQW9jP8AZj5TrLHiPaTwO3I7fSsX4dX0Wn3ctjYXMkV5as0W1gNpBxuAGeRuxg1S1u8XxeLrR7JJoLu3lLB26Tde2Mgk8/pVUoShN8z0TWr6diHSkrxfvJ2aXa29rkvw+0m906We3ulhi3OXI3fKvPGPyr0241CLW7drCOMwzp9+aQhYxnGMHHXt0rgfhx4Ve3unkvmjLqu1Vjblun4/kK7TUJ7MSXlnI3mwWyJcGCJsOnGWyepzis6q5qja3/zY6zjFxi94r7v8zO1G2lu7qK11WKa3uYoTDCy7drrnnk/jiqNpZ2ulYhgLbOnlkDBJ9fWue0/xNqhv99hqL2+lTSs8dveKJVBz0DEcduhrtBqCpEL6eG3a6i+bz8AIoPJ+X/8AVVyjOHuNen9f8Ob03KMeblsn5/1b7zK1XWtX0nVLcaTbefA8h81Y49xX6DoMZPX3ql4o8Y3iXggikPmMuJCF6H88dKz/ABbqV1KE+zbikj73dWxu68dOlP0mwQ7BNEpO0t83UYHIGf5Vqowjaclrb+mawoXk5NLQtaDez6l5kc5OxejnCqB7/l2q68ELRyLbopjcZlmKD5x/d+n86labz3iSWNYIo/uqRyR71cluYlQGMrIyEMEDfeIOcVnd30N25RtoU/iPHNonw2srWzUQ3Oo/vJCRhmZdpAP/AH0a8g0i4ks2jWQCFzzu5yD+hr2P43CbUH0cTT7UeAyeRIoGwnGc/Xj8q5O88P6KNOi1W+M6vCmxVjcKJGydoPHP8/yzV4Wa9lCL3ld/Ns8qhCcqSxL3b1+9/lsdXDCb3TcyNI8QRfnBxgkeuPWs3S7Ww8OXUt7PNcSmQ4JKqx/ng/Wm3N5qWnajZWSypaW08YYDCsJFK+p/LitPU7OO70SSAnY/LAjkE/h7ZqYfCoyejsdramnOOqeiNfS5dMbU1eUSLbXcYVJB/C2Op9yKwfFfijRvC73MOuXt9bi5UohsgGYL7jI/n3qhqIudJ8OWiWcvmXyXUZOx8KAcjbjvwc8+nSmfE/X9Nv57SLXPD9rfyQxjfEJXjROv8aj72O1OjTbqa3aae1um2/yOHFqVmoPfTXytt+Xy8zN8Pf2bcxfbtA1drmBDjMkPlOQeuRk9/epfGLy6pp0D2rIzW8gO9jh2HbB549jTPBs2nTWVzFpVjHp2VbEEcrSAZzjluT2/KrPhgTQ3l3YXkVmYEQyu9y7IIgOd3BBH51UJyg3Ulq0/wO6cY+ySn2T/AMyx4Ugv5tK1BrK33TogO+NRuUZwT27Zq74R1vyXawH2gSvwcnClsjqM+1LaeIbHT3uJLLUYjaTfKrxHcGA64OSep7nvRZW1k7yXdqFaR8O0gfJOeOlZys4tNddPy/AahzNuVnFpG1Nax3Hh9tQvLRkGdqpMuN3/ANfrXNxao9uyizsxDEx4IQLn39a1rvUYLqyZYLoT8BW8uTcAMjPHPYVnaTpUVxfvcTAvGvCAnAI+n+f8GtIPm7/0go3jdz2/Q2rNFnh8yUK5Y8ggFT749ac0UZuMSsp3cncO341JNbPvVolCv94EttH4Z4qOaUWyxm+ULIzY24OWXueBx3qNbEuSet9yEhbBWFnGsO4H5kALHt1xn1rn4Nbe6unS5JZmcjcW569TmtW9njtFDTlUXHDAn56ypdEsdUTzo4pIpG6OuAT3/HitI8rV316m8Fy+8jct4sTCRfJAYZ3g459zUjynBjTYc5GcA9uucVW08PaQiJHJAwcsc/z61u6Oltq17DFKsdtGBh3UFQ3r7elc8pOK5pIzrSVO8mrpFDQNEeW4MamMySL8rPkDnpggew/OneLfDesRSIqvGqP3jY5P+f8APWu9168n0TTIIXgN5C5MZm3bWBOT0we3evPJGa4uS+ZREuRGpcvtHpzUUqs5N1P+D/X3HDhq9XEy9qrKP33/ACa+45bV9ftPBK2//CQJezM4JVbdQzcY5JYjFbWm+LINY8PW97pUMz+cxVI7lBleATkZI6Ec4q3cWNvf/NfxRyouVHnDeVB64z/KrFvb28dtbW2kxyruyfLRRjA6YFaVXH3HFWfW+z3On3pTcqruunS3qZyaJOZEa+uGTcuTuf7nXpnjNcd4x8KWk1rJNpmqXdmr4BknyS4zyMLzkn8+9d/NPJv3SBklDeUrtLgAgdPUn6elR39gpM1pqMauABuwcYPUYP8AhV0asqck5P8AIqqvbK0+3Q43w7oF7BB5WneTfTNHmOfb8zHo24Hp1/lWz4bGsW3iG5g1CDiFNgWaIDJI47noDnriuo8HQR6FcG6aNt0iny1DZwnHJ4Pp3/8Ar1N4hv21GZ7pLaVZiAjHqB+Xsa5m+fmpNaPr/X9XIlObrci1hb8Tm0v7Jru4tFe2W6wxJJBfr6/j/kVT0u6v766dJLGWCCINiaQ4zjqQM9MU1PDGm2tyl3bQlJ2YmR2clefT8q6W6ubCO0zOPvKyyqeEIIxg5AJq6kvecYLR9eq7/f0OhzlGKlFa66dPLUwhJNeeciqGsVHFyjqdxH49azzpSAkBYyPXmksdY057g2WjWv2Wztly7AtsXB6ljz3HJPantqelliTqAJPfyzW0ZShOUVf0/wA99e5cORxTqM+irr/UNlgi92J6CvPPF2sWuoXUkAmhaGMlS+f057fSsrxF4uvb+zihYBI8hpAgIOf8K8x1nV7pbiVYSNv8JxgE9+a58LhJR957njYDK/q372u9eljV8S+H11eKGK1aFJIpBIUwACOB/PBrtdFWK3uYZLxZhbMoUyIO46VzWjq1voyXt9cR2FrINqmd9u8k84BP1rovD+s2t3Y3klpeG5SJkWSMRFd3J24z1Hfj0rapNyS7LQ9LEcquou7Zp+Ndbt/DcMGqXuZLFJRG9uAFeTOTwOOwPX0rGh1CDUL6HUNscGnSoZ3jZRlI8BuoPYA+vOOawvGPh6TxXJY38mprFDb3DCS3XDhQMYGfU89asabqWi64t3p9sCRbuIZVX5V8vkHbg9KahFRX4/ecmHg4Jp72sv6/U0NC1zwt4ja4FhbapbLErYlnKFOORnGeOa48+I20fXZINUuze2V8wNmLeLLRLnGDkDHTnGTViLwwfCoudSWa4mZY3SFXi8oEkcZwTuPoOKl8B396be4uvE10LS0jYBEdViLHnAGccZ+taygoRk1qm9O5pTUopNyenfVf8P2KsnhmbTvEkep2VwXieTfJG3BKk5OD9PWpNZ1u98O31rNpVtbW0A5efyuZvXLdeM4wMVpRazd6v4tlsrme0mtTbmWJFQq6qCMYI4PB6flWX8TbqzsNE0ixnsrqeW4mbbJHIAiAEcEYOTz6jp3rSPvz5aivpr6WvcK84wpxVtb2t01/Q9Chkttc09by1aNbkqrlYxjII6jv1PSsq5sZUvILyC9mt7iAkFkxh1PY/wB7v+dZ0l3/AMIZ4Z066TSv7RaVd7NcZSKNP7vGRu4/KritN4l0yw1PToZ9LR3zLZxZdwc8YOMgHrx2rlp3UU3s72f9a/eTGpFzdNaxTtrt6HU21zpj2KRLFbr83zoLMBC394jpn3+vNczq32DWdMnTSrtZLhpSoEXIG08A46cH9Knu9Tj0qxlnmYrFJHteNsDcO4+v0xWV8I/CVpoj+IL211GK7vri2zYW0gCvwGI4Od3OBkf/AFqf8KHtE9bqy/PXy0MalsLeaT5f6srW/qxDqemSReH5UljYX9rwfKBBKj1PGT14rmNF1qKwaM6heTeVM4VDIGkI+bHH510XhrTNba+kvL2Wa27tFchlLHHbONpzwPWt/XvA8uux2t9HEbW8spPOVYWIdN2M5UdM7f51q6kFelN99f0+86J13Bxmmtbde5esdO1nWL3y7e8juLdFzulHy4PQdyPpSa7JJ4WuLeTUbCyLRsJFmEeVcjk4PX+VSeJ015fBiab4fKaRqEm0NLcvtEwxyQ7AYPtXD+MdNvrX4babo15eW2q6tFcGV3tm3BF+YAZH3jyKwoJ1JQU2vedml0st301f5nH9aqSm4qN4rS1t/O6/4b5nL+O/FOo65q73ZLRKSdpwTtGegBJwK62y8M6p4v8Ah7CLcJm3lDyPIwwwBIJAxkkA5/lzXK+HvD3mMsd5bTJO2PlGU3fh3/CvQE8ZL4VjOmQoUXBV0GGAz3A57djiuipKUnH2C1j+Wx21qM4UeWLWtrJ7F3VbrQTJa6FDb/b9VsLYeWXPOMDocEnp/hXOpqPia4uZbe10RLeOL/WTXRMSYPck9R9K6aHUlS1TWNPa0thcx4aeOPa2B1Dk5x+FcT4u1QatOnla/byvbRtI8K3Bw3fIKnrjPHtUYeK5eWO3d9+v4mVKNSnFK663+99GdPFaW2pS6dqMd7A8lo254FYbDIDjIPf1HpUfi7Qray8NPrc0aXiLKRHCXfknnJwelZngHUtOu9JkGmRXBmRgJfNHOea6vSXe+muYNR0ae2hQcXAYvFL09hz9D+dJSdOXM9lo+9u34l15OytLf0emn9LqeOaR4hvLGdjb6Lapat826HcpBwcZbJ45711fhq8XxTb3cepW4gt5IWgLJkFiRzzz0/Lirt1rOka9d32hQW3kOvyEsAjEde/OQR9f0pTp83hrS0t9MuZizv5u91UgEDAUA5H4n8q3lq7LSd9fzLT5oJPWLWm3p/X3F/TvCOjWmm/2bI919kMpmEmVaRT9SMd/T+lR+G9OGmPdWNxvnWVj5TE7WKe/H+cVW0K61vU7iK1lnhDE5fy0+ZV9Seg49K1NTKyXs8FtdLHcpHsiPKk4B6N0z7VlK7bi31v+O/zLjCMOvTb7rGf4X0K7sNXuzLlom3YUcMCc84ro00e9glDSsoTdypOMD3PTPPrXL+Edc10XTnU7V7Z4vlErZDPnjGOnft2rR12+1u51i2m024L+WNjwSzBVH+0MkDn+nepmpupO9k/1FKVRcvL8LX3DtTubwaoXjlBhYj5QOOnOfxq9PbTX0kU8E8a7EZAHYgDPpx/hWfrusS/ahDJpQvRGAsmJSrsOMEYNamkrp72pdAYQo+60m47vx6/h6UpXSTatdA2nBabFTVtMguUitVuFBiXCvnnPr7jNVr2xvodH8i0ukiuF43ghc/4D6VT1SFLq9MEV5bMB/wAsi+CDjoRuFWdKtFRXijdpArfMATtHbAyfb1q78ltb2NlHS19CPRdHv4WzNeGeQ9dzDb9Oa7TR9PjuC0DzC3Y85jkGB6//AK6oW1lEqNIiqoTqcZx+Pr7U6USx3J8mQYAz8q8n6Z9u9c8ryvZ6nPXqOquWLsVdevLwRbZL2SeCJ8Rr0Un2GPT+tULa+e4LlAqY5JX39Oat3WnveW6q06rg5YnAwPxIqAWtvbWpS3JUD+P7xY/5NaO1rLc1pcqXL+hhXOs7L/zJrkRW0WUYs2Bn/wCvXQWl9G9o8mnn5yvzzKMFF/2T2z69aztN0vTb2ObzkZ1GGRCMZfs3TORj/OK1dGsVHmxPPDbxnaHEjYJA7Adaiu4t3XTQupyRi1Lpb+vMxr7xP/ZmpRWUOnyyXpK7WLbFRCTzz1HX25p3iPxRJPcIHRXuDhWJ4UYPGfw/LNdNrseo3Nq6KzSSsp2iWEKfX+fFcdbeF9RW6Rp/D63m+VAFklKeWuMkke/A5qocmlTstr/jd2+78zkhUjFc8rN3/P8ATv8AebWjXE93brPKqxZzllbjHoOceta1/rtjoto6tMkbyAARtyz9uMcg+/0rTbR/7J0yOGCAwvLyFXkKeoAPqAMf5NeZeJvAesa9qF5JZyGEzKB9qnPyKvfnt6VlQjCr705WXT7zOdaFb3lql572OS8R6h4m8O+JZNYntbqfR5T5mwuTHsbsOSB26461vS+J9I1/QWuRcy2duBiUzsu8kHp+P9KteHPh5pOk6RNY63dm5t5GJkkLlVZ8YwmP4R6985qvaeAPD0nOn6Vd3KK+8FJnkHpjgdK3nVp1Jqs/dkmlfpJLrZt2ZrQVWN1o42vr0be1+qRf8N3enzaetroUUclrJ8k7zDf5gx6LyTznnio5vDdo00hF9d4LE8IAOvpjiteyt1sgIIbeO1MYChAArLjvg4rcN1qCHaJYQF4A+WuX2s6Tbj1/r5s65QUX0fz/AOAzlNC1F7/WEgi2G1f5XQrxyQODznt/kVah0TT21Qq8XmCNyoJHzfyp+nX8OoWUUzxOLm4dUTJBVieBupsmn+LdLleGbULEWUjf8sVAYDPOfk5P4/jXU223bTy/rczdTkaW7f8AVzl/HmpyTeJraxu9BkutPjdIo7ht6qiNjO1VOMjP6Vljwtr2k+LrSW3N6ujXUrpH5UhAIx09iMg816z57LF5srP93IAxyDx06U7xVrmtaZ4YjutFEQazmRHkn2sSpwo4x9O9V7SUkqcVurb9fLsctSMqdpJX19PlotTy/ULg276ZPpH2pdOtP3DwS8bZFJJZh0JOc5ouxB4QvLfxBbm4kGpbmNkOQzHBOMDoN3GR+ddrpGmS6fY6nPa+VdancTCUm7XMYzxwB0xzirniWyGo6PMsVtCNVlVY4Zs4ERJXzFHoGAIz6VaqRlK1vden+V/vKknBWS1X9Oxla/dW15Et5O0ixpCB5csbAxZPXG3qe+PasmHRdO1uAxl3ksdwdbcSNtDDPPUH3x2zWz4O8L3EOiX1trM8JgI8thAM7c45BwD29KsaP4attIEzW1/5nmkDZIrZUDvnGKn2ihHlT1TsaQlGT5ZR0/UfoOlx6eoWzLmUDHnyuWbHZQT0HtWpqFxpFhaJL4jl8uJWGC0KyAP6DIIB98cVS103d7aQxabdi0Ii2u6A5b3z2/D9awPBulanNcarpmuy/awVAiMshkTpnPr3HWluud/hvqTVTmrNW/HY0NF1uSyS6abV5LnSd22CO6j3LlucD2688V1ExjsPDU9/ZxeYq43x8oA2evy8jH4Vx0tleWN+ttctDNYljGsargqQegz9evvVKzvda8IeIobS/vZJIpmIVtwbnofpzxjpQ4XblHVrVrv6fqFalFKKhpfbzt3/AMzf0WJvGds0NzbxnPB3AjOMck8evXrXl/iWBbPxTZ2+g6iRdW5WEiJ2YoQeme/Xsa9s1XUPJukuLdtskRaSWTlcjGW6ewrz/wAOaN4T1bxRdax4fkle5iJkaFy4VGOeRuHPrjNVTq8kJN7Pbtr0f4Gc3KU4ppcu/mrdvU7u+tpZtHtWgmFzqES7mKjG59oPPPXGefWuJ0Z9YOpT3y3V1bgtkfM4LH8egrlvHml3+i2SQWjOVnZriWVXGAxJAXBPYD9a7DRjrVn8PUnW6E16p6OMhQeQfTOKr2Ps4RpqzUna/kv6+Vwp1lHmlLVR/X+vw3PT9O8XWOpaLJaa75S3IiIBdCVdsHn2PfPvWeiaUNOiS5Wx3btzzIvKryMccHrXlOl6vd6PqEGsXsBeLdumGFJckE9AeKj1jw7N4n1i38T2t3G+lXkZjjiyyvGV68Hjg89a51hoUm1ey3Xm+y+WpkqMIVFCjdcz1120f4Gl8UfE+k+Hmg/saW9uLh3PBjAiwMdwuc+1a1tpOn+J9P0/UdRWazurlN0gnUhgeRt4GT0zWV4Z8B65ZxXepQ6ov9mQEeZArsC/p8vTjPrWr4m0qDXbmFZLm4XauwogUKw688dfetrpzUYStZO73v8A5HTTVSSa5r67O11p1/Mm1q207R9Oax1X7VJpzLtMcCOGK8dMjHpzmuaa3+HNuY7jSIropKrRSRXgcupx269a6XTrFrG2NtZzuCi8NK27aB6DpXIa01za6hJF5qTMoUB3X7ueQR65z3q6UW1a7VvPT1LqU4qanPV+m513hrTvDWiLEto88DXAJkEs2fpszggDPepfEi646Inh66mkjlUholwuOPvZzg/XOa5JLy0ksoLa7iDzKu4yAEE/Q8Eelbvhqy1TSNchuNMvAbZ1B2SHJye3I6+9Q7wvJ6vz6i5FJe50/rU5Xw7pIbx+H1u5urC9VSJAcHd8vBXqM9P/AK1exWOjR32io0Tvf3Ct84ZcA+31qx4ig1/S9B1a8ltrO9SSPfIkrDcMd+mOOuM9q8edPEHiTTFvdFv5dKvoi22KGUiOQds5PBz+FRZ137WMktl3Wi27pHKqvtIP2b1Wumqfftrr89ze8X6kmlh7XSoltPMyryRsASQeQDnjv1qO30y7vdChumkuILlm+VgeTjoSag8LWkr2CDxVHKdULHNxFIMdzyB/h611MszEojsDFGvyLk4HHH6VbqNWSVrXv59PmjvhCSVn1t/X9bFXRTcblg1i5ickY2lM9PXj61b8V6PfWmjpeeH2S+uJGRTGh3+UCCee+B0x2zXTRvpl5o8E6QSRTIpB5+UHgf09Kn/4R++UO3nwqk4G6M5JKHnG7BxXPGsoyUvwZw18TfTmcOj87PX8Op5V4fn1mK4nsvF2nkTooaKdFHIOeCR+HNb95a2rR28K38cKnlBCNjH2PfisTxxqnhuLTW0q6ujDcQzl8W0LFWB6BiV7e2a5+J7ubQJbaxuj5TsDC33fkHQHj6/56dMYe8pXtd7Pp5r87dDqpSlKLSTbj6a+fl+vU7K08KWEt8Lj7ZPIA2Q0sgGCO5HXPWtT7Xo9vdvaWV5JPKpIKqR2+gB7HvxWFbTTeFtAgl16YeVMrASJGH3cHjA56DrVHw5e6EbP7b4etoi5k/fLcRsyvnrjJGP/AK9ZSTceeXV2XZ/P+vOwJ803CDulula9/Mu6trN610IIXaADcRHGvPtknPH0xW3p+pGG0UXmJrlh0T7ozwM5z/kVh+PJ5550PhqKCFXQb0KKSr98Fh93GOnem+H7a5W3K6peK1wDlIoRtBPuQAKdXllCE7b9Ovz/AK+ZpTUZRtKLXqMaz1mfxebq2uIriwkVSYAGwCcZBHA/HpXUzwpbSRpOwgkbqjA9e4wfesWP+3LXV1BuZJBI+5SzjI54HB6Vzuuadb3XikXOoXN2bxCI9hfcgOOuMf1puPPNyb2j0622/wCHJhCS5IR2b76q/wCaXQ6xr1Vm8pQqS7TtTOOPU4H8/ap7RJDeb1EoaLDNJAm5Uz3zkj6Vm6nerpeltPcu7wIdsaoN2W/HtXKz/Fq4gkT+yrYmSQ+W8btsXZ3HBpKlUqQUorR/1uOtXjC8YtXPWfE039o2S+Zd3NvMq8N5hJ6dAQvGfauGsbaSz1YXc2palcsp6xzON3fktnOasjXJDbRkWkaSNEFC8Hk+p9c45rFi8T69Feypr9jFb6TGuB5MwzngD7oOecVjS96g1FXXbrv0W7FHDxw1oTXf5fP/ADZ1WoeKNUvxEjFI4IW3IoJJ9sk9eKzvt0sjnzWnuC6lcPJtQHscentWzZW1oPD0usQ4uJhHvTcPlXg9iMk+9cHqB1HV9TjmndZIyuUwdoTg9uOynpTpRjKDlHSK0+40jVoU3yU4WS+RrXlhZSxr/aQ81AMLGzMwGOpx079aw7idILl4dKtfs8W7aFjjIZj7npW/pqefaxi4AeQDeDnp70y6sIXl86VRjJ3HJ5wPb6irjNO6lqdLptu8HZlrQmeC3LTukkgO0oVyrDP8XY/X2rOl0O3mleVhNucljiQY559K0LYvCylVOB90HGMf5xUxvp1OMDjjoKilOpSbcHuOeHjN+8lL1P/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph shows granulomatous change in acute interstitial nephritis. The interstitial infiltrate is seen on the left, while the granuloma is on the right. The granuloma consists of both giant cells (arrows) and epithelioid cells with abundant cytoplasm which has an amorphous red appearance. Although these findings are characteristic of sarcoid involvement in the kidney, they can be seen with any cause (drug or infection) of acute interstitial nephritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_42_22182=[""].join("\n");
var outline_f21_42_22182=null;
var title_f21_42_22183="Penicillin G (parenteral): Drug information";
var content_f21_42_22183=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Penicillin G (parenteral): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/23/43379?source=see_link\">",
"    see \"Penicillin G (parenteral): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/46/14054?source=see_link\">",
"    see \"Penicillin G (parenteral): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pfizerpen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F207661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Crystapen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F207680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Penicillin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F207664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Actinomyces",
"      </i>",
"     </b>",
"     <b>",
"      species:",
"     </b>",
"     I.V.: 10-20 million units/day divided every 4-6 hours for 4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Clostridium perfringens:",
"      </i>",
"     </b>",
"     I.V.: 24 million units/day divided every 4-6 hours with clindamycin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Corynebacterium diphtheriae:",
"      </i>",
"     </b>",
"     I.V.: 2-3 million units/day in divided doses every 4-6 hours for 10-12 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Erysipelas:",
"     </b>",
"     I.V.: 1-2 million units every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Erysipelothrix:",
"      </i>",
"     </b>",
"     I.V.: 2-4 million units every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Fascial space infections:",
"     </b>",
"     I.V.: 2-4 million units every 4-6 hours with metronidazole",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Leptospirosis:",
"     </b>",
"     I.V.: 1.5 million units every 6 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Listeria:",
"      </i>",
"     </b>",
"     I.V.: 15-20 million units/day in divided doses every 4-6 hours for 2 weeks (meningitis) or 4 weeks (endocarditis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Lyme disease (meningitis):",
"     </b>",
"     I.V.: 20 million units/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Neurosyphilis:",
"     </b>",
"     I.V.: 18-24 million units/day in divided doses every 4 hours (or by continuous infusion) for 10-14 days (CDC, 2006; CDC, 2009; CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prosthetic joint infection:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Enterococcus spp (penicillin-susceptible), streptococci (beta-hemolytic):",
"     </i>",
"     20-24 million units daily continuous infusion every 24 hours or in divided doses every 4 hours for 4-6 weeks (Osmon, 2013);",
"     <b>",
"      Note:",
"     </b>",
"     For penicillin-susceptible",
"     <i>",
"      Enterococcus",
"     </i>",
"     spp, consider addition of aminoglycoside.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Propionibacterium acnes:",
"     </i>",
"     20 million units daily continuous infusion every 24 hours or in divided doses every 4 hours for 4-6 weeks (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Streptococcus:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Brain abscess:",
"     </i>",
"     I.V.: 18-24 million units/day in divided doses every 4 hours with metronidazole",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Endocarditis or osteomyelitis:",
"     </i>",
"     I.V.: 3-4 million units every 4 hours for at least 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Group B streptococcus (neonatal prophylaxis):",
"     </i>",
"     I.V.: 5 million units x 1 dose, then 2.5-3.0 million units every 4 hours until delivery (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Skin and soft tissue:",
"     </i>",
"     I.V.: 3-4 million units every 4 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Toxic shock:",
"     </i>",
"     I.V.: 24 million units/day in divided doses with clindamycin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Streptococcal pneumonia:",
"     </b>",
"     I.V.: 2-3 million units every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Whipple's disease:",
"     </b>",
"     I.V.: 2 million units every 4 hours for 2 weeks, followed by oral trimethoprim/sulfamethoxazole or doxycycline for 1 year",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Relapse or CNS involvement: 4 million units every 4 hours for 4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F207675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/46/14054?source=see_link\">",
"      see \"Penicillin G (parenteral): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Susceptible infections:",
"     </b>",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Infants &ge;1 month and Children:",
"     </i>",
"     100,000-400,000 units/kg/day in divided doses every 4-6 hours (maximum dose: 24 million units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Community-acquired pneumonia (CAP) (IDSA/PIDS, 2011):",
"     </b>",
"     I.V.: Infants and Children &gt;3 months:",
"     <b>",
"      Note:",
"     </b>",
"     May consider addition of vancomycin or clindamycin to empiric therapy if community-acquired MRSA suspected. In children &ge;5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Empiric treatment or",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (moderate-to-severe; MICs to penicillin &le;2.0 mcg/mL) (preferred): 200,000-250,000 units/kg/day divided every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Group A",
"     <i>",
"      Streptococcus",
"     </i>",
"     (moderate-to-severe) (preferred): 100,000-250,000 units/kg/day divided every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Meningitis",
"      </i>",
"     </b>",
"     <b>",
"      (gonococcal):",
"     </b>",
"     I.V.: 250,000 units/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-6em;margin-left:6em;\">",
"     <b>",
"      Moderate infections:",
"     </b>",
"     I.M., I.V.: 100,000-250,000 units/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Neurosyphilis:",
"     </b>",
"     I.V.: 200,000-300,000 units/kg/day divided every 4-6 hours for 10-14 days (maximum dose: 24 million units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Severe infections:",
"     </b>",
"     I.M., I.V.: 250,000-400,000 units/kg/day in divided doses every 4-6 hours (maximum dose: 24 million units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Syphilis (congenital):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants: 50,000 units/kg every  12 hours for first 7 days of life, then every 8 hours for a total of 10 days (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 50,000 units/kg every 4-6 hours for 10 days (CDC, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F207665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F207666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Uremic patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer full loading dose followed by",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of the loading dose given every 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     :  Administer full loading dose followed by",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of the loading dose given every 8-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Administer normal loading dose followed by either 25% to 50% of normal dose every 4-6 hours",
"     <b>",
"      or",
"     </b>",
"     50% to 100% of normal dose every 8-12 hours. For mild-to-moderate infections, administer 0.5-1 million units every 4-6 hours",
"     <b>",
"      or",
"     </b>",
"     1-2 million units every 8-12 hours. For neurosyphilis, endocarditis, or serious infections, administer up to 2 million units every 4-6 hours;  administer after dialysis on dialysis days",
"     <b>",
"      or",
"     </b>",
"     supplement with 500,000 units after dialysis (Heintz, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times/week, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVH: Loading dose of 4 million units, followed by 2 million units every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVHD: Loading dose of 4 million units, followed by 2-3 million units every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVHDF: Loading dose of 4 million units, followed by 2-4 million units every 4-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F207638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic dextrose solution, as potassium: 1 million units (50 mL); 2 million units (50 mL); 3 million units (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as potassium: 5 million units, 20 million units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pfizerpen&reg;: 5 million units, 20 million units [contains potassium 65.6 mg (1.68 mEq) per 1 million units, sodium 6.8 mg (0.3 mEq) per 1 million units]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium: 5 million units",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F207622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F207642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.; Administer I.M. by deep injection in the upper outer quadrant of the buttock",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     The 20 million unit dosage form may be administered by continuous I.V. infusion only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Intermittent I.V.:",
"     </i>",
"     May be dissolved in small amounts of SWFI, NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W and administered peripherally as a 50,000-100,000 unit/mL solution. In fluid-restricted patients, 146,000 units/mL in SW results in a maximum recommended osmolality for peripheral infusion. Infuse over 15-30 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Continuous I.V. infusion:",
"     </i>",
"     Determine the volume of fluid and rate of its administration required by the patient in a 24-hour period. Add the appropriate daily dosage of penicillin to this fluid. For example, if the daily dose is 10 million units and 2 L of fluid/day is required, add 5 million units to 1 L and adjust the rate of flow so the liter will be infused over 12 hours (83 mL/hour). Repeat steps (5 million units/L at 83 mL/hour) for the remaining 12 hours.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F207687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inactivated in acidic or alkaline solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Penicillin G potassium:",
"     </b>",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS, hetastarch 6%;",
"     <b>",
"      incompatible",
"     </b>",
"     with dextran 70 6% in dextrose, dextran 40 10% in dextrose;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in fat emulsion 10%, peritoneal dialysis solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amiodarone, caffeine citrate, cyclophosphamide, cyclosporine, diltiazem, enalaprilat, esmolol, fluconazole, foscarnet, heparin, heparin with hydrocortisone sodium succinate, hydromorphone, labetalol, meperidine, morphine, multiple vitamins, nicardipine, pantoprazole, potassium chloride, tacrolimus, theophylline, verapamil, vitamin B complex with C.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Magnesium sulfate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Metoclopramide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Penicillin G sodium:",
"     </b>",
"     Stable in dextran 40 10%;",
"     <b>",
"      incompatible",
"     </b>",
"     with fat emulsion 10%;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, peritoneal dialysis solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Levofloxacin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Chloramphenicol, cimetidine, colistimethate, dimenhydrinate, gentamicin, kanamycin, lidocaine, lincomycin, pantoprazole, polymyxin B sulfate, streptomycin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F207641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of infections (including sepsis, pneumonia, pericarditis, endocarditis, meningitis, anthrax) caused by susceptible organisms; active against some gram-positive organisms, generally not",
"     <i>",
"      Staphylococcus aureus",
"     </i>",
"     ; some gram-negative organisms such as",
"     <i>",
"      Neisseria gonorrhoeae",
"     </i>",
"     , and some anaerobes and spirochetes",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F207689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Penicillin may be confused with penicillamine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F207678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Coma (high doses), hyper-reflexia (high doses), seizures (high doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Contact dermatitis, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Electrolyte imbalance (high doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Pseudomembranous colitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Neutropenia, positive Coombs' hemolytic anemia (rare, high doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction, phlebitis, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myoclonus (high doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute interstitial nephritis (high doses), renal tubular damage (high doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity reactions (immediate and delayed), Jarisch-Herxheimer reaction, serum sickness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F207645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to penicillin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F207626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in asthmatic patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurovascular damage: Avoid intra-arterial administration or injection into or near major peripheral nerves or blood vessels since such injections may cause severe and/or permanent neurovascular damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended. In the presence of concomitant hepatic impairment, further dosage adjustment may be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Neonates may have decreased renal clearance of penicillin and require frequent dosage adjustments depending on age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Product contains sodium and potassium; high doses of I.V. therapy may alter serum levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolonged use: Extended duration of therapy or use associated with high serum concentrations (eg, in renal insufficiency) may be associated with an increased risk for some adverse reactions (neutropenia, hemolytic anemia, serum sickness).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F207631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F207634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5720623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Penicillin crosses the placenta and distributes into amniotic fluid. Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects. Penicillin G is the drug of choice for treatment of syphilis during pregnancy and penicillin G (parenteral/aqueous) is the drug of choice for the prevention of early-onset Group B Streptococcal (GBS) disease in newborns (consult current guidelines).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F207670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5707425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Very small amounts of penicillin G transfer into breast milk. Peak milk concentrations occur at approximately 1 hour after an IM dose and are higher if multiple doses are given. The manufacturer recommends that caution be exercised when administering penicillin to nursing women. Nondose-related effects could include modification of bowel flora and allergic sensitization.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F678881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain potassium and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Penicillin G Potassium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5000000 unit (1): $42.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20000000 unit (1): $160.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Penicillin G Sodium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5000000 unit (1): $57.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Pfizerpen-G Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5000000 unit (1): $7.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20000000 unit (1): $23.41",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F207636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic electrolyte, hepatic, renal, cardiac and hematologic function tests during prolonged/high-dose therapy; observe for signs and symptoms of anaphylaxis during first dose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F207648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Benpen (AU, NZ);",
"     </li>",
"     <li>",
"      Bentapen (PH);",
"     </li>",
"     <li>",
"      Broncobiot (PE);",
"     </li>",
"     <li>",
"      Lascacilin (PY);",
"     </li>",
"     <li>",
"      Pencarv (PH);",
"     </li>",
"     <li>",
"      Pengesod (MX);",
"     </li>",
"     <li>",
"      Penicilina Northia (AR);",
"     </li>",
"     <li>",
"      Penicillin G (BG);",
"     </li>",
"     <li>",
"      Penicillin G- Natrium (AT);",
"     </li>",
"     <li>",
"      Pisacilina (CO);",
"     </li>",
"     <li>",
"      Sodipen (MX);",
"     </li>",
"     <li>",
"      Unicil 1 Mega (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F207625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with bacterial cell wall synthesis during active multiplication, causing cell wall death and resultant bactericidal activity against susceptible bacteria",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F207644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Poor penetration across blood-brain barrier, despite inflamed meninges",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Relative diffusion from blood into CSF: Poor unless meninges inflamed (exceeds usual MICs)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CSF:blood level ratio: Normal meninges: &lt;1%; Inflamed meninges: 2% to 6%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (30%) to penicilloic acid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: &lt;6 days old: 3.2-3.4 hours; 7-13 days old: 1.2-2.2 hours; &gt;14 days old: 0.9-1.9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adults: Normal renal function: 30-50 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     End-stage renal disease: 3.3-5.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: ~30 minutes; I.V.: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (58% to 85% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists,&ldquo;ACOG Committee Opinion: Number 279, December 2002. Prevention of Early-Onset Group B Streptococcal Disease in Newborns,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2002, 100(6):1405-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/12468196/pubmed\" id=\"12468196\" target=\"_blank\">",
"        12468196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;Treatment of Bacterial Meningitis,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1988, 81(6):904-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/3368290/pubmed\" id=\"3368290\" target=\"_blank\">",
"        3368290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baddour LM, Wilson WR, Bayer AS, et al, &ldquo;Infective Endocarditis. Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association - Executive Summary:",
"      <i>",
"       Endorsed by the Infectious Diseases Society of America",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 111(23):3167-184.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/15956145/pubmed\" id=\"15956145\" target=\"_blank\">",
"        15956145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Prevention of Perinatal Group B Streptococcal Disease, Revised Guidelines from CDC, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-10):1-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/21088663/pubmed\" id=\"21088663\" target=\"_blank\">",
"        21088663",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Sexually Transmitted Diseases Treatment Guidelines - 2006,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 56(RR-11):1-94. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5511a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5511a1.htm",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/16888612/pubmed\" id=\"16888612\" target=\"_blank\">",
"        16888612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 318(7):419-26 and 318(8):490-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/3277054/pubmed\" id=\"3277054\" target=\"_blank\">",
"        3277054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gilbert DN, Moellering RC, Eliopoulos GM, et al, eds,",
"      <i>",
"       The Sanford Guide To Antimicrobial Therapy",
"      </i>",
"      , 2006, 36th ed, Hyde Park, VT: Antimicrobial Therapy, Inc, 2006, 6-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hansen JM, Kampmann J, and Laursen H, &ldquo;Renal Excretion of Drugs in the Elderly,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1970, 1(657):1170.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leikola E and Vartia KO, &ldquo;On Penicillin Levels in Young and Geriatric Subjects,&rdquo;",
"      <i>",
"       J Gerontol",
"      </i>",
"      , 1957, 12:48-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/13398605/pubmed\" id=\"13398605\" target=\"_blank\">",
"        13398605",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prober CG, Stevenson DK, and Benitz WE, &ldquo;The Use of Antibiotics in Neonates Weighing Less Than 1200 Grams,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1990, 9(2):111-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/2179837/pubmed\" id=\"2179837\" target=\"_blank\">",
"        2179837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quagliarello VJ and Scheld WM, &ldquo;Treatment of Bacterial Meningitis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 336(10):708-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/9041103/pubmed\" id=\"9041103\" target=\"_blank\">",
"        9041103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schrag S, Gorwitz R, Fultz-Butts K, et al, &ldquo;Prevention of Perinatal Group B Streptococcal Disease. Revised Guidelines from CDC,&rdquo;",
"      <i>",
"       MMWR, Recomm Rep",
"      </i>",
"      , 51(RR11):1-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/12211284/pubmed\" id=\"12211284\" target=\"_blank\">",
"        12211284",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 39(9):1267-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/15494903/pubmed\" id=\"15494903\" target=\"_blank\">",
"        15494903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wickerts CJ, Asaba H, Gunnarsson B, et al, &ldquo;Combined Carbon Haemoperfusion and Haemodialysis in the Treatment of Penicillin Intoxication,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 1980, 280(6226):1254-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wright AJ, &ldquo;The Penicillins,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(3):290-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/10090000/pubmed\" id=\"10090000\" target=\"_blank\">",
"        10090000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yoshikawa TT, &ldquo;Antimicrobial Therapy for the Elderly Patient,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1990, 38(12):1353-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/42/22183/abstract-text/2254575/pubmed\" id=\"2254575\" target=\"_blank\">",
"        2254575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9749 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-27.109.116.13-B2EFA6BE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_42_22183=[""].join("\n");
var outline_f21_42_22183=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207660\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207661\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207680\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207664\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207675\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207665\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207666\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207638\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207622\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207642\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207687\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207641\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207689\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207678\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207645\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207626\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299838\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207631\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207634\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5720623\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207670\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5707425\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F678881\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323647\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207636\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207648\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207625\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207644\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9749\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9749|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/23/43379?source=related_link\">",
"      Penicillin G (parenteral): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/46/14054?source=related_link\">",
"      Penicillin G (parenteral): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_42_22184="Oral isotretinoin therapy for acne vulgaris";
var content_f21_42_22184=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oral isotretinoin therapy for acne vulgaris",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/42/22184/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/42/22184/contributors\">",
"     Cindy Owen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/42/22184/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/42/22184/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/42/22184/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/42/22184/contributors\">",
"     Mark V Dahl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/42/22184/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/42/22184/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/42/22184/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    (13-cis retinoic acid) is effective for the treatment of severe recalcitrant nodular acne. However, isotretinoin is associated with multiple adverse effects and is teratogenic. Thus, it must be used with appropriate caution in selected patients.",
"   </p>",
"   <p>",
"    This topic will discuss clinical use of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    and related safety concerns. The pathogenesis, clinical manifestations, diagnosis, and conventional treatment of acne vulgaris are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44599?source=see_link\">",
"     \"Hormonal therapy for women with acne vulgaris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39370?source=see_link\">",
"     \"Treatment of acne vulgaris\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    counteracts the pathogenic factors that contribute to the development of acne vulgaris [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Therapy leads to shrinkage of sebaceous glands and a marked attenuation of sebum secretion. The decrease in sebum results in the inhibition of the sebum-dependent bacterium",
"    <em>",
"     Propionibacterium acnes",
"    </em>",
"    (",
"    <em>",
"     P. acnes",
"    </em>",
"    ), which is a key promoter of inflammation in acne vulgaris. Oral isotretinoin also inhibits comedogenesis by fostering keratinocyte differentiation and by normalizing desquamation. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    is effective for the treatment of acne vulgaris [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/3-10\">",
"     3-10",
"    </a>",
"    ]. The first study to show the benefit of oral isotretinoin was a case series of 14 patients with treatment-resistant severe acne [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/3\">",
"     3",
"    </a>",
"    ]. After four months of treatment, 13 out of 14 patients experienced complete clearance of their disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the Food and Drug Administration (FDA) approved usage of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    only for severe, recalcitrant, nodular acne. \"Severe, recalcitrant, nodular acne\" is defined as acne with many (greater than 5 mm) inflammatory nodules that is unresponsive to conventional therapy, including systemic antibiotics.",
"   </p>",
"   <p>",
"    Clinicians also prescribe oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    for selected patients without severe nodular recalcitrant acne. Patients for whom isotretinoin may be considered include those with the following [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/11\">",
"     11",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment-resistant acne [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Scarring acne [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Acne causing significant psychological distress [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Acne fulminans [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Antibiotic-induced gram-negative folliculitis in patients with acne vulgaris [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is initiated at a dose of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for the first month of therapy, and is subsequently increased to 1",
"    <span class=\"nowrap\">",
"     mg/kg/day.",
"    </span>",
"    Dosing can be once or twice daily. The total treatment goal is 120 to 150",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    and is typically reached over four to six months (usual duration of treatment 20 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/11,19\">",
"     11,19",
"    </a>",
"    ]. The drug is discontinued without tapering. There is some evidence that lower doses may also be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/20\">",
"     20",
"    </a>",
"    ]. Absorption of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    is improved when taken with food.",
"   </p>",
"   <p>",
"    Other acne medications are typically discontinued during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    therapy. Isotretinoin causes temporary xerosis, cutaneous atrophy, and skin fragility [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/2\">",
"     2",
"    </a>",
"    ], and topical acne medications may be poorly tolerated. Isotretinoin should not be given with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    antibiotics due to the risk of idiopathic intracranial hypertension (pseudotumor cerebri) associated with both of these drugs.",
"   </p>",
"   <p>",
"    Acne may initially worsen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    therapy; initiating therapy at 0.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    during the first month may decrease this risk. The early flare typically resolves with further treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/2\">",
"     2",
"    </a>",
"    ]. More severe flares may occur in patients presenting with severe inflammatory acne (eg, acne conglobata, acne fulminans). In some of these cases, the inflammatory nodules may ulcerate or form exuberant granulation tissue. If this happens, isotretinoin is temporarily stopped. Systemic glucocorticoids (0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    are sometimes given before isotretinoin therapy or concurrently for the first two to four weeks of treatment in an attempt to prevent severe flares. Rarely, isotretinoin may induce acne fulminans [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6474?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris\", section on 'Acne variants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     Isotretinoin",
"    </a>",
"    is associated with a number of adverse effects that can be severe and limit its use. Isotretinoin should only be prescribed by clinicians who are completely familiar with the medication. In the US, the FDA has imposed restrictions on who may prescribe and distribute isotretinoin. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Isotretinoin safety'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    is the only acne medication that can permanently alter the natural course of the disorder. The majority of patients experience long-term improvement in acne severity after one course of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/23\">",
"     23",
"    </a>",
"    ]. Continued improvement may occur for several months after cessation of therapy; at least five months should elapse before considering retreatment with isotretinoin. The vast majority of relapses (96 percent) occur within the first three years of stopping therapy; the highest relapse rates occur in patients with predominantly truncal acne or in those receiving a total cumulative dose of less than 120",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/23\">",
"     23",
"    </a>",
"    ]. In one study of 88 patients, 82 percent of patients who received cumulative doses &lt;120",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    relapsed, compared with only 20 percent of patients given &gt;120",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients who receive isotretinoin as young teenagers (under age 16) may also have an increased risk for relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the high response rate after a single course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , only a minority of patients are truly cured. In one series, 39 percent were cured but 61 percent still required the use of topical therapy (16.9 percent), topical therapy plus an oral antibiotic (25.3 percent), or another course of isotretinoin (18.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/25\">",
"     25",
"    </a>",
"    ]. Following isotretinoin treatment, acne is more likely to be responsive to conventional therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/26\">",
"     26",
"    </a>",
"    ]. Response rates after a second course of isotretinoin are similar to those following the initial course of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29706373\">",
"    <span class=\"h2\">",
"     Low dose isotretinoin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    lower than 0.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    may be effective for the treatment of some patients with acne [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/20,27\">",
"     20,27",
"    </a>",
"    ]. In a 24-week single-blind randomized trial, 60 patients with moderate acne were treated with one of three regimens of isotretinoin: 0.5 to 0.7",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    (higher dose regimen), 0.25 to 0.4",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    (lower dose regimen), or 0.5 to 0.7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily for one week every four weeks (intermittent regimen) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/27\">",
"     27",
"    </a>",
"    ]. All three treatment courses resulted in clinically significant improvement. The lower dose and higher dose regimens were similarly effective and had equivalent rates of relapse after one year; however, more adverse effects were reported in the higher dose group during treatment. A lesser degree of improvement and a lower duration of effect were detected in the patients who received intermittent therapy.",
"   </p>",
"   <p>",
"    The results of this trial suggest that treatment with less than 0.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    is as effective as a slightly higher dose regimen in patients with moderate acne and is associated with fewer adverse effects. Of note, the study excluded individuals with severe acne, a group of patients for which isotretinoin therapy is frequently indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ISOTRETINOIN SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     Isotretinoin",
"    </a>",
"    is associated with a number of adverse effects that can be severe and limit its use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Teratogenicity and the iPLEDGE program",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     Isotretinoin",
"    </a>",
"    is teratogenic; it causes both spontaneous abortions and severe life-threatening congenital malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/28\">",
"     28",
"    </a>",
"    ]. Embryopathy associated with exposure in the first trimester of pregnancy includes craniofacial, cardiac, thymic, and central nervous system malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/29\">",
"     29",
"    </a>",
"    ]. Fetal abnormalities have not been attributed to the use of isotretinoin in men [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among pregnant women exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , the risk of spontaneous abortion is approximately 20 percent; among pregnancies that progress, approximately 20 to 30 percent of neonates have evidence of embryopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/30\">",
"     30",
"    </a>",
"    ]. Although data are limited, children who appear physically normal may have a higher rate of mental retardation and impaired neuropsychological function.",
"   </p>",
"   <p>",
"    Despite stringent rules in the United States intended to prevent women who are pregnant from beginning",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , and to prevent pregnancy while taking the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/31\">",
"     31",
"    </a>",
"    ], some women taking isotretinoin still become pregnant. In 2006, the US FDA established a computer-based Risk Evaluation and Mitigation Strategy (REMS) risk management program with the goal of eliminating fetal exposure to isotretinoin (iPLEDGE). Prescribers, pharmacies dispensing isotretinoin, wholesalers distributing isotretinoin, and all patients receiving isotretinoin are required to comply with the registry requirements.",
"   </p>",
"   <p>",
"    Access to the iPLEDGE program is available online (",
"    <a class=\"external\" href=\"file://www.ipledgeprogram.com/\">",
"     www.ipledgeprogram.com",
"    </a>",
"    ). The iPLEDGE program requires the following [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All female patients of childbearing potential must select and commit to the use of two forms of birth control for at least one month prior to starting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      therapy, during therapy, and for one month after therapy. The forms of contraception that meet these requirements are specified by the iPLEDGE program.",
"     </li>",
"     <li>",
"      All female patients who can become pregnant must have two negative urine or blood pregnancy tests (with a sensitivity of at least 25",
"      <span class=\"nowrap\">",
"       mIU/mL)",
"      </span>",
"      before receiving the initial prescription. The second pregnancy test must be conducted in a CLIA-certified laboratory. For each month of therapy and one month after completing therapy, female patients must return to their physicians for evaluation, counseling, education, and a pregnancy test conducted by a CLIA-certified laboratory.",
"     </li>",
"     <li>",
"      For female patients who can become pregnant, prescribing physicians must, on a monthly basis, document in the iPLEDGE system the results of the pregnancy test as well as report the two forms of birth control being used by the patient. The clinician must also confirm that the patient has received counseling and education. For all other patients, prescribers must document that the patient was counseled on the iPLEDGE program requirements, which include knowledge of the birth defects that may result from the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      by females of child-bearing potential.",
"     </li>",
"     <li>",
"      As part of this system, physicians must certify expertise in the diagnosis and treatment of acne, and knowledge of the risk and severity of birth defects with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mucocutaneous side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucocutaneous side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , including cheilitis, dry skin and mucous membranes, epistaxis, desquamation, photosensitivity, and pruritus, are predictable and dose-dependent. The cheilitis can be significant and often requires the liberal use of topical emollients. Patients also have an increased risk of ocular symptoms related to dysfunction of meibomian glands within the conjunctiva [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/33,34\">",
"     33,34",
"    </a>",
"    ] and cutaneous staphylococcal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/35\">",
"     35",
"    </a>",
"    ]. Paronychia, pyogenic granulomas, temporary diffuse alopecia, or nail brittleness may occasionally appear [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skin fragility and cutaneous atrophy can occur during therapy, and dermabrasion and waxing should be avoided during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/2\">",
"     2",
"    </a>",
"    ]. Avoidance of chemical peels and laser treatments has also been proposed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26534738\">",
"    <span class=\"h2\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have found conflicting results on the relationship between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    therapy and inflammatory bowel disease (IBD). A 2012 meta-analysis of three case-control studies and two additional unpublished studies did",
"    <strong>",
"     not",
"    </strong>",
"    find a statistically significant relationship between isotretinoin therapy and IBD (relative risk for IBD 0.94, 95% CI 0.65-1.36) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/37\">",
"     37",
"    </a>",
"    ]. The individual results of the three published case-control studies and a subsequent population-based cohort study are briefly summarized below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A nested case-control study of 2008 patients with IBD and 19,814 matched controls found similar rates of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      use among the IBD and control groups. In the study, 1.2 percent of patients in the IBD group received isotretinoin prior to a diagnosis of IBD, and 1.1 percent of patients in the control group received isotretinoin prior to the date of IBD diagnosis for the corresponding index patients with IBD (odds ratio [OR] 1.16, 95% CI 0.73-1.77) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A nested case-control study of 2159 women with IBD and oral contraceptive use and 43,180 matched female controls found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      treatment did not appear to increase the risk for IBD [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/37\">",
"       37",
"      </a>",
"      ]. The study adjusted for potential confounders, including a diagnosis of acne and the use of oral tetracyclines (adjusted risk ratio for IBD 0.99, 95% CI 0.52-1.90).",
"     </li>",
"     <li>",
"      A nested case-control study of 8189 subjects with IBD and 21,832 matched controls found an increase in risk for ulcerative colitis among patients who had received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      (OR 4.36, 95% CI 1.97-9.66) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/39\">",
"       39",
"      </a>",
"      ]. The absolute risk for the disease was small, estimated at 14 excess cases within a population of 4428 patients with ulcerative colitis. A statistically significant relationship between Crohn&rsquo;s disease and isotretinoin treatment was not detected (OR 0.68, 95% CI 0.28-1.68).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 12-year cohort study of 46,922 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , 184,824 patients treated with topical acne medication, and 1,526,946 untreated controls (all between the ages of 12 and 29) did not find a significant association between isotretinoin use and IBD on primary analysis (rate ratio 1.14, 95% CI 0.92-1.41) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/40\">",
"     40",
"    </a>",
"    ]. Although an association between isotretinoin and IBD was detected in a subgroup of patients aged 12 to 19 years (rate ratio 1.39, 95% CI 1.03-1.87), a similar association was detected between the use of topical acne medications and ulcerative colitis (rate ratio 1.19, 95% CI 1.00-1.42), suggesting that acne may contribute to risk for IBD. More studies are necessary to determine whether isotretinoin therapy is a risk factor for IBD. Until additional information is available, during discussions of the potential adverse effects of isotretinoin with patients, it is reasonable to mention that although an increased risk for IBD has been reported, a relationship between these disorders remains to be proven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     Isotretinoin",
"    </a>",
"    has been associated with a number of other side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myalgias may occur in patients taking oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      , particularly those who engage in vigorous physical activity.",
"     </li>",
"     <li>",
"      Decreased night vision, corneal opacities, hepatotoxicity, and bone marrow suppression may occur infrequently.",
"     </li>",
"     <li>",
"      Hypertriglyceridemia occurs in up to 45 percent of patients on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      therapy and elevations of total cholesterol and low-density lipoprotein are seen in approximately 30 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/41\">",
"       41",
"      </a>",
"      ]. These elevations are transient in about 80 percent of subjects and are rarely severe enough to require termination of therapy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Monitoring and discontinuation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       Isotretinoin",
"      </a>",
"      may cause idiopathic intracranial hypertension (pseudotumor cerebri). The use of medications that share this side effect (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      antibiotics) should be avoided during therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15769?source=see_link&amp;anchor=H5#H5\">",
"       \"Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis\", section on 'Medications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diffuse skeletal hyperostosis and calcifications in ligaments and tendons may rarely occur, especially among patients being treated with high doses for longer than usual periods.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Psychiatric effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns have been raised about a possible association of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    with depression and suicide. Isotretinoin has been in the top 10 drugs reported to the FDA's Adverse Event Reporting System for depression and suicide attempts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/42\">",
"     42",
"    </a>",
"    ]. Between the time isotretinoin was marketed in 1982 and January 2005, the FDA received reports of 190 patients in the United States treated with isotretinoin who committed suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If there were no association between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    and suicide, 220 suicides would have been expected in users of isotretinoin in the US between 1982 and 2002, while there were actually only 165 suicides reported to the FDA in that time frame [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/43\">",
"     43",
"    </a>",
"    ]. However, not all such suicides would have been reported to the FDA so the interpretation of these numbers is uncertain.",
"   </p>",
"   <p>",
"    Reviews, including a systematic review, have concluded that data on suicidal behavior and depression during treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    are inadequate to establish a causal relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. Some authors have proposed that psychological distress over severe acne, rather than isotretinoin, could be a contributing factor to suicide or depression in patients treated with the drug. In a study of 3775 patients (ages 18 to 19 years), suicidal ideation was significantly more common among patients with severe acne, compared with patients with little or no acne [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/48\">",
"     48",
"    </a>",
"    ]. In addition, a retrospective cohort study (n=5756) that found an increased rate of suicide attempts in patients treated with isotretinoin compared with the general population also identified a nonsignificant trend towards elevated rates of suicide attempts prior to treatment with isotretinoin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In sum, the relationship between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    and depression and suicide is uncertain. Patients should be advised of a possible link and should be followed closely for the development of depression or suicidal ideation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=see_link\">",
"     \"Suicidal ideation and behavior in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38071?source=see_link\">",
"     \"Evaluation and management of suicidal behavior in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Monitoring and discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fasting serum triglycerides and cholesterol, liver function tests, and a complete blood count (CBC) should be obtained prior to initiating therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]. Product information for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    recommends checking fasting lipids weekly or biweekly until the lipid response has been established; however, in otherwise healthy, asymptomatic, young individuals without a personal or family history of diabetes or dyslipidemia, many practitioners perform laboratory testing on a less frequent basis. In patients receiving isotretinoin for acne, we obtain a CBC, fasting lipid profile, and liver function tests at baseline and repeat them after four and eight weeks of therapy. If these test results are normal and the dose of isotretinoin remains stable, we discontinue laboratory monitoring.",
"   </p>",
"   <p>",
"    Women of childbearing potential must have a monthly serum or urine pregnancy test throughout the duration of therapy. A pregnancy test also should be performed one month after the last dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Most of the adverse effects associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    can be managed without discontinuing the drug (eg, emollients for dry skin, nonsteroidal antiinflammatory drugs for myalgias or arthralgias, dietary manipulation for lipid abnormalities).",
"   </p>",
"   <p>",
"    Creatinine kinase (CK) levels are elevated in approximately 15 to 50 percent of patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    -induced myalgias; however, checking CK levels is not indicated in the absence of severe muscular pain [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/2\">",
"     2",
"    </a>",
"    ]. Mild, transient elevations in hepatic transaminases occur early in the course of therapy in approximately 15 to 20 percent of patients; levels typically normalize within a few weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indications for stopping therapy include severe hypertriglyceridemia (eg, above 800",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    because of the risk of acute pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/50\">",
"     50",
"    </a>",
"    ], and other marked abnormalities on laboratory testing. Discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    is recommended if hepatic transaminase levels reach more than three times greater than normal values [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/2,26\">",
"     2,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although hypertriglyceridemia usually resolves with cessation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , patients may need ongoing monitoring since one report suggests that they may be at increased risk for future hyperlipidemia and the metabolic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22184/abstract/51\">",
"     51",
"    </a>",
"    ]. In a cross-sectional study, 102 patients in whom the serum triglyceride concentration increased at least 89",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    during isotretinoin therapy (hyperresponders) were compared with 100 patients in whom the serum triglyceride concentration changed &le;9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.1",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    nonresponders). Four years after completion of isotretinoin therapy, hyperresponders were significantly more likely to have hypertriglyceridemia (odds ratio [OR] 4.8, 95% CI 1.6-13.8), hypercholesterolemia (OR 9.1, 95% CI 1.9-43), truncal obesity (OR 11.0, 95% CI 2.0-59), and hyperinsulinemia (OR 3.0, 95% CI 1.6-5.7).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/12/1218?source=see_link\">",
"       \"Patient information: Acne (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/40/20099?source=see_link\">",
"       \"Patient information: Acne (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       Isotretinoin",
"      </a>",
"      is an effective treatment for acne vulgaris that diminishes sebum production, inhibits the growth of Propionibacterium acnes (P. acnes), and inhibits comedogenesis. However, multiple adverse effects limit its widespread use. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       Isotretinoin",
"      </a>",
"      is teratogenic. Women of childbearing potential must use two forms of contraception during treatment and for one month thereafter. For patients with severe, recalcitrant, nodular acne who have not responded to other topical and oral therapies, we recommend use of oral isotretinoin (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients with less severe but treatment-resistant acne that is scarring or psychologically disabling, we also suggest use of oral isotretinoin (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Isotretinoin should NOT be administered in pregnancy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In order to diminish treatment-induced flares,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      is typically started at a low dose (0.5",
"      <span class=\"nowrap\">",
"       mg/kd/day)",
"      </span>",
"      during the first month of therapy, and then increased to 1",
"      <span class=\"nowrap\">",
"       mg/kg/day.",
"      </span>",
"      A total treatment dose of 120 to 150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of isotretinoin given over four to six months may decrease the risk of relapse. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe inflammatory acne (eg, acne conglobata, acne fulminans) may require concomitant treatment with systemic glucocorticoids starting before or at the initiation of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other systemic acne medications are typically discontinued during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      therapy. In particular, the use of isotretinoin with tetracyline-class antibiotics should be avoided due to the risk of idiopathic intracranial hypertension (pseudotumor cerebri). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients improve after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      therapy, although the majority of patients will continue to require the use of other acne therapies. Subsequent courses of isotretinoin should not be initiated until at least five months after completion of the previous treatment period. A second course of isotretinoin is needed in approximately 20 percent of patients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, all prescribing clinicians and patients are required to participate in the iPLEDGE program, an online registry initiated by the FDA to minimize the risk of fetal exposure to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Teratogenicity and the iPLEDGE program'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       Isotretinoin",
"      </a>",
"      has multiple side effects, including teratogenicity, mucocutaneous disorders, myalgias, visual changes, idiopathic intracranial hypertension, hepatotoxicity, and hyperlipidemia. Patients should be screened for these and other complaints via questioning and laboratory studies at regular follow-up visits during treatment. In women of childbearing potential, a monthly serum or urine HCG is required during the duration of therapy. HCG should be repeated one month following therapy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Isotretinoin safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An association of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      with depression and suicide has been proposed. Although studies have concluded that a causal relationship cannot be definitively established, patients should be advised of these risks, and should be asked to report any symptoms of depression. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Psychiatric effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/1\">",
"      Ward A, Brogden RN, Heel RC, et al. Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders. Drugs 1984; 28:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/2\">",
"      Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg 2008; 27:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/3\">",
"      Peck GL, Olsen TG, Yoder FW, et al. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med 1979; 300:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/4\">",
"      Jones H, Blanc D, Cunliffe WJ. 13-cis retinoic acid and acne. Lancet 1980; 2:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/5\">",
"      Farrell LN, Strauss JS, Stranieri AM. The treatment of severe cystic acne with 13-cis-retinoic acid. Evaluation of sebum production and the clinical response in a multiple-dose trial. J Am Acad Dermatol 1980; 3:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/6\">",
"      Peck GL, Olsen TG, Butkus D, et al. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol 1982; 6:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/7\">",
"      Lehucher-Ceyrac D, Weber-Buisset MJ. Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years. Dermatology 1993; 186:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/8\">",
"      McElwee NE, Schumacher MC, Johnson SC, et al. An observational study of isotretinoin recipients treated for acne in a health maintenance organization. Arch Dermatol 1991; 127:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/9\">",
"      Jones DH, King K, Miller AJ, Cunliffe WJ. A dose-response study of I3-cis-retinoic acid in acne vulgaris. Br J Dermatol 1983; 108:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/10\">",
"      Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984; 10:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/11\">",
"      Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007; 56:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/12\">",
"      Cunliffe WJ, van de Kerkhof PC, Caputo R, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997; 194:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/13\">",
"      Layton AM, Cunliffe WJ. Guidelines for optimal use of isotretinoin in acne. J Am Acad Dermatol 1992; 27:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/14\">",
"      Cooper AJ, Australian Roaccutane Advisory Board. Treatment of acne with isotretinoin: recommendations based on Australian experience. Australas J Dermatol 2003; 44:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/15\">",
"      Seukeran DC, Cunliffe WJ. The treatment of acne fulminans: a review of 25 cases. Br J Dermatol 1999; 141:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/16\">",
"      Karvonen SL. Acne fulminans: report of clinical findings and treatment of twenty-four patients. J Am Acad Dermatol 1993; 28:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/17\">",
"      B&ouml;ni R, Nehrhoff B. Treatment of gram-negative folliculitis in patients with acne. Am J Clin Dermatol 2003; 4:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/18\">",
"      Neubert U, Plewig G, Ruhfus A. Treatment of gram-negative folliculitis with isotretinoin. Arch Dermatol Res 1986; 278:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/19\">",
"      Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/20\">",
"      Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol 2006; 54:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/21\">",
"      L&oacute;pez-V&iacute;lchez MA, Vicente Villa MA, Garc&iacute;a-Fructuoso MT, et al. [Acne fulminans after the treatment with isotretinoin]. An Esp Pediatr 1999; 51:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/22\">",
"      Tan BB, Lear JT, Smith AG. Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone. Clin Exp Dermatol 1997; 22:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/23\">",
"      Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris--10 years later: a safe and successful treatment. Br J Dermatol 1993; 129:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/24\">",
"      Azoulay L, Oraichi D, B&eacute;rard A. Isotretinoin therapy and the incidence of acne relapse: a nested case-control study. Br J Dermatol 2007; 157:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/25\">",
"      White GM, Chen W, Yao J, Wolde-Tsadik G. Recurrence rates after the first course of isotretinoin. Arch Dermatol 1998; 134:376.",
"     </a>",
"    </li>",
"    <li>",
"     Patton TJ, Zirwas MJ, Wolverton SE. Systemic retinoids. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Elsevier, 2007. p.275.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/27\">",
"      Lee JW, Yoo KH, Park KY, et al. Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. Br J Dermatol 2011; 164:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/28\">",
"      Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985; 313:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/29\">",
"      Centers for Disease Control and Prevention (CDC). Accutane-exposed pregnancies--California, 1999. MMWR Morb Mortal Wkly Rep 2000; 49:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/30\">",
"      Sladden MJ, Harman KE. What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin? Arch Dermatol 2007; 143:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/31\">",
"      Vastag, B. More stringent rules on accutane. JAMA 2002; 287:832.",
"     </a>",
"    </li>",
"    <li>",
"     www.ipledgeprogram.com (Accessed on April 23, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/33\">",
"      Neudorfer M, Goldshtein I, Shamai-Lubovitz O, et al. Ocular adverse effects of systemic treatment with isotretinoin. Arch Dermatol 2012; 148:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/34\">",
"      Mathers WD, Shields WJ, Sachdev MS, et al. Meibomian gland morphology and tear osmolarity: changes with Accutane therapy. Cornea 1991; 10:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/35\">",
"      Leyden JJ, James WD. Staphylococcus aureus infection as a complication of isotretinoin therapy. Arch Dermatol 1987; 123:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/36\">",
"      Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol 2001; 45:S150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/37\">",
"      Etminan M, Bird ST, Delaney JA, et al. Isotretinoin and Risk for Inflammatory Bowel Disease: A Nested Case-Control Study and Meta-analysis of Published and Unpublished Data. JAMA Dermatol 2013; 149:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/38\">",
"      Bernstein CN, Nugent Z, Longobardi T, Blanchard JF. Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study. Am J Gastroenterol 2009; 104:2774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/39\">",
"      Crockett SD, Porter CQ, Martin CF, et al. Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. Am J Gastroenterol 2010; 105:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/40\">",
"      Alhusayen RO, Juurlink DN, Mamdani MM, et al. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. J Invest Dermatol 2013; 133:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/41\">",
"      Zane LT, Leyden WA, Marqueling AL, Manos MM. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol 2006; 142:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/42\">",
"      Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol 2001; 45:515.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/cder/drug/InfoSheets/HCP/IsotretinoinHCP.htm (Accessed on August 12, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/44\">",
"      Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg 2005; 24:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/45\">",
"      Magin P, Pond D, Smith W. Isotretinoin, depression and suicide: a review of the evidence. Br J Gen Pract 2005; 55:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/46\">",
"      Hull PR, D'Arcy C. Acne, depression, and suicide. Dermatol Clin 2005; 23:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/47\">",
"      Bigby M. Does isotretinoin increase the risk of depression? Arch Dermatol 2008; 144:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/48\">",
"      Halvorsen JA, Stern RS, Dalgard F, et al. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol 2011; 131:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/49\">",
"      Sundstr&ouml;m A, Alfredsson L, Sj&ouml;lin-Forsberg G, et al. Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. BMJ 2010; 341:c5812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/50\">",
"      McCarter TL, Chen YK. Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy. Am J Gastroenterol 1992; 87:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22184/abstract/51\">",
"      Rodondi N, Darioli R, Ramelet AA, et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study. Ann Intern Med 2002; 136:582.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 38 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-B6CE745EC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_42_22184=[""].join("\n");
var outline_f21_42_22184=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29706373\">",
"      Low dose isotretinoin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ISOTRETINOIN SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Teratogenicity and the iPLEDGE program",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mucocutaneous side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26534738\">",
"      Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Psychiatric effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Monitoring and discontinuation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38071?source=related_link\">",
"      Evaluation and management of suicidal behavior in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44599?source=related_link\">",
"      Hormonal therapy for women with acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15769?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/40/20099?source=related_link\">",
"      Patient information: Acne (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/12/1218?source=related_link\">",
"      Patient information: Acne (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=related_link\">",
"      Suicidal ideation and behavior in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39370?source=related_link\">",
"      Treatment of acne vulgaris",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_42_22185="Evaluation of inguinal swelling in children";
var content_f21_42_22185=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"86\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of inguinal swelling in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/42/22185/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/42/22185/contributors\">",
"     David J Mathison, MD, MBA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/42/22185/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/42/22185/contributors\">",
"     George A Woodward, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/42/22185/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/42/22185/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/42/22185/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7223724\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric inguinal swelling occurs mostly from inguinal hernias, especially in boys, who are affected six times more often than girls [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/1\">",
"     1",
"    </a>",
"    ]. However, it is important to consider the different features and characteristics of masses in the inguinal or groin area to exclude other causes, such as congenital anomalies, infections, and neoplasms. This discussion will be limited to an approach to swelling of the",
"    <strong>",
"     inguinal",
"    </strong>",
"    area.",
"   </p>",
"   <p>",
"    Evaluation and treatment of hernias, lymphadenopathy, cryptorchidism, and isolated scrotal swelling in children are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link\">",
"       \"Overview of inguinal hernia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=see_link\">",
"       \"Approach to the child with peripheral lymphadenopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=see_link\">",
"       \"Undescended testes (cryptorchidism) in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43766?source=see_link\">",
"       \"Causes of painless scrotal swelling in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2663?source=see_link\">",
"       \"Evaluation of scrotal pain or swelling in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7223753\">",
"    <span class=\"h1\">",
"     INGUINAL ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inguinal area can be generally described as the region between the anterior superior iliac spine to the pubic symphysis, which contains a variety of structures that surround the inguinal and femoral canal. The key landmarks of the inguinal canal include: the inguinal ligament, the internal and external inguinal rings, the round ligament (in females) and the spermatic cord (in males) (",
"    <a class=\"graphic graphic_figure graphicRef61841 \" href=\"UTD.htm?7/18/7461\">",
"     figure 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    The anatomic region known as Hesselbach&rsquo;s triangle helps differentiate indirect hernias, which pass outside this triangle through the inguinal canal, from direct hernias which protrude into this space (",
"    <a class=\"graphic graphic_figure graphicRef61841 \" href=\"UTD.htm?7/18/7461\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef83015 \" href=\"UTD.htm?22/58/23461\">",
"     figure 2",
"    </a>",
"    ). Hesselbach&rsquo;s triangle is defined laterally by the inferior epigastric artery, medially by the lateral border of the rectus muscle, and inferiorly by the inguinal ligament. The femoral canal contains the femoral artery, nerve, and vein that exit the femoral ring into the proximal thigh.",
"   </p>",
"   <p>",
"    Indirect hernias result from two anatomic defects: weakening of the fascia of the transversalis muscle fibers at the internal abdominal ring, and the potential space from a persistent processus vaginalis (",
"    <a class=\"graphic graphic_figure graphicRef83013 \" href=\"UTD.htm?13/29/13782\">",
"     figure 3",
"    </a>",
"    ). In males, the obliteration of the processus vaginalis occurs during the first two years of life, but as many as 40 percent remain patent, 20 percent of which will later develop into inguinal hernias. Indirect inguinal hernias in males and females occur more frequently on the right, the side where the migration of the testicle or round ligament occurs last. The female counterpart of the processus vaginalis commonly disappears by eight months of gestation, although patency may persist into childhood. If patency persists, the patent processus is termed the canal of Nuck. Embryology of the testes and ovaries are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of inguinal hernia in children\", section on 'Embryology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inguinal lymph nodes are important structures adjacent to the inguinal canal that are present in the superficial and deep planes. The superficial nodes drain lymph from the skin in the perineum, gluteal region, and lower abdominal wall as well as the vaginal mucosa, penis, scrotum, anal canal, anterior leg, lateral leg, and medial foot. The deep inguinal nodes lie beneath the fascia and medial to the femoral vein and drain the superficial nodes in addition to the clitoris, the glans of the penis, the medial ipsilateral leg, and the lateral ipsilateral foot.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7223760\">",
"    <span class=\"h1\">",
"     CAUSES OF INGUINAL SWELLING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of inguinal swelling are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef83582 \" href=\"UTD.htm?24/2/24619\">",
"     table 1",
"    </a>",
"    ). In most instances careful clinical evaluation with selected use of ultrasonography can rapidly establish the etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11662269\">",
"    <span class=\"h2\">",
"     Inguinal hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inguinal hernias in children may present as intermittent, reducible, or incarcerated inguinal masses. Inguinal hernias may be indirect or direct (",
"    <a class=\"graphic graphic_figure graphicRef61841 \" href=\"UTD.htm?7/18/7461\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef83015 \" href=\"UTD.htm?22/58/23461\">",
"     figure 2",
"    </a>",
"    ) with indirect hernias occurring much more frequently than direct hernias and much more commonly in males than females. (See",
"    <a class=\"local\" href=\"#H7223753\">",
"     'Inguinal anatomy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of inguinal hernia in children\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indirect hernias appear when abdominal contents pass lateral to the epigastric artery, through the inguinal canal, and into the scrotum or labia through the external inguinal ring (",
"    <a class=\"graphic graphic_figure graphicRef61841 \" href=\"UTD.htm?7/18/7461\">",
"     figure 1",
"    </a>",
"    ). They may contain omentum, bowel, and rarely, the appendix (Amyand hernia). In males, the scrotum is full which helps differentiate inguinal hernias from retractile, ectopic, or undescended testes (",
"    <a class=\"graphic graphic_picture graphicRef83101 \" href=\"UTD.htm?31/11/31926\">",
"     picture 1",
"    </a>",
"    ). In females, reproductive organs are often present, including the ovary, fallopian tube, and rarely, the uterus (",
"    <a class=\"graphic graphic_picture graphicRef83100 \" href=\"UTD.htm?36/19/37182\">",
"     picture 2",
"    </a>",
"    ). It can be difficult to differentiate a sliding hernia of the ovary from a hydrocele of the canal of Nuck since both can present as non-painful, palpable, movable inguinal masses in females. The ovary, however, can become incarcerated within the canal, presenting as a painful mass. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of inguinal hernia in children\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of inguinal hernia in children\", section on 'Inguinal mass in a female'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosis and treatment of inguinal hernias varies by gender and presenting features, and is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of inguinal hernia in children\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2467130\">",
"    <span class=\"h2\">",
"     Inguinal lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphadenopathy is characterized by non-tender swelling or enlargement of the lymph nodes. Lymph node swelling can occur secondary to a generalized or a localized process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=see_link&amp;anchor=H6#H6\">",
"     \"Causes of peripheral lymphadenopathy in children\", section on 'Localized lymphadenopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=see_link&amp;anchor=H12#H12\">",
"     \"Causes of peripheral lymphadenopathy in children\", section on 'Generalized lymphadenopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although inguinal adenopathy may arise adjacent to the inguinal canal, it can be differentiated from an indirect inguinal hernia because of the characteristic rubbery and movable, but fixed nature of the swelling and its location outside of the inguinal canal. In addition, the enlarged lymph node will produce a mass that does not extend into the scrotum or labia. Direct and femoral hernias may be confused with lymphadenopathy because the bulge is either above (direct) or below (femoral) the inguinal canal (",
"    <a class=\"graphic graphic_figure graphicRef83015 \" href=\"UTD.htm?22/58/23461\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef83045 \" href=\"UTD.htm?37/45/38613\">",
"     figure 4",
"    </a>",
"    ) and the swelling does not extend into the genitalia. However, unless incarcerated, these hernias will have a cystic quality on palpation. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Generalized lymphadenopathy with inguinal involvement",
"      </strong>",
"      can be associated with infectious disease (HIV, EBV, miliary tuberculosis, etc), metabolic disease (Gaucher, Niemann-Pick, etc), rheumatologic disease (eg, JIA, SLE, etc), immunologic disease (eg, chronic granulomatous disease, serum-like sickness reaction, etc), malignancy (eg, leukemia, lymphoma, etc), inflammatory disease (eg, sarcoidosis, Churg-Strauss syndrome, etc), lymphoproliferative disease (eg, hemophagocytic lymphohistiocytosis, Castleman&rsquo;s disease) or medication reaction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=see_link&amp;anchor=H12#H12\">",
"       \"Causes of peripheral lymphadenopathy in children\", section on 'Generalized lymphadenopathy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=see_link&amp;anchor=H19#H19\">",
"       \"Causes of peripheral lymphadenopathy in children\", section on 'Uncommon but important causes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Localized inguinal lymphadenopathy",
"      </strong>",
"      can be associated with nearby skin and soft tissue infections that drain to the inguinal lymph nodes, which can include regional sites, such as the buttocks, genitals, groin, or the ipsilateral lower extremity. Localized infections causing inguinal lymphadenopathy can include fungal disease (eg, tinea corporis), parasitic disease (eg, filariasis, etc), bacterial skin disease (eg, furuncle, cellulitis, impetigo), and venereal disease (eg, herpes simplex, primary syphilis, lymphogranuloma venereum). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=see_link&amp;anchor=H10#H10\">",
"       \"Causes of peripheral lymphadenopathy in children\", section on 'Inguinal'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2467137\">",
"    <span class=\"h2\">",
"     Inguinal lymphadenitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphadenitis can be differentiated from lymphadenopathy by the presence of tenderness, often accompanied by erythema and fluctuance.",
"    <strong>",
"    </strong>",
"    Tender lymph nodes in the groin (or axilla) are sometimes termed &ldquo;buboes&rdquo;, derived from the exudative lymph nodes characteristic of bubonic plague. The term is now used to describe the tender and swollen lymph nodes associated with local skin infections or ulcerative lymphadenitis caused by venereal diseases, often in conjunction with genital ulcerative lesions. If secondary swelling from the lymphadenitis involves the genitalia, differentiating this condition from an incarcerated inguinal hernia may be difficult, especially when pain limits the inguinal examination. In these instances, ultrasonography can be diagnostic.",
"   </p>",
"   <p>",
"    Inguinal lymphadenitis can be divided into the following categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Animal and tick vectors",
"      </strong>",
"      &ndash; Infections spread by animal or tick-borne transmission to the lower extremity can cause a regional lymphadenitis from draining lymph proximal to the area of entry. These infections can cause lymphadenopathy, but typically the nodes are tender. Examples of these diseases include: tularemia, plague, brucellosis, and cat-scratch disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of tularemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16058?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of brucellosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11512?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23289?source=see_link\">",
"       \"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Direct skin-borne infection",
"      </strong>",
"      &ndash; Skin bacteria (eg, strep, staph, etc) can directly infect the inguinal nodes causing a primary bacterial lymphadenitis, similar to but much less common than cervical lymphadenitis that frequently occurs in young children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8632?source=see_link&amp;anchor=H4#H4\">",
"       \"Etiology and clinical manifestations of cervical lymphadenitis in children\", section on 'Pathophysiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Venereal disease (buboes)",
"      </strong>",
"      &ndash; Buboes are caused by either Hemophilus ducreyi (Chancroid) or the L1, L2, and L3 serovars of Chlamydia trachomatis (lymphogranuloma venereum). Both of these diseases have characteristic ulcerative lesions associated with the buboes (",
"      <a class=\"graphic graphic_picture graphicRef76843 \" href=\"UTD.htm?16/5/16464\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef61366 \" href=\"UTD.htm?12/29/12755\">",
"       picture 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10696?source=see_link\">",
"       \"Chancroid\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21063?source=see_link\">",
"       \"Lymphogranuloma venereum\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22377483\">",
"    <span class=\"h2\">",
"     Granuloma inguinale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granuloma inguinale (donovanosis) is a genital infection that is usually sexually acquired and is most prevalent in tropical regions including India, Papua New Guinea, the Caribbean, South America, and Australia.",
"   </p>",
"   <p>",
"    Infection with",
"    <em>",
"     Klebsiella granulomatis comb. nov.",
"    </em>",
"    (previously",
"    <em>",
"     Calymmatobacterium granulomatis",
"    </em>",
"    ), the causative agent of granuloma inguinale, can cause pseudo-buboes in the inguinal area which are typically associated with ulcers on the genitalia. Pseudo-buboes may feel like swollen or obstructed lymph nodes but are caused by subcutaneous granulation and are eventually broken down and replaced by ulcers. There are several types of ulcers, but the ulcero-vegetative variety is most common and is characterized by a beefy-red non-tender ulcer that bleeds readily (",
"    <a class=\"graphic graphic_picture graphicRef83016 \" href=\"UTD.htm?15/14/15589\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Evaluation and treatment of granuloma inguinale is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=see_link\">",
"     \"Approach to the patient with genital ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11662500\">",
"    <span class=\"h2\">",
"     Spermatic cord hydrocele",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hydrocele of the spermatic cord occurs when fluid accumulates along the cord in the inguinal canal or upper scrotum, but is separated from the testes (",
"    <a class=\"graphic graphic_figure graphicRef83047 \" href=\"UTD.htm?40/18/41252\">",
"     figure 5",
"    </a>",
"    ). Whereas an indirect hernia occurs from a failure of the processus vaginalis to close, a cord hydrocele occurs from an abnormal closure of the processus vaginalis where the distal portion closes and midportion remains patent along the cord. Cord hydroceles are much less common than indirect hernias. In a large series of ultrasounds performed to evaluate for inguinal masses or swelling, a cord hydrocele was present in only 1.5 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although mixed forms have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/3\">",
"     3",
"    </a>",
"    ], cord hydroceles are typically classified into one of two types [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Non-communicating (encysted)",
"      </strong>",
"      &ndash; This is the",
"      <strong>",
"      </strong>",
"      most common variety and is characterized by fluid pooling along the length of the cord but not communicating with the peritoneal cavity or tunica vaginalis. Since the encysted type does not communicate with the peritoneal cavity, the size does not change with increases in intra-abdominal pressure, such as crying fits or coughing, nor is this type reducible.",
"     </li>",
"     <li>",
"      <strong>",
"       Communicating (funicular)",
"      </strong>",
"      &ndash; Unlike the encysted type, the funicular type communicates freely with the peritoneal cavity at the internal ring. Therefore, the swelling in the inguinal area can enlarge with increased intra-abdominal pressure, and can decrease in size when the patient relaxes. Communicating cord hydroceles can be difficult to distinguish from indirect inguinal hernias on physical examination, and ultrasound is frequently required to establish the diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of type, children with spermatic cord hydroceles warrant referral to a surgeon with pediatric and genitourinary expertise. Herniotomy is frequently performed to prevent later development of an indirect inguinal hernia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11662518\">",
"    <span class=\"h2\">",
"     Testes: retractile, ectopic, or undescended",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a testicle is not located in the scrotum, it may be retractile, ectopic or undescended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Retractile testes",
"      </strong>",
"      &ndash; An atraumatic, non-tender inguinal mass in the presence of an &ldquo;empty&rdquo; hemi-scrotum is suggestive of a retractile testis if it can be brought back into the scrotum. The testes can move up into the inguinal canal as a result of an exaggerated cremasteric reflex. The retractile testis can be &ldquo;milked&rdquo; back into the scrotum by gently applying downward pressure across the top of the palpable mass. Testicular retraction can recur, and no treatment is necessary if the testis is freely movable. However, these patients warrant referral to an urologist for follow-up because approximately one-third of retractile testicles can become undescended with time.",
"     </li>",
"     <li>",
"      <strong>",
"       Ectopic or undescended testes",
"      </strong>",
"      &ndash; An ectopic testis is characterized by a testis that naturally descends through the external ring, but then becomes lodged outside of the natural path, most commonly in a superficial pouch near the external ring or less commonly in the suprapubic region, femoral canal, perineum, or contralateral scrotal compartment (",
"      <a class=\"graphic graphic_figure graphicRef74686 \" href=\"UTD.htm?12/53/13137\">",
"       figure 6",
"      </a>",
"      ). Undescended testes can be one-sided (70 percent) or bilateral (",
"      <a class=\"graphic graphic_picture graphicRef51355 \" href=\"UTD.htm?4/46/4832\">",
"       picture 6",
"      </a>",
"      ) (30 percent) and may present as a mass in the inguinal canal. Undescended testicles are associated with an underdeveloped scrotum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The goal of the genital examination is to determine if a suspected testicular mass in the inguinal canal of a patient without significant blunt scrotal trauma is a retractile, ectopic, or undescended testis. If the testicular mass cannot be moved into the scrotum, then an ectopic or undescended testis is suggested. An undescended testis can lodge anywhere along its line of descent, including the inguinal canal, the external inguinal ring, or intra-abdominally (",
"    <a class=\"graphic graphic_picture graphicRef72440 \" href=\"UTD.htm?43/23/44415\">",
"     picture 7",
"    </a>",
"    ). While an intra-abdominal testis will not be palpable, remnants of the gubernaculum or dissociated epididymis and vas deferens may be present in the inguinal canal. If the testicular mass is tender or causes pain, this suggests a torsion of an undescended or ectopic testis, sometimes referred to as a cryptorchid testicular torsion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=see_link&amp;anchor=H8#H8\">",
"     \"Undescended testes (cryptorchidism) in children and adolescents\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Differentiation between a retractile and a truly undescended testis can be difficult in some patients and may require consultation with a pediatric urologist. The genital examination in a male with retractile versus suspected ectopic or undescended testis is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=see_link&amp;anchor=H10#H10\">",
"     \"Undescended testes (cryptorchidism) in children and adolescents\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11662534\">",
"    <span class=\"h2\">",
"     Testicular dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular dislocation is an uncommon event that occurs in the setting of acute or recent blunt genitourinary trauma, especially straddle injuries sustained in a motorcycle collision. With significant force to the pelvis, the testes can become displaced, often into a superficial pouch anterior to the external oblique aponeurosis, and rarely into the penile, pubic, canalicular, or perineal areas.",
"   </p>",
"   <p>",
"    Clinical findings typically consist of a unilateral tender mass present in the inguinal area in association with an empty hemiscrotum in a patient without a prior history of cryptorchidism or orchiectomy. Rarely, bilateral dislocations may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. A traumatic testicular dislocation can be difficult to recognize on initial examination, especially when associated with swelling, ecchymosis, obesity, and pelvic injury. As an example, in an observational study of 1967 abdominal blunt trauma patients over a 15 year period, nine testicular dislocations were reported and all were missed on initial evaluation. Most were not diagnosed until 3 to 60 days post-injury [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/8\">",
"     8",
"    </a>",
"    ]. When testicular dislocation is suspected, prompt surgical consultation should be obtained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35000?source=see_link&amp;anchor=H2573814#H2573814\">",
"     \"Scrotal trauma in children and adolescents\", section on 'Indications for subspecialty consultation or referral'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical repair is often necessary since manual reduction is successful in only 15 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/9\">",
"     9",
"    </a>",
"    ]. A previously dislocated testis has impaired spermatogenesis and may have an increased risk for malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2467390\">",
"    <span class=\"h2\">",
"     Femoral hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Femoral hernias are very uncommon. In children, a hernia in the groin area is almost 250 times more likely to be an indirect hernia than a femoral one [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/10\">",
"     10",
"    </a>",
"    ]. Children with femoral hernias have swelling in the upper thigh, below the inguinal ligament and medial to the femoral artery, often in association with crampy abdominal pain (",
"    <a class=\"graphic graphic_figure graphicRef83045 \" href=\"UTD.htm?37/45/38613\">",
"     figure 4",
"    </a>",
"    ). Despite the difference in anatomic location, pediatric femoral hernias can be clinically difficult to distinguish from the inguinal variety and are frequently misdiagnosed preoperatively by surgeons and referring physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Femoral hernias are less likely to be incarcerated than the inguinal variety, but incarcerated femoral hernias are often complicated by sliding ovaries, especially in female infants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/13\">",
"     13",
"    </a>",
"    ]. In adults, femoral hernias are more common in older women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31321?source=see_link\">",
"     \"Classification, clinical features and diagnosis of inguinal and femoral hernias in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When suspected, prompt surgical consultation is warranted as femoral hernias are more apt to present with strangulation and to require emergency surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29000?source=see_link\">",
"     \"Overview of treatment for inguinal and femoral hernias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26662415\">",
"    <span class=\"h2\">",
"     Tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of different tumors have been reported in the inguinal area, ranging from benign to malignant. Benign lesions of the inguinal canal can include, but are not limited to: lipomas, hematomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/14\">",
"     14",
"    </a>",
"    ], mesothelial cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/15\">",
"     15",
"    </a>",
"    ], dermoid cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], lymphangiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/14\">",
"     14",
"    </a>",
"    ], and fibrous hamartomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Careful attention is necessary to distinguish features of malignant lesions which could include systemic symptoms (eg, weight loss, fever, or masses in other regions) or a non-cystic, non-lipomatous feeling mass which may be associated with fixed (unmovable) lymph nodes. The most common malignant lesions of the groin are soft tissue sarcomas; however, only 2 percent of both rhabdo- and non-rhabdomyosarcomas arise in the groin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Hodgkin and non-Hodgkin lymphoma may rarely present with inguinal lymphadenopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of Hodgkin lymphoma in children and adolescents\", section on 'Lymphadenopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10266?source=see_link&amp;anchor=H1876635#H1876635\">",
"     \"Overview of pediatric non-Hodgkin lymphoma\", section on 'Signs and symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other malignancies, such as primary neuroblastoma, have also been reported in the inguinal canal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, neuroblastoma can spread into the spermatic cord [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Malignant lesions in the pelvis can metastasize or locally spread to the canal by pushing through the internal ring. Malignancies with lymphatic spread can involve the inguinal lymph nodes. But despite the close proximity, inguinal lymph node metastases from testicular cancers are rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26662423\">",
"    <span class=\"h2\">",
"     Appendicitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of the vermiform appendix, whether inflamed or not, inside a hernial sac is known as Amyand hernia. Amyand hernia complicates 1 percent of all inguinal hernias with one-third of these cases having associated acute appendicitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/23\">",
"     23",
"    </a>",
"    ]. It is unclear whether appendicitis is an incidental finding or rather if there is a causal relationship with these cases. But a ruptured appendicitis can present with a tender inguinal mass secondary to localized abscess formation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment is as for perforated appendicitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/2/31785?source=see_link&amp;anchor=H13#H13\">",
"     \"Acute appendicitis in children: Management\", section on 'Appendiceal perforation/gangrene'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11662608\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients, a careful history and physical examination establish the underlying cause of an inguinal swelling. In selected patients, ultrasonography is a helpful diagnostic tool.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7223781\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the history in children with inguinal swelling include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Duration of symptoms",
"      </strong>",
"      &ndash; Is the onset acute, subacute, or chronic?",
"     </li>",
"     <li>",
"      <strong>",
"       Pain",
"      </strong>",
"      &ndash; Is the mass painful (in infants, this can be characterized by excessive fussiness, irritability, or an abnormal cry)? (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link&amp;anchor=H18#H18\">",
"       \"Overview of inguinal hernia in children\", section on 'Incarcerated mass'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Signs of obstruction",
"      </strong>",
"      &ndash; Has there been vomiting, abdominal distension, or lack of bowel movements? (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link&amp;anchor=H18#H18\">",
"       \"Overview of inguinal hernia in children\", section on 'Incarcerated mass'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Signs of systemic disease",
"      </strong>",
"      &ndash; Are there associated symptoms of fever, night sweats, weight loss greater than 10 percent of body weight, or other systemic disease in the absence of an obvious cause? (See",
"      <a class=\"local\" href=\"#H2467137\">",
"       'Inguinal lymphadenitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26662415\">",
"       'Tumor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Signs of localized infection",
"      </strong>",
"      &ndash; Are there any skin lesions located in the upper thigh or lower abdominal regions? (See",
"      <a class=\"local\" href=\"#H2467130\">",
"       'Inguinal lymphadenopathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2467137\">",
"       'Inguinal lymphadenitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Change in size of the mass",
"      </strong>",
"      &ndash; Does the mass grow larger with increase in intra-abdominal pressure (eg, cough, straining, vomiting, Valsalva, etc)? Commonly an intercurrent illness such as a URI with cough or a child who is constipated with straining and encopresis can make a hernia more pronounced. (See",
"      <a class=\"local\" href=\"#H11662269\">",
"       'Inguinal hernia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Trauma",
"      </strong>",
"      &ndash; Has the patient suffered significant genitourinary trauma? (See",
"      <a class=\"local\" href=\"#H11662534\">",
"       'Testicular dislocation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Past medical history",
"      </strong>",
"      &ndash; Key questions include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Does the child have a history of conditions that predisposed to indirect inguinal hernias (eg, previous repair, prematurity, abdominal wall defects [eg, prune belly syndrome], connective tissue disorders [eg, Ehlers-Danlos syndrome], abnormalities of the genitourinary system [eg, bladder exstrophy])? (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of inguinal hernia in children\", section on 'Associated conditions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Was scrotal location of the testes documented in the neonatal period (retractile versus ectopic or undescended testes)? (See",
"      <a class=\"local\" href=\"#H11662518\">",
"       'Testes: retractile, ectopic, or undescended'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Is there a history of tick or animal exposure (eg, cat scratch, rabbit, or rodent)? (See",
"      <a class=\"local\" href=\"#H2467137\">",
"       'Inguinal lymphadenitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Is the patient sexually active? Has the patient traveled to areas endemic for granuloma inguinale (eg, India, Papua New Guinea)? (See",
"      <a class=\"local\" href=\"#H2467137\">",
"       'Inguinal lymphadenitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22377483\">",
"       'Granuloma inguinale'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Family history",
"      </strong>",
"      &ndash; Pertinent family history includes the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Are there family members who have had an inguinal hernia?",
"     </li>",
"     <li>",
"      Is there a history of unexplained genital anomalies, abnormal pubertal development, or infertility (all suggestive of cryptorchidism)? (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=see_link&amp;anchor=H2#H2\">",
"       \"Undescended testes (cryptorchidism) in children and adolescents\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7223788\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following aspects of the physical examination should be noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Visualization and palpation",
"      </strong>",
"      &ndash; The inguinal canal should be assessed for tenderness, compressibility, warmth, feel, color, and size change with maneuvers such as Valsalva or patient relaxation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The hallmark of an indirect inguinal hernia is a firm mass that emerges through the external inguinal ring and enlarges with increased intra-abdominal pressure (",
"      <a class=\"graphic graphic_figure graphicRef61841 \" href=\"UTD.htm?7/18/7461\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef83013 \" href=\"UTD.htm?13/29/13782\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef83101 \" href=\"UTD.htm?31/11/31926\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef83100 \" href=\"UTD.htm?36/19/37182\">",
"       picture 2",
"      </a>",
"      ). A bulge that is above the inguinal ligament and not located in the inguinal canal indicates a direct hernia (",
"      <a class=\"graphic graphic_figure graphicRef83015 \" href=\"UTD.htm?22/58/23461\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef51224 \" href=\"UTD.htm?23/31/24050\">",
"       figure 7",
"      </a>",
"      ). A swelling that is more pronounced in the upper thigh is suggestive of a femoral hernia (",
"      <a class=\"graphic graphic_figure graphicRef83045 \" href=\"UTD.htm?37/45/38613\">",
"       figure 4",
"      </a>",
"      ). Both direct and femoral hernias are much less common than indirect hernias. (See",
"      <a class=\"local\" href=\"#H11662269\">",
"       'Inguinal hernia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2467390\">",
"       'Femoral hernia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the female patient with a palpable hernia, the ovary with or without the fallopian tube may appear as a round mass although it can also slide in and out of the hernia and not be palpable on examination. When a tender mass is present, ovarian torsion is suggested. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link&amp;anchor=H24#H24\">",
"       \"Overview of inguinal hernia in children\", section on 'Inguinal mass in a female'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A cord hydrocele will show swelling along the inguinal canal without extension into the scrotum. The encysted (non-communicating) type will not fluctuate in size with Valsalva or relaxation maneuvers whereas the funicular (communicating) type should. Transillumination can show a translucent swelling suggesting a fluid-filled cord, however this is not a sensitive test to evaluate the inguinal area. (See",
"      <a class=\"local\" href=\"#H11662500\">",
"       'Spermatic cord hydrocele'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Normal lymph nodes should be &le;2 cm diameter and are oval, firm, slightly movable, and non-tender. Lymph nodes &gt;2 cm are consistent with lymphadenopathy. Fixed (unmovable) lymph nodes are suspicious for malignancy or granulomatous disease. Inguinal lymphadenopathy should prompt evaluation of other lymph chains (cervical, axillary, etc) to differentiate signs of a localized or systemic disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=see_link&amp;anchor=H16#H16\">",
"       \"Approach to the child with peripheral lymphadenopathy\", section on 'Diagnostic approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Localized tenderness to the lymph nodes is consistent with lymphadenitis. Tender inguinal nodes should prompt thorough evaluation of the genitals for presence of ulcers or other lesions suggestive of a sexually transmitted infection. Additionally, evaluation of the ipsilateral lower extremity is required to evaluate for bite marks suggestive of vector-borne diseases, although the bites can occur from days to months prior to lymph node involvement, depending on the disease. (See",
"      <a class=\"local\" href=\"#H2467137\">",
"       'Inguinal lymphadenitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Reduction",
"      </strong>",
"      &ndash; If a hernia is suspected, manual reduction is both diagnostic and therapeutic. Inability to reduce the hernia is suggestive of an incarcerated hernia. In a female patient, an incarcerated inguinal hernia should be presumed to have associated torsion of the ovary until proven otherwise. Signs of a strangulated hernia are an irreducible mass with necrotic discoloration secondary to venous and lymphatic obstruction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link&amp;anchor=H25#H25\">",
"       \"Overview of inguinal hernia in children\", section on 'Incarcerated inguinal hernia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link&amp;anchor=H24#H24\">",
"       \"Overview of inguinal hernia in children\", section on 'Inguinal mass in a female'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Inspection of Scrotal Contents (in males)",
"      </strong>",
"      &ndash; The presence of an empty hemiscrotum differentiates ectopic or undescended testes from masses, other than those with a testicular origin, that occur in the inguinal region. In the setting of inguinal swelling, the presence of an",
"      <strong>",
"       empty",
"      </strong>",
"      hemiscrotum suggests a dislocated, retractile, ectopic, or undescended testes. These findings can be differentiated as follows::",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Dislocated testicles occur after acute, high force trauma. (See",
"      <a class=\"local\" href=\"#H11662534\">",
"       'Testicular dislocation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the testes can be successfully milked into the empty hemi-scrotum, then the diagnosis of a retractile testes is made. (See",
"      <a class=\"local\" href=\"#H11662518\">",
"       'Testes: retractile, ectopic, or undescended'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the testicular mass cannot be moved into the scrotum in the absence of trauma, then an ectopic or undescended testes is suggested. An undescended testes can lodge anywhere along its line of descent, including the inguinal canal, the external inguinal ring, or intra-abdominally (",
"      <a class=\"graphic graphic_picture graphicRef72440 \" href=\"UTD.htm?43/23/44415\">",
"       picture 7",
"      </a>",
"      ). While an intra-abdominal testes will not be palpable, remnants of the gubernaculum or dissociated epididymis and vas deferens may be present in the inguinal canal. If the testicular mass is tender or causes pain, this suggests a torsion of an undescended or ectopic testes, sometimes referred to as a cryptorchid testicular torsion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=see_link&amp;anchor=H8#H8\">",
"       \"Undescended testes (cryptorchidism) in children and adolescents\", section on 'Evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7223797\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing is usually unnecessary in the evaluation of inguinal swelling caused by indirect inguinal hernia, uncomplicated lymphadenopathy, or lymphadenitis due to a localized skin infection.",
"   </p>",
"   <p>",
"    The diagnostic approach to children with peripheral lymphadenopathy or lymphadenitis varies from observation and reassurance to comprehensive diagnostic testing and aggressive medical and surgical therapy, depending upon the findings from the history and physical examination (",
"    <a class=\"graphic graphic_algorithm graphicRef52799 \" href=\"UTD.htm?38/49/39710\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef64444 \" href=\"UTD.htm?7/11/7344\">",
"     algorithm 2",
"    </a>",
"    ). It is not necessary to identify the underlying etiology in every patient since most cases are benign and self-limited. The pace of the evaluation is dictated by how ill the patient appears. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to the child with peripheral lymphadenopathy\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Boys with ectopic or undescended testicles warrant additional evaluation depending upon the age of presentation. Laboratory testing for these patients is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=see_link\">",
"     \"Undescended testes (cryptorchidism) in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with localized inguinal adenopathy secondary to ulcerative venereal disease require pathogen-specific testing for syphilis and herpes simplex virus in addition to testing for chlamydia and gonorrhea. Additional testing may be necessary for signs of chancroid, lymphogranuloma venereum, and granuloma inguinale. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=see_link&amp;anchor=H21#H21\">",
"     \"Approach to the patient with genital ulcers\", section on 'Laboratory testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=see_link&amp;anchor=H16#H16\">",
"     \"Sexually transmitted diseases: Overview of issues specific to adolescents\", section on 'Screening and diagnostic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Masses suspicious for malignancy warrant additional evaluation to establish the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical assessment of the child with suspected cancer\", section on 'Lymphadenopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical assessment of the child with suspected cancer\", section on 'Establishing the diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7223833\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Ultrasound with Doppler",
"      </strong>",
"      &ndash; While ultrasound is highly technician dependent, it is the optimum study for the majority of causes of inguinal swelling in females. In males, most indirect inguinal hernias can be diagnosed and managed without specific testing. However, ultrasound is also useful for evaluation of spermatic cord hydroceles and undescended or ectopic testes. Ultrasound can readily differentiate the features of hernias, hydroceles, atypical masses, testes, and the female reproductive organs. Doppler flow offers additional utility and is indicated for the emergent evaluation of torsion in the displaced testes, testicular dislocation, or incarcerated and entrapped ovary.",
"     </li>",
"     <li>",
"      <strong>",
"       Computed tomography (CT)",
"      </strong>",
"      &ndash; CT is typically not necessary but may offer some utility in the setting of blunt abdominal trauma with testicular dislocation or when evaluating inguinal masses suspicious of malignancy, both for staging and to help better define the mass and it&rsquo;s tissue of origin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7223842\">",
"    <span class=\"h1\">",
"     APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to inguinal swelling differs in boys versus girls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2469141\">",
"    <span class=\"h2\">",
"     Male",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to inguinal swelling starts with recognizing the potentially emergent conditions that require acute management or immediate intervention, which are always signified by the presence of pain (",
"    <a class=\"graphic graphic_algorithm graphicRef83583 \" href=\"UTD.htm?18/49/19216\">",
"     algorithm 3",
"    </a>",
"    ). In boys, a painful inguinal lump may indicate an incarcerated or strangulated indirect inguinal hernia, lymphadenitis, torsion of an undescended testis, or when occurring after major genitourinary trauma, a testicular dislocation. An incarcerated or strangulated femoral hernia is identified by a painful lump that is located below the inguinal ligament in the mid- or upper- thigh. Other differentiating features include the presence of fever, erythema, or induration which suggests localized cellulitis with lymphadenitis and an empty scrotum in patients with a dislocated or torsed undescended testicle. (See",
"    <a class=\"local\" href=\"#H7223788\">",
"     'Physical examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Boys with incarcerated indirect or direct inguinal hernias or incarcerated femoral hernias should undergo prompt manual reduction followed by elective surgical repair. Incarcerated hernias that cannot be manually reduced and strangulated hernias with signs of bowel obstruction warrant emergency surgery. Timely surgical consultation is also indicated for patients with, testicular dislocation or torsed undescended testis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of inguinal hernia in children\", section on 'Incarcerated inguinal hernia'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2467390\">",
"     'Femoral hernia'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11662534\">",
"     'Testicular dislocation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Causes of inguinal swelling that are not painful include lymphadenopathy, retractile testis, undescended or ectopic testis, a reducible indirect inguinal hernia, spermatic cord hydrocele, or soft tissue tumor. Typically the presence of lymphadenopathy and a reducible inguinal hernia are obvious upon physical examination. The other causes usually require ultrasound to diagnose and delineate the condition. (See",
"    <a class=\"local\" href=\"#H7223833\">",
"     'Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Further evaluation and treatment depend upon the condition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Boys with a reducible inguinal hernia or spermatic cord hydrocele should be referred for elective surgical repair. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link&amp;anchor=H17#H17\">",
"       \"Overview of inguinal hernia in children\", section on 'Reducible mass'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H11662500\">",
"       'Spermatic cord hydrocele'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic approach to children with peripheral lymphadenopathy or lymphadenitis varies from observation and reassurance to comprehensive diagnostic testing and aggressive medical and surgical therapy, depending upon the findings from the history and physical examination (",
"      <a class=\"graphic graphic_algorithm graphicRef52799 \" href=\"UTD.htm?38/49/39710\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef64444 \" href=\"UTD.htm?7/11/7344\">",
"       algorithm 2",
"      </a>",
"      ). It is not necessary to identify the underlying etiology in every patient since most cases are benign and self-limited. The pace of the evaluation is dictated by how ill the patient appears. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=see_link&amp;anchor=H16#H16\">",
"       \"Approach to the child with peripheral lymphadenopathy\", section on 'Diagnostic approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ulcerated lesions require further diagnostic testing for sexually transmitted diseases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=see_link&amp;anchor=H21#H21\">",
"       \"Approach to the patient with genital ulcers\", section on 'Laboratory testing'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=see_link&amp;anchor=H16#H16\">",
"       \"Sexually transmitted diseases: Overview of issues specific to adolescents\", section on 'Screening and diagnostic testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Boys with ectopic or undescended testicles warrant additional evaluation depending upon the age of presentation and should be referred to a pediatric urologist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=see_link\">",
"       \"Undescended testes (cryptorchidism) in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Masses suspicious for malignancy warrant additional evaluation to establish the diagnosis followed by treatment according to the specific neoplasm identified. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical assessment of the child with suspected cancer\", section on 'Lymphadenopathy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link&amp;anchor=H23#H23\">",
"       \"Clinical assessment of the child with suspected cancer\", section on 'Establishing the diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2469148\">",
"    <span class=\"h2\">",
"     Female",
"    </span>",
"    &nbsp;&mdash;&nbsp;In girls, painful inguinal swelling is caused by an incarcerated or strangulated inguinal hernia, cellulitis, or lymphadenitis (",
"    <a class=\"graphic graphic_algorithm graphicRef83584 \" href=\"UTD.htm?38/44/39630\">",
"     algorithm 4",
"    </a>",
"    ). An incarcerated or strangulated femoral hernia is identified by a painful lump that is located below the inguinal ligament in the mid- or upper- thigh. Other differentiating features include the presence of fever, erythema, or induration which suggests localized cellulitis with lymphadenitis. (See",
"    <a class=\"local\" href=\"#H7223788\">",
"     'Physical examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because incarcerated or strangulated indirect inguinal hernias in girls frequently contain reproductive organs (eg, ovary or fallopian tube), the clinician should attempt a gentle reduction and then obtain an US if not successful. If the US shows that reproductive organs are not present, then further efforts at reduction are appropriate. Prompt surgical consultation is warranted for symptomatic girls with entrapped hernias that cannot be reduced. (See",
"    <a class=\"local\" href=\"#H7223788\">",
"     'Physical examination'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7223833\">",
"     'Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Infant females in particular, may have herniated reproductive organs that are",
"    <strong>",
"     not",
"    </strong>",
"    incarcerated or strangulated [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22185/abstract/1\">",
"     1",
"    </a>",
"    ]. This is characterized by a palpable, often pearly, movable mass in an asymptomatic female infant. Gentle reduction in these patients will not be successful and further delineation by ultrasound followed by elective referral to a surgeon with pediatric expertise is warranted.",
"   </p>",
"   <p>",
"    Other causes of non-painful inguinal swelling in girls include reducible inguinal hernias, lymphadenopathy, or soft tissue tumors. As in boys, a reducible inguinal hernia should be referred for elective repair. Additional evaluation of lymphadenopathy depends upon the degree of illness in the patient (",
"    <a class=\"graphic graphic_algorithm graphicRef52799 \" href=\"UTD.htm?38/49/39710\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef64444 \" href=\"UTD.htm?7/11/7344\">",
"     algorithm 2",
"    </a>",
"    ), the presence of genital ulcers, or clinical suspicion for malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=see_link\">",
"     \"Approach to the child with peripheral lymphadenopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=see_link\">",
"     \"Approach to the patient with genital ulcers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=see_link&amp;anchor=H16#H16\">",
"     \"Sexually transmitted diseases: Overview of issues specific to adolescents\", section on 'Screening and diagnostic testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical assessment of the child with suspected cancer\", section on 'Establishing the diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7223716\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of inguinal swelling in children are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef83582 \" href=\"UTD.htm?24/2/24619\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H7223760\">",
"     'Causes of inguinal swelling'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The approach to an inguinal mass is largely determined by the patient&rsquo;s gender and the presence of pain (",
"    <a class=\"graphic graphic_algorithm graphicRef83583 \" href=\"UTD.htm?18/49/19216\">",
"     algorithm 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef83584 \" href=\"UTD.htm?38/44/39630\">",
"     algorithm 4",
"    </a>",
"    ). Most masses arise from either an indirect inguinal hernia or from inflammation of the inguinal lymph nodes.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/1\">",
"      Huang CS, Luo CC, Chao HC, et al. The presentation of asymptomatic palpable movable mass in female inguinal hernia. Eur J Pediatr 2003; 162:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/2\">",
"      Rathaus V, Konen O, Shapiro M, et al. Ultrasound features of spermatic cord hydrocele in children. Br J Radiol 2001; 74:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/3\">",
"      Chang YT, Lee JY, Wang JY, et al. Hydrocele of the spermatic cord in infants and children: its particular characteristics. Urology 2010; 76:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/4\">",
"      Martin LC, Share JC, Peters C, Atala A. Hydrocele of the spermatic cord: embryology and ultrasonographic appearance. Pediatr Radiol 1996; 26:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/5\">",
"      Tsurukiri J, Kaneko N, Mishima S. Bilateral traumatic testicular dislocation. Urology 2011; 78:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/6\">",
"      Tsai HN, Wu WJ, Huang SP, et al. Bilateral traumatic testicular dislocation--a case report. Kaohsiung J Med Sci 2002; 18:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/7\">",
"      Bromberg W, Wong C, Kurek S, Salim A. Traumatic bilateral testicular dislocation. J Trauma 2003; 54:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/8\">",
"      Ko SF, Ng SH, Wan YL, et al. Testicular dislocation: an uncommon and easily overlooked complication of blunt abdominal trauma. Ann Emerg Med 2004; 43:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/9\">",
"      Singer AJ, Das S, Gavrell GJ. Traumatic dislocation of testes. Urology 1990; 35:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/10\">",
"      Ollero Fresno JC, Alvarez M, Sanchez M, Roll&aacute;n V. Femoral hernia in childhood: review of 38 cases. Pediatr Surg Int 1997; 12:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/11\">",
"      Chapman WH, Barcia PJ. Femoral hernia in children: an infrequent problem revisited. Mil Med 1991; 156:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/12\">",
"      Nayeem N. Femoral hernia in children. Br J Clin Pract 1990; 44:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/13\">",
"      Tsushimi T, Takahashi T, Gohra H, et al. A case of incarcerated femoral hernia in an infant. J Pediatr Surg 2005; 40:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/14\">",
"      Poenaru D, Jacobs DA, Kamal I. Unusual findings in the inguinal canal: a report of four cases. Pediatr Surg Int 1999; 15:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/15\">",
"      Aarabi S, Drugas G, Avansino JR. Mesothelial cyst presenting as an irreducible inguinal mass. J Pediatr Surg 2010; 45:e19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/16\">",
"      Leeming R, Olsen M, Ponsky JL. Inguinal dermoid cyst presenting as an incarcerated inguinal hernia. J Pediatr Surg 1992; 27:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/17\">",
"      Prada-Arias M, Ortiz-Rey JA, Fern&aacute;ndez-Eire P, et al. Dermoid cyst of the spermatic cord in children. J Pediatr Surg 2010; 45:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/18\">",
"      Zampieri N, Carabaich A, Corroppolo M, et al. Two patients with tumours presenting as inguino-scrotal masses. Eur J Cancer Care (Engl) 2008; 17:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/19\">",
"      Karplus G, Krasin MJ, Rodriguez-Galindo C, et al. Retrospective study of the surgical management and outcome of nonrhabdomyosarcoma soft tissue sarcomas of the groin and axilla in children. J Pediatr Surg 2009; 44:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/20\">",
"      Raney RB Jr, Crist W, Hays D, et al. Soft tissue sarcoma of the perineal region in childhood. A report from the Intergroup Rhabdomyosarcoma Studies I and II, 1972 through 1984. Cancer 1990; 65:2787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/21\">",
"      Leo ME, McManus MJ, Strawbridge LR, Kramer SA. Bilateral primary neuroblastomas in the inguinal canal. J Urol 1992; 148:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/22\">",
"      K&ouml;seolu V, Akata D, Kutluk T, et al. Neuroblastoma with spermatic cord metastasis in a child: sonographic findings. J Clin Ultrasound 1999; 27:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/23\">",
"      Cankorkmaz L, Ozer H, Guney C, et al. Amyand's hernia in the children: a single center experience. Surgery 2010; 147:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22185/abstract/24\">",
"      Kynes JM, Rauth TP, McMorrow SP. Ruptured appendicitis presenting as acute scrotal swelling in a 23-month-old toddler. J Emerg Med 2012; 43:47.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13883 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_42_22185=[""].join("\n");
var outline_f21_42_22185=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7223716\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7223724\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7223753\">",
"      INGUINAL ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7223760\">",
"      CAUSES OF INGUINAL SWELLING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11662269\">",
"      Inguinal hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2467130\">",
"      Inguinal lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2467137\">",
"      Inguinal lymphadenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22377483\">",
"      Granuloma inguinale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11662500\">",
"      Spermatic cord hydrocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11662518\">",
"      Testes: retractile, ectopic, or undescended",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11662534\">",
"      Testicular dislocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2467390\">",
"      Femoral hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26662415\">",
"      Tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26662423\">",
"      Appendicitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11662608\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7223781\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7223788\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7223797\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7223833\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7223842\">",
"      APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2469141\">",
"      Male",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2469148\">",
"      Female",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7223716\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13883\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13883|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?38/49/39710\" title=\"algorithm 1\">",
"      Approach to generalized adenopathy in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?7/11/7344\" title=\"algorithm 2\">",
"      Approach to inguinal adenopathy in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?18/49/19216\" title=\"algorithm 3\">",
"      Inguinal swelling in a boy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?38/44/39630\" title=\"algorithm 4\">",
"      Inguinal swelling in a girl",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13883|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/18/7461\" title=\"figure 1\">",
"      Groin hernia anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/58/23461\" title=\"figure 2\">",
"      External view of a direct inguinal hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/29/13782\" title=\"figure 3\">",
"      Indirect inguinal hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/45/38613\" title=\"figure 4\">",
"      Femoral hernia anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/18/41252\" title=\"figure 5\">",
"      Congenital anomalies of the processus vaginalis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/53/13137\" title=\"figure 6\">",
"      Ectopic testes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/31/24050\" title=\"figure 7\">",
"      Direct inguinal hernia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13883|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/11/31926\" title=\"picture 1\">",
"      Indirect inguinal hernia in a male",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/19/37182\" title=\"picture 2\">",
"      Indirect inguinal hernia in a female infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/5/16464\" title=\"picture 3\">",
"      Penile ulcer due to chancroid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/29/12755\" title=\"picture 4\">",
"      Inguinal syndrome in LGV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/14/15589\" title=\"picture 5\">",
"      Ulcero-vegetative granuloma inguinale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/46/4832\" title=\"picture 6\">",
"      Bilateral cryptorchidism2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/23/44415\" title=\"picture 7\">",
"      Undescended testicle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13883|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/2/24619\" title=\"table 1\">",
"      Causes of inguinal swelling in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/2/31785?source=related_link\">",
"      Acute appendicitis in children: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=related_link\">",
"      Approach to the child with peripheral lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=related_link\">",
"      Approach to the patient with genital ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43766?source=related_link\">",
"      Causes of painless scrotal swelling in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30744?source=related_link\">",
"      Causes of peripheral lymphadenopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10696?source=related_link\">",
"      Chancroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31321?source=related_link\">",
"      Classification, clinical features and diagnosis of inguinal and femoral hernias in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=related_link\">",
"      Clinical assessment of the child with suspected cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16058?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of brucellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11512?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of tularemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8632?source=related_link\">",
"      Etiology and clinical manifestations of cervical lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2663?source=related_link\">",
"      Evaluation of scrotal pain or swelling in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21063?source=related_link\">",
"      Lymphogranuloma venereum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23289?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32874?source=related_link\">",
"      Overview of Hodgkin lymphoma in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=related_link\">",
"      Overview of inguinal hernia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10266?source=related_link\">",
"      Overview of pediatric non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29000?source=related_link\">",
"      Overview of treatment for inguinal and femoral hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35000?source=related_link\">",
"      Scrotal trauma in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=related_link\">",
"      Sexually transmitted diseases: Overview of issues specific to adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=related_link\">",
"      Undescended testes (cryptorchidism) in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_42_22186="Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents";
var content_f21_42_22186=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/42/22186/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/42/22186/contributors\">",
"     Kennon Heard, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/42/22186/contributors\">",
"     Richard Dart, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/42/22186/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/42/22186/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/42/22186/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/42/22186/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/42/22186/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5084915\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since its clinical introduction in 1950,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (N-acetyl-p-aminophenol; APAP; paracetamol) has become the most widely used analgesic and antipyretic in the United States. The popularity of acetaminophen among pediatricians increased when concerns were raised about an association between",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    and Reye's syndrome.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    is available in hundreds of over-the-counter and prescription medications. Although it is remarkably safe when used at therapeutic doses, overdose of acetaminophen has been recognized to cause fatal and nonfatal hepatic necrosis since 1966 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, repeated supratherapeutic doses can cause hepatotoxicity in children with certain risk factors, including decreased oral intake [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    poisoning in children and adolescents will be presented here. Management of acetaminophen poisoning in children and adolescents and the evaluation and management of acetaminophen poisoning in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13114?source=see_link\">",
"     \"Management of acetaminophen (paracetamol) poisoning in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5084922\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    remains a major cause of overdose in children throughout the world. In the United States, pediatric acetaminophen exposures account for approximately 30,000 reports to the National Poison Data System annually [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/5\">",
"     5",
"    </a>",
"    ]. The outcome of acetaminophen poisoning in children and adolescents is nearly always good if the antidote, N-acetylcysteine (NAC), is administered within 8 to 10 hours of ingestion. Mortality is rare in children and adolescents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13114?source=see_link&amp;anchor=H33#H33\">",
"     \"Management of acetaminophen (paracetamol) poisoning in children and adolescents\", section on 'N-acetylcysteine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5084929\">",
"    <span class=\"h2\">",
"     Patterns of exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential for toxicity from",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose in children and adolescents largely depends upon the circumstances surrounding the exposure:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5084936\">",
"    <span class=\"h3\">",
"     Intentional",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intentional",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ingestions are more prevalent among older children and adolescents. These ingestions tend to be single event, high-dose ingestions. The suicidal intent of these ingestions may be disclosed by the child or adolescent after ingestion, or discovered only through toxicologic screening. Children and adolescents who ingest acetaminophen as a suicide gesture may underestimate its toxicity and more frequently develop hepatotoxicity than young children with exploratory ingestions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Intentional poisoning of infants with acetaminophen has been reported in cases of child abuse and is also associated with significant toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link&amp;anchor=H20#H20\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\", section on 'Forced ingestion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5084944\">",
"    <span class=\"h3\">",
"     Unintentional",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unintentional ingestions are more common among younger children. These ingestions may occur through \"exploratory\" behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/9\">",
"     9",
"    </a>",
"    ] or inappropriate dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/10-13\">",
"     10-13",
"    </a>",
"    ], even under medical supervision [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5084951\">",
"    <span class=\"h4\">",
"     Exploratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of exploratory ingestions in the home involves small doses and often can be managed without referral to an emergency department [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Significant morbidity and mortality rarely occur [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/2-4,19,20\">",
"     2-4,19,20",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5084958\">",
"    <span class=\"h4\">",
"     Inappropriate dosing by a caregiver",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to exploratory ingestions, inadvertent repeated therapeutic overdose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    in young children frequently causes severe toxicity or death [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/2-4,19\">",
"     2-4,19",
"    </a>",
"    ]. Diagnosis of these unintentional ingestions due to inappropriate dosing may be delayed, since the symptoms and signs are nonspecific and may mimic those of the acute illness for which acetaminophen was being administered. The history of ingestion is also often difficult to obtain because parents may be reluctant to acknowledge that they made an error that contributed to their child&rsquo;s illness. Per manufacturer recommendations, the use of weight to select the best dose is preferred although the use of age is an acceptable alternative. (See",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     \"Acetaminophen (paracetamol): Pediatric drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inappropriate dosing may occur in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When adult",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      formulations are administered to children (eg, substitution of 325 or 500 mg tablet for 80 or 160 mg tablet) (",
"      <a class=\"graphic graphic_table graphicRef79854 \" href=\"UTD.htm?30/9/30876\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Through misreading (or unclear) instruction guidelines for liquid preparations (eg, substituting the infant drop formulation [100",
"      <span class=\"nowrap\">",
"       mg/mL]",
"      </span>",
"      for the less concentrated elixir or syrup [32 to 33",
"      <span class=\"nowrap\">",
"       mg/mL])",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef79854 \" href=\"UTD.htm?30/9/30876\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Through \"intentional\" overdose, when parents perceive that effective therapy has not been achieved with pediatric formulations (eg, 160 mg per 5 mL) in the appropriate dose (10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      and increase the frequency or dosage of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/3,4,21\">",
"       3,4,21",
"      </a>",
"      ], or combine acetaminophen with other antipyretics [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/22\">",
"       22",
"      </a>",
"      ], exceeding dose and duration on product labeling.",
"     </li>",
"     <li>",
"      There are reports suggesting that some conditions may predispose children to liver injury from therapeutic",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      doses. However, many of these reports are of low quality and lack sufficient information for a formal causality assessment [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/23\">",
"       23",
"      </a>",
"      ]. Putative risk factors are starvation, post-operative condition, inborn errors of metabolism and CYP 2E1 induction by other medications such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/52/17225?source=see_link\">",
"       rifampin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/24/38278?source=see_link\">",
"       isoniazid",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      By consuming multiple",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      -containing products (ie, prescription products and non-prescription products or single substance and combination products).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A profile of the child at increased risk for hepatotoxicity from sustained supratherapeutic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    dosing at home has been derived from case series. Characteristic features include a sick child who is younger than two years of age and is exposed in one of the following ways [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/4,11,19,24-26\">",
"     4,11,19,24-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dosing that exceeds more than 90",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      for more than one day (eg, only 20 percent greater than the maximum recommended daily dose of 75",
"      <span class=\"nowrap\">",
"       mg/kg).",
"      </span>",
"     </li>",
"     <li>",
"      Administration of multiple doses of adult-strength preparations",
"     </li>",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      suppositories",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although hepatoxicity has been reported in a few children who received multiple therapeutic doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/4\">",
"     4",
"    </a>",
"    ], the ascertainment of dose through parent recall in these cases is questionable. Furthermore, a study of therapeutic dosing in a group of 100 hospitalized children and adolescents who received therapeutic doses of acetaminophen (greater than or equal to six doses of 10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose over a 48-hour period) and were at risk for acetaminophen toxicity due to decreased oral intake failed to find any hepatotoxicity attributable to acetaminophen [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/27\">",
"     27",
"    </a>",
"    ]. Thus, the likelihood of toxicity from multiple therapeutic doses of acetaminophen in the majority of children appears low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2978491\">",
"    <span class=\"h4\">",
"     Iatrogenic IV overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    has been available in the United Kingdom since 2003 and was available for use in the United States in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/28\">",
"     28",
"    </a>",
"    ]. Tenfold iatrogenic overdoses have been described in hospitalized young children receiving intravenous acetaminophen for pain relief [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/29\">",
"     29",
"    </a>",
"    ]. The typical error occurs when the dose in mg is mistakenly given as the volume in mL. Other errors include human error when determining the volume to infuse by pump, duplicated doses, and intravenous injection of the oral suspension [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment is controversial and consultation with a poison control center or medical toxicologist is strongly advised. (See",
"    <a class=\"local\" href=\"#H5087304\">",
"     'Additional resources'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13114?source=see_link&amp;anchor=H5088338#H5088338\">",
"     \"Management of acetaminophen (paracetamol) poisoning in children and adolescents\", section on 'Approach'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5084965\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS AND TOXICOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     Acetaminophen (paracetamol)",
"    </a>",
"    is available in a variety of oral formulations, rectal suppositories, and an intravenous preparation. Toxicity, consisting primarily of hepatotoxicity, occurs when a large portion of the toxic, highly reactive, electrophilic intermediated, N-acetyl-p-benzoquinoneimine is produced after",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link&amp;anchor=H4#H4\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\", section on 'Biochemical toxicity'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    is rapidly and completely absorbed from the gastrointestinal tract, with peak serum concentrations reached from one-half to two hours after a therapeutic oral dose [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/30\">",
"     30",
"    </a>",
"    ]. Peak serum concentrations are reached within four hours in most cases of overdose of immediate-release preparations. However, following massive overdose, overdose of extended-release preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/31-33\">",
"     31-33",
"    </a>",
"    ] or with coingestions that delay gastric emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/34\">",
"     34",
"    </a>",
"    ], peak serum concentrations may be delayed beyond four hours. The various suppository preparations have different absorption characteristics, and reach peak concentration at variable times [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elimination half-lives range from two to four hours for all",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    preparations. However, elimination may appear to be prolonged for extended-release preparations because of prolonged tablet dissolution and absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/32,38\">",
"     32,38",
"    </a>",
"    ]. Elimination is delayed in cases with hepatotoxicity; serum half-lives greater than four hours are considered a marker of poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The metabolism of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    at therapeutic (",
"    <a class=\"graphic graphic_figure graphicRef68213 \" href=\"UTD.htm?20/49/21279\">",
"     figure 1",
"    </a>",
"    ) and toxic doses is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link&amp;anchor=H4#H4\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\", section on 'Biochemical toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5084972\">",
"    <span class=\"h2\">",
"     Risk factors in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver damage caused by excess N-acetyl-p-benzoquinoneimine (NAPQI) can occur in four circumstances (",
"    <a class=\"graphic graphic_figure graphicRef68213 \" href=\"UTD.htm?20/49/21279\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Excessive intake of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"     </li>",
"     <li>",
"      Decreased capacity for glucuronidation or sulfation",
"     </li>",
"     <li>",
"      Increased cytochrome P450 (CYP2E1) activity",
"     </li>",
"     <li>",
"      Depletion of glutathione stores",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of risk factors influence the propensity of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    to cause hepatotoxicity in children through the mechanisms listed above, including patient age, pattern of ingestion, nutritional status, concomitant use of CYP2E1-inducing drugs, comorbid illnesses, and genetic background [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/2,45\">",
"     2,45",
"    </a>",
"    ]. These factors, summarized briefly below, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link&amp;anchor=H5#H5\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\", section on 'Clinical factors influencing toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Age",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Following acute overdose, children younger than six years of age appear to be less susceptible to hepatotoxicity than older children and adults [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/46-51\">",
"       46-51",
"      </a>",
"      ]. The reasons for this are unclear, but several hypotheses have been proposed:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Compared with adults, infants and young children are believed to have greater capacity for conjugation with sulfate [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/48,50,52\">",
"       48,50,52",
"      </a>",
"      ]. Adult patterns of metabolism are reached between 10 and 12 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Young children are likely protected by an increased supply and regeneration of glutathione [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/50,53\">",
"       50,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Young children have a greater propensity to vomit after",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ingestion [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/48,51\">",
"       48,51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Repeated excessive dosing",
"      </strong>",
"      &ndash; In both children and adults, repeated excessive dosing is associated with greater morbidity and mortality than a single acute overdose [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/3,54\">",
"       3,54",
"      </a>",
"      ]. Repeated excessive dosing is often associated with other risk factors for hepatotoxicity, such as fasting or delayed presentation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13114?source=see_link&amp;anchor=H39#H39\">",
"       \"Management of acetaminophen (paracetamol) poisoning in children and adolescents\", section on 'Management of chronic poisoning'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"       \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Nutritional status",
"      </strong>",
"      &ndash; Fasting or malnutrition depletes hepatic stores of glucuronide",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      glutathione, leading to increased microsomal metabolism of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      and accumulation of free NAPQI, respectively, predisposing to hepatic injury (",
"      <a class=\"graphic graphic_figure graphicRef68213 \" href=\"UTD.htm?20/49/21279\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/55-61\">",
"       55-61",
"      </a>",
"      ]. Patients at greatest risk appear to be those who consume multiple excessive doses rather than a single overdose. This scenario is common among children suffering from an acute febrile illness, who may receive multiple doses or prolonged duration of acetaminophen.",
"     </li>",
"     <li>",
"      <strong>",
"       Comorbidities",
"      </strong>",
"      &ndash; Intercurrent or febrile illness appears to predispose some children to hepatotoxicity after multiple supratherapeutic doses [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]. The mechanism is not clear. It is speculated that intercurrent or febrile illnesses lower the threshold for hepatic injury, alter the clearance of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/62\">",
"       62",
"      </a>",
"      ], or are associated with other risk factors for hepatotoxicity (eg, decreased oral intake) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/2\">",
"       2",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients with Gilbert syndrome may be predisposed to hepatotoxicity because of impaired glucuronidation [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]. However, studies are not consistent and at least one study reports that the pattern of metabolites in urine of patients with Gilbert syndrome is similar to normal subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/66\">",
"       66",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=see_link\">",
"       \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients with chronic liver disease usually have low cytochrome oxidase enzyme activity, which may be protective following acetaminophen overdose, even though the elimination half-life may be prolonged [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/67,68\">",
"       67,68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Medications and coingestants",
"      </strong>",
"      &ndash; Concomitant use of agents that induce CYP2E1 enzymes can cause hepatotoxicity in the absence of overt",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      overdose and may worsen outcome when an intentional overdose has occurred. Examples of such agents include ethanol,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/24/38278?source=see_link\">",
"       isoniazid",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/52/17225?source=see_link\">",
"       rifampin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/69,70\">",
"       69,70",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In addition, drugs that compete for glucuronidation pathways (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/55/27512?source=see_link\">",
"       zidovudine",
"      </a>",
"      ) may potentiate acetaminophen hepatotoxicity by increasing the CYP2E1-dependent metabolism of acetaminophen [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/71\">",
"       71",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <strong>",
"       Genetic background",
"      </strong>",
"      &ndash; Polymorphisms in the cytochrome oxidase enzyme system may contribute to diminished or excessive oxidative metabolism of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      , and thereby affect predisposition to hepatic injury [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/72,73\">",
"       72,73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5084979\">",
"    <span class=\"h1\">",
"     DOSAGE FORMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    is available in the following preparations (",
"    <a class=\"graphic graphic_table graphicRef79854 \" href=\"UTD.htm?30/9/30876\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate-release for oral administration (eg, liquids, caplets, capsules, tablets)",
"     </li>",
"     <li>",
"      Immediate release suppositories",
"     </li>",
"     <li>",
"      Sustained-release oral tablets (eg, bilayer tablets of Tylenol Extended Relief&reg;) formulations",
"     </li>",
"     <li>",
"      Intravenous formulation (10",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      concentration)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among the oral formulations, the concentration may range from 32 to 33",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    (syrups, elixirs) to 100",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    (infant drops) for liquid preparations in the United States, and the strength may range from 80 to 650 mg for pills, capsules, or suppositories. In addition, varying amounts of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    are contained in over-the-counter cough and cold preparations. Given the variety of formulations and range of dosages within similar formulations (eg, chewable tablets), the potential for unintentional overdose due to confusion over concentration and frequency is high [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As of 2011, in an effort to minimize pediatric dosing errors, the Consumer Healthcare Products Association, in conjunction with the US Federal Drug Administration, is phasing out formulations that contain 100 mg per ml (infant",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    drops) so that pediatric liquid preparations obtained in the United States after that time will all contain a concentration of 32",
"    <span class=\"nowrap\">",
"     mg/ml",
"    </span>",
"    (160 mg per 5 mL). However, 100 mg per mL solutions are likely to continue to be given to children from infant acetaminophen drops preparations purchased by caregivers before this phase out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5084986\">",
"    <span class=\"h1\">",
"     TOXIC DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    for children younger than 12 years is 10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose, every four to six hours, not to exceed five doses per 24-hour period (maximum daily dose 75",
"    <span class=\"nowrap\">",
"     mg/kg).",
"    </span>",
"    The therapeutic dose for children 12 years and older and adults is 325 to 1000 mg per dose every four to six hours (maximum daily dose 4 g). Therapeutic serum concentrations range from 10 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (66 to132",
"    <span class=\"nowrap\">",
"     &micro;mol/L).",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    toxic dose may vary among individuals according to baseline glutathione levels and other factors (see",
"    <a class=\"local\" href=\"#H5084972\">",
"     'Risk factors in children'",
"    </a>",
"    above), but in general:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The minimal toxic dose for an acute ingestion is 150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for a child or 7.5 to 10 g for an adult [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/75\">",
"       75",
"      </a>",
"      ]. Referral for emergency department evaluation is generally recommended for acute ingestions greater than 200",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in children younger than six years of age or 10 grams, whichever is",
"      <strong>",
"       less",
"      </strong>",
"      . (See",
"      <a class=\"local\" href=\"#H5085021\">",
"       'Acute overdoses'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Toxicity is likely to occur with single ingestions greater than 250",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or ingestions of greater than 12 g in a 24-hour period [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/76,77\">",
"       76,77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Virtually all patients who ingest doses in excess of 350",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      develop severe liver toxicity (defined as peak aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater than 1000",
"      <span class=\"nowrap\">",
"       IU/L)",
"      </span>",
"      unless treated [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/76\">",
"       76",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"       \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In chronic overdose (eg, multiple supratherapeutic oral or rectal doses), the minimum toxic threshold for children appears to be 150 to 175",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      over two to four days, particularly in the setting of a febrile illness and decreased oral intake [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/2-4\">",
"       2-4",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H5085028\">",
"       'Chronic overdoses'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5084993\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial manifestations of acute",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    poisoning in children and adolescents are often mild and nonspecific, and do not predict subsequent hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/78\">",
"     78",
"    </a>",
"    ]. Nonetheless, clinicians must promptly recognize acetaminophen poisoning in order to minimize subsequent morbidity and mortality, since N-acetylcysteine (NAC), the antidote for acetaminophen, is most effective if administered within 8 to 10 hours of ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/79-81\">",
"     79-81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5085000\">",
"    <span class=\"h2\">",
"     Acute exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of acute single-dose exposures is often divided into four sequential stages. These stages (",
"    <a class=\"graphic graphic_table graphicRef57032 \" href=\"UTD.htm?15/60/16332\">",
"     table 2",
"    </a>",
"    ) are described in detail separately and include the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I (up to 24 hours after overdose) &ndash; Asymptomatic, but less commonly: nausea, vomiting, and, in patients with very large doses, lethargy and malaise",
"     </li>",
"     <li>",
"      Stage II (24 to 72 hours after overdose) &ndash; Right upper quadrant pain, elevation in liver enzymes, prothrombin time (PT) and international normalized ratio of PT, and, in severe cases, evidence of nephrotoxicity (elevated blood urea nitrogen, creatinine, oliguria)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pancreatitis (elevated serum amylase, lipase)",
"     </li>",
"     <li>",
"      Stage III (72 to 96 hours) &ndash; Evidence of liver failure and, in severe cases, renal failure and multi-organ failure; death most commonly occurs in this stage",
"     </li>",
"     <li>",
"      Stage IV (4 to 14 days) &ndash; Recovery",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5085007\">",
"    <span class=\"h2\">",
"     Chronic exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of chronic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    intoxication (repeated excessive dosing) is often difficult and requires the combination of astute history-taking and recognition of typical clinical and laboratory abnormalities. Clinicians must specifically ask about acetaminophen ingestion (including dose and frequency of administration) since patients and caregivers may not include it when asked about potentially toxic drugs. Signs and symptoms are insidious in onset, often nonspecific, and easily confused with alternative diagnoses (eg, viral syndrome). Serum concentrations of acetaminophen in this setting do not correlate with toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Establishing the diagnosis of chronic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    poisoning frequently involves exclusion of other causes of clinical hepatitis. (See",
"    <a class=\"local\" href=\"#H5085049\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5085014\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for emergency department evaluation of children and adolescents with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    intoxication varies depending upon the age of the child and the maximum possible ingested dose. Most pediatric acetaminophen exposures are low-dose exposures that do not require medical attention [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/18\">",
"     18",
"    </a>",
"    ]. Consultation with a regional poison control center (1-800-222-1222) is encouraged when making triage decisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5085021\">",
"    <span class=\"h2\">",
"     Acute overdoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because most children and adolescents with acute",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose are asymptomatic at presentation, the history of exposure largely determines the need for medical evaluation, laboratory testing, and treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Prehospital triage",
"      </strong>",
"      &ndash; Prehospital evaluation involves determination of the maximal possible dose, pattern of ingestion, and whether the child has any risks for hepatotoxicity (eg, fasting, coingestion of other drugs, underlying medical conditions). Consultation with a poison control center (1-800-222-1222) is helpful in assessing the need for emergency referral, particularly if the ingested product contains other pharmaceuticals, such as opiates (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32230?source=see_link\">",
"       codeine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/23/39287?source=see_link\">",
"       oxycodone",
"      </a>",
"      , antihistamine, etc) or is an extended-release product. Some health care providers may choose to refer children younger than six years of age with acute acetaminophen exposures that are less than 200",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      especially when significant uncertainty exists concerning the maximum ingested acetaminophen dose",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the patient's weight.",
"      <br/>",
"      <br/>",
"      Consensus guidelines developed by the American Association of Poison Control Centers and based upon observational studies suggest that children and adolescents who meet the following criteria after acute overdose be referred to an emergency department for evaluation of acetaminophen toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/82\">",
"       82",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Exposure to 200",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or 10 grams, whichever is LESS, acutely or over 24 hours",
"     </li>",
"     <li>",
"      Ingestion of an unknown amount of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"     </li>",
"     <li>",
"      Ingestion of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      with intent for self harm",
"     </li>",
"     <li>",
"      Known exposure to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      with signs of toxicity (eg, vomiting, right upper quadrant pain, altered mental status)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       History",
"      </strong>",
"      &ndash; The evaluation of the child or adolescent with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      intoxication should include as much detail about the ingestion as possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When did the ingestion occur?",
"     </li>",
"     <li>",
"      How much",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      was ingested? (The strength or concentration of acetaminophen in the product of concern must be carefully delineated) (",
"      <a class=\"graphic graphic_table graphicRef79854 \" href=\"UTD.htm?30/9/30876\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Was the child or adolescent taking",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      on a regular basis (including in over-the-counter preparations)?",
"     </li>",
"     <li>",
"      Was the ingestion intentional with a desire for self-harm? &nbsp;",
"     </li>",
"     <li>",
"      Does the child or adolescent have any underlying medical problems or take any medication on a regular basis?",
"     </li>",
"     <li>",
"      Does the child or adolescent have symptoms (nausea, vomiting, diaphoresis, pallor, lethargy, malaise, right upper quadrant pain, hepatomegaly)?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Physical examination",
"    </strong>",
"    &ndash; Most children with acute",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdoses present for care soon after ingestion and are asymptomatic with a normal physical examination. Examination of children with acetaminophen intoxication should include evaluation for encephalopathy, jaundice, right upper quadrant pain, liver enlargement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tenderness, and bleeding. Because the clinical manifestations of acetaminophen intoxication occur in distinct stages (",
"    <a class=\"graphic graphic_table graphicRef57032 \" href=\"UTD.htm?15/60/16332\">",
"     table 2",
"    </a>",
"    ), the examination must be repeated over time.",
"    <br/>",
"    <br/>",
"    The clinical features of toxic metabolic encephalopathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22506?source=see_link\">",
"     \"Acute toxic-metabolic encephalopathy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5085028\">",
"    <span class=\"h2\">",
"     Chronic overdoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus guidelines developed by the American Association of Poison Control Centers and based upon observational studies suggest that children and adolescents who meet the following criteria be referred to an emergency department for evaluation of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    toxicity after the following supratherapeutic exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/82\">",
"     82",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or 6 grams, whichever is LESS, per 24 hour period over 48 hours",
"     </li>",
"     <li>",
"      In children less than six years of age, 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or more per 24 hour period for the preceding 72 hours or longer",
"     </li>",
"     <li>",
"      Children with conditions that predispose to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      toxicity (eg, fasting, liver disease) with an ingestion of 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or 4 grams, whichever is LESS, per day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children who have received multiple excessive doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    should be evaluated with a serum acetaminophen concentration and aminotransferases, PT, and bilirubin. However, the treatment nomogram for acetaminophen poisoning should",
"    <strong>",
"     not",
"    </strong>",
"    be used to determine the risk of toxicity. The treatment nomogram was derived from patients who had ingested a single dose and one time point so it",
"    <strong>",
"     cannot",
"    </strong>",
"    be used for risk stratification of patients who have multiple ingestions over more than a few hours [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/3,20,63\">",
"     3,20,63",
"    </a>",
"    ]. The last dose",
"    <strong>",
"     cannot",
"    </strong>",
"    be used as a surrogate for single-point ingestions because earlier exposure may have caused hepatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevation of aminotransferases indicates hepatic injury, regardless of the serum",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    concentration and treatment with N-acetylcysteine should be provided. As an example, of 249 patients over the age of 12 years who had received more than 4 g per 24 hours of acetaminophen, 15 percent with serum aspartate aminotransferases of 50 to 1000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    developed liver toxicity and 16 percent with serum aspartate aminotransferases &gt;1000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    died or received liver transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children who have residual",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (&gt;10",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [66",
"    <span class=\"nowrap\">",
"     &micro;mol/L])",
"    </span>",
"    but normal aminotransferases and a history suggestive of acetaminophen overdose may also be at risk for hepatic injury and warrant antidotal therapy with N-acetylcysteine.",
"   </p>",
"   <p>",
"    Consultation with a regional poison control center (1-800-222-1222) or a medical toxicologist can help in tailoring duration of therapy and monitoring disease progression. The management of these children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13114?source=see_link&amp;anchor=H39#H39\">",
"     \"Management of acetaminophen (paracetamol) poisoning in children and adolescents\", section on 'Management of chronic poisoning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5085035\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with a history of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose should undergo measurement of serum acetaminophen concentration. In patients who are expected to develop hepatic toxicity based upon history and initial serum acetaminophen concentration, additional laboratory tests include: prothrombin time (PT), international normalized ratio of PT (PT-INR), AST, ALT, electrolytes, blood urea nitrogen (BUN), creatinine. These studies should also be performed in patients who ingested repeated supratherapeutic doses. In addition, ill-appearing patients may need blood gas analysis to determine serum pH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5085042\">",
"    <span class=\"h3\">",
"     Acetaminophen level",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following an acute ingestion, the risk of toxicity is best predicted by relating the time of ingestion to the serum",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    concentration. The dose history helps guide treatment decisions, but it is not sufficient evidence on which to base treatment after an acute overdose. Most studies have found no correlation between the amount of acetaminophen reportedly ingested and the serum concentration measured [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/9,84,85\">",
"     9,84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The serum",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    concentration should be measured between 4 and 24 hours after an acute overdose of an immediate-release or intravenous preparation. The concentration should be plotted on the acetaminophen nomogram to determine the need for NAC therapy (",
"    <a class=\"graphic graphic_figure graphicRef83590 \" href=\"UTD.htm?24/56/25472\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although the peak level after an intravenous overdose will occur sooner than after oral ingestion, a four hour level is still recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/29\">",
"     29",
"    </a>",
"    ]. Until more experience with intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose is obtained, the clinician is encouraged to contact a regional poison control center for assistance with assessment and management of these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13114?source=see_link&amp;anchor=H5088338#H5088338\">",
"     \"Management of acetaminophen (paracetamol) poisoning in children and adolescents\", section on 'Approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is presently insufficient experience to know whether the treatment nomogram for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    poisoning can accurately assess risk following acute overdose of sustained-release acetaminophen products. Some authorities (including the manufacturer) recommend that both a four- and eight-hour serum acetaminophen concentration be measured and treatment with NAC initiated if either concentration is above the \"possible hepatic toxicity\" line of the nomogram. It is likely that a single acetaminophen concentration plotted on the nomogram and below the treatment line is adequate to exclude the need for NAC treatment. Until more clinical experience has been gained, our recommendation is to follow the conservative approach of the manufacturer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link&amp;anchor=H25#H25\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\", section on 'Evaluation after acute overdose'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Most clinical chemistry laboratories report the plasma",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    levels in",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    rather than",
"    <span class=\"nowrap\">",
"     &micro;mol/L.",
"    </span>",
"    The units should be confirmed to ensure proper plotting on the treatment nomogram for acetaminophen poisoning. To convert",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     &micro;mol/L,",
"    </span>",
"    multiply by 6.62.",
"   </p>",
"   <p>",
"    Serum",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    concentrations obtained before four hours may be useful in detecting occult acetaminophen ingestions in patients who do not (or cannot) provide an ingestion history. However, because concentrations obtained before four hours may not represent peak concentrations, they should be repeated at four hours [",
"    <a class=\"abstract\" href=\"UTD.htm?21/42/22186/abstract/78\">",
"     78",
"    </a>",
"    ], and the four-hour concentration plotted on the treatment nomogram.",
"   </p>",
"   <p>",
"    Serum",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    concentrations obtained more than 24 hours after ingestion are difficult to interpret. Patients with an unknown time of ingestion and a serum acetaminophen concentration &gt;10",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (66",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevation of aminotransferases are usually treated with NAC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13114?source=see_link&amp;anchor=H33#H33\">",
"     \"Management of acetaminophen (paracetamol) poisoning in children and adolescents\", section on 'N-acetylcysteine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5085049\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ingestion may or may not be known. Unlike many other etiologies of hepatitis, acetaminophen-induced hepatitis is acute in onset and progresses rapidly; in severe exposure with delayed presentation or untreated with NAC, it is characterized by marked elevation of plasma aminotransferases (greater than 3000",
"    <span class=\"nowrap\">",
"     IU/L),",
"    </span>",
"    and is associated with a rising PT. In cases of occult exposure, the differential diagnosis includes other causes of hepatic failure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral hepatitis (hepatitis A, hepatitis B, hepatitis C, Epstein Barr virus, cytomegalovirus, varicella) &ndash; Viral hepatitis usually can be distinguished from",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      -induced liver injury by aminotransferases that are almost always less than 3000",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      and positive serology. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16295?source=see_link&amp;anchor=H5#H5\">",
"       \"Overview of hepatitis A virus infection in children\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31386?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of hepatitis B virus infection in children\", section on 'Clinical manifestations and diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inborn errors of metabolism (eg, Wilson's disease, alpha-1 antitrypsin deficiency, fatty acid oxidation abnormalities) &ndash; These diseases tend to progress slowly and are typically associated with elevations in plasma aminotransferases that are less than 1000",
"      <span class=\"nowrap\">",
"       IU/L.",
"      </span>",
"      Characteristic associated findings and specific testing can confirm the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"       \"Causes of metabolic myopathies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H65234856#H65234856\">",
"       \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug- or toxin-induced hepatitis &ndash; A variety of toxic agents can cause acute hepatitis, which in many circumstances may be clinically indistinguishable from",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      poisoning (",
"      <a class=\"graphic graphic_table graphicRef79913 \" href=\"UTD.htm?43/1/44060\">",
"       table 3",
"      </a>",
"      ). Known exposure to these agents, absence of any history of acetaminophen exposure, and no clinically detectable serum acetaminophen help establish the diagnosis.",
"     </li>",
"     <li>",
"      Hepatobiliary disease &ndash; Most children with hepatobiliary disease have a history of biliary atresia, long term requirement for hyperalimentation, or predisposition to pigmentary gallstones (eg, sickle cell anemia, hemolytic anemia). &nbsp;",
"     </li>",
"     <li>",
"      Reye syndrome &ndash; Reye syndrome is a rare cause of rapidly progressive encephalopathy with hepatic failure that often begins several days after apparent recovery from a viral illness, especially varicella or influenza A or B. This disease has virtually disappeared in concert with advisories",
"      <strong>",
"       not",
"      </strong>",
"      to use salicylates in febrile children. The liver pathology typically shows steatosis rather than the centrilobular necrosis that is characteristic of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      poisoning. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22506?source=see_link&amp;anchor=H28202936#H28202936\">",
"       \"Acute toxic-metabolic encephalopathy in children\", section on 'Reye syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ischemic hepatitis (\"shock liver\") &ndash; Ischemic hepatitis typically follows a period of severe, prolonged hypotension. Other features suggestive of ischemic hepatitis include an early rise in serum LDH, a ratio of serum alanine aminotransferase to LDH &lt;1.5 early in the course, and a rapid fall in serum aminotransferase levels after the initial rise. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18568?source=see_link&amp;anchor=H4#H4\">",
"       \"Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5087304\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5087276\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      overdoses in children younger than six years of age involve acute ingestions that are typically exploratory and have a low likelihood for serious toxicity. Following acute overdose, these children appear to be less susceptible to hepatotoxicity than older children and adults. (See",
"      <a class=\"local\" href=\"#H5084951\">",
"       'Exploratory'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5084972\">",
"       'Risk factors in children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute intentional ingestions in children older than six years of age and adolescents (ie, suicide attempts) have a higher potential for serious",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      toxicity than exploratory ingestions in younger children and may also involve multiple ingestants in addition to acetaminophen. Multiple supratherapeutic doses of acetaminophen in young children administered orally or rectally by caregivers or large iatrogenic intravenous dosing errors are also associated with serious toxicity. (See",
"      <a class=\"local\" href=\"#H5084936\">",
"       'Intentional'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5084958\">",
"       'Inappropriate dosing by a caregiver'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5084979\">",
"       'Dosage forms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The toxic dose of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      depends upon the age of the child and whether the exposure is acute or chronic. Referral for emergency department evaluation is generally recommended for acute ingestions greater than 200",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in children younger than six years of age or 10 grams, whichever is",
"      <strong>",
"       less",
"      </strong>",
"      ; intentional ingestions with a desire for self-harm; patients who are symptomatic; or situations where the ingested dose is unknown. Consultation with a poison control center (1-800-222-1222) is helpful in assessing the need for emergency referral, particularly if the ingested product contains other pharmaceuticals, such as opiates (eg, acetaminophen with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32230?source=see_link\">",
"       codeine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/23/39287?source=see_link\">",
"       oxycodone",
"      </a>",
"      , antihistamine, etc) or is an extended-release product. (See",
"      <a class=\"local\" href=\"#H5084986\">",
"       'Toxic dose'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5085021\">",
"       'Acute overdoses'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5087304\">",
"       'Additional resources'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who present within 24 hours after an acute",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      overdose are generally asymptomatic with a normal physical examination (",
"      <a class=\"graphic graphic_table graphicRef57032 \" href=\"UTD.htm?15/60/16332\">",
"       table 2",
"      </a>",
"      ). The likelihood for serious toxicity is determined by plotting a serum acetaminophen concentration obtained between 4 and 24 hours after ingestion on the acetaminophen nomogram (",
"      <a class=\"graphic graphic_figure graphicRef83590 \" href=\"UTD.htm?24/56/25472\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5085000\">",
"       'Acute exposures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5085021\">",
"       'Acute overdoses'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5085042\">",
"       'Acetaminophen level'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who present more than 24 hours after a potentially toxic",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      overdose are more likely to have manifestations of hepatotoxicity (",
"      <a class=\"graphic graphic_table graphicRef57032 \" href=\"UTD.htm?15/60/16332\">",
"       table 2",
"      </a>",
"      ) and should be evaluated with a serum acetaminophen concentration, serum alanine and aspartate aminotransferases, prothrombin time",
"      <span class=\"nowrap\">",
"       (PT)/",
"      </span>",
"      international normalized ratio of PT, and bilirubin. However, the treatment nomogram for acetaminophen poisoning should",
"      <strong>",
"       not",
"      </strong>",
"      be used to determine the risk of toxicity. Consultation with a poison control center or medical toxicologist is encouraged to guide assessment of poisoning risk and need for specific treatment. (See",
"      <a class=\"local\" href=\"#H5085028\">",
"       'Chronic overdoses'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5085035\">",
"       'Laboratory evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5087304\">",
"       'Additional resources'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ingestions involving chronic administration of supratherapeutic doses of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      may be difficult to diagnose unless the caregivers are specifically questioned about acetaminophen and over-the-counter medication use (eg, dose, preparation, dosing interval). Evaluation of children who have received multiple supratherapeutic doses includes measurement of aminotransferases and serum acetaminophen concentration and exclusion of alternative causes of severe liver injury. The treatment nomogram should",
"      <strong>",
"       not",
"      </strong>",
"      be used to determine the risk of toxicity. Children with elevated aminotransferases or residual acetaminophen after prolonged acetaminophen overdoses are at risk for hepatotoxicity. (See",
"      <a class=\"local\" href=\"#H5085028\">",
"       'Chronic overdoses'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5085049\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/1\">",
"      Davidson DG, Eastham WN. Acute liver necrosis following overdose of paracetamol. Br Med J 1966; 2:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/2\">",
"      Sztajnkrycer MJ, Bond GR. Chronic acetaminophen overdosing in children: risk assessment and management. Curr Opin Pediatr 2001; 13:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/3\">",
"      Rivera-Penera T, Gugig R, Davis J, et al. Outcome of acetaminophen overdose in pediatric patients and factors contributing to hepatotoxicity. J Pediatr 1997; 130:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/4\">",
"      Heubi JE, Barbacci MB, Zimmerman HJ. Therapeutic misadventures with acetaminophen: hepatoxicity after multiple doses in children. J Pediatr 1998; 132:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/5\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila) 2011; 49:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/6\">",
"      Myers WC, Otto TA, Harris E, et al. Acetaminophen overdose as a suicidal gesture: a survey of adolescents' knowledge of its potential for toxicity. J Am Acad Child Adolesc Psychiatry 1992; 31:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/7\">",
"      Hickson GB, Altemeier WA, Martin ED, Campbell PW. Parental administration of chemical agents: a cause of apparent life-threatening events. Pediatrics 1989; 83:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/8\">",
"      Hickson GB, Greene JW, Ghishan FK, Craft LT. Apparent intentional poisoning of an infant with acetaminophen. Am J Dis Child 1983; 137:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/9\">",
"      Gee P, Ardagh M. Paediatric exploratory ingestions of paracetamol. N Z Med J 1998; 111:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/10\">",
"      American Academy of Pediatrics. Committee on Drugs.. Acetaminophen toxicity in children. Pediatrics 2001; 108:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/11\">",
"      Kearns GL, Leeder JS, Wasserman GS. Acetaminophen intoxication during treatment: what you don't know can hurt you. Clin Pediatr (Phila) 2000; 39:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/12\">",
"      Blake KV, Bailey D, Zientek GM, Hendeles L. Death of a child associated with multiple overdoses of acetaminophen. Clin Pharm 1988; 7:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/13\">",
"      Smith DW, Isakson G, Frankel LR, Kerner JA Jr. Hepatic failure following ingestion of multiple doses of acetaminophen in a young child. J Pediatr Gastroenterol Nutr 1986; 5:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/14\">",
"      Nadir A, McFadden R, Griggs J, et al. Parental and medical over-administration of acetaminophen causing lethal hepatotoxicity in a 10-year-old. J Okla State Med Assoc 1994; 87:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/15\">",
"      Hynson JL, South M. Childhood hepatotoxicity with paracetamol doses less than 150 mg/kg per day. Med J Aust 1999; 171:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/16\">",
"      Penna AC, Dawson KP, Penna CM. Is prescribing paracetamol 'pro re nata' acceptable? J Paediatr Child Health 1993; 29:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/17\">",
"      Mohler CR, Nordt SP, Williams SR, et al. Prospective evaluation of mild to moderate pediatric acetaminophen exposures. Ann Emerg Med 2000; 35:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/18\">",
"      Bond GR, Krenzelok EP, Normann SA, et al. Acetaminophen ingestion in childhood--cost and relative risk of alternative referral strategies. J Toxicol Clin Toxicol 1994; 32:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/19\">",
"      Heubi JE, Bien JP. Acetaminophen use in children: more is not better. J Pediatr 1997; 130:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/20\">",
"      Miles FK, Kamath R, Dorney SF, et al. Accidental paracetamol overdosing and fulminant hepatic failure in children. Med J Aust 1999; 171:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/21\">",
"      Kearns GL, Leeder JS, Wasserman GS. Acetaminophen overdose with therapeutic intent. J Pediatr 1998; 132:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/22\">",
"      Mofenson HC, McFee R, Caraccio T, Greensher J. Combined antipyretic therapy: another potential source of chronic acetaminophen toxicity. J Pediatr 1998; 133:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/23\">",
"      Heard K, Bui A, Mlynarchek SL, et al. Toxicity From Repeated Doses of Acetaminophen in Children: Assessment of Causality and Dose in Reported Cases. Am J Ther 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/24\">",
"      Alander SW, Dowd MD, Bratton SL, Kearns GL. Pediatric acetaminophen overdose: risk factors associated with hepatocellular injury. Arch Pediatr Adolesc Med 2000; 154:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/25\">",
"      Kozer E, Barr J, Bulkowstein M, et al. A prospective study of multiple supratherapeutic acetaminophen doses in febrile children. Vet Hum Toxicol 2002; 44:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/26\">",
"      Henretig FM, Selbst SM, Forrest C, et al. Repeated acetaminophen overdosing. Causing hepatotoxicity in children. Clinical reports and literature review. Clin Pediatr (Phila) 1989; 28:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/27\">",
"      James LP, Wilson JT, Simar R, et al. Evaluation of occult acetaminophen hepatotoxicity in hospitalized children receiving acetaminophen. Pediatric Pharmacology Research Unit Network. Clin Pediatr (Phila) 2001; 40:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/28\">",
"      Gray T, Hoffman RS, Bateman DN. Intravenous paracetamol--an international perspective of toxicity. Clin Toxicol (Phila) 2011; 49:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/29\">",
"      Dart RC, Rumack BH. Intravenous acetaminophen in the United States: iatrogenic dosing errors. Pediatrics 2012; 129:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/30\">",
"      Forrest JA, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. Clin Pharmacokinet 1982; 7:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/31\">",
"      Bizovi KE, Aks SE, Paloucek F, et al. Late increase in acetaminophen concentration after overdose of Tylenol Extended Relief. Ann Emerg Med 1996; 28:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/32\">",
"      Cetaruk EW, Dart RC, Hurlbut KM, et al. Tylenol Extended Relief overdose. Ann Emerg Med 1997; 30:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/33\">",
"      Stork CM, Rees S, Howland MA, et al. Pharmacokinetics of extended relief vs regular release Tylenol in simulated human overdose. J Toxicol Clin Toxicol 1996; 34:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/34\">",
"      Tighe TV, Walter FG. Delayed toxic acetaminophen level after initial four hour nontoxic level. J Toxicol Clin Toxicol 1994; 32:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/35\">",
"      Birmingham PK, Tobin MJ, Henthorn TK, et al. Twenty-four-hour pharmacokinetics of rectal acetaminophen in children: an old drug with new recommendations. Anesthesiology 1997; 87:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/36\">",
"      van Lingen RA, Deinum HT, Quak CM, et al. Multiple-dose pharmacokinetics of rectally administered acetaminophen in term infants. Clin Pharmacol Ther 1999; 66:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/37\">",
"      Cullen S, Kenny D, Ward OC, Sabra K. Paracetamol suppositories: a comparative study. Arch Dis Child 1989; 64:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/38\">",
"      Douglas DR, Sholar JB, Smilkstein MJ. A pharmacokinetic comparison of acetaminophen products (Tylenol Extended Relief vs regular Tylenol). Acad Emerg Med 1996; 3:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/39\">",
"      Schi&oslash;dt FV, Ott P, Christensen E, Bondesen S. The value of plasma acetaminophen half-life in antidote-treated acetaminophen overdosage. Clin Pharmacol Ther 2002; 71:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/40\">",
"      Bessems JG, Vermeulen NP. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit Rev Toxicol 2001; 31:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/41\">",
"      Mitchell JR, Thorgeirsson SS, Potter WZ, et al. Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther 1974; 16:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/42\">",
"      Miners JO, Drew R, Birkett DJ. Mechanism of action of paracetamol protective agents in mice in vivo. Biochem Pharmacol 1984; 33:2995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/43\">",
"      Mitchell JR, Jollow DJ, Potter WZ, et al. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther 1973; 187:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/44\">",
"      Mitchell JR, Jollow DJ, Potter WZ, et al. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther 1973; 187:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/45\">",
"      Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/46\">",
"      Rumore MM, Blaiklock RG. Influence of age-dependent pharmacokinetics and metabolism on acetaminophen hepatotoxicity. J Pharm Sci 1992; 81:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/47\">",
"      Tarloff JB, Khairallah EA, Cohen SD, Goldstein RS. Sex- and age-dependent acetaminophen hepato- and nephrotoxicity in Sprague-Dawley rats: role of tissue accumulation, nonprotein sulfhydryl depletion, and covalent binding. Fundam Appl Toxicol 1996; 30:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/48\">",
"      Rumack BH. Acetaminophen overdose in young children. Treatment and effects of alcohol and other additional ingestants in 417 cases. Am J Dis Child 1984; 138:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/49\">",
"      Rumack BH, Peterson RG. Acetaminophen overdose: incidence, diagnosis, and management in 416 patients. Pediatrics 1978; 62:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/50\">",
"      Penna A, Buchanan N. Paracetamol poisoning in children and hepatotoxicity. Br J Clin Pharmacol 1991; 32:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/51\">",
"      Peterson RG, Rumack BH. Age as a variable in acetaminophen overdose. Arch Intern Med 1981; 141:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/52\">",
"      Miller RP, Roberts RJ, Fischer LJ. Acetaminophen elimination kinetics in neonates, children, and adults. Clin Pharmacol Ther 1976; 19:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/53\">",
"      Lauterburg BH, Vaishnav Y, Stillwell WG, Mitchell JR. The effects of age and glutathione depletion on hepatic glutathione turnover in vivo determined by acetaminophen probe analysis. J Pharmacol Exp Ther 1980; 213:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/54\">",
"      Schi&oslash;dt FV, Rochling FA, Casey DL, Lee WM. Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997; 337:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/55\">",
"      Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994; 272:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/56\">",
"      Price VF, Jollow DJ. Effect of glucose and gluconeogenic substrates on fasting-induced suppression of acetaminophen glucuronidation in the rat. Biochem Pharmacol 1989; 38:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/57\">",
"      Price VF, Miller MG, Jollow DJ. Mechanisms of fasting-induced potentiation of acetaminophen hepatotoxicity in the rat. Biochem Pharmacol 1987; 36:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/58\">",
"      McLean AE. Nutrition and the intracellular site of toxic injury. World Rev Nutr Diet 1978; 29:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/59\">",
"      Sauerwein RW, Mulder JA, Mulder L, et al. Inflammatory mediators in children with protein-energy malnutrition. Am J Clin Nutr 1997; 65:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/60\">",
"      Pessayre D, Dolder A, Artigou JY, et al. Effect of fasting on metabolite-mediated hepatotoxicity in the rat. Gastroenterology 1979; 77:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/61\">",
"      Kozer E, Evans S, Barr J, et al. Glutathione, glutathione-dependent enzymes and antioxidant status in erythrocytes from children treated with high-dose paracetamol. Br J Clin Pharmacol 2003; 55:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/62\">",
"      Nahata MC, Powell DA, Durrell DE, Miller MA. Acetaminophen accumulation in pediatric patients after repeated therapeutic doses. Eur J Clin Pharmacol 1984; 27:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/63\">",
"      Alonso EM, Sokol RJ, Hart J, et al. Fulminant hepatitis associated with centrilobular hepatic necrosis in young children. J Pediatr 1995; 127:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/64\">",
"      de Morais SM, Uetrecht JP, Wells PG. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. Gastroenterology 1992; 102:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/65\">",
"      Esteban A, P&eacute;rez-Mateo M. Gilbert's disease: a risk factor for paracetamol overdosage? J Hepatol 1993; 18:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/66\">",
"      Ullrich D, Sieg A, Blume R, et al. Normal pathways for glucuronidation, sulphation and oxidation of paracetamol in Gilbert's syndrome. Eur J Clin Invest 1987; 17:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/67\">",
"      Benson GD. Acetaminophen in chronic liver disease. Clin Pharmacol Ther 1983; 33:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/68\">",
"      Farrell GC, Cooksley WG, Powell LW. Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes. Clin Pharmacol Ther 1979; 26:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/69\">",
"      Bray GP, Harrison PM, O'Grady JG, et al. Long-term anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure. Hum Exp Toxicol 1992; 11:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/70\">",
"      Nolan CM, Sandblom RE, Thummel KE, et al. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. Chest 1994; 105:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/71\">",
"      Shriner K, Goetz MB. Severe hepatotoxicity in a patient receiving both acetaminophen and zidovudine. Am J Med 1992; 93:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/72\">",
"      Ueshima Y, Tsutsumi M, Takase S, et al. Acetaminophen metabolism in patients with different cytochrome P-4502E1 genotypes. Alcohol Clin Exp Res 1996; 20:25A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/73\">",
"      Critchley JA, Nimmo GR, Gregson CA, et al. Inter-subject and ethnic differences in paracetamol metabolism. Br J Clin Pharmacol 1986; 22:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/74\">",
"      Vale JA, Proudfoot AT. Paracetamol (acetaminophen) poisoning. Lancet 1995; 346:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/75\">",
"      Lewis RK, Paloucek FP. Assessment and treatment of acetaminophen overdose. Clin Pharm 1991; 10:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/76\">",
"      Prescott LF. Paracetamol overdosage. Pharmacological considerations and clinical management. Drugs 1983; 25:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/77\">",
"      Makin AJ, Wendon J, Williams R. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology 1995; 109:1907.",
"     </a>",
"    </li>",
"    <li>",
"     Smilkstein MJ. Acetaminophen. In: Goldfrank's Toxicologic Emergencies, Goldfrank LR, Flomenbaum NE, Lewin NA, et al.  (Eds), Appleton &amp; Lange, Stanford 1998. p.541.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/79\">",
"      Smilkstein MJ, Bronstein AC, Linden C, et al. Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med 1991; 20:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/80\">",
"      Prescott LF, Illingworth RN, Critchley JA, et al. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J 1979; 2:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/81\">",
"      Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988; 319:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/82\">",
"      Dart, RC, Erdman, AR, Olson, KR, et al. Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2006; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/83\">",
"      Daly FF, O'Malley GF, Heard K, et al. Prospective evaluation of repeated supratherapeutic acetaminophen (paracetamol) ingestion. Ann Emerg Med 2004; 44:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/84\">",
"      Read RB, Tredger JM, Williams R. Analysis of factors responsible for continuing mortality after paracetamol overdose. Hum Toxicol 1986; 5:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/42/22186/abstract/85\">",
"      Ambre J, Alexander M. Liver toxicity after acetaminophen ingestion. Inadequacy of the dose estimate as an index of risk. JAMA 1977; 238:500.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17161 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-EF161DC620-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_42_22186=[""].join("\n");
var outline_f21_42_22186=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5087276\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5084915\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5084922\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5084929\">",
"      Patterns of exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5084936\">",
"      - Intentional",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5084944\">",
"      - Unintentional",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5084951\">",
"      Exploratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5084958\">",
"      Inappropriate dosing by a caregiver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2978491\">",
"      Iatrogenic IV overdose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5084965\">",
"      PHARMACOKINETICS AND TOXICOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5084972\">",
"      Risk factors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5084979\">",
"      DOSAGE FORMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5084986\">",
"      TOXIC DOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5084993\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5085000\">",
"      Acute exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5085007\">",
"      Chronic exposures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5085014\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5085021\">",
"      Acute overdoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5085028\">",
"      Chronic overdoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5085035\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5085042\">",
"      - Acetaminophen level",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5085049\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5087304\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5087276\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/17161\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/17161|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/49/21279\" title=\"figure 1\">",
"      Acetaminophen metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/56/25472\" title=\"figure 2\">",
"      Acetaminophen poisoning nomogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/17161|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/9/30876\" title=\"table 1\">",
"      Acetaminophen preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/60/16332\" title=\"table 2\">",
"      Acetaminophen toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/1/44060\" title=\"table 3\">",
"      Drugs toxins causing ALF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=related_link\">",
"      Acetaminophen (paracetamol): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22506?source=related_link\">",
"      Acute toxic-metabolic encephalopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=related_link\">",
"      Approach to the child with occult toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=related_link\">",
"      Causes of metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=related_link\">",
"      Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18568?source=related_link\">",
"      Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13114?source=related_link\">",
"      Management of acetaminophen (paracetamol) poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16295?source=related_link\">",
"      Overview of hepatitis A virus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31386?source=related_link\">",
"      Overview of hepatitis B virus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=related_link\">",
"      Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_42_22187="TEE in mitral stenosis";
var content_f21_42_22187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Transesophageal echocardiography in mitral stenosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general",
"agreement that transesophageal echocardiography should be performed for",
"the following reasons in patients with mitral stenosis:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess the presence of absence of left atrial thrombus and to further evaluate the severity of mitral regurgitation in patients being considered for percutaneous mitral balloon valvotomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; To assess mitral valve morphology and hemodynamics if transthoracic echocardiography provides suboptimal data",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or",
"general agreement that transesophageal echocardiography is not useful",
"in patients with mitral stenosis in the following setting:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Transthoracic echocardiography provides satisfactory data on mitral valve morphology and hemodynamics",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_42_22187=[""].join("\n");
var outline_f21_42_22187=null;
var title_f21_42_22188="Causes of reactive lymphocytosis";
var content_f21_42_22188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F58246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F58246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of reactive lymphocytosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Viral",
"       </td>",
"       <td>",
"        Infectious mononucleosis (Epstein-Barr virus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytomegalovirus (CMV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mononucleosis syndrome (adenovirus type 12, herpes virus-6)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV-1 (during early seroconversions associated with CMV) (chronic, associated with post-splenectomy state)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HTLV-1 associated benign T cell lymphocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mumps, varicella, influenza, hepatitis, rubella, roseola",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infectious lymphocytosis (Coxsackie virus B2, enteroviruses including poliovirus, others)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Bacterial",
"       </td>",
"       <td>",
"        Pertussis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        (Occasional) cat-scratch fever, tuberculosis, brucellosis, syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protozoal",
"       </td>",
"       <td>",
"        Toxoplasmosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parasitic",
"       </td>",
"       <td>",
"        Babesiosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rickettsial",
"       </td>",
"       <td>",
"        (Occasional) scrub typhus",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_left\" rowspan=\"2\">",
"        Hypersensitivity",
"       </td>",
"       <td>",
"        Drug-induced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum sickness",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_left\" rowspan=\"3\">",
"        Stress",
"       </td>",
"       <td>",
"        Post trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post splenectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cigarette smokers",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_left\" rowspan=\"3\">",
"        Autoimmune",
"       </td>",
"       <td>",
"        Lymphocytosis of large granular lymphocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignant thymoma",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_left\">",
"        Endocrine",
"       </td>",
"       <td>",
"        Hyperthyroidism",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_left\">",
"        Pre-malignant states",
"       </td>",
"       <td>",
"        Monoclonal B cell lymphocytosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_42_22188=[""].join("\n");
var outline_f21_42_22188=null;
var title_f21_42_22189="Pediatric supraventricular tachycardia rapid overview";
var content_f21_42_22189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rapid overview: Emergent management of supraventricular tachycardia (SVT) in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide oxygen and ventilation immediately as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Goals: identify the unstable patient; distinguish SVT from sinus tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Clinical assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Potential causes of sinus tachycardia (dehydration, fever, pain, drugs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Signs of poor perfusion (poor capillary refill, hypotension, pallor, diminished mental status)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Signs of heart failure (increased work of breathing, rales, hepatomegaly)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        12-lead ECG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The following are consistent with SVT:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rate: infants 220 to 280 bpm; children &amp; adolescents 180 to 240 bpm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Relentlessly regular rhythm, without variation with respiration or activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abnormal P waves (absent or negative in II, III, and aVF)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        For wide QRS complex, assume the origin is ventricular (although in children, most are SVT with aberrant conduction)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Goal is to terminate the abnormal rhythm. Consult pediatric cardiology early.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children with SVT who are stable are unlikely to deteriorate suddenly.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consult pediatric cardiology and begin treatment with adenosine and/or vagal maneuvers.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Vagal maneuvers:",
"        </strong>",
"        For infants, apply bag containing ice water to the face above the nose and mouth for 15 to 30 seconds. Do not obstruct ventilation. In older children, bearing down or blowing into an occluded straw for 15 to 20 seconds provides vagal stimulation. Do not use carotid massage or orbital pressure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Adenosine:",
"        </strong>",
"        With continuous ECG monitoring, administer rapidly through IV closest to the central circulation. Initial dose: 0.1 mg/kg (max 6 mg); if no response in two minutes, repeat dose 0.2 mg/kg (max 12 mg). Follow each dose immediately with a saline flush of 5 mL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Unstable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For unstable patients (depressed mental status, hypotension), begin treatment to convert to sinus rhythm immediately. Continue oxygen and ventilation as needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Without IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Synchronized cardioversion: Cardiovert immediately all unstable patients without IV access. Use 0.5 to 1 J/kg.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        With IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Synchronized cardioversion:",
"        </strong>",
"        Cardiovert all unstable patients with IV access, if adenosine is not immediately available or if there is no response to adenosine. Use 0.5 to 1 J/kg. If not effective, increase to 2 J/kg.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Adenosine:",
"        </strong>",
"        May give to unstable patients with narrow complex SVT with IV, if available immediately, while preparing to cardiovert. Initial dose: 0.1 mg/kg (max 6 mg); if no response in two minutes, repeat dose 0.2 mg/kg (max 12 mg). Follow each dose immediately with a saline flush of 5 mL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Procainamide:",
"        </strong>",
"        Use procainamide as an alternative or if there is no response to adenosine. Dose: patients under one year receive a loading dose of 7 to 10 mg/kg over 30 to 45 minutes; older children receive a loading dose of 15 mg/kg over 30 to 45 minutes (maximum 500 mg in 30 minutes). Follow with a continuous infusion starting at 40 to 50 mcg/kg per minute (maximum 2 grams/day).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Amiodarone:",
"        </strong>",
"        Give for wide complex tachycardia when cardioversion is unsuccessful or for unstable narrow complex SVT instead of procainamide after cardioversion and adenosine are unsuccessful. Dose: 5 mg/kg IV over 20 to 60 minutes. If no response, repeat the bolus dose up to a total of 15 mg/kg. If response, then follow bolus with a continuous infusion of 10 to 15 mg/kg per",
"        <strong>",
"         24 hours",
"        </strong>",
"        (0.4 to 0.6 mg/kg per",
"        <strong>",
"         hour",
"        </strong>",
"        ).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Vagal maneuvers:",
"        </strong>",
"        Do not delay treatment to administer vagal maneuvers in unstable patients. Attempt while preparing for cardioversion or drug therapy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_42_22189=[""].join("\n");
var outline_f21_42_22189=null;
var title_f21_42_22190="Burns and multitrauma";
var content_f21_42_22190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F75896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F75896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Optimal times for interventions for multitrauma burn patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 308px; background-image: url(data:image/gif;base64,R0lGODlh3gE0AfcAAP///wAAAP8AAAAz/wCZZv8QEP/w8ECzjIDMs/9gYIiIiP8wMP/Q0PDz/8Dm2RBA/xEREWCA/93d3f+goMDN/6Cz/yBN/0Bm/+Dm/1VVVaqqqiIiIoCZ///g4JmZmWZmZjMzM/9AQP/AwHd3d+7u7kRERP8gIP+AgNDZ/7u7u8zMzDBZ/6DZxiCmef+QkNDs4/+wsBCfcODz7GC/oDCsg5DTvPD59lC5lv9wcHCN/5Cm//9QUFBz/7Df0LDA/3DGqdDQ0CAgIBAQEFBQUAAZfwAv74CAgKCgoGBgYAAJBvDw8E8AAAAcEwBCLMDAwD8AAACPXwByTODg4EBAQAA59XBwcB8s3wBMMwBynwBmsq8AALCwsDAwMAA5Jt8AAA8AAM8AAAAPTyCFqCCVab+/v9Dm7ABM2B8AACCfgoApj585Jp8jcDB5z39MM0CA2a8PT58AAABSz5C2qQA/629cz0BDUFCphuDW798TDA+PXz8mvwCMeYB5398WMO8DDwCSbw8v7xBTPI8AAJ9jrwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADeATQBAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPq3YszAN+/gM36DUy4MNfBhhMrlop4sePHSBtDnkzZp+TKmDPTvKy5s2eVnD+LHg0yNOnTqC2aTs26NcPVrmPLFgh7tu3UtW/rFp37ZAAFPzd42E185OUAyH9X/PChoYcNPBUkVw5AuEMJASTonQ5Ce/GYx1MA/0gRQAVF5s6h71RQQqB0gdYbYveON4B4EhuAf4cZHr4HFSAgNwIA2JWAnH4eQBAABB6Qh1wJz6kQwAcGIjfcdNUNt0GF7Y23wYL2pcSeexn4l6F/BR4IQIUh3hWiBBuYhx4A6DEnnQcBVKjffhz1h6MKEIgnQZDYDYgjCSlsoJ0GEJAwY4I7CpQgAM8NZN2GJGCnAQkQAEdCiydJl9yAJ8YnXJFUBpBldtslB4J4M9YIwnBoHsljjwYlx6CDyXkwH4HZiZmcBE+qB4ACASJHpaFXDpcheQOBadKIBOZXpqNnsjnfn3m1qECTcTY345+c3plRfwKRRwJBpAYKQkGFCv8kIXCQVmmimQ0iJmlJlNLYXKMoappdqS6KByihzfmq7LHMmnpqnsYCwGVzJGSQQqsSkDccgACM0KGtTGr3gV9Mrnqpf19qkGa0k3aogqXWgWAkg9h+ya5dLX4AQbevAihqstg6+2xBkqaQaAkSBPwpcs0BmaOtKz7oFwmJnnsijgEEaB5KggZApnUOgkCvsOIid+9c3JkHYwAbgPCvQAELfFFvM5Ur881C0fzSuAs6ivPPPekM9NBuCc3QAQdsdcEFn4UQAtEdGb0QAQRsNcAAnwkgANR4ckS11Vh7pjXXG0mt0NdaXZ311mQPvBHaWaktNtttz9wR3FjJ3dnYddv/7XXVaYe9N919U2R2QnhfpbdmfBdu+N2Axy0444Q7HtHhCCVu1eKZNW755ZCDvfbnE2F+kOZVcY6Z56Q7ZLpBqFOlemWst/5a6IGPbvtDrxcU+1SzU1b77gn1TtDvUgUP2RFLLHEE8Q0ZPxDyUSm/mBJcPAGHIE9woQT0CkkvEPVQWa8YEktorfUSSIBfPO6SayaEF+oL4IUQE4igvwHuR8oREFe4AhBy9xgRTOAEIViAAAJQP60xsIEmCMEJYNAB4kkPCUloQhOS0L68TS4wBoABDkLQQK2dQQv100IQduA0EpbQBAmYAP8+ZzwjMAEKVIMCE4xgFSAMATlDGOBf/0SAAwXWzwQ7mKAIAHCEL4BBa2D4wvMKYkAENnAHMnSc8YIQBapRLQpBqAoQhECEIhSBCEIQIl5gkIAC1G8BOIDBDAtihAA84QkB4OFCRHACIwqgAAlgQN+MFwAvelF8ORkCEa52NSIM4S4iaKP6AClHhkjBCU6QAkQ64AI/hgAGbdtiF70IxqoEoAiMHEARAnCBCHCAAnDpwAlMoD4T4ECQJmFAAmoJSqjV8IY5ZEIgpIKCHFjglKlcZSoHwIMKNEAtMNjBJAPJEgOcwI0CCMESh2Y8BHQhgxvsAgF68JQKrICRYVgkI4lQBwroIAIWYOQDOPBMshjABbTUGhZjYv9NbCZgjjczXgsIIAcjGAEIPyDADJpSgXheLQI+GGMZz5hGgmBABw6dZz2/0gFJ/hEHFaRJR7VWABf8rHcvIEAMCOIAArRgKRS4wNU0OhAfAlGNBfGBTAdgAVh2ZaRaW8AEdCICI4YAoKbqXUIXejwCyAApDcjBTOlZkYZeLQcbvYoIXJjNbfLkBCTtpbN6N1ByEuQA4zwKChzKg6xSJKpXWwEKtMrVBIT0JwwwIg4E9joZaA4BBECAUXQwU59qhAIPGMADfECVrarPrkXBQVCRWpzXsYAASStIDzBLlAZE4Gpt9UgDzjmACkQFqAKA7FFg4MYC4HI/r5tBYA2S0pf/CmW0V9OBSD47AA44BbWqTUpetTZU2GJkoA44XeR+goLEPsCwIZHqACKwlH5qLQR3ra40BWDS75jOr8slCHKB0twBrAADJqnAQ5MyAWxqUyq7TK13L3LZzBoErWbtSQUSuwK3jkS9vTVKUbVmArFKxQVaS0BlL5JQwR6kwT4BcAT8SxIAm1YoHdhuSbEygQQTx3T4RQhgHbwTCbeEA1e7sE+sqT4cUJYqHZavbkxHNRsgZLP2zYmJXfLZB8y1JzDIJ3a7EmMF3wZztU1IS3N8kx2/RKYPoLBIXVhgsBT5yBa57A0SkuSc+GC9McHtCnLCYq2d4MVbifFeZ4M5CCMu/7w0KS91ZyLnmwT5utkNS4yLGxvMoTW5b8ZJeXlgky+XVqTbrfJZwCoAA7MGc1R7akIG+gKbYIC/Un4Jin0sk2uaGc1i2aVr+1yRlK5UIX+uiZgzDROZjvklA87ma9VCwgKA+jOHw/FCUj0T3EZZJw1IbA5aYgDJ/pHPbDGAAhfgmsMB9ge7TutMevxjnRgauie5swB2cOuzMMCNRsZNRW5AABYsZMQzkS62c/JZC7DaIwZItFfjIgLiProi41UIumNi4Z80IJ7DNglrteZiuzB61qM5HPn2/RIUXDUoFLjauj3SARcuAOF0kaYJul0Zs7XUtvomALRfEmxmDkWq7v8WiQuweYK9GICWO0CN2erLkCXD5Jz9Hcq/BxBwirswBBi/CwO01t2EU4ThSuYsjxVbbaEYuukaWfkfi/4XBAsg6JkxG1rNvRCbtwTAjDUKDwbAtI1UHM+G0TjHH2M2StfcpS0pr2+PcukB6DYjUt9wYl4uY1xPxAbkGx+cTbLzsiOFsL+2SLyDmufC1LvRvJlIS2ngkMB/ZOwpV8o550yRgQug5ZABawEa3/GJAJapDLF8Rwg7AKgfJeKtn8jiBXDxyijwaZ6RGrlr4BC3o8ThdnfKZw3/EBHkE/SV+TZ3cz8RGhAA0Ed7PkpwS2in1F3FDTG2CeZdGQSPvjNSUz3/r00i1cQ7BcWZX8hwU7t2xZAQ91mXyMcfEmKTXDsqO5+7QvLuaM10wI1URxlGo2UP4WYkUXI9BxXqZX4GMXtHdRreR3qOYTQGyBBIJxJj92pTIVOcR0XYFICj8X7xFxH11xAXCBKs53pPAXvoVRDGVnus8X8CgGyQYTQx4FQPUQMEsGUjUXf6RxVjR3wdoFftlxmiV4R8ITTgBRFeJxIyRXxUgQESJxDt9Uf9xxoKFHMCGBFN2BBd+BGI14JXMXwGEF9DZhtDJwDctxhCc3pMSACUFxJ1d3dYUXJrYGbEIVkbNxlCI1skVnmDtxFPyBV8MABWUABrOBt8h3wTSILS/wcRqicRCyiGV1GGfgAIwfcdMKA1EkgYQhNpERGJEFFyP2gV6zcIivVuriGCbAcRSxgRvtcRGagVVYiIABBPpagbMniFnviGTNYQ47cRsKeCUVGG1zVDX8aAuwFWe8iGEOGGjgh9GrFzCUgV68eIAMCBPEJL2FgYOlOBDkFuXLcR6KeKS1GLa8iC+/F4nZiEEBGMDnGCFgF8YVcVxvaAB6GN+8GKiaEzNyhpzzhbgmhyVaFsBKcQUjgAE2cbHaA1ifgXNAN4gXhuCrURk1gVItBavEgQw8cjzKgYNDN5kqd0GEGKVWF1MLgQCbmQiuhG3QiRD0Fz8keSF4FyVGGM7P/3ECimgcXRYbZmGDQjj28XhxcBfCypFOsHggtRcthHHAoUboFBM+JIEaKIEDJVfVExcKMmEejHI+zojfT3iBJRlQaRjJToFIy2AEhIEEzJI9IEf4BBMzVGlQRgYxaBi8W4XVA5EQtojjHokL3YEBJZEc4njVzJU34pFOtHgxSBl/shWcwWlQ7xhe8olhLRlk+hlVgniam4HwbgRozZKQ4hkxNRghLRkU+Bkmu5EDJVjcsoACYgmSYokKZHmxFhlE6Bk3uZEer4HYsYl+FIALx3dLYJEfrIFAa5fB9xnD35R6u5Fr0BjwE5chHRm0uhfLYIEtZZHNwIkw3xjxVBmQ3/4ZjnyHgjgZqa6Jzu2BBkORDiuRB9yRTGxm0ksZI8QkK7iS9eCHfhyZ8PkX/adZAmgZ7F8ZXbsZ+/GIoTiRBdqRRDaG8nYZ/72Hf1MZuoR5ejmFhNWRTYuZkhsZNeyYkHaoHFKRE3WGkOAaLsZZ4qgZnfIU35iTLAWG4XIZ0IIaFHMZ/PqREN+h0NKQDt+Ba5YaOVaZgJQaBEgZNr1hIuWhy7FKNxkRugaBF+2BA4mqRGFJoqoV7pRxw/6qFFw54LGo8lehBIqpitBaYoQZ5Omk0VuhBdZhHPxhAJeZZBMXApyW+d6aOAqZ9dR5MU8Z4EwZxCEWNqaRNsShxP6iIM/6GDPGgRgioQ2xkU8QWlLxFxyqiLIloXtSGUEGFqrDldSRpfLzkThLobi8qpDCFbw3kRyDOpK5alOwGrt/GjQaoWtUGkCqoQp9oTDEBLW7kTvXobqSqjC1GYGYGsB0GrO6F8eaoTwGent5GGt4oWtdGe92WZgyqqQWGoO8oSZ6ob+EkXsDGYGTGVBsGsOWF1/xQUV7obBhqlf0qUFyGPw5oTlUoU4XobJFSq0PmnCVqbfyipVyOtODF7WtoTdXeUsVFvPymvCqGDF2oRulYQ92oTBlkACesTKvod3QmxCeGpXAio6loTwxWsRdGku+GTcgEbrKoRoLqtHagTymcCav/KsTy1jTMIsgihq2O5XCU7E3j6rTahsrqBYLEJF7ChrBkxlwJxsTMRY/i4FFyamKfxmZAnpFNTlxvBa3X6VR72FImqG2AFl2wBG9h6ELz2WTN7E/G1pE4Rn8XxpVrLZf6ZEVX6tWQWXxubFGNLrBT6r0kXsMQpWGyrE8nZt0mBqVZLGmlItFixGhWrEY76rjSRsTebFFC7ip8XpiFbpv15APsaEx16FUHbGh2WtGcbcgN7ES2FBlN4E85arUyxua1BS4obFquxdXeTBWSHE0OrFdH6HWXbFrurrRjxB1SgkDchtZBbFKMbGwawqbiqEPm2EWyQszZxZV1hubZRrGn/sRppixAaahPGZqlWEb2u4bDPOxXiO6acOQet+xKkGhYL67E7W70IMX8cEU9YML8twbdj0aO7gWCRGb6DyxHqRQU7KBOJSxZGq4jUexamQZoZcU5uAKjVpEDZSRYErBu7BLeC8bkAPBGYWgYqBROYexY7R4e6sYmqS8EkPJC+Nb4Y8at/lLlbIbe7QUsbCRamga4YoY6xqBKzuxZ/KxuShb5eYRo+CxGHCwBPHBLO2r5TwcPTqjVW7BSmwbQWobcvqxLB2xatWRwKlLtbYRo2LBCfhZUiCxIxRp9ucbqo0WEHXBZqDL8N0QCxCwAWXBLcCxe2e7Vao8ORixAxexEo/0Z8keoRgQwXdHwa4DsWodHIe5xY9QgA5loS+UoX6psa7DvCB2HJDEFYFgA7OEgS8aWUb+G9sYG7omwQc3oR8bShU4wRAnwXn4waBhzLBfHGDLGAB7F7I5HLd1F3mSzBV4fHCBHGFXFOuQgAwFwRD6wXHzwbkwzEPYu8EMG4BzG5HZGxD0kXEby+6knJ22ykxslziHy3G7HCf1GOPZy/YhEaUzoReqtc8MbBhgwXSYy6sEkW9qzHR8qtCOHFN8zPhYHFsoG146wVnLHJEpGQxCgQxKwRztrPcvHPrCFZWqi7o6zBOvm7IUedF1HFihHJomGr9RzShLuUmLwQ4FwRKP+9GIM8GtIkwl3BGRJLEabMEK9oERlJe1vMFir9GaGszbIMugxRy99JAChKEd46GbtMGrTEylnBGdNsEMI8o+MoEY/8GK7MGqkL0tmaX+sczQcxy2AdtpVR1aMBy1/BGbdcELDnl5tFrw8R1pNRzqzxkXN9EEXsEFEsmFV5vp5xza7h0IGNyhNdsBBxvQ2xyp9Rci4sG8XbxPocEW0cEVXqEMbsGQztGj/60FRxGfz7n4nFsAbxxwkR2p/B0aixS2ab1QZBygTRsQ8R1AmBk2gMGUfdGSx9GAYx0019aBIh2Q3Iwb89GTf9Gdl8FZex1QLBpRQhWyZdEPCcGsNYqxP/fMi/zNT5GGATkdcIsd2sAdfQHbjSbRBCzBB3TRESCZADgd6sMdaoMdy2XRB1DQCFPREXPRA4jLKuoditEd2nbRAInRD5PBGOShBHbBuW7d3LvN9N9RBSBYUSAV52WdO3MdoH7qYWPj0EXXKszRDOZ24erhvnhJWyUdojDgBxCp/aexE6eAArrhu4+b0i3t4sJdIH4dQYAV54QNQ8gnKNmxkyaNpNIRnGfRDJmOQIYQcE0AZMLBvUeBuAbRWSwda8St4YMQFqQABjIDCwd+KfgbXNfRRdLt4C0eAVEWN5IG2mguS2wYxFrROSEeAF3bYTUWSA9dK6sXN+zhofm+Bn/8XNbLnaGIHY4EXfPAJ7yQzQ34foA7HgBaHbFEHZAiFbE8sjm2awqDGuli54x72hERHaKZXKzoJzUk4Zj8fkkeE7Y9rVFQHbUlyRAlN3hT7bPR4VjTHj463WoA2hBdFSrG4qsIfqqKHm7vvjLw18rw4AuD4QaPWozoJisScb3pfnNdEYTz4Q/w0RBuBCGwte6rwfY/cAom7VAqDTTNEYnsrH2x4R9n0QsqXXd7JqshHrwE4QnrrIsqfQDGEDN9iqzlJyPBnid9zkif7VBSHk5E7wDaGDMQDpd1Jn0uuSUNEYRGrd9k7xDoFWgk4chtbroxGBT9EYgz0QMkXs5y3yDv8hAwePM07WGvwY7xd+EMP7EPfuEDoI1TZ/NTD/GT+K1UWBGBLNkQbdECer0YlOA3YpM/3mGkfo8AIhkgZh4g8R4RVh8A089OzsGlmI9QAgnoS18AqR4xSx6iW8HzePGmmI9DkzED1tEBKvfm50qBpxWTQq9ijvGaJHu0EzECeYjA7B9gxGNWgtMBI27Ypxe0uBGM7s8mC+9nvv7QAgWzEQ1VQfV5BvGDJI9z+BGPAI5weh+BqBVp3/M+VlARXdGVYH9TaBGAgtVS6OEKqvETbgfK2PM2ulWJMuGtLE90aBGInD9Zhv5CPR+yrV+AlPWkWPGVh75TuB/OEF8gmx+x3/YQNo9fc4w1uhdRqPt+a1n/VwGPHIrfuZnxKy5ebfAWCwjxqiR/syMRhd6M3sz/wpARA/CBC4YQPAQYQJFS5k2NDhQ4gRJU6kWNHiRYQoLAwYoAPjR5AhRY4EGULAAgMkVV4McBABgRkJIwyI4JBBgZMpV1pkMZDGi51BhQ4lOrIBD44XGhRl2tTpQwM4Ezwl2hLASwQIMXDE0PBmTqoOX8QgEINFWLRp1UrU8WDAAx9r5c6tKEKAgAl0Q1q9QeDsQQ4DLnjFiVLvQRsHBhY83NjxShQrOPJY+tjy2hN3GVyeaFWxA4QbKzD8OtVyjYExenBm3fph4LceXc8eukNA/wGdtBVaJQsUQIUBFkhLZf2CxmIZupVfjpwUxXLoHw0sOBn9oNWBCC8M4LCw9OyXZbNaJ7+2LccclcuvHy7ANPSWL8oe3Dqga8LvtGUoJtDiL3sAi8IAqdgCNBAAGO5yIbqWHCDggINmqgk/4pbroQWfQDtwQ5UokCy40Tgsz4W78lquJdRuAKABtyigEKzoECDrQQ1FtBGjCtwaYAUXb4Qugds2U64lrH4L7kXDyLNBRp/+8/FJiBrgQMcLeoRyNpMK6GBIAPqqAQDJZAPgqyTXW3LGFmow6Eo2F5JSxxVCbPOy6WCcraXPKHirMjJzA/DM1Gbwbc453+TIAh3UI//0sKjsbK0lsmSQ8KA+bWThOJ/UXLRNQ9/K4b5N6foqBNpaGqgBjp6r1McXZpiRIBbWDPXJCjZKSs5Z1crvUQdb0EGwMQvz00cbLh1osVhz9ZECAt+K4Dll0UrQPdcCcPAA0VadU4YaMB3ogBoGjfZADDiwNTgOQB2XqQnueu+yAF4S4y1tN+XW2/5mYCG5dQ2kIAIdd+QA2n6HapdazgIQKI4B6BB2XRlYuOHVfPctGMAKmg0uh7gu3ungdx0L4IA9OOrD0X4dQIC/Y2M4AAEHZPV4uQYyDlgwHQieGSSQ4Y0hiwH0QHlmlVlu+WUWxN15Nh9yOPctHjiwcumKen7/LAACqBjgDS2pZugFFmbA99gWXq7BAX69vgwDmzlye4UcKtBZ7YasbiwALAawogAh6W4I7JUxPHbwsmdA4OyY/dYLBR0ieJqjFaL2YW6/7dYrADMGSKNvxSNygAUEbjiA4sGPPeB0BFJnwQHW0+68qAYo4OCCxw+9IAcOKqCAco8PDmHYtQLg6I7XQWK9BgRmOGDs0ptP7XToUU8d5uJDil2HHC642e23L7ggAg7C14EC8svn/UoYHh4pAPbbd/99+OOXf37667f/fvzz139//vv3/38ABlCAAyRgAQ14QP5drnoLZGADRWIVB0ZQghPcDQUteEEGQhCDG+Tg0jTY/0EQhlBZHxRhCU14JRKeUIUrNFAKWfhCGJ4ohjOkoW5cWEMc5jB4OuRhD9VyQx8GUYjrG2IRjUjEGmYgAAqIoAcCUAIAaCAAECjKCALwgSNiBIibkoAS2TeCh0iRigBQQAAy8BElMhEhKpiiQ8T4lDeS0YwfiWMZzygSEkAAAiSIYhuLAoIApOAiQDDiFglFgg0EQANyhGJD4iiSNFbkkUyZJEgqOZIyqvGSO5HiHSsyhCAcQQlCNOScyojFgwBSA2IsAfs0wMb2jcCOAFBiBhJZAg3cMpXtA4EKaLnEhLCRilYEQSshoAJYflGO7DujGD+gSD+20gMk8CIwiWlMZP+6T5ZzpCb7IOCBPkLgmcBcozZnWctb5vKJB/FAIp8oAYW0Ep7hHKca28m+EvARkExU4ghI8MUA+LOantzAGCviBPYJoQpS8GEp2xTJgzxTAWIkQQraWMc59hMAiQRjIgWJkDJu4JdqPIgwAUDMk64To/xcohTbpwFVSiAAIm2lID2KUitCEaNn3CcAVEnRSu70lx0N6EYDaVEolrGRCNEjQoB60ZkCwIkg8Ckw+/nPWGpUIUr0pUWC4L4pbIGHDmUTRAEg0ThCIJBCjWRPe+qBVnpzpMFsoxXPWEaqxtGd7cvAI09ZxhHI9H0KsKsc8+pHOwoWnlb8wBthyUenIjb/o8B06xLH2T6DAuCfVD2IY9lHgmdiEasS6OlV2dfVcZbAnwjhKkIAOAUdkvVKp0TIT/2o1hSwlbK7VYBFj/lGswLApIXFazgPkkhwRtageYRAK1Wg2IQQNwCHHWNi2bfYK3o2AJDtrGTP2FbehtYhTe0uFR8r3tGWNqBY7epJ4yrSg7TWq2AVa2wLhkhFGta4ThSpbw9yTt5WdaJtLCMVgzvcORbXvykFAR8JO0kvchaQd+yrdKm64FlWdpVtfGxCMDxZJlZ2wMeMoicPIs/yCvezUhTpVM96xar687QK4S9CCnoRhAZAoQztoWyv1MX2oVKMiezlib8I4BAHOK6ApzQwOUta1wRP18hFVYBaZ7rhzLpUjaBtXwkkYOEpb/OM3ZwiOLXL3TAjWcBr9gAg2UfS/5LzzFJ1Zz6Fe0tAyjgAXXXzE7vayYuAUpSkpNsmechcNDMFkB+tCCGLSIZC+7GITlwqUxibRUxnWtOb5nSnPf1pUIda1KMmdalNfWpUp1rVq2Z1q139aljHWtazpnWtbX1rXOda17vmda99/WtgB1vY0QkIADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the optimal times for intervention in competing types of injury - penetrating, blunt, and burn. The priority of intervention changes over time (hours) and should be sequential.",
"    <br>",
"     Penetrating injuries are best evaluated and addressed immediately. In the following minutes and/or hours, blunt injuries associated with thoracic or abdominal organs should be addressed. Cutaneous burns are the last priority and management can be initiated in the hours following stabilization and management of penetrating and blunt injuries.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_42_22190=[""].join("\n");
var outline_f21_42_22190=null;
var title_f21_42_22191="Paraphim forcep technique";
var content_f21_42_22191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Forceps traction techniques for reduction of paraphimosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 327px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFHAbgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKUup2MGow6fLe2yX86lorZpVEkgGclV6kcHn2q7Xx3461PW9V8f658S9K067utK8M6pBaW93HPGI1ghJWZChbewdpAcqCAGbPfH13p93Bf2NteWkgkt7iNZonHRlYAg/kaALNFFFABRRSFgOpoAWioXnUVA90B3qXJIai2XaMisw3g9aab5fWlzor2bNWissXy+tSLfD+9RzoORmhRVWO7Q8H9KsIwYcHNUmmS00OooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKxbLxRoGoXKW1hrml3Ny/wB2KG7jd2+gBzW1Xwj4Fmtv+Ed8FG3k0rUtTtNaScaPZ2bJqMmJGOWuBnKdDjAGMc8UAfd1FFFABRRRQAUU0uBTTKo70rjsSUVCbhB3pPtMf96i6CzJ6KhFxGe9SBwehouFmOooBzRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAATgE1htqAaNSD1AP6Vr3LbLaVvRCf0rz20uma3jyf4R/KsK03GxvRhz3OgkvS3Q1XacnvVONiafXO5NnSopErTH1qFpiO9KaglOBU3KSFa4I70wXxBxmqjy9qqSNh80rstRRtRagwcc10Og3fnzzKTnCAj8zXCo53iun8JyZ1Qr/egY/ky/wCNa0pPmSMq0FyNnX0UUV2nnhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVTnvEXIzjBI/HNXK4Se+Z7icZ6SuP/HjWVWfIjWlT52b0+oDnaaqPese9ZiOW5NSZrmdRs6lTSLRuWPemmc+tV801qnmZXKiwLtlPWrEOokd6y3qIuVp87QciZ1EOpA9TWha3Kzs6g5wAfzzXFRzH1rW8Pzk6uUJ4aAn8Qw/xranVbdjCpSSTaOpooorpOUKKKKACiiigAooooAKKKKACiiigAooooAp6u/l6Vev/AHYXb/x015zasERB6ACu/wDEjbdA1A+sLL+Yx/WvO4my4FcmI3R24Ve6zYgbIqeq0AAAqyOlYI2Yh6VXm6GrDdKrzHigEZk5INVZGqzdHk1QkcZxUs2iWI2+YV0fhVsa1D/tROv6qf6VykTfMK6Twy3/ABOrL3Lr/wCOH/CrpfGjOsvcZ6BRRRXonlBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5ej7riU+srn/wAeJr1CvJdPfzMN/e+b+tc2J6HZhV8RuRfdFTCoYvuiphXMbsKRjS1G5NMBrmqs7cVJIxFVZm4qWUkEUvz4zW5oDf8AE6tj6o4/kf6VyvmFZK6Dw9JnWbH33j/xw/4VVN+8iaq91neUUUV6J5gUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBjeLjjw9d/RR/48K85VysteieMjjw5dn3T/wBDWvNg2ZK4sR8SPQwi9xm3a7nANaCDAqlY/wCrFXh0rJGj3ENVrjpVk1BMMihiRkXDDpWZcDByK07uPBzWfKoqGbRIYHw4FdV4ZP8AxOtPP+2//ot65HG18103hmT/AImdgfSUD81I/rVU/iQqy91npdFFFemeOFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEVw/l28r/3VJ/SvJ9JGEQeij+Ven62/laPfv8A3IHb/wAdNeZ2WFYD0rkxO6O3CL3ZG5F90VMKggOVFT1gbMKawp1NamIglWs+4UitN6z7sgVLLizKmOGrd8MOP7YsGJwBIwP4o2Kwp+TWnoTFL6zb/pvGPzYD+tOD95FVFeDR6hRRRXpHkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGD43OPDN19Y/wD0YteaRN83NemeNhnwzd+xjP8A4+teZ9CK4sT8SPRwfwM6GwYeWKvqeKyLN8IK0I5BisUy5IlZsVXkkFOdxVWRh602wSI7ghhWTcDBOK0ZWGOtZ1wwyalmsClklq3/AA2SNRsh/wBN0/nWCrDzK6Dw2A2rWQ/6bA/zNFP4kFX4Weo0UUV6h4wUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZHix9nh69/2kEf8A30QP6151AcPXf+NP+Rauv96L/wBGLXnsDZeuLE/EehhF7j9Tetj8gqzVS1PyCrIasi2OprGl3CmMaYiKRgKz7pgc1anbrWbcscVLNIopyH5qv6c22aBvSVG/8eFZLyfPzWjYOC0Z9HX+YpR3LktD1uiiivUPGCiiigAooooAKKKKACiiigAooooAKKKKAMjxam7w5fj0jLflzXkzS+9eu+JBnw9qYHX7NJj/AL5NeKwWl7eEGMbVPc1xYndHoYN+67mxb3youCasDUkA+9VGPwxdOuTI+fp/9eq154furdQzXG0E4AKkkn0A7n6VhaR0OUO5qtqSf3qhfUkH8VY39i3pUv5oWMfxSERg/TcRQmkjBeW9idRyfLYnaPUlVYAe+apU5voS6tNdTQl1IHvVV7sN/EK1tO8N29yGRlcypgkbyQQc4IOBkcHtVqTwZGw+VCPxNJ05dRqrDdM5pJhvzmuk8Gzeb4gsV/6aE/8AjpNY+oeGbq1y0DEgdmq74BEyeLLGK4jKMC5yeh/dtRBNSVwqSTg2j2SiiivTPICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDB8b/APIt3I9WjH/kRa89th81eg+OePDV03o0f/oa1wFmcgE1w4j40ehhf4b9TYtzhRU2TVeFhtFPLCskaMeXphlphYdaidh60DFmfIrNuG61ZkcY61RmYE0mXFFOYc5q3p7EIT6YP65qs+DVvTFywX+8wH6gUluXJ6HsVFFFeqeIFFFFABRRRQAUUUUAFFFFABRRRQAVFPLHBC8szhI0BZmY4AHrUtcF4l1RtXvv7Ns2zZxt+9YdJGB6fQY/E1FSagrmlOm5uxFqN/P4kuNkW+LTkb5U5Bfn7zf4dvrWpa2NtZRDcBkVDbRpaQBVGCBWJrervESkYLuegFcbl9qW52KN/djsbl1qsEXAwBWRqOo2t5AYnO05DK6nBRuoIPrXIzQXV8xa5mdUP8KnApf7MW5tWt1z9ptvnjKcNLGeo9yCP85oi5T2epU4RppXWh0Vu8LAXskUTuz+TKQoJjkA+Ug9lZecdj9a0o7+IZzhgRgg9CK5LRYijzWTXBeG+iKqxOSki/Mh+vH6VTto7pre6aW6fchSNegIcnLA8c4UE1Uk52kiIcsLwfy+Z1emagthbxshxHHNLbAZ/h4dM+uAGH41qQeI0ZsHGK4ZbR5tLs4JXJDM9wTnB5ICk/hmm/2e8I/dSOPxzSqzakVRpRlG77npongv48DGTXPapaSWsyzWzFJYzlHXgg+1c/puoXNnMFkOR611Ud6l5Dgn5sVHOpb7l+zcHpsdJ4U1waxZHzcJdwnbKg4+jD2Nb1eUxTzaJqyX0AJj6SoP41/z0r1C2njuYEmgYPHIoZWHQiuujU5lZ7nFXpcjutmTUUUVsYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGH41UN4avAfRD/AOPivO7ZgqCvQ/GzbfDF6fZB/wCPivLluMAAc1xYn40ejhFeD9TZSfApkt0EGSapwLLL9xSauJos8/L8CsFdm7stypJqSjoc1Wk1InpW5H4bH8VSf8I5F3p8shc8Ecw16TTRc5610U/htMfKazrjQni5U8UnFotTiyiHzWhpz7Pn/ukN+uaoNbGM4ZhmpYJAoKtvw3BO08D8qS3G9Ue2UVnW2s6bdECC9t2Y9F3gH8jWgCCAQcg9xXqJp7HitNbi0UUUxBRRRQAUUUUAFFFFABRRVXULuKxsprmc4jiUsff2o2BanP8AjTXDZW4sbNv9NnHUdY06E/XsPzrC0a1FrECR8xFVrFZL+9n1K9H72Zt2OyjsPwAxVm/v47WPJPPYVwTnzO56MIckeVbk17cgA81zV9PGjFmNLfagWQsThQM5rmjv1J/MkJFvkhVHBf3PtWerOmnB7IsS6s8xK2URkxwW6KPxpkK3vnx3D3QjljbcgiGcH61bhtzgKo2qOABwBVyO3wOlWlbVG7pRtaWpNFZ2msMLseZbX8TBpBE5AD9mA6Ed+nsatNbWmqyyi4TbdwMDPEjEI5IADgdwRgeo6Vnxv9gvYLr+DPlyj1Q9/wAKsTH7D4gaaTgeYquPVHAU/wDjwz+FdkZJq55FWi4zcU9ldFDXxcPqbtbzCPYqoFK5BGMjvx96qkOpXUAxdRZQdXj5H5dRW3q1sV1KUHoyg59+Qf0ArNltyvINc1WPvM9HCwjKlEtQSw3iAoQc9CKs27NatyeK514nt3NxaZDLy0Y6OO+PQ/zratbtL+0Dr1IzWDjYqUXF2ZvFkurf1yKteC9WfTr/APsy6b/Rpm/dE/wt6fQ/zrmdJvjDd/ZpD15XPpWtq1qHh8xOGHII61UJOL5kc9SCa5WeqUVi+FNTOq6THLIczx/u5fqO/wCIwa2q9FO6ujy5JxdmFFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVNQvrawg828mWJOgLdSfQDvVHxFrMekWysF8y4kJEUecZ9ST6CuNEc9/cG7v5DJKeg6BR6D2rGpV5NFub0qPOuZ6Iu+I9bbWbOSytLZlt3I3SycE4IPA7cgdfyrEtNJCsC/NarNFCMcCo/t0QOM1xyk5O8jtguVWitC7aRxwoAFFTtdBeKzftiEfLzWbqGpC2w06OiE43jkD60+awuS71Oha9HrimPeAdWrj7vU4ni4mBRujg9DVSDXVZAkzgODtJzxj1oux8iO5F0CeDUVzKjrhzkelcpaalLqV0IrI7YlPzPWrdTCMBQdzd6ltjUC4BAq/KoUU1fs5OMjNcdrPiAWzmCAedcdwDwv1PrWGmvanES0mxxnOCuMewpqLaubKk2rnp8lhFMvAFQW01/oc4kspCYc5aJiSjDvx2PuOazPCOvLqUWPuuMBlJrp50EkRBHWjbYxb6PY7HSdQg1OyS5tz8rcEHqp7g+9Xa898G3jWOutZsf3N1nA7BgDz+Qx+VehV3Up88bnn1qfs5WCiiitDIKKKKACiiigArk/HExlay09D8srGWQD0XGAfbJz+FanifVhpOnNKCPMOduRnAHJP9PqRXDeHZbrUtQnudQkMk2duW/hGTgD8+1ZVn7tu5tQjeXN2L18yWdqFHy4HWuQVm1GbznJKAnaPaup8VWr3FrJGh2uRgHnH0NchZP8AYboWzklWQSxk9SrDIB9+1ccovfsd8JJWT6lTWyZLq2skOFlYl8f3QMmrUKqGCKAFHAA7CqVw4bX0bt5TY+uRVu2bMlEdjtorRs1YI84q6kHHSorPGRWoijbWiRnOVjJvbTzYJE6FlIB9D2NQ3Q+32FlcA/NNEYWJ67wDgn/vkn8a15sVj2ZMcOpWw6wyC6jA6kZBYD/x0VrDqjjxGjjMt3j/AGuz0y97yIY3HocDOffKj86qTJgVas0MllqlqnzNFILmIeufm/LIxUU7K0YdTlWAYH260qq2ZeDk0nTfRmNJ8r1TsXNpqs0A4jcCRR6A5BH5g1PdP++wKp3bAarCe4hyfpk1zvY76y91Mt3AebVohCcGPDMfTkAD8yBXoUcJls8EZ4rg9FUiVpGGXukDKO52OGwPfAA/GvS7FQbHeCCrLkEdCKqMNEzzZ1HzNdjkbI3VlqU8llLIjxRtKUQ48xRywHqcZODkHGMenpPh7U/7TsBKdvmqdr7c4PAII9iCPocjtXDWTKnii1LY2mTa2emCCDn8DWt8MQ4tJQxJHkQnn/el/piujDu8bHLiVadzuKKKK3OcKKKKACiiigAooooAKKKKACiiigAooooAKKKr3pK2dwV+8I2I+uKARwE051bV57pzuiDFYvQICQP8fxqedhHGcdqqaEB9mGPQfyp+rPsgavNbvqepy2fKjndZ1JbeOSWVvlUcAdSfQVyya1qc7F4beIJ2BBJx9c1X1mZrrXUhLfIoxj361tabtTCYpxStdnbTgnFsr2viV4pAt9A8P+2mSPxFdTaXsV3EEco8bjg8EEVm3WmxXURDIMnvXOvbXuizF7cF4Ccsh6H/AANPkvsRKCexq65pFvp91HdvC8mnMw82NGIC89eO1dBBomhSW8c1vYI8TjKs0jk+4PzVmafqL3dicRl4WXa6MMgdeD+RpPCdyltcvp3nI8TkmIBgSpzwD6dcVvR/lkjza6fxRZpRCDS/tEFtEIyWDKB2BHr9Q1c1ruqztL9jsmzcN/rHHVB6D3rZ8Yx3cRga0GHlzEzHqO4x+G6s7RtJFqm+T5pG5JPJzWdSFptnXhfegmyrZ6THbwB5Buc8kn1qOWNGRvlGBWzettQisW8fyNMu5T1EZA+p4H6mpPQTtFsoeE5mtLu3lQ4WQ7WFev27eZAreoryDR4isFqe+8EV63p5P2VM+lQ9zzpbGTqDNaX8VxHwY3Dj6g5/pXqqkMoYcgjINeW67gKT6A/yr02yUraQK33gig/XFdGGerRyYraLJ6KKK6jkCiiigAooooA4v4jxySWsYj6m3mAPbIMbfyVqwvA8ytHn+8A3P0rvvENqbrS5PLj8yWI+ai9SxAIKj3Kll/GvLbJjo2r+UGzbS/vYH7Mp5rCsnpLsdFCSu4vqdvqkAYbu2K8z1eNnlRlGHgt0J9ckA4/UivR7+5E2h3jqfmEDsCPXaTXFb4Tf6kJ2GTKCV7lVLEjHocbfqRUKN4u3Uvn5ZK/S5yV5N5d/azNxhije2eDn8a0oZNsuKydRiadLjePmZjKv0J61YspTcWcU/wDHja31HX/GsNrpHrYaV1Z9Tq7SYDBrRS5G2uYtLodCavC5AHWrTKnT1NOW4HrVS3mVNctXJwkymBvryV/U5/Csm8vccA1kPqw+3/ZeRKqiYP2HODj3xVQnaSM6+H5qTOz0txa63BA/AZWtWJ9OCn44Oaq33+itNbk8xOVx6D+EfkRSa7MM2V/HwZgkvHQOOD+OGb/vmo/GbbbmC6j4ju4g3H94Yz/MflW1Re76HBhJXrLzRiFvMuPxqo7mfUbxk5ESiFfryT+pNOaX7LayXLclRhQe7dAKdoNsSkSn5nkfcxPU+prkb0PTxMtoo6S1tvN0tXts+ZbKJoyOrLg8D8iPqK6vRL5W01oRwoUPH7KSQV/4CQR9MVzlzHdaK0c0HywS52MAP3bkcjp0OM4PH5Ck0uf7Np0cgPEbtCR6BlDD9Urpt7ja2PF5n7RJ77EOr3jR6iWj+9gqMdckEAj6ZzXo/gm38i1uumUdIQR3Cov9WavPm06T+yF1idMKbtFQnumGyfoTtFej+ED/AKNeofvJckH/AL4Q1VCNo3JxErzsuhv0UUVsYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTWAZSp5BGDTqKAPLtKJtrqa0k+9E5j/EEiptYUmA1Y8a2ZsNbhv4hiK54fHZwP6j+RpXUXFt/vCvOlHlbiepGSklNHjesFrfWXk7qwYfSt2KQKyOpyjAMD7Uvi7SSX81V+ZeD7is3Rpd8DW7n54/mXPUjuPzoT0OyhK0rPqdvp06SRjNXZrSOZOQDmuRs7toWxmtu31LgfNVplTpyTui5oNsttfajaqAN0azr9AdpH5kmsG50qC0v7q8gJWZJDIcdMHDY/I/nWzYXobxFZHjEqtEx9cjCj8zWT45u20ktchN6MvK9ASCAc/gw/Kui/uJnmxh+/lTl9o6rXAs2lQ3gGQuHPsOjfoTWfJsjjq54YmF/4bMT/ADMgIOe/Y/rXM3M7wI1u5O6IlOfTsfyxSrL7RWBb5nTZDfTBpCBWPrz/AOiwWq/fncEj2H+RVpSZZcnpVKxVtU1vzVBMUfyr9B/nNc9z0q75Y8vc3NM08l7ZAOE5Nd/bjZCo9BWXo1mI13uPmNX7u4WGJmJ6Dis0cMnfRFKSI6hrFtaLz5jhW/3c5b9Aa9QrhvAOnPNPLqtwvHMcOe/95v6fnXc12YeNo3fU4sTJOXKugUUUVucwUUUUAFFFFABXlfjaySJLtTkLaXIljK9QrgMR+fH0r1SvP/iFGGmv1H8VrC34+YwP6UbgnbVGXI8+npe6Xef61YmVSOjgg4I9qxry0Nz4hltc7fNmOT0+Xljj3xmvR9V0WPXtFs5VYR3YhVo5OxyoJU+1cGkyReI4pZOkkAcH3KqM/qawSdNSOiUlVce5U8S6YY5BNEnygbSB6VyJ36Zcu+0tay/eA6qfUV6xKsd1ERwQa5bVdMUBl25WuPZnowk/mcxuyolgYPGehXkUfa3xioZNHljlZ7GZ42PUDofqO9MeHV14EcT+5TH9aaaZ2RxK+0iVRJK/eqSW7PrF1dYBRUEKnrk45olsdZuQUkkKKeqxjA/z+NR2/hm/ibdDI8Z9VJFVp3CWK10jodbFIbzwjJEcmS1kDe4Bz/g/51dvil74Lt7l+lpJubHJC9/55/Cszwzb3Ns09neS7zdRlVY9c4BH8gPxrU8EqLvS9Q02U8MrqR+JH8jXbG043PClJ0qmnR3Rx0Mc+t38YSN0tIj8qnqfc+9egaLpS25WSRQCAAKl0i1ggtI5FQIGUNj046VDq2rpCNiHLegrz2+56Lk5amnrF9BJaPayDcjjaQOvsR755rB0ERy/abO8/wBWHRpdpxwjjcR/wEk1u+GPDF1qmy81ItBanlY+juP6D36/zq94r06Cx8QaVNHGqWs6G0dVGAOCB+jH/vmuujGWvNscFeUU0o7o6LxZYJceFL22hQBY4g6IowPkIYAf984rK8CXfmzNuOTPbI4/3kJVz+bCui0OdrrSLZ5TvcL5chPOWUlW/UGuJ8Nf8S2/ggPAtL2SzPqysSFP4sQa6DlPRqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCjq+nxapp8trPwrjhh1U9iPevPLaWbTruSwvxtmjOAezDsR7V6jWJ4k0GDWoVyfKuY/8AVzAZI9j6isa1Pm1W5vQq8nuy2OO1C0S6jPGc1wus6DLbyi4sxtkjO4Y6H2rr2lu9MuTaajEUcdD1DD1HqKsCaCcYODmuLZnoJteh57BMl3wP3dwPvRHgg+o9RSs0iHGDXV6l4csb87/uP1DLwQayZvDeowjFveiRR0Eign86q9zqhirK0kZttcyxXVvMMkxSBh9c8fqa6X4kaaNR0eZYjwsiSqfVcjP6HNYR0LWHBDTxAegUDP412qKuoeHbNpB8k0Bhb1IGU/kK6aOsXE8/GVF7WNSJj+ArnZeS2zcK4yB+H+INVvGdqLe+SdmCJICrMxAAI5H6E/lVHw1ZT6Ne2081yZQ7hCCTlDzkfoa7Dxlp0V9p7F03qCJAB1ODkgfyqkuanYydX2WI9pH1+885WRtQP2XTgXU8SS4wMegrt9A0VLG3UEDf1JosYtO06FfswTaRkEd6bc6uSCE4FcTkd0pSqO7Nme4SBOoGKp6ZYXHiC/2R5S0QjzJPT2HvRomgX+tsJZy9vadfMYcuP9kf16V6RptjBp1pHbWi7YkHHqT6n3rWlSc9ZbHLVrKnpHcmhhSCFIoVCxooVVHQD0qWiiu488KKKKACiiigAooooAK4rx3H+9uGP8VmB/3yxP8AWu1rkfHYyYlHV7S5/RV/xoA3fDj7/D+lt/etYj/44K860vTIdU1uwt7osFfT1YMhwVYKOR/9eu/8INu8MaX/ALNui/kAP6VyXh8FPE2hE/x2RA/75b/Ck0mrMabTuivqelah4fPm7murLPMiAgp/vD+vT6URSw3kYPGTXphAIwa47XfChaRrnRisUp5aA8I3+6e306fSuWpQtrE7KeIT0n95xuraM4RprMYkHOOxrGtbu7kBC2Uz7SVJVCQD0Iziuvg1F7WYwahE0Mo4KuMH6+496Lo2gZrq3VJImGLqAf8ALVMYJH+0P1HHpWUIRbszedWaXuq5y5e9726R+8kqKfyLZ/ShYb26fyormyMh6RxzAue5A4xn8a6q00qxQ7IzHjaHjdVAEiHO1vrxg+/tinapaW8emXBRwHWMshB5DAZU/mBVckU7NfiZ+0m1dP8AA5ebTja2sd9E7vJG4YluDjPTHbnH5VH4fuUsvGUwU4gldZAP9lwM/wAxXRX11DIlykxAF3Ekhx2LIAcfiM1wUjGO/sp/utzC3sc5H6nH4V0UvdvDsc1e8rT7nV67LLY3lxYxg7vMLIBySGOeP+BbhXV+DfB626rf6zGJLtsMkT8iP3Pq38vrUulpb3OuaTqLxh2mgZFP918Zz+QcfjXa0KiuZyYSrtwUEFcz8QrfzvDUsoXMltIkyEdjnaT/AN8s1dNVe/tlvbG5tZPuTxNGfoQR/WtjAxPCFz5qXSDlTsuF9AHXkf8AfSsfxrA8QRSQeJdUSM4eeKK7i9Ay/KPxyCaPAt08UllHN8r5ltZF7K3DL/6Cw/GtHxxF5Wp6LeAYVpGtX994+X8sMaAOuhkSaJJIzlHUMpHcGn1jeFJvN0OBD96DMJHcBThc/wDAdprZoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCpqFjbX8HlXkKyp1AbqD6g9q5LUPA+WL6beFP+mcwyP++h/ga7iiolTjPdGkKs4fCzzKTwtr0R+RYZPdJB/UCkTw74hJw0CqPeVa9OorL6tA1+tz7I86i8I6xIcyz20Y/wB8k/lio9PtnsbO+0ydg8tlccEcDY4BXA/AmvSa4XWojb+NZl/gv7UMPd04/kv61pCnGGxnUqyqfEc7caQslhqd7HKRLaukwi25G1iNxzn2c10aMLvSIX65Tn8qg0xA+om2k/1V1FJayegDLnP1yMfjUfhGRpdKlt5RiWFtrD0PQj86tJLYzcm9xvhzwlZ39q7TXc4McjIY0AAXuB37EV1dh4Z0mxKtFaK8g/jkJc/rWN4dnNn4ie3c4S6TA/31ycflurtKlU4rWxbqzas2FFFFWZhRRRQAUUUUAFFFFABRRRQAVyvjRd13Ye8U6/nsrqq5zxaALjTHPTzGT8wD/wCy0ASeBX3+FbA+zj8nYf0rm9KOPEfhjnrA6/8AkNzW/wDD0bfCNkuclWlB/wC/jH+tYGmL/wAVF4YPoko/8hvQB6HRRRQBjeJ9HTWdMeDISdTvikP8Len0PT9eorzzStIgmuWt7y7ntJt/lnIBEcnTa3Pfsc4P5V65XP8AiTQhfo1zZhFvQu0hx8sy/wB1v6Ht9KmUIy3RcakofCzjL/T5LBxpcl1tNm4aOdlIzDJjdwDwAw9f4azrrS7qWTU4GuwqWsUzM/JDFMZAGf8AaAq7dtc3BSRXmW6tMxm3nwSo7oxxkjjIOcelFlHDJDvtWZYHyrRcYzuDEEYyDlQcZ7elTKlGTuyo1pxVkbHh3w3a6m01xfNKwhdYFjVsAhUU5z16se9cd8RNLTTNYuo7aIRxFEuYVXOARyf1D16f4KINjd+v2k5/79pWL8U7ASWlnfKuTE5if6EZBP4jH/AqtRSdyHJtWZk+HL1zohMRLyWUomUDqy5Bx9DjFenRSJLEkkbBkcBlI6EeteMeBLny75YHPyyoYWB9un6CvUPCsrHTTbOfntZDD/wHgrj2wQPwpkm1RRRQB5zdRNYeIdajjUlhIl/CB/EchiP++iwrovG8Yu/Ck1xA2THsuI2HoCMn/vkmqPi1VtvEukXJHy3CPbSHtjIx/wChtWro8AvPDclhMwJCSWrDrtXkKP8AvkrQBW8JzKLy+gXiOTZcx57hhg/oF/OumrzzwVcs1xpMmCDJG9vID2ABI/H5VFeh0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXIePlFvNo2pdoLny2/3HHJ/8dx+NdfWD43tRd+F79MZMaCYevyEMf0BFAHL34eG5Zoh+9jcOgPA3KQRn8qdprpD4q1BIuYLrFzGTxkOA+cfViKdcSfaba2u+8sau31IGR+eayWnWLUdNkB+dd9uf9wEOv4fvCP8AgNAGtre+3ljuoBmWBxKo9SDnB9jjFd9DKk0SSxMGR1DKR3B6GuQ1KMSQ7uvGa0fBN0ZdINs5y9o5i/4D1X9Dj8KAOiooooAKKKKACiiigAooooAKKKKACue8ZD/R9OI6i7H5eW9dDWB4xH+gWzf3bhT/AOOsP60AVvh63/Eouoyf9VeSJ+gP9axbTCav4efPIklT+Y/rWp8P2w+uQ+l60n/fQx/7LWOzBL/Qz6X7L/4/igD0aiiigAooooA4vx3ZfZp7bV4lwoIgucd1J+Vj9Dx+I9K5yOH7FeyXQJ8uSURzp1Ckr8je3KuPwHrXpeq2Sajp1zaSnCzIUz3UkcH6jrXmVr5t7pskDDbO8Zt5EJwfMQhkB99yqv8AwI0Adj4PLR3F/CeEISVfc4IP6Ba1/ENl/aOi3lqBud4yUB/vjlf1ArkfCl+HuNNuSciRWtpD2ycEH65VR+Nd/QB8/wBjIbXUt6HjcJAR37H9MV65o0yJqqOOl9ACD23Jnj8mY/hXmviixGm+IJ4gNqLKVX02sAVA/NB+FdTo94TodvdLky6fIHIHUr0YD6rkUAei0U1WDqGUgqRkEdCKdQBy/wARLcy+H/PQZe1lSYfTO0/o2fwp/hi6D3syg/JdQpcqPVgArn/0CtvUrVb7Trq1c4WeJoyfTIIrg/Cl0Y7XTJ3+V4Jzbyr7Pxgn0DEH8KAKiMdM1TVIeQLO9Fyqj+5kPj/vkKPxr1AEEAg5B7ivPvE0P2fxmxA+S9tcnP8AeXOf0RfzrrvDM/n6HZknLIvlE+pQlc/pmgDUooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKZLGssTxyDKOpVh6g0+igDzLRGdvD3ky/660leFx3Bzn+ZYfhWHqkgiuGU8HckgPc4JXA/77J/Cun8gW3irXLL+GcC5TPc/eOPxdvyrjvF+6F1lUfMAQPrigD0G2cXGmxv1ytV/DUptPEQTnZdIY2H+0uWBP4bh+NVPDF0J9HjIbgDg+1QalcCykScuiSRuskYdgNxBBA+nGKAPTKKit5UuLeKeI5jkQOp9QRkVLQAUUUUAFFFFABRRRQAUUUUAFYfjEf8AEjdv7ssX6uB/WtysfxYu7QZx/txH/wAiLQBh+BWxrmvR9MmJwPrvz/Ssm9bbe6R7asV/8jAVe8HS/wDFY6jGOjWqN+QT/wCKqhrWEazfumrSE/hMT/SgD0uiiigAooooAK828Q2psPFVzHHlI71BcRMv8EgJJI98gn6sK9JrlPiHaF9Jhvo/9bZShwep2kgEfntP4UActopL/wBoQQgJIri4hA6I2dwA9Qp4/CvTLG5S8s4LmMEJKgcA9RkZxXksN4LLxHbTD/VXCZGfTjI/XP516N4XlCwXFn0MEhZR6q5LA/nuH4UAcx8TtPVpoLnbkSxlGPTBU5H44Y/981keC70QTT2l22ElG1XI4J6DJ7HP/wBau98Z2wn0CZyu4wsJR7DOGP8A3yWry+1IhvCjkhWyjEdcEYNAHqfhG5W40ZI92WtpHt29thIH/ju2tquH8H3hi1y4gkwq3kYmUDgCRchwPU5Dn6AV3FABXnDW6R+I9e00EhZsyqRxhmAbj/vrFej1wnjJfsPivTL/AKLMnltj1U9/++x+VACeMp1mtPD+shcKJAGX0DqCQf8AvgitfwdJsOoWh58uRZB7BgRj80J/GsfV49/hDV7QDLWcwlTPURlgxP5Fx+FS+ELs/wBoWbMflurcqfeRQP6K9AHcUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHGeKYxbeLtGvP4Z1a2Y+/IUfm/6Vx/ja2YwSAD5gTXd/ESEt4e+0IcSWs0cqH3zt/9mzXN+J1W7thcRD5J4xIv0IH+NAHCaVfTR2EUa3V1EvKiO3UZODjBORjjHrVprWTBc2SW4JyZr6f5s/TjP/fJrM0pnSW5gD3CHdnEP3mHQjGenSr/AJCQAsbOKNv715OC312DGfxBoA9c8A3wvPD8a+asjQMYiy5APcY9ucfhXS15n8LtRX+0Lq0aeOVpEBHloURdpJCgYH95j+FemUAFFFFABRRRQAUUUUAFFFFABWZ4mGdAvz/diL/98/N/StOqOuRmXRdQjAyXt5Fx9VIoA4jws3l+Oif+etoV/RD/AOy1V8Skrbbv7upTn/yIau6Zayw+M9LlKkKYmVj/AMBfH8hUXiq2kbSLnapJF9M4+m4mgD0eiiigAoJA6miuL8aanLY6lCkblVMQbA9cmtaNJ1ZcqHFXdjs9w9RUN7bR3lnPbTDMcyGNsehGDXljeI7rzMea/wCdep2b+ZaQOerID+lXiMNKhbm6jlBxPFNVhlgs2WYfvtOnKsR0xkg49vvH8q7zw5eYm068J+W4Q2svoG6oT+Ix/wACql4z00R6/wCYF/cahEUcf7QAGfb+D9az/BiTS6Td2EmUnj+aNj1V1PB+uQDXOSen3EKTwSQyjdHIpRh6gjFeL6nA9vcMshzJGxRj6spKkj8RXstnOt1awzoCqyIGAPUZGcVw/izRJZdWmkhTKSgSZHQNjBH/AI6D+NAGXBdNHa2moxjMllKrkL1MbnDKPcspH0avUgQwBByDyCK4Hw7opCPHdwI5GTGXUEqevB7dK7DRYpINMgt5uWhHlg+qj7v6YoAv1ynxHtfO8PCdR89rKkgx1wTtI/8AHs/hXV1X1C1S9sri2lHySoUP4jFAHJaeVviiE4i1Oze2c/7YU4/TfWD4Zkljs7SZlKyWs4LDuEyCw/VxXc6VpS2dtEinJicMp7jsR+RIqeDSbeKSciMbZWJI/En+tAGnRSKMAD2paACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKwfF9++nafDLE20tKEJHptJ/pVwg5yUV1Gld2N7NFeYy+KroEASmu38L3jX+iwzyHLsWBP0JrathZ0Y80ipQcdSzrlp9v0i9tB96WJlU+jEcH88V57pbi+8LQN/FEzRHPXHDD/wBCxXqFecWFuLPWvEGm4wA/nRjsFznA/B1H4VzEHnF7EbfWm6hJMqcHB6dj9atxxJEATbWcJ/vXUu8/98j+q1L4thMc/mKOQQR9e1NhizGHjgsIozyJriTJb3Ckn/0GgDQ0DVRaazaTi6kmET7ikUASNV/iPb+HcOle4V4N9qBCodQubnaQfKs4vLTPvwM/9817H4XuGuNCtGkBDqhjYN1+Ulcn64zQBrUUUUAFFFFABRRRQAUUUUAFIwDAg9CMUtFAEP2aLzFfb8y9DSSW0UilXQFSSSPep6KACiiopi4iYxKrSAEqpOAT6Z5xQBLXmfxRmEWrWvvB/wCzGmz/ABQlgmeKbQyksbFWVrrBUg9D8lcr4u8Uf8JDcwTfZhbGJCmBJvzznOcCvZwWBrU6qlOOnqjeFOSd2Zr3JDlq990Zt+k2Lf3oEP8A46K+b2mPQ13tp8UZLGwt7caVHIIY1jDG4K7sADONtdeY4OpWjFUlexdWDlax6pqFjFfRIso5Rtyn0NV7bR4YLl5l4djk+571g+BPFt14pNzI2mLa20OF83z9+5j2A2jt/Suyr5+rSnRm4T3RzSi4uzI4YlhTYgwoJI/PNPZQ3UZpaKzEIFA6ACloooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArkPia4j0G3Y9rlf/QXqDWPH9npOpz2V3YXolibBI24YEZBHzdMVy3jHxrZ6/pKWttbXETrKJMybcYAPHB969HCYOt7SM3HQ1hCV07HM3F0S+QeBXrfw2l87wtC3pI4/WvD3nOa7bwj48tdB0ZbOe0mmYOz7kYAc162YYadSio01d3NakW1ZHslcL4sUWPjHSrzOFukMDDscHGT/wB9r+VN8O/EO213V4dPtdOulkfJLsykIoHJP+etXviVaGbQo7mPiS1lVsjrhvlx+ZU/hXztahUoy5aisznlFx0ZxHjG1/dSccgmub0mT/RFYW9rJImVL3BGFAPAxkA9a7vxIgu7JZ0HyzxiQD0yBx+tcF4dWJtSa3uE3xlw2D69/wClZEmqZp5Ywk2pSKp6QWUJGfb+EfzrvvhpO0dtcWUiTx/8tkE/3z2bt0GF/OpIrOOOAC2jSNWA4jUDP19aNKie21e3nAONxRvdW4x+e0/hQB2lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHlnxg8OH7K2u2KYePAulX+JeAH/DofbntXjyXh9a+sJI0ljZJFDIwwykZBHpXzJ8UvDL+Edd/cgnTLol7Zs529NyH6Z/EY96+myXFKqvq891t6djroTv7rMw3O49ataVZXGs6rbafZfNPO+0Z6KOpP0ABNck2oADg19CfBTwo2l6T/bOox4v71QYlbrHF1H4t1Ptj3r1cfWWCouo9+nqa1Jciud/4f0m30TSYNPtBiKIYyerN3Y+5PNaVFFfCyk5Nyk9Wee3cKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHFfErw1/bWlNdWcedStlJQDrIvUr9e49+O9eBi9+bGeK+sa8B+NHhJtHvW1zT4/wDQLl/36r0ikPf2Vv0PHcV9BkuLV/q9R+n+X+R00J/ZZxzXWRwaZJMdud1YJvwB1r0b4L+GX8Q6t/at5HnTLJ/lz0ll4IHuB1P4CvoMQ44ak6s9l/VjplaKuz1H4XeF/wCwdHFzeJjUrtQ0mesa9k/qff6V2GpWq3thcWz/AHZUK/QkcGrNFfCVq0q03UnuzzpScndnLQaNv0mGB15jyvPpkn+tYUPgkRX4nUY5Oa9FCgUuBWQjNtLAJCqtzgVaS1iXovNWKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArnvG/hq08WeH7jTLz5Gb54ZQMmKQdGH9R3GRXQ0VVOcqclODs0NNp3R8s/Df4cXuqeOrux1yAx2ekSA3QPSVs5VB6hhzn+79RX1NUaxojOVUBnOWwOWOAMn8ABUlduYZhUx01KeiS2/P7/+AXUquo7sKKKK4DMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACs/WdMtdZ0u50+/j8y2uEKOvfHqD6jrWhRTTcXdbhsfIGs+A9XsfH0fheJWlluJAbeYghXiOfnOPQA59wa+qPC2h23hvQbPSrLJht0xubq7Hksfckk1ektIHu47poUNzEjRpIR8yqxBIB9CVX8qs16WPzWpjoQhLS2/m+5rUquokmFFFFeYZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_42_22191=[""].join("\n");
var outline_f21_42_22191=null;
